# Patent

## Title
Method of detecting at least one mechanism of resistance to carbapenems by mass spectrometry

## Abstract

The present invention pertains to a method of detection, by mass spectrometry, of at least one marker of at least one mechanism of resistance to at least one antimicrobial, resistance of at least one microorganism contained in a sample, characterized in that the antimicrobial is a carbapenem, and said resistance markers are proteins or peptides. Preferably, said proteins or peptides are proteins from said microorganism.

## Background
This is a Division of application Ser. No. 14/111,083 filed Oct. 10, 2013, which in turn is a national stage of PCT/EP2012/057323, filed Apr. 20, 2012, which claims the benefit of U.S. Provisional Application No. 61/477,915 filed Apr. 21, 2011. The disclosure of the prior applications is hereby incorporated by reference herein in its entirety.


The present invention relates to the field of microbiology. More precisely, the invention relates to the detection of at least one mechanism of resistance to carbapenems of at least one microorganism from a sample by using mass spectrometry.
Since Pasteur's discovery of microbes, microorganisms have been studied by microscopy and biochemical analyses. These conventional methods are often long and tedious, and analytical alternatives were sought very early on. This is why the analysis of bacteria by mass spectrometry was initiated from 1975 by J. Anhalt and C. Fenselau [1].
This preliminary work was followed by the study of fatty acids from the wall of the microorganisms using gas chromatography combined with mass spectrometry (GC-MS) [2]. This method was popularised under the English term FAME, standing for Fatty Acid Methyl Ester. It currently constitutes a reference method for taxonomic studies. However, its use remains limited to certain specialised laboratories dealing with the treatment of the sample by saponification, hydrolysis and derivation.
In 1996, the works by M. Claydon et al. [3] as well as by T. Krishnamurthy and P. Ross [4] demonstrated the possibility of identifying different bacterial species with a MALDI-TOF mass spectrometer (English acronym for Matrix Assisted Laser Desorption Ionization-Time Of Flight). The analysis combines the acquisition of a mass spectrum and the interpretation of expert software. It is extremely simple and can be carried out in a few minutes. However it has only been making it into medical analysis laboratories fairly recently [5]. Its clinical use is currently limited to the identification of bacteria and yeast species. It is not routinely used to identify resistances to antimicrobials.
Yet the identification of resistances to antimicrobials such as antibiotics is an essential element in ensuring optimal patient care.
Other mass spectrometry methods, particularly in tandem, have been proposed to meet these needs. By way of example, it is possible to cite the work of C. Fenselau et al. for identifying β-Lactamase with a quadripole-TOF (Q-TOF) [6].
However these research results are not applicable to routine clinical use. They were obtained with research instruments requiring highly qualified personnel. The analysis times, often greater than one hour per sample, are incompatible with the workload of a microbiological analysis laboratory.
More recently, S. Hofstadler et al. [7] proposed a method combining a microbial genome amplification by PCR to a detection of the PCR products by electrospray-TOF (ESI-TOF). This method is now fully automated [8]. However, it requires a PCR amplification with the flaws inherent in molecular biology, namely extraction yield, cost of the probes, etc.
In this context, the objective of the present invention is to propose a method of detecting mechanisms of resistance to carbapenems which makes it possible to overcome the disadvantages of the prior art methods, namely providing an inexpensive method, without reagents specific to each species, particularly compared to molecular biology methods, which gives a result in a short amount of time, less than one hour, and which can be used in routine clinical work, without requiring highly qualified personnel.
To this end, the invention proposes a new method of detecting, by mass spectrometry, at least one mechanism of resistance to at least one antimicrobial of at least one microorganism from a sample, characterised in that the antimicrobial is a carbapenem and in that proteins and/or peptides are detected as markers of said mechanism of resistance to at least one carbapenem-class antibiotic.
Preferably, the resistance markers are proteins from said at least one microorganism. Advantageously, markers of resistance to several different antimicrobials can be detected simultaneously.
As indicated in application PCT/FR2010/052181, markers of type and/or virulence of said microorganisms can be detected in the same way by mass spectrometry prior to or at the same time as the detection of the resistance mechanism markers.
Markers of resistance to at least one carbapenem-class antimicrobial is understood to mean molecules of protein origin which are characteristic of said properties.
Carbapenems are antibiotics belonging to the beta-lactam family and their main representatives are imipenem, meropenem, ertapenem and doripenem. These molecules are broken down by the beta-lactamases 2df, 2f and 3a of the classification by Bush and Jacoby ([9], Antimicrobial Agents and Chemotherapy, 2010; 54 (3): 969-976).
Determination of the resistance to at least one antimicrobial is understood to mean determining the susceptibility of a microorganism to being destroyed by an antimicrobial. The proteins involved in the resistance mechanisms will differ depending on the family and the species.
The nomenclature of the beta-lactamases, beta-lactam-resistant bacterial enzymes, is not standardised. They are either classified in four molecular classes (A to D) on the basis of their primary structure, or in functional groups on the basis of the target substrates and their resistance to inhibitors (for an overview, see [9] Bush and Jacoby, supra). For molecular classification, sequencing techniques have made more precise classification possible: for example, 183 variants of the TEM protein have been described (labelled TEM-i, with i being between 1 and 183). For the functional classification, Bush and Jacoby (supra) have proposed new functional subgroups:

    
    
        the group 1 enzymes are cephalosporinases belonging to the molecular class C. CMY and FOX are plasmid-borne enzymes, belonging to this subgroup.
        the group 2 enzymes belong to molecular classes A and D. This group is itself subdivided into subgroups, 2b, 2be, 2br, 2ber, 2d, 2de, 2df, 2f, etc. CTX-M (2be) and TEM (including 2be, 2br) are enzymes belonging to this subgroup. The subgroup 2b corresponds to broad-spectrum beta-lactamases which are inhibited by clavulanic acid, sulfobactam, or tazobactam. The subgroup 2be corresponds to extended-spectrum beta-lactamases (ESBL), which are also inhibited by clavulanic acid, sulfobactam or tazobactam. The subgroup 2br corresponds to beta-lactamases from the subgroup 2b which are insensitive to inhibition by clavulanic acid, sulfobactam or tazobactam. The subgroup 2df includes OXAs having a spectrum extended to carbapenems. Group 2f corresponds to carbapenemase beta-lactamases such as KPC.
        group 3 encompasses the metallo-beta-lactamases which hydrolyse carbapenems, such as IMP, VIM, SPM, GIM, SIM, AIM, KHM, DIM or NDM.
    
    


NDM-1 beta-lactamase was described in 2010 (Kumarasamy et al., 2010, Lancet Infect. Dis., 10:597-602). It corresponds to a metallo-beta-lactamase which confers a resistance to all beta-lactams except aztreonam.
KPC beta-lactamases were described from 2001 in the United States (Yigit et al., 2001, Antimicrobio. Agents Chemother., 45:1151-1161) and then throughout the world. They correspond to class-A beta-lactamases which confer a resistance to cephalosporins and to carbapenems, in particular to imipenem and to meropenem. IMP beta-lactamases were described from 1994 in Japan (Osano et al., 1994, Antimicrobio. Agents Chemother., 38:71-78) and then throughout the world. They correspond to metallo-beta-lactamases which confer a resistance to cephalosporins and to carbapenems, but which do not confer resistance to Temocillin and to aztreonam.
VIM beta-lactamases were described from 1999 in Europe (Lauretti et al., 1999, Antimicrobio. Agents Chemother., 43:1584-1590) and then throughout the world. They correspond to metallo-beta-lactamases which confer a resistance to cephalosporins and to carbapenems, but which do not confer resistance to aztreonam.
The first GES beta-lactamase was isolated in 1998 in French Guiana (Poirel et al., 2000, Antimicrobio. Agents Chemother., 43:622-632). This enzyme (GES-1) conferred an ESBL resistance. The second isolate from a bacterium bearing a GES beta-lactamase was achieved in 2000 in South Africa (Poirel et al., 2001, Antimicrobio. Agents Chemother., 45:2598-2603). This enzyme (GES-2) conferred a resistance to cephalosporins and to carbapenems such as imipenem.
IND beta-lactamases were described for the first time in 1999 (Bellais et al., 1999, FEMS Microbio. Lett., 171:127-132). They correspond to metallo-beta-lactamases which confer a resistance to cephalosporins and to carbapenems.
SME beta-lactamases were described for the first time in 1994 (Naas et al., 1994, Antimicrobio. Agents Chemother., 38:1262-1270). They correspond to class-A beta-lactamases which confer a resistance to cephalosporins and to carbapenems.
OXA beta-lactamases (or oxacillinases) correspond to Class-D beta-lactamases. According to their primary sequence, they can confer resistances to cephalosporins or to cephalosporins and to carbapenems (Poirel et al., 2010, Antimicrobio. Agents Chemother., 54:24-38).
The method of the invention can be employed to detect mechanisms of resistance to carbapenems in bacteria. Thus, for example, as bacteria in which it is possible to seek a mechanism of resistance to carbapenems according to the method of the invention, non-exhaustive mention may be made of: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, Bacillus spp, Stenotrophomonas maltophilia, Aeromonas spp, Bacteroides fragilis, Pseudomonas otitidis and Enterobacter cloacae, and more generally, the Enterobacteriaceae, which carry the blaNDM-1 or blaKPC resistance gene. It should further be noted that the strains known to be resistant to carbapenems are also resistant to cephalosporins and to penicillins.
Thus, the method according to the invention also makes it possible to detect a mechanism of resistance to said antibiotics.
The sample on which the method of the invention can be employed is any sample susceptible of containing a target microorganism. The sample can be of biological origin, either animal, vegetable or human. In this case it may correspond to a specimen of biological fluid (whole blood, serum, plasma, urine, cerebrospinal fluid, organic secretion, for example), a tissue specimen or isolated cells. This specimen can be used such as it is, insofar as the markers of mechanisms of bacterial resistance to beta-lactams are available in the sample tested, or it can, prior to the analysis, undergo preparation by enrichment, extraction, concentration, purification, culturing, in accordance with methods known to the person skilled in the art.
The sample can be of industrial origin, or, according to a non-exhaustive list, can be an air specimen, a water specimen, a surface specimen, a part or a manufactured product, or a food product. Amongst the food samples, non-exhaustive mention can be made of a sample of a dairy product (yogurts, cheeses), of meat, of fish, of egg, of fruit, of vegetable, of water, of a beverage (milk, fruit juice, soda, etc.). These food samples can also come from sauces or ready meals. Finally, a food sample can come from an animal feed, such as animal meals.
Upstream of the detection by mass spectrometry, the sample to be analysed is preferably pretreated to produce peptides from the entirety of the proteins present in the sample to fragment these proteins into peptides, for example by digestion with a proteolytic enzyme (protease), or by the action of a chemical reagent. In fact, the cleaving of the protein can be performed by a physico-chemical treatment, by a biological treatment or by a combination of the two treatments. Amongst the useable treatments, mention can be made of treatment by hydroxyl radicals, in particular with H2O2. Treatment by hydroxyl radicals results in a cutting of the peptide bonds which takes place randomly on any of the protein's peptide bonds. The hydroxyl radical concentration determines the number of cleavages performed, and therefore the length of the peptide fragments obtained. Other chemical treatments can also be used such as, for example, cyanogen bromide (CNBr) treatment which specifically splits the peptide bonds at the carboxyl group of the methionyl residues. It is also possible to perform partial acid cleaving at the aspartyl residues by heating a solution of proteins in trifluoroacetic acid to 1000° C.
Treatment of the proteins by enzymatic digestion is nevertheless preferred over physico-chemical treatment because it preserves more of the structure of the protein, and is easier to control. “Enzymatic digestion” is understood to mean the single or combined action of one or more enzymes under appropriate reaction conditions. The enzymes carrying out the proteolysis, which are called proteases, cut the proteins at specific locations. Each protease generally recognises a sequence of amino acids within which it always makes the same cut. Certain proteases recognise a single amino acid or a sequence of two amino acids between which they perform a cleavage, whereas other proteases only recognise longer sequences. These proteases can be endoproteases or exoproteases. Amongst the known proteases, mention may be made of the following as described in WO2005/098071:

    
    
        specific enzymes such as trypsin which splits the peptide bond at the carboxyl group of the Arg and Lys residues, endolysin which cleaves the peptide bond of the —CO group of the lysines, chymotrypsin which hydrolyses the peptide bond at the carboxylic group of the aromatic residues (Phe, Tyr and Tip), pepsin which makes a cut at the NH2 group of the aromatic residues (Phe, Tyr and Trp), the protease V8 from the V8 strain of Staphylococcus aureus which cleaves the peptide bond at the carboxylic group of the Glu residue;
        the non-specific enzymes such as thermolysin from the bacteria Bacillus thermoproteolyticus which hydrolyses the peptide bond of the NH2 group of hydrophobic amino acids (Xaa-The, Xaa-Ile, Xaa-Phe), subtilisin and pronase which are bacterial proteases which hydrolyse practically all the bonds and can transform the proteins into oligopeptides under controlled reaction conditions (enzyme concentration and duration of reaction).
    
    


Several proteases may be used simultaneously, if their modes of action are compatible, or they may be used successively. Within the framework of the invention, the digestion of the sample is preferably performed by the action of a protease enzyme, for example trypsin.
The generation of peptides using a chemical reagent or a protease can be obtained by means of a simple reaction in solution. It can also be performed with a microwave oven [10], or under pressure [11], or even with an ultrasound device [12]. In these three latter cases, the protocol will be much faster.
Amongst the peptides thus obtained, the peptides specific to the protein are referred to as proteotypic peptides. It is these which will be assayed by mass spectrometry. According to the invention, the markers of the mechanisms of bacterial resistance to carbapenems are proteins from the bacterium in which the mechanisms of resistance to cephalosporins are to be sought. In particular, said proteins are digested into peptides, preferably by an enzyme, and more preferably by trypsin.
Similarly, the sample containing protein markers characterising mechanisms of bacterial resistance to carbapenems can also be pretreated for the purposes of purification. This purification pretreatment can be employed before or after the peptide production step as described above.
The sample purification pretreatment is widely known to the person skilled in the art and may in particular employ the techniques of centrifugation, filtration, electrophoresis or chromatography. These separating techniques can be used alone or in combination with one another to obtain a multidimensional separation. For example, multidimensional chromatography can be used by combining separation by ion exchange chromatography with reversed-phase chromatography, as described by T. Fortin et al. [13], or H. Keshishian et al. [14]. In these publications, the chromatography medium can be in a column or in a cartridge (solid-phase extraction).
The electrophoretic or chromatographic fraction (or the retention time in monodimensional or multidimensional chromatography) of the proteotypic peptides is characteristic of each peptide, and employing these techniques therefore makes it possible to select the proteotypic peptide or peptides to be assayed. Such a fractionation of the produced peptides makes it possible to increase the specificity of the subsequent assay by mass spectrometry.
An alternative to the electrophoresis or chromatography techniques for the fractionation of the peptides consists in specifically purifying the N-glycopeptides ([15] and patent application WO 2008/066629). However, such a purification only makes it possible to quantify the peptides which have undergone an N-glycosylation post-translational modification. Not all proteins are glycosylated though, which therefore limits its use.
The mass spectrometry to be employed in the method of the invention is widely known to the person skilled in the art as a powerful tool for analysing and detecting different types of molecules. Generally, any type of molecule able to be ionised can be detected according to its molecular mass with the aid of a mass spectrometer. According to the nature of the molecule to be detected, whether of protein or metabolic origin, certain mass spectrometry technologies can be more suitable. Nevertheless, whatever mass spectrometry method is used for the detection, this latter includes a step of ionising the target molecule into so-called molecular ions, in the present case a step of ionising the characterising markers, and a step of separating the molecular ions obtained according to their mass.
All mass spectrometers therefore comprise:

    
    
        an ionising source intended to ionise the markers present in the sample to be analysed, i.e. to confer a positive or negative charge upon these markers;
        a mass analyser intended to separate the ionised markers, or molecular ions, according to their mass-to-charge ratio (m/z);
        a detector intended to measure the signal produced either directly by the molecular ions, or by ions produced from molecular ions as detailed hereafter.
    
    


The ionisation step necessary for employing mass spectrometry can be performed via any method known to the person skilled in the art. The ionising source makes it possible to transform the molecules to be assayed into a gaseous and ionised state. An ionising source can be used either in positive mode to study the positive ions, or in negative mode to study the negative ions. Several types of sources exist and will be used depending on the result sought and the molecules analysed. In particular, mention may be made of:

    
    
        electron ionisation (EI), chemical ionisation (CI) and desorption chemical ionisation (DCI)
        fast atom bombardment (FAB), metastable atom bombardment (MAB) or ion bombardment (SIMS, LSIMS) http://fr.wikipedia.org/wiki/Spectrom%C3%A9trie_de_masse_%C3%A0_ionisation_secondaire
        inductively coupled plasma (ICP) http://fr.wikipedia.org/wiki/Torche_%C3%A0_plasma_(chimie)
        atmospheric-pressure chemical ionisation (APCI) and atmospheric-pressure photoionisation (APPI) http://fr.wikipedia.org/wiki/Ionisation_chimique_%C3%A0_pression_atmosph%C3%A9rique
        electronebulisation or electrospray (ESI) http://fr.wikipedia.org/wiki/Ionisation_par_%C3%A9lectron%C3%A9buliseur_(ESI)
        matrix-assisted laser desorption/ionisation (MALDI), surface-activated laser desorption/ionisation (SELDI) or desorption/ionisation on silicon (DIOS) http://fr.wikipedia.org/wiki/D%C3%A9sorption-ionisation_laser_assist%C3%A9e_par_matrice
        ionisation/desorption by interaction with metastable species (DART)
    
    


In particular, ionisation can be employed as follows: the sample containing the target molecules is introduced into an ionisation source, where the molecules are ionised in gaseous state and thus transformed into molecular ions which correspond to the initial molecules. An electrospray ionisation (ESI) source makes it possible to ionise a molecule by making it pass from a liquid state into a gaseous state. The molecular ions obtained therefore correspond to the molecules present in liquid state, with, in positive mode, one, two, or even three or more additional protons and therefore carry one, two, or even three or more charges. For example, when the target molecule is a protein, an ionisation of the proteotypic peptides obtained after fractionation of the target protein, by means of an electrospray source functioning in positive mode, leads to polypeptide ions in gaseous state, with one, two, or even three or more additional protons and which therefore carry one, two, or even three or more charges, and makes it possible to move from a liquid state to a gaseous state [16]. This type of source is particularly well suited when the target molecules or proteotypic peptides obtained are separated beforehand by reversed-phase liquid chromatography. Nevertheless, the ionisation yield of the molecules present in the sample may vary depending on the concentration and the nature of the different species present. This phenomenon leads to a matrix effect well known to the person skilled in the art.
A MALDI ionisation source will allow ionisation of the molecules from a solid-state sample.
The mass analyser in which the step of separating the ionised markers according to their mass-to-charge ratio (m/z) is performed is any mass analyser known to the person skilled in the art. Mention can be made of low-resolution analysers, quadripole or quadrupole (Q), 3D ion trap (IT) or linear ion trap (LIT), also called ion trap, and high-resolution analysers which make it possible to measure the exact mass of the analytes and which in particular use the magnetic sector linked to an electric sector, the time of flight (TOF), Fourier transform ion cyclotron resonance (FT-ICR), orbitrap.
The separation of the molecular ions depending upon their m/z ratio can be employed just once (single mass spectrometry or MS), or several successive MS separations can be conducted. When two successive MS separations are carried out, the analysis is called MS/MS or MS2. When three successive MS separations are carried out, the analysis is called MS/MS/MS or MS3, and more generally, when n successive MS separations are carried out, the analysis is called MSn.
Amongst the techniques which employ several successive separations, SRM (Selected Reaction Monitoring) mode when detecting or assaying a single target molecule, or MRM (Multiple Reaction Monitoring) mode when detecting or assaying several target molecules are particular uses of MS2 separation. Similarly the MRM3 mode is a particular use of MS/MS/MS separation. This is referred to as targeted mass spectrometry.
In the case of a detection in single MS mode, it is the mass-to-charge ratio of the molecular ions obtained which is correlated to the target molecule to be detected.
In the case of detection in MS/MS mode, essentially two steps are added, compared to an MS assay, which are:

    
    
        a fragmentation of the molecular ions, then called precursor ions, to give ions called 1st generation fragment ions, and
        a separation of the ions called 1st generation fragment ions according to their mass (m/z)2, the ratio (m/z)1 corresponding to the ratio (m/z) of the precursor ions.
    
    


It is therefore the mass-to-charge ratio of the 1st generation fragment ions thus obtained which is correlated to the target molecule to be detected. First-generation fragment ion is understood to be an ion derived from the precursor ion, following a fragmentation step and of which the mass-to-charge ratio m/z is different from the precursor ion.
The (m/z)1 and (m/z)2 pairs are called transitions and are representative of the characteristic ions to be detected.
The choice of the characteristic ions which are detected to be correlated to the target molecule is made by the person skilled in the art in accordance with the standard methods. Their selection will advantageously lead to the most sensitive, specific and robust assays possible, in terms of reproducibility and reliability. In the methods developed for the selection of proteotypic peptides (m/z)1, and of the first-generation fragment (m/z)2, the choice is essentially based on the intensity of the response. For more details, it is possible to refer to V. Fusaro et al. [17]. Commercially available software, such as the MIDAS and MRM Pilot software from Applied Biosystems or MRMaid [18] can be used by the person skilled in the art to allow him to predict all the possible transition pairs. He can also make use of a database called PeptideAtlas constructed by F Desiere et al. [19] to compile all of the MRM transitions of peptides described by the scientific community. This database PeptideAtlas is freely available on the internet. For non-protein molecules, it is also possible to use databases, such as, for example, the one accessible through the Cliquid software from the company Applied Biosystems (United States of America).
An alternative approach to selecting the proteotypic peptides (m/z)1 and (m/z)2 consists in using MS/MS fragmentation spectra obtained during other work. This work can be, for example, the phases of biomarker discovery and identification by proteomic analysis. This approach was proposed by Thermo Scientific during user conferences [18]. It makes it possible to generate a list of candidate transitions from the peptides identified through testing by the SIEVE (Thermo Scientific) software. Certain criteria were detailed by J. Mead et al. [18] for the choice of the ions (m/z)1 and (m/z)2 and are detailed hereafter:

    
    
        peptides with internal cleavage sites, i.e. with internal Lysine or Arginine, must be avoided, unless the Lysine or Arginine is followed by Proline,
        peptides with Aspargine or Glutamine must be avoided because they may deaminate,
        peptides with Glutamine or Glutamic Acid at the N-terminal must be avoided because they may cyclise spontaneously,
        peptides with Methionine must be avoided because they may be oxidised,
        peptides with Cysteine must be avoided because they may be non-reproducibly modified during a potential step of denaturation, reduction and blocking of the thiol functions,
        peptides with Proline may be considered to be favourable because they generally produce intense fragments in MS/MS with a very strong single peak. However, a very strong single fragment does not make it possible to validate the identity of the transition in a complex mixture. Indeed, only the simultaneous presence of several characteristic fragments makes it possible to verify that the precursor ion sought has actually been detected,
        the peptides having a Proline adjacent to the C-terminal (Position n-1) or in second position relative to the C-terminal (position n-2) should be avoided because, in this case, the size of the first-generation peptide fragment is generally considered to be too small to be sufficiently specific,
        the selection of fragments having a mass greater than the precursor should be given preference in order to promote specificity. To this end, it is necessary to select a dicharged precursor ion and select the most intense first-generation ion fragment having a mass greater than the precursor, i.e. a monocharged first-generation fragment ion.
    
    


The fragmentation of the selected precursor ions is performed in a fragmentation cell such as the triple quadripole model [20], ion trap model [21], or time-of-flight (TOE) model [22], which also make it possible to separate ions. The fragmentation or fragmentations will be conventionally performed by collision with an inert gas such as argon or nitrogen, within an electrical field, by photo-excitation or photo-dissociation using an intense light source, collision with electrons or radical species, by applying a potential difference, for example in a time-of-flight tube, or by any other activation mode. The characteristics of the electrical field determine the intensity and nature of the fragmentation. Thus, the electrical field applied in the presence of an inert gas, for example in a quadripole, determines the collision energy provided to the ions. This collision energy will be optimised, by the person skilled in the art, to increase the sensitivity of the transition to be assayed. By way of example, it is possible to vary the collision energy between 5 and 180 eV in q2 in an AB SCIEX QTRAP® 5500 mass spectrometer from the company Applied Biosystems (Foster City, United States of America). Similarly, the duration of the collision step and the excitation energy within, for example, an ion trap will be optimised by the person skilled in the art to lead to the most sensitive assay. By way of example, it is possible to vary this duration, called excitation time, between 0.010 et 50 ms and the excitation energy between 0 and 1 (arbitrary unit) in Q3 in an AB SCIEX QTRAP® 5500 mass spectrometer by the company Applied Biosystems.
Finally, the detection of the selected characteristic ions takes place in the conventional manner, particularly by means of a detector and a processing system. The detector collects the ions and produces an electrical signal whose intensity depends on the amount of ions collected. The signal obtained is then amplified such that it can be processed by computer. A computer data processing assembly makes it possible to transform the information received by the mass spectrum detector.
The principle of the SRM mode, or even of the MRM mode, is to specifically select a precursor ion, fragment it, and then specifically select one of its fragment ions. For such applications, triple quadripole or hybrid triple quadripole/ion trap devices are generally used.
In the case of a triple quadripole device (Q1q2Q3) used in MS2 mode, with a view to assaying or detecting a target protein, the first quadripole (Q1) makes it possible to filter the molecular ions corresponding to the proteotypic peptides characteristic of the protein to be assayed and obtained during an earlier digestion step, depending on their mass-to-charge ratio (m/z). Only the peptides having the mass-to-charge ratio of the proteotypic peptide sought, which ratio is called (m/z)1, are transmitted into the second quadripole (q2) and act as precursor ions for the subsequent fragmentation. The analyser q2 can fragment the peptides of mass-to-charge ratio (m/z)1 into first-generation fragment ions. Fragmentation is generally obtained through collision of the precursor peptides with an inert gas, such as nitrogen or argon in q2. The first-generation fragment ions are transmitted into a third quadripole (Q3) which filters the first-generation fragment ions depending on a specific mass-to-charge ratio, called (m/z)2. Only the first-generation fragment ions having the mass-to-charge ratio of a fragment characteristic of the sought proteotypic peptide (m/z)2 are transmitted into the detector in order to be detected, or even quantified.
This mode of operation exhibits a double selectivity, with regard to the selection of the precursor ion on the one hand, and the selection of the first-generation fragment ion on the other hand. Mass spectrometry in SRM or MRM mode is therefore advantageous for quantification.
When the mass spectrometry employed in the method according to invention is tandem mass spectrometry (MS2, MS3, MS4 or MS5), several mass analysers can be linked to one another. For example, a first analyser separates the ions, a collision cell makes it possible to fragment the ions, and a second analyser separates the fragment ions. Certain analysers, such as the ion traps or the FT-ICR, constitute several analysers in one and make it possible to fragment the ions and analyse the fragments directly.
According to preferred embodiments of the invention, the method of the invention comprises one or more of the following characteristics:

    
    
        the mass spectrometry employed for the properties of potential resistance to at least one antimicrobial is MS/MS spectrometry, which has the advantage of producing a fragment which is specific to the molecule to be detected or quantified, and thus of providing great specificity to the assaying method;
        the MS/MS spectrometry is MRM which has the advantage of using an analysis cycle time in the mass spectrometer of several tens of milliseconds, which makes it possible to detect or quantify, with a high degree of sensitivity, a large number of different molecules in a multiplexed manner;
        where applicable, the determination of the type properties and of the virulence factor is performed in the same mass spectrometry apparatus as the determination of the markers of resistance to at least one antimicrobial, preferably simultaneously, which has the advantage of reducing the analysis time and the cost of the instrument, which also facilitates the processing and the yielding of the results.
    
    


In addition to determining the resistance to an antibiotic, it is necessary to identify the microorganism or microorganisms present in the sample to be tested.
The methods of identifying microorganisms are widely known to the person skilled in the art, as described for example by Murray P. R. et al. in Manual of Clinical Microbiology, 2007, 9th edition, and especially in Vol. I, Section III, chapters 15 and 16 for bacteria and yeasts, Vol. II, Section VI, chapter 82 for viruses, and Vol. II, Section X, chapter 135 for protozoa. As an example of conventional identification methods, mention can be made of the determination of the biological profile, by using the Vitek 2 (bioMérieux) identification cards, for example, or even by using molecular biology techniques with identification criteria based on the study of the presence of certain genes, and on the study of their sequence.
Identification can be performed directly from the sample in which the identification is made, or the microorganisms contained in the sample can be cultured using methods well known to the person skilled in the art with optimal culture media and culturing conditions tailored to the species of microorganisms to be sought, as described by Murray P. R. et al. in Manual of Clinical Microbiology, 2007, 9th edition, Vol. I, Section III, chapter 14, and in particular in Vol. I, Section IV, chapter 21 for bacteria, and Vol. II, Section VI, chapter 81 for viruses, Vol. II, Section VIII, chapter 117 for yeasts, and Vol. II, Section X, chapter 134 for protozoa.
Thus, generally, in the case of an identification using a biochemical method of a bacterium in a specimen, it is first necessary to obtain it in a pure culture, for example after seeding on agar. Molecular biology (PCR) can in certain cases be applied directly to the sample to be analysed.
Instead of cultivating the microorganisms, they can be concentrated by capture directly in the sample by means of active surfaces. Such a method was described by W.-J. Chen et al. [10] who captured different bacterial species with the aid of magnetic beads with an Fe3O4/TiO2-activated surface. Capture by other means is also possible, such as a capture by lectins [23], or by antibodies [24], or by Vancomycin [25]. The capture makes it possible to concentrate the microorganisms and thus to reduce or even eliminate the culture step. This results in a considerable time saving.
The identification may also be performed by mass spectrometry, in accordance with the techniques described previously, preferably by MS, by MS/MS, or even by MS followed by MS/MS spectrometry, which constitutes one embodiment of the invention. In this case too, the sample can be subjected to a culture step beforehand, such as seeding on agar.
The use of an MS identification method is advantageous in that it may be carried out in a few minutes, and in that it requires a mass spectrometer with a single analyser, i.e. a less complex instrument than a tandem mass spectrometer used in MS/MS.
The use of a method of identification by MS followed by MS/MS spectrometry is also advantageous. It makes it possible to check the identity of the ions observed by MS, which increases the specificity of the analysis.
The use of an MRM-type MS/MS identification method has the advantage of being more sensitive and simpler than the conventional MS followed by MS/MS approaches. This method requires neither a high-performance software to process the information between the acquisition of the MS spectrum and of the MS/MS spectrum, nor a change in the setting of the machine parameters for linking up MS then MS/MS spectra.
The method of identification by MS may be employed with an electrospray source on a raw sample, as described by S. Vaidyanathan et al. [26] or by R. Everley et al. [27] after chromatographic separation. Different m/z ranges thus make it possible to identify the microorganisms. S. Vaidyanathan et al. used a window of between 200 and 2000 Th, and R. Everley et al. used a window of between 620 and 2450 Th. The mass spectra may also be deconvoluted to access the mass of the proteins independently of their charge state. R. Everley et al. therefore used masses of between about 5,000 and 50,000 Da. Alternatively, the method of identification by MS can also be employed with the aid of a MALDI-TOF, as described by Claydon et al. [3] and T. Krishnamurthy and P. Ross [4]. The analysis combines acquisition of a mass spectrum and interpretation of expert software. It is extremely simple and can be carried out in a few minutes. This method of identification is currently becoming more widespread in medical analysis laboratories [28].
The identification of bacteria by MS followed by MS/MS via their proteins present in the sample has been applied widely by a number of teams. By way of example, mention can be made of the recent work of Manes N. et al. [29], who studied the peptidome of Salmonella enterica, or the work of R. Nandakumar et al. [30] or of L. Hernychova et al. [31] who have studied the proteome of bacteria after digestion of the proteins with trypsin. The conventional approach consists in i) acquiring an MS spectrum, ii) successively selecting each precursor ion observed on the MS spectrum with an intense signal, iii) successively fragmenting each precursor ion and acquiring its MS/MS spectrum, iv) interrogating protein databases such as SWISS-PROT or NCBI, through software such as Mascot (Matrix Science, London, United Kingdom) or SEQUEST (Thermo Scientific, Waltham, United States of America), to identify the peptide which has a strong probability of matching the MS/MS spectrum observed. This method may lead to the identification of a microorganism if a protein or a peptide characteristic of the species is identified.
One of the advantages of the use of mass spectrometry lies in that it is particularly useful for quantifying molecules, in the present case the markers of the mechanisms of bacterial resistance to beta-lactams. To this end, the current intensity detected is used, which is proportional to the quantity of target molecule. The current intensity thus measured may serve as a quantitative measurement making it possible to determine the quantity of target molecule present, which is characterised by its expression in International System (SI) mol/m3 or kg/m3 units, or by multiples or sub-multiples of these units, or by the usual derivatives of the SI units, including multiples or sub-multiples thereof. As a non-limiting example, the units such as ng/ml or fmol/l are units characterising a quantitative measurement.
A calibration is nevertheless necessary in order to be able to correlate the measured area of the peak, which corresponds to the current intensity induced by the detected ions, to the quantity of target molecule to be assayed. For this purpose, the calibrations conventionally used in mass spectrometry may be employed, within the framework of the invention. MRM assays are conventionally calibrated with the aid of external standards or, preferably, with the aid of internal standards such as described by T. Fortin et al. [13]. If the target molecule is a proteotypic peptide which permits the assaying of a protein of interest, the correlation between the quantitative measurement and the quantity of target proteotypic peptide, and subsequently of protein of interest, is obtained by calibrating the measured signal relative to a standard signal for which the quantity to be assayed is known. The calibration may be performed using a calibration curve, for example obtained by successive injections of standard proteotypic peptide at different concentrations (external calibration), or preferably by internal calibration using a heavy peptide as an internal standard, for example in accordance with the AQUA, QconCAT or PSAQ methods detailed below. “Heavy peptide” is understood to mean a peptide corresponding to the proteotypic peptide, but in which one or more atoms of carbon 12 (12C) is (are) replaced by carbon 13 (13C), and/or one or more atoms of nitrogen 14 (14N) is (are) replaced by nitrogen 15 (15N).
The use of heavy peptides as internal standards (AQUA) was also proposed in US patent application 2004/0229283. The principle is to artificially synthesise proteotypic peptides with amino acids containing isotopes which are heavier than the usual natural isotopes. Such amino acids are obtained, for example, by replacing some of the atoms of carbon 12 (12C) with carbon 13 (13C), or by replacing some of the atoms of nitrogen 14 (14N) with nitrogen 15 (15N). The artificial peptide (AQUA) thus synthesised has strictly the same physicochemical properties as the natural peptide (with the exception of a higher mass). It is generally added, at a given concentration, to the sample, upstream of assaying by mass spectroscopy, for example between the treatment entailing the cleaving of the proteins in the sample of interest and the fractionation of the peptides obtained after the treatment step. Thus, the AQUA peptide is co-purified with the natural peptide to be assayed, during fractionation of the peptides. The two peptides are therefore injected simultaneously into the mass spectrometer, for assaying. They then undergo the same ionisation yield in the source. The comparison of the peak areas of the natural and AQUA peptides, whose concentration is known, makes it possible to calculate the concentration of the natural peptide and thus the concentration of the protein to be assayed. A variation of the AQUA technique was proposed by J.-M. Pratt et al. [32] under the name QconCat. This variant is also described in patent application WO 2006/128492. It consists in concatenating various AQUA peptides and producing the artificial polypeptide in the form of a heavy recombinant protein. The recombinant protein is synthesised with amino acids comprising heavy isotopes. In this way, it is possible to obtain a standard to calibrate the simultaneous assay of several proteins at lower cost. The QconCAT standard is added from the start, upstream of the treatment entailing the cleaving of the proteins and prior to the steps of protein fractionation, denaturation, reduction and blocking of the protein thiol functions, if these are present. The QconCAT standard therefore undergoes the same treatment cycle entailing the cleaving of the proteins as the natural protein, which makes it possible to take account of the yield from the treatment step which entails the cleaving of the proteins. In fact, the treatment, particularly by digestion, of the natural protein may not be complete. In this case, the use of an AQUA standard would lead to underestimating the quantity of natural protein. For full assaying, it may therefore be important to take into account the yields from treatment which entails the cleaving of the proteins. However, V. Brun et al. [33] have shown that the QconQAT standards sometimes do not exactly reproduce the treatment yield particularly by digestion of the natural protein, undoubtedly due to a three-dimensional conformation different from the QconCAT protein.
V. Brun et al. [33] then proposed the use of a method dubbed PSAQ, and described in patent application WO 2008/145763. In this case, the internal standard is a recombinant protein having the same sequence as the natural protein but synthesised with heavy amino acids. The synthesis is performed ex-vivo with heavy amino acids. This standard has strictly the same physicochemical properties as the natural protein (with the exception of a higher mass). It is added from the start, before the protein fractionation step, when the latter is present. It is therefore co-purified with the native protein, during the protein fractionation step. It exhibits the same treatment yield, particularly by digestion, as the native protein. The heavy peptide obtained after cleaving is also co-purified with the natural peptide, if a peptide fractionation step is performed. The two peptides are therefore injected simultaneously into the mass spectrometer, to be quantitatively assayed. They then undergo the same ionisation yields in the source. Comparison of the peak areas of the natural and the reference peptides in the PSAQ method makes it possible to calculate the concentration of the protein to be assayed taking into account all of the steps of the assay method.
All of these techniques, namely AQUA, QconCAT or PSAQ or any other calibration technique, used in the mass spectrometry assays and in particular in MRM or MS assays, may be employed to carry out calibration, within the framework of the invention.
Preferably, the mass spectrometry used in the detection method according to the invention is MS/MS. More preferably, the mass spectrometry is MRM.
The method of the invention makes it possible to detect resistances to carbapenems, characterised by the detection of at least one peptide as a resistance marker. Said resistance marker peptide preferably belongs to the proteins NDM, KPC, GES, IMP, IND, SME, VIM or OXA.
In particular, the detection of a mechanism of resistance to carbapenems induced by the expression of an NDM protein is characterised by the detection of at least one peptide belonging to an NDM protein and its different sequence variants SEQ ID No. 1 and SEQ ID No. 1078 to SEQ ID No. 1080.







SEQ ID No. 1:


MELPNIMHPVAKLSTALAAALMLSGCMPGEIRPTIGQQMETGDQRFGDLV


 


FRQLAPNVWQHTSYLDMPGFGAVASNGLIVRDGGRVLVVDTAWTDDQTAQ


 


ILNWIKQEINLPVALAVVTHAHQDKMGGMDALHAAGIATYANALSNQLAP


 


QEGMVAAQHSLTFAANGWVEPATAPNFGPLKVFYPGPGHTSDNITVGIDG


 


TDIAFGGCLIKDSKAKSLGNLGDADTEHYAASARAFGAAFPKASMIVMSH


 


SAPDSRAAITHTARMADKLR


 


SEQ ID No. 1078


MELPNIMHPVAKLSTALAAALMLSGCMAGEIRPTIGQQMETGDQRFGDLV


 


FRQLAPNVWQHTSYLDMPGFGAVASNGLIVRDGGRVLVVDTAWTDDQTAQ


 


ILNWIKQEINLPVALAVVTHAHQDKMGGMDALHAAGIATYANALSNQLAP


 


QEGMVAAQHSLTFAANGWVEPATAPNFGPLKVFYPGPGHTSDNITVGIDG


 


TDIAFGGCLIKDSKAKSLGNLGDADTEHYAASARAFGAAFPKASMIVMSH


 


SAPDSRAAITHTARMADKLR


 


SEQ ID No. 1079


MELPNIMHPVAKLSTALAAALMLSGCMPGEIRPTIGQQMETGDQRFGDLV


 


FRQLAPNVWQHTSYLDMPGFGAVASNGLIVRDGGRVLLVDTAWTDDQTAQ


 


ILNWIKQEINLPVALAVVTHAHQDKMGGMDALHAAGIATYANALSNQLAP


 


QEGLVAAQHSLTFAANGWVEPATAPNFGPLKVFYPGPGHTSDNITVGIDG


 


TDIAFGGCLIKDSKAKSLGNLGDADTEHYAASARAFGAAFPKASMIVMSH


 


SAPDSRAAITHTARMADKLR


 


SEQ ID No. 1080


MELPNIMHPVAKLSTALAAALMLSGCMPGEIRPTIGQQMETGDQRFGDLV


 


FRQLAPNVWQHTSYLDMPGFGAVASNGLIVRDGGRVLVVDTAWTDDQTAQ


 


ILNWIKQEINLPVALAVVTHAHQDKMGGMDALHAAGIATYANALSNQLAP


 


QEGMVAAQHSLTFAANGWVEPATAPNFGPLKVFYPGPGHTSDNITVGIDG


 


TDIAFGGCLIKDSKAKSLGNLGDADTEHYAASARAFGAAFPKASMIVMSH


 


SAPDSRAAITHTARMADKLR






said peptides being chosen, preferably, from the peptides of sequence SEQ ID No. 2 to SEQ ID No. 9 and SEQ ID No. 1083 as defined hereafter:












Peptide




SEQ ID


No.
Amino acid sequence
Position of the peptide in the NDM protein(s)







SEQ ID
AAITHTAR
257-264 for the proteins of SEQ No. 1, 1078,


No. 2

1079, 1080


 


SEQ ID
AFGAAFPK
235-242 for the proteins of SEQ No. 1, 1078,


No. 3

1079, 1080


 


SEQ ID
ASMIVMSHSAPDSR
243-256 for the proteins of SEQ No. 1, 1078,


No. 4

1079, 1080


 


SEQ ID
FGDLVFR
46-52 for the proteins of SEQ No. 1, 1078,


No. 5

1079, 1080


 


SEQ ID
MELPNIMHPVAK
1-12 for the proteins of SEQ No. 1, 1078, 1079,


No. 6

1080


 


SEQ ID
QEINLPVALAVVTHAHQDK
107-125 for the proteins of SEQ No. 1, 1078,


No. 7

1079, 1080


 


SEQ ID
SLGNLGDADTEHYAASAR
217-234 for the proteins of SEQ No. 1, 1078,


No. 8

1079, 1080


 


SEQ ID
VLVVDTAWTDDQTAQILNWIK
86-106 for the proteins of SEQ No. 1, 1078,


No. 9

1080


 


SEQ ID
LSTALAAALMLSGCMAGEIR
13-32 for the protein of SEQ No. 1078


No. 1081


 


SEQ ID
LSTALAAALMLSGCMPGEIR
13-32 for the protein of SEQ No. 1, 1079, 1080


No. 1082


 


SEQ ID
VLLVDTAWTDDQTAQILNWIK
86-106 for the protein of SEQ No. 1079


No. 1083









Preferably, the resistance markers are NDM markers, chosen from the peptides of sequence SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 5, or SEQ ID No. 7.
The detection of a mechanism of resistance to carbapenems induced by the expression of a KPC protein is characterised by the detection of at least one peptide belonging to a KPC protein and to its different sequence variants SEQ ID No. 10 to SEQ ID No. 19 and SEQ ID No. 1084 to SEQ ID No. 1093.







SEQ ID No. 10:


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 11:


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 12:


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVRWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGGYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 13:


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVRWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 14:


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGGYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 15:


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAID


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 16:


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGGYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 17:


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGAYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLG


 


SEQ ID No. 18:


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVRWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 19:


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVLWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 1084


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGGYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 1085


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGGYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 1086


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 1087


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 1088


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPSDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 1089


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELEMNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 1090


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVRWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 1091


MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMD


 


TGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNA


 


LVRWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAF


 


MRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAA


 


PQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVW


 


PTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ


 


SEQ ID No. 1092


RLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGA


 


TVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWS


 


PISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIG


 


DTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQ


 


FVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGAYGTANDYAVVWPTGRA


 


PIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLG


 


SEQ ID No. 1093


SLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDT


 


GSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNAL


 


VRWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFM


 


RSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAP


 


QRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGGYGTANDYAVVWP


 


TGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ






said peptides being chosen, preferably, from the peptides of sequence SEQ ID No. 20 to SEQ ID No. 33 and SEQ ID No. 1094 to SEQ ID No. 1097 as defined hereafter:












Peptide




SEQ


ID No.
Amino acid sequence
Position of the peptide in the KPC protein(s)







SEQ
AAVPADWAVGDK
221-232 for the protein of SEQ No. 1093; 222-233 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,


20

17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090,




1091, 1092


 


SEQ
APIVLAVYTR
254-263 for the protein of SEQ No. 1093; 255-264 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,


21

17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090,




1091, 1092


 


SEQ
AVTESLQK
183-190 for the protein of SEQ No. 1093; 184-191 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,


22

17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090,




1091, 1092


 


SEQ
ELGGPAGLTAFMR
139-151 for the protein of SEQ No. 1093; 140-152 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,


23

17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090,




1091, 1092


 


SEQ
FPLCSSFK
64-71 for the protein of SEQ No. 1093; 65-72 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,


24

17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090,




1091, 1092


 


SEQ
GFLAAAVLAR
72-81 for the protein of SEQ No. 1093; 73-82 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,


25

17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090,




1091, 1092


 


SEQ
GNTTGNHR
211-218 for the protein of SEQ No. 1093; 212-219 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,


26

17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090,




1091, 1092


 


SEQ
LALEGLGVNGQ
282-292 for the protein of SEQ No. 1093; 283-293 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,


27

18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091


 


SEQ
LTLGSALAAPQR
191-202 for the protein of SEQ No. 1093; 192-203 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,


28

17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090,




1091, 1092


 


SEQ
NALVPWSPISEK
94-105 for the protein of SEQ No. 1092; 99-110 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 14, 15, 16, 17,


29

1084, 1085, 1086, 1087, 1088, 1089


 


SEQ
QQFVDWLK
203-210 for the protein of SEQ No. 1093; 204-211 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,


30

17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090,




1091, 1092


 


SEQ
SIGDTTFR
152-159 for the protein of SEQ No. 1093; 153-160 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,


31

17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090,




1091, 1092


 


SEQ
SQQQAGLLDTPIR
82-94 for the protein of SEQ No. 1093; 83-95 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,


32

17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090,




1091, 1092


 


SEQ
WELELNSAIPGDAR
163-176 for the protein of SEQ No. 1093; 164-177 for the


ID No.

proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,


33

17, 18, 19, 1084, 1085, 1086, 1087, 1090, 1091, 1092


 


SEQ
NALVR
98-102 for the proteins of SEQ No. 1093; 99-103 for the


ID No.

proteins of sequence SEQ ID No. 12, 13, 18, 1090, 1091


1094


 


SEQ
TGTCGAYGTANDYAVVWPTGR
229-249 for the protein of SEQ No. 1092; 234-254 for the


ID No.

protein of sequence SEQ ID No. 17


1095


 


SEQ
WELELNSAIPSDAR
164-177 for the protein of SEQ No. 1088


ID No.


1096


 


SEQ
WELEMNSAIPGDAR
164-177 for the protein of SEQ No. 1089


ID No.


1097









Preferably, the resistance markers are KPC markers, chosen from the peptides of sequence SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 23, SEQ ID No. 25, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 31, or SEQ ID No. 32.
The detection of a mechanism of resistance to carbapenems and/or to cephalosporins induced by the expression of a GES protein is characterised by the detection of at least one peptide belonging to a GES protein and to its different sequence variants SEQ ID No. 34 to SEQ ID No. 50.







SEQ ID No. 34:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 35:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVKWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 36:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWS


 


PATERFLASGHMTVLEAAQLAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 37:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMNDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 38:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMSDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 39:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVKWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMSDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 40:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGSRNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 41:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGARNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 42:


MRFIHALLLAGTAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRTAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWS


 


PATERFLASGHMTVLEAAQAAVQLCDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 43:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVKWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMNDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 44:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKESEMSDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 45:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMSDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGARNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 46:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAEIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMSDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 47:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVKWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGARNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 48:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRTAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVKWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 49:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRTAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVKWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMSDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK


 


SEQ ID No. 50:


MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEI


 


VAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWS


 


PATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKI


 


GDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTH


 


TIERWLIGNQTGDATLRAGFPKDWVVGEKTGACANGARNDIGFFKAQERD


 


YAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK






said peptides being chosen, preferably, from the peptides of sequence SEQ ID No. 51 to SEQ ID No. 79 as defined hereafter:













Peptide





SEQ ID


Clinical


No.
Amino acid sequence
Position of the peptide in the GES protein(s)
interest







SEQ ID
AAEIGVAIVDPQGEIVAGHR
36-55 for the protein of SEQ No. 46
carba


No. 51


 


SEQ ID
AAQIGVAIVDPQGEIVAGHR
36-55 for the proteins of SEQ No. 34, 35, 36, 37, 38,
ESBL


No. 52

39, 40, 41, 42, 43, 44, 45, 47, 48, 49, 50


 


SEQ ID
AGFPK
218-222 for the proteins of SEQ No. 34, 35, 36, 37,
ESBL


No. 53

38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
DTTTPIAMAR
174-183 for the proteins of SEQ No. 34, 35, 36, 37,
ESBL


No. 54

38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
DWVVGEK
223-229 for the proteins of SEQ No. 34, 35, 36, 37,
ESBL


No. 55

38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
DYAVAVYTTAPK
250-261 for the proteins of SEQ No. 34, 35, 36, 37,
ESBL


No. 56

38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
EIGGPAAMTQYFR
136-148 for the proteins of SEQ No. 34, 35, 36, 37,
ESBL


No. 57

38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
EPEMGDNTPGDLR
161-173 for the proteins of SEQ No. 34, 35, 36, 40,
ESBL


No. 58

41, 42, 47, 48, 50


 


SEQ ID
EPEMNDNTPGDLR
161-173 for the proteins of SEQ No. 37, 43
carba


No. 59


 


SEQ ID
EPEMSDNTPGDLR
161-173 for the proteins of SEQ No. 38, 39, 45, 46,
carba


No. 60

49


 


SEQ ID
ESEMSDNTPGDLR
161-173 for the protein of SEQ No. 44
carba


No. 61


 


SEQ ID
FAMCSTFK
60-67 for the proteins of SEQ No. 34, 35, 36, 37, 38,
ESBL


No. 62

39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
FIHALLLAGTAHSAYASEK
3-21 for the proteins of SEQ No. 34, 35, 36, 37, 38,
ESBL


No. 63

39, 40, 41, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
FIHALLLAGTAHSAYASEK
3-21 for the protein of SEQ No. 42
carba


No. 64


 


SEQ ID
FPLAALVFER
68-77 for the proteins of SEQ No. 34, 35, 36, 37, 38,
ESBL


No. 65

39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
IDSGTER
78-84 for the proteins of SEQ No. 34, 35, 36, 37, 38,
ESBL


No. 66

39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
IGDSVSR
150-156 for the proteins of SEQ No. 34, 35, 36, 37,
ESBL


No. 67

38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
LSAVER
262-267 for the proteins of SEQ No. 34, 35, 36, 37,
ESBL


No. 68

38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
LSYGPDMIVEWSPATER
89-105 for the proteins of SEQ No. 34, 36, 37, 38,
ESBL


No. 69

40, 41, 42, 44, 45, 46, 50


 


SEQ ID
LSYGPDMIVK
89-98 for the proteins of SEQ No. 35, 39, 43, 47, 48,
carba


No. 70

49


 


SEQ ID
NDIGFEK
239-245 for the proteins of SEQ No. 34, 35, 36, 37,
ESBL


No. 71

38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
TDLEK
26-30 for the proteins of SEQ No. 34, 35, 36, 37, 38,
ESBL


No. 72

39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
TGACANGAR
230-238 for the protein of SEQ No. 50
carba


No. 73


 


SEQ ID
TGTCANGAR
230-238 for the proteins of SEQ No. 41, 45, 47
carba


No. 74


 


SEQ ID
TGTCANGGR
230-238 for the proteins of SEQ No. 34, 35, 36, 37,
ESBL


No. 75

38, 39, 42, 43, 44, 46, 48, 49


 


SEQ ID
TGTCANGSR
230-238 for the protein of SEQ No. 40
carba


No. 76


 


SEQ ID
VLYGGALTSTSTHTIER
188-204 for the proteins of SEQ No. 34, 35, 36, 37,
ESBL


No. 77

38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
WLIGNQTGDATLR
205-217 for the proteins of SEQ No. 34, 35, 36, 37,
ESBL


No. 78

38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50


 


SEQ ID
WSPATER
99-105 for the proteins of SEQ No. 34, 35, 36, 37,
carba


No. 79

38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50









In the clinical interest column, the ESBL and carba entries correspond to the GES beta-lactamase activities which the corresponding peptide makes it possible to detect. Therefore, the detection of a carba peptide will indicate the presence of a carbapenemase beta-lactamase capable of hydrolysing carbapenems.
If no peptide referred to as carba is detected, the detection of a peptide referred to as ESBL will indicate the presence of a beta-lactamase with an extended spectrum (ESBL) capable of hydrolysing penicillins, first-generation cephalosporins such as cephaloridine and cefalotin, and at least one antibiotic from the oxyimino-beta-lactam class such as cefotaxime, ceftazidime or monobactams such as aztreonam.
The detection of a mechanism of resistance to carbapenems induced by a GES protein is thus characterised by the detection of at least one resistance-marking carba peptide chosen from the sequences SEQ ID No. 51, 59, 60, 61, 64, 70, 73, 74, 76, 79.
The detection of a mechanism of resistance to carbapenems induced by the expression of an IMP protein is characterised by the detection of at least one peptide belonging to an IMP protein and to its different sequence variants SEQ ID No. 80 to SEQ ID No. 105.







SEQ ID No. 80:


MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFEEVNGVVGVV


 


PKHGLVVLVNAEAYLIDTPFTAKDTEKLVTWFVERGYKIKGSISSHFHSD


 


STGGIEWLNSRSIPTYASELTNELLKKDGKVQATNSFSGVNYWLVKNKIE


 


VFYPGPGHTPDNVVVWLPERKILFGGCFIKPYGLGNLGDANIEAWPKSAK


 


LLKSKYGKAKLWPSHSEVGDASLLKLTLEQAVKGLNESKKPSKPSN


 


SEQ ID No. 81:


MKKLSVFFMFLFCSIAASGEALPDLKIEKLDEGVYVHTSFEEVNGWGWPK


 


HGLVVLVNTDAYLIDTPFTAKDTEKLVTVVFVERGYKIKGSISSHFHSDS


 


TGGIEWLNSOSIPTYASELTNELLKKDGKVQAKNSFSGASYVVLVKKKIE


 


IFYPGPGHTPDNVVVWLPEHRVLFGGCFVKPYGLGNLGDANLEAWPKSAK


 


LLVSKYGKAKLVVPSHSEVGDASLLKRTLEQAVKGLNESKKLSKPSN


 


SEQ ID No. 82:


MSKLSVFFIFLFCSIATAAEPLPDLKIEKLDEGVYVHTSFEEVNGWGVVP


 


KHGLVVLVDAEAYLIDTPFTAKDTEKLVTWFVERGYKIKGSISSHFHSDS


 


TGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFGGVNYVVLVKNKIE


 


VFYPGPGHTPDNLVVWLPERKILFGGCFIKPYGLGNLGDANLEAWPKSAK


 


LLISKYGKAKLVVPSHSEAGDASLLKLTLEQAVKGLNESKKPSKLSN


 


SEQ ID No. 83:


MKKLFVLCVCFLCSITAAGAALPDLKIEKLEEGVYVHTSFEEVNGWGVVS


 


KHGLVVLVNTDAYLIDTPFTATDTEKLVNWFVERGYKIKGTISSHFHSDS


 


TGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFSGVSYWLVKNKIEV


 


FYPGPGHTQDNVVVVVLPEKKILFGGCFVKPDGLGNLGDANLEAWPKSAK


 


ILMSKYGKAKLVVSSHSEIGDASLLKRTWEQAVKGLNESKKPSQPSN


 


SEQ ID No. 84:


MSKLFVFFMFLFCSITAAAESLPDLKIEKLDEGVYVHTSFEEVNGWGWPK


 


HGLVVLVNTEAYLIDTPFTAKDTEKLVTWFVERGYKIKGSISSHFHSDST


 


GGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFSGASYVVLVKKKIEV


 


FYPGPGHTPDNVVVWLPENRVLFGGCFVKPYGLGNLGDANVEAWPKSAKL


 


LMSKYGKAKLVVPSHSEVGDASLLKRTLEQAVKGLNESKKPSKPSN


 


SEQ ID No. 85:


MSKLFVFFMFLFCSITAAGESLPDLKIEKLDEGVYVHTSFEEVNGWGVIP


 


KHGLVVLVNTDAYLIDTPFTAKDTENLVNWFVERGYRIKGSISSHFHSDS


 


TGGIEWLNSQSIPTYASELTNELLKKDGKVQAKYSFSGVSYVVLVKKKIE


 


VFYPGPGHAPDNVVVWLPENRVLFGGCFVKPYGLGNLGDANLEAWPKSAK


 


LLMSKYSKAKLWPSHSDIGDSSLLKLTVVEQTVKGFNESKKSTTAH


 


SEQ ID No. 86:


MKKLFVLCVFFFCNIAVAEESLPDLKIEKLEEGVYVHTSFEEVKGWSVVT


 


KHGLVVLVKNDAYLIDTPITAKDTEKLVNWFVERGYKIKGSISTHFHGDS


 


TAGIEVVLNSQSIPTYASELTNELLKKDNKVQAKHSFNGVSYSLIKNKIE


 


VFYPGPGHTQDNVVVWLPEKKILFGGCFVKPDGLGYLGDANLEAINPKSA


 


KILMSKYGKAKLVVSSHSDIGDVSLLKRTVVEQAVKGLNESKKSSQPSD


 


SEQ ID No. 87:


MNKLSVFFMFMFCSITAAGESLPDLKIEKLDEGVYVHTSFEEVNGVVGVV


 


PKHGLVVLVNTEAYLIDTPFTAKDTEKLVTINFVERGYKIKGSISSHFHS


 


DSTGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFSGGSYINLVNNK


 


IEVFYPGPGHTPDNVVVVVLPENRVLFGGCFVKPYGLGNLGDANLEAWPK


 


SAKILMSKYGKAKLVVSSHSETGNASLLKLTWEQAVKGLKESKKPSLPSN


 


SEQ ID No. 88:


MKKLFVLCVFFLCNIAAADDSLPDLKIEKLEKGVYVHTSFEEVKGWGVVT


 


KHGLVVLVKNDAYLIDTPITAKDTEKLVNINFIEHGYRIKGSISTHFHGD


 


STAGIEWLNSQSISTYASELTNELLKKDNKVQATNSFSGVSYSLIKNKIE


 


VFYPGPGHTQDNVVVVVLPEKKILFGGCFVKPDGLGNLGDANLEAWPKSA


 


KILMSKYGKAKLVVSSHSEIGNASLLQRTVVEQAVKGLNESKKPLQPSS


 


SEQ ID No. 89:


MKKLFVLCVFLFCSITAAGESLPDLKIEKLEEGVYVHTSFEEVNGWGVVS


 


KHGLVILVNTDAYLIDTPFTAKDTEKLVTVVFVERGYKIKGSISSHFHSD


 


STGGIEWLNSQSIPTYASELTNDLLKQNGKVQAKNSFSGVSYVVLVKNKI


 


EVFYPGPGHTQDNVVVINLPEKKILFGGCFVKPYGLGNLDDANVVAWPHS


 


AEILMSRYGNAKLVVPSHSDIGDASLLKLTWEQAVKGLKESKKPSEPSN


 


SEQ ID No. 90:


MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFKEVNGWGVVP


 


KHGLVVLVNAEAYLIDTPFTAKDTEKLVTVVFVERGYKIKGSISSHFHSD


 


STGGIEWLNSRSIPTYASELTNELLKKDGKVQATNSFSGVNYVVLVKNKI


 


EVFYPGPGHTPDNVWVVLPERKILFGGCFIKPYGLGNLGDANIEAWPKSA


 


KLLKSKYGKAKLVVPSHSEVGDASLLKLTLEQAVKGLNESKKPSKPSN


 


SEQ ID No. 91:


MKKLFVLCVCFLCSITAAGAALPDLKIEKLEEGVYVHTSFEEVNGWGVVS


 


KHGLVVLVNTDAYLIDTPFTATDTEKLVNWFVERGYKIKGTISSHFHSDS


 


TGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFSGVSYVVLVKNKIE


 


VFYPGPGHTQDNVVVWLPEKKILFGGCFVKPDGLGNLGDANLEAWPKSAK


 


ILMSKYVKAKLVVSSHSEIGDASLLKRTWEQAVKGLNESKKPSQPSN


 


SEQ ID No. 92:


MKKLFVLCVCFLCSITAAGAALPDLKIEKLEEGVYVHTSFEEVNGWGWSK


 


HGLVVLVNTDAYLIDTPFTATDTEKLVNWFVERGYKIKGTISSHFHSDST


 


GGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFSGVSYWLVKNKIEVF


 


YPGPGHTQDNVVVWLPEKKILFGGCFVKPDGLGNLGDANLEAWPKSAKIL


 


MSKYGKAKLVVSSHSEIGDASLLKRTWEQAVKGLNESRKPSQPSN


 


SEQ ID No. 93:


MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFEEVNGWGVVP


 


KHGLVVLVNAEAYLIDTPFTAKDTEKLVTVVFVERGYKIKGSISSHFHSD


 


STGGIEWLNSRSIPTYASELTNELLKKDGKVQATNSFSGVNYVVLVKNKI


 


EVFYPGPGHTPDNVVVWLPERKILFGGCFlKPYGLGNLSDANIEAWPKSA


 


KLLKSKYGKAKLVVPGHSEVGDASLLKLTLEQAVKGLNESKKPSKPSN


 


SEQ ID No. 94:


MSKLSVFFIFLFCSIATAAEPLPDLKIEKLDEGVYVHTSFEEVNGWGVFP


 


KHGLVVLVDAEAYLIDTPFTAKDTEKLVIVVFVERGYKIKGSISSHFHSD


 


STGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFGGVNYWLVKNKIE


 


VFYPGPGHTPDNLVVVVLPERKILFGGCFIKPYGLGNLGDANLEAWPKSA


 


KLLISKYGKAKLVVPSHSEAGDASLLKLTLEQAVKGLNESKKPSKLSN


 


SEQ ID No. 95:


MKKLFVLCVFVFCSITVAGETLPNLRVEKLEEGVYVHTSYEEVKGWGVVT


 


KHGLVVLIGADAYLIDTPFTAKDTEKLVNWFVERGYKIKGTVSSHFHSDS


 


TGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFDGVSYVVLAKDKIE


 


VFYPGPGHTQDNVVVWLPEKEILFGGCFVKPHGLGNLGDANLEAWPESAK


 


ILMEKYGKAKLVVSGHSETGDATHLKRTWEQAVKGLKESKKTLQPSN


 


SEQ ID No. 96:


MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFEEVNGWGVVP


 


KHGLVVLVNAEAYLIDTPFTAKDTEKLVTWFVERGYKIKGSISSHFHSDS


 


TGGIGWLNSRSIPTYASELTNELLKKDGKVQATNSFSGVNYWLVKNKIEV


 


FYPGPGHTPDNVVVWLPERKILFGGCFIKPYGLGNLGDANIEAWPKSAKL


 


LKSKYGKAKLVVPGHSEVGDASLLKLTLEQAVKGLNESKKPSKPSN


 


SEQ ID No. 97:


MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFEEVNGWGVVP


 


KHGLVVLVNAEAYLIDTPFTAKDTEKLVIWFVERGYKIKGSISSHFHSDS


 


TGGIEWLNSRSIPTYASELTNELLKKDGKVQATNSFSGVNYWLVKNKIEV


 


FYPGPGHTPDNVVVVVLPERKILFGGCFIKPYGLGNLGDANIEAWPKSAK


 


LLKSKYGKAKLVVPGHSEVGDASLLKLTLEQAVKGLNESKKPSKPSN


 


SEQ ID No. 98:


MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFEEVNGWGVFP


 


KHGLVVLVNAEAYLIDTPFTAKDTEKLVTVVFVERGYKIKGSISSHFHSD


 


STGGIEWLNSRSIPTYASELTNELLKKDGKVQATNSFSGVNYVVLVKNKI


 


EVFYPGPGHTPDNVVINVLPERKILFGGCFIKPYGLGNLGDANIEAWPKS


 


AKLLKSKYGKAKLVVPSHSEVGDASLLKLTLEQAVKGLNESKKPSKPSN


 


SEQ ID No. 99:


MKKLFVLCIFLFCSITAAGASLPDLKIEKLEEGVYVHTSFEEVNGWGVVS


 


KHGLVVLVNTDAYLIDTPFTAKDTEKLVNWFVERGYKIKGSISSHFHSDS


 


TGGIEWLNSQSIPTYASVLTNELLKKDGKVQAKNSFSGVSYWLVKNKIEV


 


FYPGPGHTQDNVVVWLPKNKILFGGCFVKPYGLGNLDDANVEAWPHSAEK


 


LISKYGNAKLVVPSHSDIGDASLLKLIVVEQAVKGLNESKKSNTVH


 


SEQ ID No. 100:


MKKLFVLCVCFLCSITAAGAALPDLKIEKLEEGVYVHTSFEEVNGWGVFS


 


KHGLVVLVNTDAYLIDTPFTATDTEKLVNWFVERGYKIKGTISSHFHSDS


 


TGGIEINLNSQSIPTYASELTNELLKKDGKVQAKNSFSGVSYVVLVKNKI


 


EVFYPGPGHTQDNVVVVVLPEKKILFGGCFVKPDGLGNLGDANLEAVVPK


 


SAKILMSKYVKAKLVVSSHSEIGDASLLKRTVVEQAVKGLNESKKPSQPS


 


N


 


SEQ ID No. 101:


MKKLFVLCIFLFCSITAAGASLPDLKIEKLEEGVYVHTSFEEVNGVVGVA


 


SKHGLVVLVNTDAYLIDTPFTAKDTEKLVNVVFVERGYKIKGSISSHFHS


 


DSTGGIEWLNSQSIPTYASVLTNELLKKDGKVQAKNSFSGVSYVVLVKNK


 


IEVFYPGPGHTQDNVVVVVLPKNKILFGGCFVKPYGLGNLDDANVEAINP


 


HSAEKLISKYGNAKLVVPSHSDIGDASLLKLTVVEQAVKGLNESKKSNTV


 


H


SEQ ID No. 102:


MKKLFVLCVCFLCSITAAGARLPDLKIEKLEEGVYVHTSFEEVNGVVGVV


 


SKHGLVVLVNTDAYLIDTPFTATDTEKLVNWFVERGYKIKGTISSHFHSD


 


STGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFSGVSYVVLVKNKI


 


EVFYPGPGHTQDNVVVWLPEKKILFGGCFVKPDGLGNLGDANLEAVVPKS


 


AKILMSKYVKAKLVVSSHSEIGDASLLKRTVVEQAVKGLNESKKPSQPSN


 


SEQ ID No. 103:


MKKLFVLCIFLFLSITASGEVLPDLKIEKLEEGVYLHTSFEEVSGINGVV


 


TKHGLVVLVNNDAYLIDTPFTNKDTEKLVAWFVGRGFTIKGSVSSHFHSD


 


STGGIEWLNSQSIPTYASELTNELLKKNGKVQATNSFSGVSYWLVKNKIE


 


IFYPGPGHTQDNVVVVVLPENKILFGGCFVKPDGLGNLDDANLKAWPKSA


 


KILMSKYGKAKLWSGHSEIGNASLLKLTWEQAVKGLKESKKPLLPSN


 


SEQ ID No. 104:


MKKLFVLCVCFFCSITAAGAALPDLKIEKLEEGVFVHTSFEEVNGWGVVT


 


KHGLWLVNTDAYLIDTPFTATDTEKLVNWFVERGYEIKGTISSHFHSDST


 


GGIEWLNSQSIPTYASELTNELLKKSGKVQAKYSFSEVSYVVLVKNKIEV


 


FYPGPGHTQDNLVVVVLPESKILFGGCFIKPHGLGNLGDANLEAWPKSAK


 


ILMSKYGKAKLVVSSHSEKGDASLMKRTWEQALKGLKESKKTSSPSN


 


SEQ ID No. 105:


MKKLFVLCIFLFCSITAAGESLPDLKIEKLEDGVYVHTSFEEVNGWGVVT


 


KHGLVFLVNTDAYLIDTPFAAKDTEKLVNWFVERGYKIKGSISSHFHSDS


 


SGGIEWLNSQSIPTYASELTNELLKKNGKVQAKNSFSGVSYWLLKNKIEI


 


FYPGPGHTQDNVVVWLPEKKILFGGCFVKPYGLGNLDDANVEAWPHSAEI


 


LMSRYGNAKLVVPSHSDVGDASLLKLTANEQAVKGLKESKKPSQPSN






said peptides being chosen, preferably, from the peptides of sequence SEQ ID No. 106, SEQ ID No. 108 to SEQ ID No. 130, SEQ ID No. 133 to SEQ ID No. 173, SEQ ID No. 175 to SEQ ID No. 180, as defined hereafter:












Peptide




SEQ ID

Position of the peptide in the IMP


No.
Amino acid sequence
protein(s)







SEQ ID
DTENLVNWFVER
73-84 for the protein of SEQ No. 85


No. 106


 


SEQ ID
EILFGGCFVK
170-179 for the protein of SEQ No. 95


No. 107


 


SEQ ID
EVNGWGVVPK
42-51 for the proteins of SEQ No. 80, 81,


No. 108

82, 84, 87, 90, 93, 96, 97


 


SEQ ID
GDASLMK
219-225 for the protein of SEQ No. 104


No. 109


 


SEQ ID
GFNESK
234-239 for the protein of SEQ No. 85


No. 110


 


SEQ ID
GFTIK
85-89 for the protein of SEQ No. 103


No. 111


 


SEQ ID
GLNESK
234-239 for the proteins of SEQ No. 80, 81,


No. 112

82, 83, 84, 86, 88, 90, 91, 93, 94, 96, 97, 98,




99, 100, 101, 102


 


SEQ ID
GLNESR
234-239 for the protein of SEQ No. 92


No. 113


 


SEQ ID
GSISSHFHSDSTGGIEWLNSR
90-110 for the proteins of SEQ No. 80, 90,


No. 114

93, 97, 98


 


SEQ ID
GSISSHFHSDSTGGIGWLNSR
90-110 for the protein of SEQ No. 96


No. 115


 


SEQ ID
GVYVHTSFEEVK
33-44 for the proteins of SEQ No. 86, 88


No. 116


 


SEQ ID
GWGVVTK
45-51 for the proteins of SEQ No. 88, 95,


No. 117

103, 104, 105


 


SEQ ID
GWSVVTK
45-51 for the protein of SEQ No. 86


No. 118


 


SEQ ID
GYEIK
85-89 for the protein of SEQ No. 104


No. 119


 


SEQ ID
HGLVFLVNTDAYLIDTPFAAK
52-72 for the protein of SEQ No. 105


No. 120


 


SEQ ID
HGLVILVNTDAYLIDTPFTAK
52-72 for the protein of SEQ No. 89


No. 121


 


SEQ ID
HGLVVLIGADAYLIDTPFTAK
52-72 for the protein of SEQ No. 95


No. 122


 


SEQ ID
HGLVVLVDAEAYLIDTPFTAK
52-72 for the proteins of SEQ No. 82, 94


No. 123


 


SEQ ID
HGLVVLVK
52-59 for the proteins of SEQ No. 86, 88


No. 124


 


SEQ ID
HGLVVLVNAEAYLIDTPFTAK
52-72 for the proteins of SEQ No. 80, 90,


No. 125

93, 96, 97, 98


 


SEQ ID
HGLVVLVNNDAYLIDTPFTNK
52-72 for the protein of SEQ No. 103


No. 126


 


SEQ ID
HGLVVLVNTDAYLIDTPFTAK
52-72 for the proteins of SEQ No. 81, 85,


No. 127

99, 101


 


SEQ ID
HGLVVLVNTEAYLIDTPFTAK
52-72 for the proteins of SEQ No. 84, 87


No. 128


 


SEQ ID
HSFNGVSYSLIK
134-145 for the protein of SEQ No. 86


No. 129


 


SEQ ID
IEVFYPGPGHTQDNVVVWLPK
148-168 for the proteins of SEQ No. 99, 101


No. 130


 


SEQ ID
ILFGGCFIK
171-179 for the proteins of SEQ No. 80, 82,


No. 131

90, 93, 94, 96, 97, 98, 104


 


SEQ ID
ILFGGCFVK
171-179 for the proteins of SEQ No. 83, 86,


No. 132

88, 89, 91, 92, 95, 99, 100, 101, 102, 103,




105


 


SEQ ID
ILMEK
200-204 for the protein of SEQ No. 95


No. 133


 


SEQ ID
ILMSK
200-204 for the proteins of SEQ No. 83, 86,


No. 134

87, 88, 91, 92, 100, 102, 103, 104


 


SEQ ID
LDEGVYVHTSFK
30-41 for the protein of SEQ No. 90


No. 135


 


SEQ ID
LEEGVYVHTSFEEVK
30-44 for the protein of SEQ No. 86


No. 136


 


SEQ ID
LEEGVYVHTSYEEVK
30-44 for the protein of SEQ No. 95


No. 137


 


SEQ ID
LFVLCVCFLCSITAAGAR
4-21 for the protein of SEQ No. 102


No. 138


 


SEQ ID
LLISK
200-204 for the proteins of SEQ No. 82, 94


No. 139


 


SEQ ID
LLMSK
200-204 for the proteins of SEQ No. 84, 85


No. 140


 


SEQ ID
LLVSK
200-204 for the protein of SEQ No. 81


No. 141


 


SEQ ID
LPDLK
22-26 for the proteins of SEQ No. 80, 81,


No. 142

82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93,




94, 96, 97, 98, 99, 100, 101, 102, 103, 104,




105


 


SEQ ID
LTLEQAVK
226-233 for the proteins of SEQ No. 80, 82,


No. 143

90, 93, 94, 96, 97, 98


 


SEQ ID
LTWEQAVK
226-233 for the proteins of SEQ No. 87, 89,


No. 144

99, 101, 103, 105


 


SEQ ID
LTWEQTVK
226-233 for the protein of SEQ No. 85


No. 145


 


SEQ ID
LVAWFVGR
77-84 for the protein of SEQ No. 103


No. 146


 


SEQ ID
LVNWFIEHGYR
77-87 for the protein of SEQ No. 88


No. 147


 


SEQ ID
LVNWFVER
77-84 for the proteins of SEQ No. 83, 85,


No. 148

86, 91, 92, 95, 99, 100, 101, 102, 104, 105


 


SEQ ID
LVTWFVER
77-84 for the proteins of SEQ No. 80, 81,


No. 149

82, 84, 87, 89, 90, 93, 94, 96, 97, 98


 


SEQ ID
LVVPGHSEVGDASLLK
210-225 for the proteins of SEQ No. 93, 96,


No. 150

97


 


SEQ ID
LVVPSHSDIGDASLLK
210-225 for the proteins of SEQ No. 89, 99,


No. 151

101


 


SEQ ID
LVVPSHSDIGDSSLLK
210-225 for the protein of SEQ No. 85


No. 152


 


SEQ ID
LVVPSHSDVGDASLLK
210-225 for the protein of SEQ No. 105


No. 153


 


SEQ ID
LVVPSHSEAGDASLLK
210-225 for the proteins of SEQ No. 82, 94


No. 154


 


SEQ ID
LVVPSHSEVGDASLLK
210-225 for the proteins of SEQ No. 80, 81,


No. 155

84, 90, 98


 


SEQ ID
LVVSGHSEIGNASLLK
210-225 for the protein of SEQ No. 103


No. 156


 


SEQ ID
LVVSGHSETGDATHLK
210-225 for the protein of SEQ No. 95


No. 157


 


SEQ ID
LVVSSHSDIGDVSLLK
210-225 for the protein of SEQ No. 86


No. 158


 


SEQ ID
LVVSSHSEIGDASLLK
210-225 for the proteins of SEQ No. 83, 91,


No. 159

92, 100, 102


 


SEQ ID
LVVSSHSEIGNASLLQR
210-226 for the protein of SEQ No. 88


No. 160


 


SEQ ID
LVVSSHSEK
210-218 for the protein of SEQ No. 104


No. 161


 


SEQ ID
LVVSSHSETGNASLLK
210-225 for the protein of SEQ No. 87


No. 162


 


SEQ ID
NDAYLIDTPITAK
60-72 for the proteins of SEQ No. 86, 88


No. 163


 


SEQ ID
NSFDGVSYWLAK
134-145 for the protein of SEQ No. 95


No. 164


 


SEQ ID
NSFGGVNYWLVK
134-145 for the proteins of SEQ No. 82, 94


No. 165


 


SEQ ID
NSFSGASYWLVK
134-145 for the proteins of SEQ No. 81, 84


No. 166


 


SEQ ID
NSFSGGSYWLVNNK
134-147 for the protein of SEQ No. 87


No. 167


 


SEQ ID
NSFSGVSYWLLK
134-145 for the protein of SEQ No. 105


No. 168


 


SEQ ID
NSFSGVSYWLVK
134-145 for the proteins of SEQ No. 83, 89,


No. 169

91, 92, 99, 100, 101, 102, 103


 


SEQ ID
SIPTYASELTNELLK
111-125 for the proteins of SEQ No. 80, 81,


No. 170

82, 83, 84, 85, 86, 87, 90, 91, 92, 93, 94, 95,




96, 97, 98, 100, 102, 103, 104, 105


 


SEQ ID
TLEQAVK
227-233 for the proteins of SEQ No. 80, 81,


No. 171

82, 84, 90, 93, 94, 96, 97, 98


 


SEQ ID
TWEQALK
227-233 for the protein of SEQ No. 104


No. 172


 


SEQ ID
TWEQAVK
227-233 for the proteins of SEQ No. 83, 86,


No. 173

87, 88, 89, 91, 92, 95, 99, 100, 101, 102,




103, 105


 


SEQ ID
VLFGGCFVK
171-179 for the proteins of SEQ No. 81, 84,


No. 174

85, 87


 


SEQ ID
VQATNSFSGVNYWLVK
130-145 for the proteins of SEQ No. 80, 90,


No. 175

93, 96, 97, 98


 


SEQ ID
VQATNSFSGVSYSLIK
130-145 for the protein of SEQ No. 88


No. 176


 


SEQ ID
VQATNSFSGVSYWLVK
130-145 for the protein of SEQ No. 103


No. 177


 


SEQ ID
YGNAK
205-209 for the proteins of SEQ No. 89, 99,


No. 178

101, 105


 


SEQ ID
YSFSEVSYWLVK
134-145 for the protein of SEQ No. 104


No. 179


 


SEQ ID
YSFSGVSYWLVK
134-145 for the protein of SEQ No. 85


No. 180









The detection of a mechanism of resistance to carbapenems induced by the expression of the IND protein is characterised by the detection of at least one peptide belonging to the IND protein and to its different sequence variants SEQ ID No. 181 to SEQ ID No. 187.







SEQ ID No. 181:


MKKSIRFFIVSILLSPFASAQVKDFVIEPPIKNNLHIYKTFGVFGGKEYS


 


ANSMYLVTKKGVVLFDVPWEKIQYQSLMDTIKKRHNLPVVAVFATHSHDD


 


RAGDLSFFNNKGIKTYATAKTNEFLKKDGKATSTEIIKTGKPYRIGGEEF


 


VVDFLGEGHTADNVVVWFPKYNVLDGGCLVKSNSATDLGYIKEANVEQWP


 


KTINKLKAKYSKATLIIPGHDEWKGGGHVEHTLELLNKK


 


SEQ ID No. 182:


MKKSIQLLMMSMFLSPLINAQVKDFVIEPPVKPNLYLYKSFGVFGGKEYS


 


ANAVYLTTKKGVVLFDVPWQKEQYQTLMDTIQKRHHLPVIAVFATHSHDD


 


RAGDLSFYNQKGIKTYATAKTNELLKKDGKATSTEIIKTGKPYKIGGEEF


 


MVDFLGEGHTVDNVVVWFPKYKVLDGGCLVKSRTATDLGYTGEANVKQWP


 


ETMRKLKTKYAQATLVIPGHDEWKGGGHVQHTLDLLDKNKKPE


 


SEQ ID No. 183:


MKKSIQLLMMSMFLSPLINAQVKDFVIEPPVKPNLYLYKSFGVFGGKEYS


 


ANAVYLTTKKGWLFDVPWQKEQYQTLMDTIQKRHHLPVIAVFATHSHDDR


 


AGDLSFYNQKGIKTYATAKTNELLKKDGKATSTEIIKTGKPYKIGGEEFM


 


VDFLGEGHTVDNVVVWFPKYKVLDGGCLVKSRTATDLGYTGEANVKQWPE


 


TMRKLKTKYAQATLVIPGHEEWKGGGHVQHTLDLLDKNKKPE


 


SEQ ID No. 184:


MKKRIQFFMVSMMLSSLFSAQVKDFVIEPPIKKNLHIYKTFGVFGGKEYS


 


ANSVYLVTQKGVVLFDVPWEKVQYQSLMDTIQKRHNLPVIAVFATHSHDD


 


RAGDLSFFNNKGIKTYATSKTNEFLKKDGKATSTEIIKTGKPYRIGGEEF


 


VVDFLGEGHTADNVVVWFPKYNVLDGGCLVKSKAATDLGYIKEANVEQWP


 


KTINKLKSKYSKASLVIPGHDEWKGGGHVKHTLELLNKK


 


SEQ ID No. 185:


MRKNVRIFTVLSLFLINFFNAQARDFVIEQPFGKQLYLYKTFGVFDGKEY


 


STNALYLVTKKGVVLFDVPWQKTQYQSLMDTIKKRHNLPVIAVFATHSHS


 


DRAGDLSFYNKKGIPTYATAKTNELLKKEGKATSSKLTKIGKKYKIGGEE


 


FTVDFLGEGHTADNVVVWFPKYNVLDGGCLVKSSAAVDLGYTGEANVEQW


 


PATMKKLQAKYPSTAKVIPGHDEWKGNDHVKHTLELLDQQKQ


 


SEQ ID No. 186:


MKKRIQFFMVSMMLAPMFNAQVKDFVIEPPIKNNLHIYKTFGVFGGKEYS


 


ANSVYLVTKKGVVLFDVPWEKAQYQSLMDTIKKRHNLPVIAVFATHSHDD


 


RAGDLSFFNNKGIKTYATSKTNEFLKKDGKATSTEIIKTGKPYRIGGEEF


 


TVDFLGEGHTADNVVVVVFPKYNVLDGGCLVKSNSATDLGYIKEANVEQW


 


PITIDKLKAKYSKATLIIPGHDDWKGGGHVEHTLELLNKK


 


SEQ ID No. 187:


MKRRIQFFMVSMMLTPLFSAQVKDFVIEPPIKKNLYIYKTFGVFGGKEYS


 


ANSVYLVTKTGVVLFDVPWEKAQYQSLMDTIKKRHNLPVVAVFATHSHDD


 


RAGDLSFFNNKGIKTYATPKTNQFLKRDGKATSTELIKPGKPYRFGGEEF


 


VVDFLGEGHTADNVVVWFPKYKVLDGGCLVKSNSATDLGYIKEANLEQWP


 


KTMHKLKTKYSEAVLIIPGHDEWKGGGHVEHTLELLDKK






said peptides being chosen, preferably, from the peptides of sequence SEQ ID No. 188 to SEQ ID No. 197, SEQ ID No. 200, SEQ ID No. 201, SEQ ID No. 203 to SEQ ID No. 262, as defined hereafter:












Peptide




SEQ ID


No.
Amino acid sequence
Position of the peptide in the IND protein(s)







SEQ ID
AATDLGYIK
184-192 for the protein of SEQ No. 184


No. 188


 


SEQ ID
AGDLSFFNNK
102-111 for the proteins of SEQ No. 181, 184, 186,


No. 189

187


 


SEQ ID
AGDLSFYNK
103-111 for the protein of SEQ No. 185


No. 190


 


SEQ ID
AGDLSFYNQK
102-111 for the proteins of SEQ No. 182, 183


No. 191


 


SEQ ID
AQYQSLMDTIK
72-82 for the proteins of SEQ No. 186, 187


No. 192


 


SEQ ID
ASLVIPGHDEWK
213-224 for the protein of SEQ No. 184


No. 193


 


SEQ ID
ATLIIPGHDDWK
213-224 for the protein of SEQ No. 186


No. 194


 


SEQ ID
ATLIIPGHDEWK
213-224 for the protein of SEQ No. 181


No. 195


 


SEQ ID
ATSSK
132-136 for the protein of SEQ No. 185


No. 196


 


SEQ ID
ATSTEIIK
131-138 for the proteins of SEQ No. 181, 182, 183,


No. 197

184, 186


 


SEQ ID
ATSTELIK
131-138 for the protein of SEQ No. 187


No. 198


 


SEQ ID
ATSTELIKPGK
131-141 for the protein of SEQ No. 187


No. 199


 


SEQ ID
ATSTELIKPGKPYR
131-144 for the protein of SEQ No. 187


No. 200


 


SEQ ID
DFVIEPPIK
24-32 for the proteins of SEQ No. 181, 184, 186, 187


No. 201


 


SEQ ID
DFVIEPPVK
24-32 for the proteins of SEQ No. 182, 183


No. 202


 


SEQ ID
DFVIEPPVKPNLYLYK
24-39 for the proteins of SEQ No. 182, 183


No. 203


 


SEQ ID
DFVIEQPFGK
25-34 for the protein of SEQ No. 185


No. 204


 


SEQ ID
EANLEQWPK
193-201 for the protein of SEQ No. 187


No. 205


 


SEQ ID
EANVEQWPITIDK
193-205 for the protein of SEQ No. 186


No. 206


 


SEQ ID
EANVEQWPK
193-201 for the proteins of SEQ No. 181, 184


No. 207


 


SEQ ID
EQYQTLMDTIQK
72-83 for the proteins of SEQ No. 182, 183


No. 208


 


SEQ ID
EYSANAVYLTTK
48-59 for the proteins of SEQ No. 182, 183


No. 209


 


SEQ ID
EYSANSMYLVTK
48-59 for the protein of SEQ No. 181


No. 210


 


SEQ ID
EYSANSVYLVTK
48-59 for the proteins of SEQ No. 186, 187


No. 211


 


SEQ ID
EYSANSVYLVTQK
48-60 for the protein of SEQ No. 184


No. 212


 


SEQ ID
EYSTNALYLVTK
49-60 for the protein of SEQ No. 185


No. 213


 


SEQ ID
FFIVSILLSPFASAQVK
7-23 for the protein of SEQ No. 181


No. 214


 


SEQ ID
GGGHVEHTLELLDK
225-238 for the protein of SEQ No. 187


No. 215


 


SEQ ID
GGGHVEHTLELLNK
225-238 for the proteins of SEQ No. 181, 186


No. 216


 


SEQ ID
GGGHVK
225-230 for the protein of SEQ No. 184


No. 217


 


SEQ ID
GGGHVQHTLDLLDK
225-238 for the proteins of SEQ No. 182, 183


No. 218


 


SEQ ID
GIPTYATAK
113-121 for the protein of SEQ No. 185


No. 219


 


SEQ ID
GNDHVK
226-231 for the protein of SEQ No. 185


No. 220


 


SEQ ID
GVVLFDVPWEK
61-71 for the proteins of SEQ No. 181, 184, 186, 187


No. 221


 


SEQ ID
GVVLFDVPWQK
62-72 for the protein of SEQ No. 185; 61-71 for the


No. 222

protein of sequence SEQ ID No. 182; 61-71 for the




protein of sequence SEQ ID No. 183


 


SEQ ID
HHLPVIAVFATHSHDDR
85-101 for the proteins of SEQ No. 182, 183


No. 223


 


SEQ ID
HNLPVIAVFATHSHDDR
85-101 for the proteins of SEQ No. 184, 186


No. 224


 


SEQ ID
HNLPVIAVFATHSHSDR
86-102 for the protein of SEQ No. 185


No. 225


 


SEQ ID
HNLPVVAVFATHSHDDR
85-101 for the proteins of SEQ No. 181, 187


No. 226


 


SEQ ID
HTLELLDQQK
232-241 for the protein of SEQ No. 185


No. 227


 


SEQ ID
HTLELLNK
231-238 for the proteins of SEQ No. 181, 184, 186


No. 228


 


SEQ ID
IFTVLSLFLINFFNAQAR
7-24 for the protein of SEQ No. 185


No. 229


 


SEQ ID
IQFFMVSMMLAPMFNAQVK
5-23 for the protein of SEQ No. 186


No. 230


 


SEQ ID
IQFFMVSMMLSSLFSAQVK
5-23 for the protein of SEQ No. 184


No. 231


 


SEQ ID
IQFFMVSMMLTPLFSAQVK
5-23 for the protein of SEQ No. 187


No. 232


 


SEQ ID
IQYQSLMDTIK
72-82 for the protein of SEQ No. 181


No. 233


 


SEQ ID
NLHIYK
34-39 for the proteins of SEQ No. 181, 184, 186


No. 234


 


SEQ ID
NLYIYK
34-39 for the protein of SEQ No. 187


No. 235


 


SEQ ID
NNLHIYK
33-39 for the proteins of SEQ No. 181, 186


No. 236


 


SEQ ID
QLYLYK
35-40 for the protein of SEQ No. 185


No. 237


 


SEQ ID
QWPETMR
198-204 for the proteins of SEQ No. 182, 183


No. 238


 


SEQ ID
SFGVFGGK
40-47 for the proteins of SEQ No. 182, 183


No. 239


 


SEQ ID
SIQLLMMSMFLSPLINAQVK
4-23 for the proteins of SEQ No. 182, 183


No. 240


 


SEQ ID
SNSATDLGYIK
182-192 for the proteins of SEQ No. 181, 186, 187


No. 241


 


SEQ ID
TATDLGYTGEANVK
184-197 for the proteins of SEQ No. 182, 183


No. 242


 


SEQ ID
TFGVFDGK
41-48 for the protein of SEQ No. 185


No. 243


 


SEQ ID
TFGVFGGK
40-47 for the proteins of SEQ No. 181, 184, 186, 187


No. 244


 


SEQ ID
TGKPYK
139-144 for the proteins of SEQ No. 182, 183


No. 245


 


SEQ ID
TGKPYR
139-144 for the proteins of SEQ No. 181, 184, 186


No. 246


 


SEQ ID
TGVVLFDVPWEK
60-71 for the protein of SEQ No. 187


No. 247


 


SEQ ID
TNEFLK
121-126 for the proteins of SEQ No. 181, 184, 186


No. 248


 


SEQ ID
TNELLK
122-127 for the protein of SEQ No. 185; 121-126 for


No. 249

the proteins of sequence SEQ ID No. 182, 183


 


SEQ ID
TNQFLK
121-126 for the protein of SEQ No. 187


No. 250


 


SEQ ID
TQYQSLMDTIK
73-83 for the protein of SEQ No. 185


No. 251


 


SEQ ID
TYATAK
116-121 for the protein of SEQ No. 185; 115-120 for


No. 252

the proteins of sequence SEQ ID No. 181, 182, 183


 


SEQ ID
TYATPK
115-120 for the protein of SEQ No. 187


No. 253


 


SEQ ID
TYATSK
115-120 for the proteins of SEQ No. 184, 186


No. 254


 


SEQ ID
VIPGHDEWK
217-225 for the protein of SEQ No. 185; 216-224 for


No. 255

the protein of sequence SEQ ID No. 182; 216-224 for




the protein of sequence SEQ ID No. 184


 


SEQ ID
VLDGGCLVK
173-181 for the proteins of SEQ No. 181, 182, 183,


No. 256

184, 186, 187; 174-182 for the protein of sequence




SEQ ID No. 185


 


SEQ ID
VQYQSLMDTIQK
72-83 for the protein of SEQ No. 184


No. 257


 


SEQ ID
YAQATLVIPGHDEWK
210-224 for the protein of SEQ No. 182


No. 258


 


SEQ ID
YAQATLVIPGHEEWK
210-224 for the protein of SEQ No. 183


No. 259


 


SEQ ID
YNVLDGGCLVK
171-181 for the proteins of SEQ No. 181, 184, 186;


No. 260

172-182 for the protein of sequence SEQ ID No. 185


 


SEQ ID
YPSTAK
211-216 for the protein of SEQ No. 185


No. 261


 


SEQ ID
YSEAVLIIPGHDEWK
210-224 for the protein of SEQ No. 187


No. 262









The detection of a mechanism of resistance to carbapenems induced by the expression of the SME protein is characterised by the detection of at least one peptide belonging to the SME protein and to its different sequence variants SEQ ID No. 263 to SEQ ID No. 265.







SEQ ID No. 263:


MSNKVNFKTASFLFSVCLALSAFNAHANKSDAAAKQIKKLEEDFDGRIGV


 


FAIDIGSGNIFGYRSDERFPLCSSFKGFLAAAVLERVQQKKLDINQKVKY


 


ESRDLEYHSPITTKYKGSGMTLGDMASAALQYSDNGATNIIMERFLGGPE


 


GMTKFMRSIGDNEFRLDRWELELNTAIPGDKRDTSTPKAVANSLNKLALG


 


NVLNAKEKAIYQNWLKGNITGDARIRASVPADVVVVGDKTGSCGAYGTAN


 


DYAVIWPKNRAPLIVSIYTTRKSKDDKHSDKTIAEASRIAIQAID


 


SEQ ID No. 264:


MSNKVNFKTASFLFSVCLALSAFNAHANKSDAAAKQIKKLEEDFDGRIGV


 


FAIDTGSGNTFGYRSDERFPLCSSFKGFLAAAVLERVQQKKLDINQKVKY


 


ESRDLEYYSPITTKYKGSGMTLGDMASAALQYSDNGATNIIMERFLGGPE


 


GMTKFMRSIGDNEFRLDRWELELNTAIPGDKRDTSTPKAVANSLNKLALG


 


NVLNAKVKAIYQNWLKGNTTGDARIRASVPADWVVGDKTGSCGAYGTAND


 


YAVIWPKNRAPLIVSIYTTRKSKDDKHSDKTIAEASRIAIQAID


 


SEQ ID No. 265:


MSNKVNFKTASFLFSVCLALSAFNAHANKSDAAAKQIKKLEEDFDGRIGV


 


FAIDTGSGNTFGYRSDERFPLCSSFKGFLAAAVLERVQQKKLDINQKVKY


 


ESRDLEYHSPITTKYKGSGMTLGDMASAALQYSDNGATNIIMERFLGGPE


 


GMTKFMRSIGDNEFRLDRWELELNTAIPGDKRDTSTPKAVANSLNKLALG


 


NVLNAKVKAIYQNWLKGNTTGDARIRASVPADVINVGDKTGSCGAIGTAN


 


DYAVIWPKNRAPLIVSIYTTRKSKDDKHSDKTIAEASRIAIQAID






said peptides being chosen, preferably, from the peptides of sequence SEQ ID No. 266 to SEQ ID No. 287 as defined hereafter:












Peptide




SEQ ID

Position of the peptide in the SME


No.
Amino acid sequence
protein(s)







SEQ ID
AIYQNWLK
209-216 for the proteins of SEQ No. 263,


No. 266

264, 265


 


SEQ ID
APLIVSIYTTR
260-270 for the proteins of SEQ No. 263,


No. 267

264, 265


 


SEQ ID
ASVPADWVVGDK
227-238 for the proteins of SEQ No. 263,


No. 268

264, 265


 


SEQ ID
AVANSLNK
189-196 for the proteins of SEQ No. 263,


No. 269

264, 265


 


SEQ ID
DLEYHSPITTK
104-114 for the proteins of SEQ No. 263,


No. 270

265


 


SEQ ID
DLEYYSPITTK
104-114 for the protein of SEQ No. 264


No. 271


 


SEQ ID
DTSTPK
183-188 for the proteins of SEQ No. 263,


No. 272

264, 265


 


SEQ ID
FLGGPEGMTK
145-154 for the proteins of SEQ No. 263,


No. 273

264, 265


 


SEQ ID
GFLAAAVLER
77-86 for the proteins of SEQ No. 263,


No. 274

264, 265


 


SEQ ID
GNTTGDAR
217-224 for the proteins of SEQ No. 263,


No. 275

264, 265


 


SEQ ID
IGVFAIDTGSGNTFGYR
48-64 for the proteins of SEQ No. 263,


No. 276

264, 265


 


SEQ ID
LALGNVLNAK
197-206 for the proteins of SEQ No. 263,


No. 277

264, 265


 


SEQ ID
LDINQK
92-97 for the proteins of SEQ No. 263,


No. 278

264, 265


 


SEQ ID
LEEDFDGR
40-47 for the proteins of SEQ No. 263,


No. 279

264, 265


 


SEQ ID
SDAAAK
30-35 for the proteins of SEQ No. 263,


No. 280

264, 265


 


SEQ ID
SIGDNEFR
158-165 for the proteins of SEQ No. 263,


No. 281

264, 265


 


SEQ ID
TASFLFSVCLALSAFNAHANK
9-29 for the proteins of SEQ No. 263, 264,


No. 282

265


 


SEQ ID
TGSCGAIGTANDYAVIWPK
239-257 for the protein of SEQ No. 265


No. 283


 


SEQ ID
TGSCGAYGTANDYAVIWPK
239-257 for the proteins of SEQ No. 263,


No. 284

264


 


SEQ ID
TIAEASR
281-287 for the proteins of SEQ No. 263,


No. 285

264, 265


 


SEQ ID
WELELNTAIPGDK
169-181 for the proteins of SEQ No. 263,


No. 286

264, 265


 


SEQ ID
FPLCSSFK
69-76 for the proteins of SEQ No. 263,


No. 287

264, 265









The detection of a mechanism of resistance to carbapenems induced by the expression of a VIM protein is characterised by the detection of at least one peptide belonging to a VIM protein and to its different sequence variants SEQ ID No. 288 to SEQ ID No. 313.







SEQ ID No. 288:


MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIA


 


DGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEI


 


EKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNE


 


lPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCA


 


IYELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLL


 


KHTTNVVKAHTNRSVVE


 


SEQ ID No. 289:


MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIA


 


DGVVVSHIATKSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEI


 


EKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGSE


 


IPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCA


 


IYELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLL


 


KHTTNVVKAHTNRSVVE


 


SEQ ID No. 290:


MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNElPVGEVRLYQIA


 


DGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEI


 


EKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNE


 


IPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCA


 


VHELSRTSAGNVADADLAEWPTSVERIQKHYPEAEWIPGHGLPGGLDLLQ


 


HTANVVKAHKNRSVAE


 


SEQ ID No. 291:


MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNElPVGEVRLYQIA


 


DGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIE


 


KQIGLPVTRAVSTHFHDDRVGGVDVLRKAGVATYASPSTRRLAEAEGNE1


 


PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCAV


 


LALSRTSAGNVADADLAEWPTSVERIOKHYPEAEWIPGHGLPGGLDLLQH


 


TANVVTAHKNRSVAE


 


SEQ ID No. 292:


MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIA


 


DGVWSHIATRSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIE


 


KQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGSEI


 


PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAI


 


YELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK


 


HTTNVVKAHTNRSVVE


 


SEQ ID No. 293:


MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIA


 


DGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIE


 


KQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSARRLAEVEGNEI


 


PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCA1


 


YELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK


 


HTTNVVKAHTNRSVVE


 


SEQ ID No. 294:


MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQ1A


 


DGVVVSHIATQSFDGAVYPSNGL1VRDGDELLLIDTAWGAKNTAALLAEI


 


EKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSIRRLAEVEGNE


 


IPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCA


 


IYELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLL


 


KHTTNVVKAHTNRSVVE


 


SEQ ID No. 296:


MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIA


 


DGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEI


 


EKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNE


 


lPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCA


 


IYELSRTSAGNVADADLAEWPTSIER1QQHYPEAQYVIPGHGLPGGLDLL


 


KHTTNWKAHTNRSVVE


 


SEQ ID No. 296:


MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIA


 


DGVWSH1ATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIE


 


KQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGSEI


 


PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAI


 


YELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK


 


HTTNVVKAHTNRSVVE


 


SEQ ID No. 297:


MLKVISSLLVYMTASVMAVASPLAHSGEPSSEYPTVNElPVGEVRLYQIA


 


DGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEI


 


EKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNE


 


IPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCA


 


VHELSRTSAGNVADADLAEWPTSVERIOKHYPEAEVVIPGHGLPGGLDLL


 


QHTANVVKAHKNRSVAE


 


SEQ ID No. 298:


MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNElPVGEVRLYQIA


 


DGV1NSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEI


 


EKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNE


 


lPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLWYVPSANVLYGGCAV


 


HELSSTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK


 


HTTNVVKAHTNRSVVE


 


SEQ ID No. 299:


MLKVISSLLFYMTASLMAVASPLAHSGESRGEYPTVSEIPVGEVRLYQID


 


DGVVVSHIATHTFDGVVYPSNGLIVRDGDELWDTAWGTKNTVALLAEIEK


 


QIGLPVTRSVSTHFHDDRVGGVDALRAAGVATYASPSTRRLAEAEGNEVP


 


THSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCAVL


 


ELSRTSAGNVADADLAEWPGSVERIQQHYPEAEVVIPGHGLPGGLDLLQH


 


TANVVKAHTNRSVAE


 


SEQ ID No. 300:


MFKLLSKLLVYLTASMMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIA


 


DGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIE


 


KQ1GLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNEl


 


PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCA1


 


YELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK


 


HTTNVVKAHTNRSVVE


 


SEQ ID No. 301:


MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIA


 


DGVWSHIATQSFDGAVYPSNGLIVRDGDELLL1DTAWGAKNTAALLAEIE


 


KQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNEI


 


PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLFGGCAI


 


YELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK


 


HTTNVVKAHTNRSVVE


 


SEQ ID No. 302:


MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIA


 


DGVWLHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIE


 


KQ1GLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNEl


 


PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAI


 


YELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK


 


HTTNVVKAHTNRSVVE


 


SEQ ID No. 303:


MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIA


 


DGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIE


 


KQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNEl


 


PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAI


 


YELSSTSAGNVADADLAEWPTS1ERIQQHYPEAQFVIPGHGLPGGLDLLK


 


HTTNVVKAHTNRSVVE


 


SEQ ID No. 304:


MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNEIPVGEVRLYQ1A


 


DGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIE


 


KQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNEl


 


PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSAKVLYGGCAV


 


HELSRTSAGNVADADLAEWPTSVERIQKHYPEAEVVIPGHGLPGGLDLLQ


 


HTANVVKAHKNRSVAE


 


SEQ ID No. 305:


MFKLLSKLLVYLTAS1MAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIA


 


DGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIE


 


KQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNEI


 


PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAI


 


YELSLTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK


 


HTTNWKAHTNRSWE


 


SEQ ID No. 306:


MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNEIPVGEVRLYQIA


 


DGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIE


 


KQIGLPVTRAVSTHFHDDRVGGVDVLRKAGVATYASPSTRRLAEAEGNEI


 


PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCAV


 


LALSRTSAGNVADADLAEWPTSVERIQKHYPEAQFVIPGHGLPGGLDLLK


 


HTTNVVKAHTNRSVVE


 


SEQ ID No. 307:


MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNElPVGEVRLYQIA


 


DGVWSHISTQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIE


 


KQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNEl


 


PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCAV


 


HELSSTSAGNVADADLAEWPTSVERIQKHYPEAEVVIPGHGLPGGLDLLQ


 


HTANVVKAHKNRSVAE


 


SEQ ID No. 308:


MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNElPVGEVRLYQIA


 


DGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEI


 


EKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNE


 


IPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCA


 


VLELSRTSAGNVADADLAEWPTSVER1QKHYPEAEVVIPGHGLPGGLDLL


 


QHTANVVKAHKNRSVAE


 


SEQ ID No. 309:


MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVNEIPVGEVRLYQIA


 


DGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIE


 


KQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNEI


 


PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAI


 


YELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK


 


HTTNVVKAHTNRSVVE


 


SEQ ID No. 310:


MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNEIPVGEVRLYQ1A


 


DGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEI


 


EKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNE


 


IPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCA


 


VHELSSTSAGNVADADLAEWPTSVERIQKHYPEAEVVIPGHGLPGGLDLL


 


QHTANVVKAHKNRSVAE


 


SEQ ID No. 311:


MFQIRSFLVGISAFVMAVLGSAAYSAQPGGEYPTVDDIPVGEVRLYKIGD


 


GVVVSHIATQKLGDTVYSSNGLIVRDADELLLIDTAWGAKNTVALLAEIE


 


KQIGLPVTRSISTHFHDDRVGGVDVLRAAGVATYTSPLTRQLAEAAGNEV


 


PAHSLKALSSSGDVVRFGPVEVFYPGAAHSGDNLVVYVPAVRVLFGGCAV


 


HEASRESAGNVADANLAEWPATIKRIQQRYPEAEVVIPGHGLPGGLELLQ


 


HTTNWKTHKVRPVAE


 


SEQ ID No. 312:


MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIA


 


DGVWSHIATRSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIE


 


KQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLANEIPTHS


 


LEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAIYELS


 


RTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLKHTTN


 


VVKAHTNRSVVE


 


SEQ ID No. 313:


MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNEIPVGEVRLYQIA


 


DGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEI


 


EKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNE


 


IPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCA


 


VLELSSTSAGNVADADLAEWPTSVERIQKHYPEAEVVIPGHGLPGGLDLL


 


QHTANVVKAHKNRSVAE






said peptides being chosen, preferably, from the peptides of sequence SEQ ID No. 314 to SEQ ID No. 346 as defined hereafter:












Peptide




SEQ ID


No.
Amino acid sequence
Position of the peptide in the VIM protein(s)







SEQ ID
AAGVATYASPSAR
128-140 for the protein of SEQ No. 293


No. 314


 


SEQ ID
AAGVATYASPSIR
128-140 for the protein of SEQ No. 294


No. 315


 


SEQ ID
AAGVATYASPSTR
128-140 for the proteins of SEQ No. 288, 289,


No. 316

290, 292, 295, 296, 297, 298, 299, 300, 301,




302, 303, 304, 305, 307, 308, 309, 310, 312,




313


 


SEQ ID
AAGVATYTSPLTR
127-139 for the protein of SEQ No. 311


No. 317


 


SEQ ID
AGVATYASPSTR
129-140 for the proteins of SEQ No. 288, 289,


No. 318

290, 291, 292, 295, 296, 297, 298, 299, 300,




301, 302, 303, 304, 305, 306, 307, 308, 309,




310, 312, 313


 


SEQ ID
AHTNR
254-258 for the protein of SEQ No. 312; 258-262


No. 319

for the proteins of sequence SEQ ID No.




288, 289, 292, 293, 294, 295, 296, 298, 299,




300, 301, 302, 303, 305, 306, 309


 


SEQ ID
ALSSSGDVVR
156-165 for the protein of SEQ No. 311


No. 320


 


SEQ ID
AVSTHFHDDR
110-119 for the proteins of SEQ No. 288, 289,


No. 321

290, 291, 292, 293, 294, 295, 296, 297, 298,




300, 301, 302, 303, 304, 305, 306, 307, 308,




309, 310, 312, 313


 


SEQ ID
DADELLLIDTAWGAK
75-89 for the protein of SEQ No. 311


No. 322


 


SEQ ID
DGDELLLIDTAWGAK
76-90 for the proteins of SEQ No. 288, 289, 290,


No. 323

291, 292, 293, 294, 295, 296, 297, 298, 300,




301, 302, 303, 304, 305, 306, 307, 308, 309,




310, 312, 313


 


SEQ ID
DGDELLLIDTAWGTK
76-90 for the protein of SEQ No. 299


No. 324


 


SEQ ID
ESAGNVADANLAEWPATIK
205-223 for the protein of SEQ No. 311


No. 325


 


SEQ ID
GEYPTVSEIPVGEVR
31-45 for the proteins of SEQ No. 288, 289, 292,


No. 326

293, 294, 295, 296, 299, 300, 301, 302, 303,




305, 312


 


SEQ ID
HTTNVVK
247-253 for the protein of SEQ No. 312; 251-257


No. 327

for the proteins of sequence SEQ ID No.




288, 289, 292, 293, 294, 295, 296, 298, 300,




301, 302, 303, 305, 306, 309; 250-256 for the




protein of sequence SEQ ID No. 311


 


SEQ ID
IGDGVWSHIATQK
48-60 for the protein of SEQ No. 311


No. 328


 


SEQ ID
LANEIPTHSLEGLSSSGDAVR
142-162 for the protein of SEQ No. 312


No. 329


 


SEQ ID
LGDTVYSSNGLIVR
61-74 for the protein of SEQ No. 311


No. 330


 


SEQ ID
LYQIADGVWSHIATK
46-60 for the protein of SEQ No. 289


No. 331


 


SEQ ID
LYQIADGVWSHIATR
46-60 for the proteins of SEQ No. 292, 312


No. 332


 


SEQ ID
NTAALLAEIEK
91-101 for the proteins of SEQ No. 288, 289,


No. 333

290, 291, 292, 293, 294, 295, 296, 297, 298,




300, 301, 302, 303, 304, 305, 306, 307, 308,




309, 310, 312, 313


 


SEQ ID
NTVALLAEIEK
90-100 for the protein of SEQ No. 311; 91-101


No. 334

for the protein of sequence SEQ ID No. 299


 


SEQ ID
QIGLPVTR
102-109 for the proteins of SEQ No. 288, 289,


No. 335

290, 291, 292, 293, 294, 295, 296, 297, 298,




299, 300, 301, 302, 303, 304, 305, 306, 307,




308, 309, 310, 312, 313; 101-108 for the protein




of sequence SEQ ID No. 311


 


SEQ ID
QLAEAAGNEVPAHSLK
140-155 for the protein of SEQ No. 311


No. 336


 


SEQ ID
SFDGAVYPSNGLIVR
61-75 for the proteins of SEQ No. 288, 289, 290,


No. 337

291, 292, 293, 294, 295, 296, 297, 298, 300,




301, 302, 303, 304, 305, 306, 307, 308, 309,




310, 312, 313


 


SEQ ID
SISTHFHDDR
109-118 for the protein of SEQ No. 311


No. 338


 


SEQ ID
SVSTHFHDDR
110-119 for the protein of SEQ No. 299


No. 339


 


SEQ ID
TSAGNVADADLAEWPGSVER
206-225 for the protein of SEQ No. 299


No. 340


 


SEQ ID
TSAGNVADADLAEWPTSIER
202-221 for the protein of SEQ No. 312; 206-225


No. 341

for the protein of sequence SEQ ID No. 288,




289, 292, 293, 294, 295, 296, 298, 300, 301,




302, 303, 305, 309


 


SEQ ID
TSAGNVADADLAEWPTSVER
206-225 for the proteins of SEQ No. 290, 291,


No. 342

297, 304, 306, 307, 308, 310, 313


 


SEQ ID
VGGVDALR
120-127 for the protein of SEQ No. 299


No. 343


 


SEQ ID
VGGVDVLR
120-127 for the proteins of SEQ No. 288, 289,


No. 344

290, 291, 292, 293, 294, 295, 296, 297, 298,




300, 301, 302, 303, 304, 305, 306, 307, 308,




309, 310, 312, 313; 119-126 for the protein of




sequence SEQ ID No. 311


 


SEQ ID
VLFGGCAVHEASR
192-204 for the protein of SEQ No. 311


No. 345


 


SEQ ID
VLYGGCAVHELSR
193-205 for the proteins of SEQ No. 290, 297,


No. 346

304









The detection of a mechanism of resistance to carbapenems and/or to cephalosporins induced by the expression of an OXA protein is characterised by the detection of at least one peptide belonging to an OXA protein and to its different sequence variants SEQ ID No. 347 to SEQ ID No. 508.








SEQ ID No. 347:



MSRLLLSGLLATGLLCAVPASAASGCFLYADGNGQTLSSEGDCSSQLPPASTFKIPL


 


ALMGYDSGFLVNEEHPALPYKPSYDGWLPAWRETTTPRRWETYSVVWFSQQITE


 


WLGMERFQQYVDRFDYGNRDLSGNPGKHDGLTQAWLSSSLAISPEEQARFLGKM


 


VSGKLPVSAQTLQYTANILKVSEVEGWQIHGKTGMGYPKKLDGSLNRDQQIGWFV


 


GWASKPGKQLIFVHTVVQKPGKQFASIKAKEEVLAALPAQLKKL


 


SEQ ID No. 348:


IACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLARASKEYLPA


 


STFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVSAVPVFQQI


 


AREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEDQLRISAVNQVEFLESLYLNKLSA


 


SKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKETEVYFF


 


AFNMDIDNESKLPLRKSIPTKIMESEGIIGG


 


SEQ ID No. 349:


MKKILLLHMLVFVSATLPISSVASDEVETLKCTIIADAITGNTLYETGECARRVSPCSS


 


FKLPLAIMGFDSGILQSPKSPTWELKPEYNPSPRDRTYKQVYPALWQSDSVVWFSQ


 


QLTSRLGVDRFTEYVKKFEYGNQDVSGDSGKHNGLTQSWLMSSLTISPKEQIQFLL


 


RFVAHKLPVSEAAYDMAYATIPQYQAAEGWAVHGKSGSGWLRDNNGKINESRPQ


 


GWFVGWAEKNGRQVVFARLEIGKEKSDIPGGSKAREDILVELPVLMGNK


 


SEQ ID No. 350:


MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIWADERQADRAMLV


 


FDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLR


 


SAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNAGPSTSNGDYWIEGSLAISAQE


 


QIAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVE


 


WPTGSVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR


 


SEQ ID No. 351:


MQRSLSMSGKRHFIFAVSFVISTVCLTFSPANAAQKLSCTLVIDEASGDLLHREGSC


 


DKAFAPMSTFKLPLAIMGYDADILLDATTPRWDYKPEFNGYKSQQKPTDPTIWLKDS


 


IVWYSQELTRRLGESRFSDYVQRFDYGNKDVSGDPGKHNGLTHAWLASSLKISPEE


 


QVRFLRRFLRGELPVSEDALEMTKAVVPHFEAGDWDVQGKTGTGSLSDAKGGKAP


 


IGWFIGWATRDDRRVVFARLTVGARKGEQPAGPAARDEFLNTLPALSENF


 


SEQ ID No. 352:


MKTFAAYVIIACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLAR


 


ASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVS


 


AVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLE


 


SLYLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVE


 


KETEVYFFAFNMDIDNESKLPLRKSIPTKIMESEGIIGG


 


SEQ ID No. 353:


IACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLARASKEYLPA


 


STFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVSAVPVFQQIT


 


REVGEVRMQKYLKKFSYGNQNISGGIDKFWLEDQLRISAVNQVEFLESLYLNKLSAS


 


KENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKETEVYFFA


 


FNMDIDNESKLPLRKSIPTKIMESEGIIGG


 


SEQ ID No. 354:


IACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLARASKEYLPA


 


STFKIPSAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVSAVPVFQQIA


 


REVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLESLYLNKLSAS


 


KENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKETEVYFFA


 


FNMDIDNESKLPLRKSIPTKIMESEGIIGG


 


SEQ ID No. 355:


MIIRFLALLFSAVVLVSLGHAQEKTHESSNWGKYFSDFNAKGTIVVVDERTNGNSTS


 


VYNESRAQQRYSPASTFKIPHTLFALDAGAVRDEFHVFRWDGAKRSFAGHNQDQN


 


LRSAMRNSTVWVYQLFAKEIGENKARSYLEKLNYGNADPSTKSGDYWIDGNLAISA


 


NEQISILKKLYRNELPFRVEHQRLVKDLMIVEAKRDWILRAKTGWDGQMGWWVGW


 


VEWPTGPVFFALNIDTPNRMEDLHKREAIARAILQSVNALPPN


 


SEQ ID No. 356:


MAIRIFAILFSTFVFGTFAHAQEGMRERSDWRKFFSEFQAKGTIVVADERQTDRVILV


 


FDQVRSEKRYSPASTFKIPHTLFALDAGAARDEFQVFRWDGIKRSFAAHNQDQDLR


 


SAMRNSTVWIYELFAKEIGEDKARRYLKQIDYGNADPSTSNGDYWIDGNLAIAAQEQ


 


IAFLRKLYHNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRIGWWVGWVEW


 


PTGPVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR


 


SEQ ID No. 357:


MKTFAAYVITACLSSTALASSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNNLA


 


RASKEYLPASTFKIPSAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLSLRGAIQV


 


SAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFL


 


ESLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWV


 


EKGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG


 


SEQ ID No. 358:


MKTFAAYVITACLSSTALASSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNNLA


 


RASKEYLPASTFKIPNAIIGLETGVSKNEHQVFKWDGKPRAMKQWERDLSLRGAIQV


 


SAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEDQLRISAVNQVEFLE


 


SLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVE


 


KGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG


 


SEQ ID No. 359:


MKTFAAYVITACLSSTALASSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNNLA


 


RASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLSLRGAIQV


 


SAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFGLEGQLRISAVNQVEFLE


 


SLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVE


 


KGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG


 


SEQ ID No. 360:


MKNTIHINFAIFLIIANIIYSSASASTDISTVASPLFEGTEGCFLLYDASTNAEIAQFNKA


 


KCATQMAPDSTFKIALSLMAFDAEIIDQKTIFKWDKTPKGMEIWNSNHTPKTWMQFS


 


VVWVSQEITQKIGLNKIKNYLKDFDYGNQDFSGDKERNNGLTEAWLESSLKISPEEQ


 


IQFLRKIINHNLPVKNSAIENTIENMYLQDLDNSTKLYGKTGAGFTANRTLQNGWFEG


 


FIISKSGHKYVFVSALTGNLGSNLTSSIKAKKNAITILNTLNL


 


SEQ ID No. 361:


ANIIYSSASASTDISTVASPLFEGTEGCFLLYDVSTNAEIAQFNKAKCATQMAPDSTF


 


KIALSLMAFDAEIIDQKTIFKWDKTPKGMEIWNSNHTPKTWMQFSVVWVSQEITQKI


 


GLNKIKNYLKDFDYGNQDFSGDKERNNGLTEAWLESSLKISPEEQIQFLRKIINHNLP


 


VKNSAIENTIENMYLQDLENSTKLYGKTGAGFTANRTLQNGWFEGFIISKSGHKYVF


 


VSALTGNLGSNLTSSIKAKKNAITIL


 


SEQ ID No. 362:


IFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLVFDPVRSKKR


 


YSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLRSAMRNSTV


 


WVYELFAKEIGDDKARRYLKKIDYGNAYPSTSNGDYWIEGSLAISAQEQIAFLRKLYR


 


NELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVEWPTGSVFFA


 


LNIDTPNRMDDLFKREAIVRAIL


 


SEQ ID No. 363:


MIIRFLALLFSAVVLVSLGHAQDKTHESSNWGKYFSDFNAKGTIVVVDERTNGNSTS


 


VYNESRAQQRYSPASTFKIPHTLFALDAGAVRDEFHVFRWDGAKRSFAGHNQDQN


 


LRSAMRNSTVWVYQLFAKEIGENKARSYLEKLNYGNADPSTKSGDYWIDGNLAISA


 


NEQISILKKLYRNELPFRVEHQRLVKDLMIVEAKRDWILRAKTGWDGQMGWWVGW


 


VEWPTGPVFFALNIDTPNRMEDLHKREAIARAILQSVNALPPN


 


SEQ ID No. 364:


MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKSYFDEAQTQGVIIIKEGK


 


NLSTYGNALARANKEYVPASTFKMLNALIGLENHKATTNEIFKWDGKKRTYPMWEK


 


DMTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIGTQVDNFWLVGPL


 


KITPVQEVNFADDLAHNRLPFKLETQEEVEKMLLIKEVNGSKIYAKSGWGMGVTPQV


 


GWLTGWVEQANGKKIPFSLNLEMKEGMSGSIRNEITYKLLENLGII


 


SEQ ID No. 365:


MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKSYFDEAQTQGVIIIKEGK


 


NLSTYGNALARANKEYVPASTFKMLNALIGLENHKATTNEIFKWDGKKRTYPMWEK


 


DMTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIGTQVDNFWLVGPL


 


KITPVQEVNFADDLAHNRLPFKLETQEEVKKMLLIKEVNGSKIYAKSGWGMGVTPQV


 


GWLTGWVEQANGKKIPFSLNLEMKEGMTGSIRNEITYKSLENLGII


 


SEQ ID No. 366:


MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKADINEIFKWKGEKRSFTAWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPL


 


KVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQV


 


GWLTGWVEQPDGKIVAFALKMEMRSEMPASIRNELLMKSLKQLNII


 


SEQ ID No. 367:


MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLV


 


FDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLR


 


SAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNADPSTSNGDYCIEGSLAISAQEQ


 


IAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVE


 


WPTGSVFFALNIDTPNRMDDLFKREAIVRAIL


 


SEQ ID No. 368:


MKTFAAYVITACLSSTALASSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNNLA


 


RASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLSLRGAIQV


 


SAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFL


 


ESLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWV


 


EKGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG


 


SEQ ID No. 369:


MAIRFLTILLSTFFLTSFVHAQEHVLERSDWKKFFSDLRAEGAIVISDERQAEHALLVF


 


GQERAAKRYSPASTFKLPHTLFALDADAVRDEFQVFRWDGVKRSFAGHNQDQDLR


 


SAMRNSAVWVYELFAKEIGKDKARHYLKQIDYGNADPSTIKGDYWIDGNLEISAHEQ


 


ISFLRKLYRNQLPFQVEHQRLVKDLMITEAGRNWILRAKTGWEGRFGWWVGWVE


 


WPTGPVFFALNIDTPNRTDDLFKREAIARAILRSIDALPPN


 


SEQ ID No. 370:


MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLV


 


FDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLR


 


SAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNADPSTSNGDYWIEGSIAISAQEQ


 


IAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVE


 


WPTGSVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR


 


SEQ ID No. 371:


MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKSYFDEAQTQGVIIIKEGK


 


NLSTYGNALARANKEYVPASTFKMLNALIGLENHKATTNEIFKWDGKKRTYPMWEK


 


DMTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIGTQVDNFWLVGPL


 


KITPVQEVNFADDLAHNRLPFKLETQEEVKKMLLIKEVNGSKIYAKSGWGMGVTPQV


 


GWLTGWVEQANGKKIPFSLNLEMKEGMSGSIRNEITYKSLENLGII


 


SEQ ID No. 372:


MAIRFLTILLSTFFLTSFVHAQEHVLERSDWKKFFSDLRAEGAIVISDERQAEHALLVF


 


GQERAAKRYSPASTFKLPHTLFALDADAVRDEFQVFRWDGVKRSFAGHNQDQDLR


 


SAMRNSAVVWYELFAKEIGEDKARRYLKQIDYGNADPSTIKGDYWIDGNLEISAHEQ


 


ISFLRKLYRNQLPFQVEHQRLVKDLMITEAGRNWILRAKTGWEGRFGWWVGWVE


 


WPTGPVFFALNIDTPNRTDDLFKREAIARAILRSIDALPPN


 


SEQ ID No. 373:


MAIRFFTILLSTFFLTSFVYAQEHVVIRSDWKKFFSDLQAEGAIVIADERQAKHTLSVF


 


DQERAAKRYSPASTFKIPHTLFALDADAVRDEFQVFRWDGVNRSFAGHNQDQDLR


 


SAMRNSTVWVYELFAKDIGEDKARRYLKQIDYGNVDPSTIKGDYWIDGNLKISAHEQ


 


ILFLRKLYRNQLPFKVEHQRLVKDLMITEAGRSWILRAKTGWEGRFGWWVGWIEW


 


PTGPVFFALNIDTPNRTDDLFKREAIARAILRSIDALPPN


 


SEQ ID No. 374:


MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVERIGFGNAEIGQQVDNFWLVGPL


 


KVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAAMDIKPQ


 


VGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII


 


SEQ ID No. 375:


MAIQIFAILFSTFVLATFAHAQDGTLERSDWGKFFSDFQAKGTIVVADERQADHAILV


 


FDQARSMKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVKRSFAGHNKDQDLR


 


SAMRNSTVWVYELFAKEIGDGKARRYLKQIGYGNADPSTSHGDYWIEGSLAISAQE


 


QIAFLRKLYQNDLPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGSMGWWVGWV


 


EWPTGPVFFALNIDTPNRMDDLFKREAIARAILLSIEALPPNPAVHSDAAR


 


SEQ ID No. 376:


MKNTIHINFAIFLIIANIIYSSASASTDISTVASQLFEGTEGCFLLYDASTNAEIAQFNKA


 


KCAAQMAPDSTFKIALSLMAFDAEIIDQKTIFKWDKIPKGMEIWNSNHTPKTWMQFS


 


VVWVSQEITQKIGLNKIKNYLKDFDYGNQDFSGDKERNNGLTEAWLESSLKISPEEQ


 


IQFLRKIINHNLPVRNSAIENTIDNMYLQDLENSTKLYGKTGAGFTANRTLQNGWFEG


 


FIISKSGHKYVFVSALTGSLGSNLTSSIKAKKNAITILNTLNL


 


SEQ ID No. 377:


MLLFMFSIISFGNENQFMKEIFERKGLNGTFVVYDLKNDKIDYYNLDRANERFYPASS


 


FKIFNTLIGLENGIVKNVDEMFYYYDGSKVFLDSWAKDSNLRYAIKVSQVPAYKKLAR


 


ELGKERMQEGLNKLNYGNKEIGSEIDKFWLEGPLKISAMEQVKLLNLLSQSKLPFKL


 


ENQEQVKDITILEKKDDFILHGKTGWATDNIWPIGWFVGWIETSDNIYSFAINLDISD


 


SKFLPKREEIVREYFKNINVIK


 


SEQ ID No. 378:


MRVLALSAVFLVASIIGMPAVAKEWQENKSWNAHFTEHKSQGVVVLWNENKQQGF


 


TNNLKRANQAFLPASTFKIPNSLIALDLGVVKDEHQVFKWDGQTRDIATWNRDHNLI


 


TAMKYSVVPVYQEFARQIGEARMSKMLHAFDYGNEDISGNVDSFWLDGGIRISATE


 


QISFLRKLYHNKLHVSERSQRIVKQAMLTEANGDYIIRAKTGYSTRIEPKIGWWVGW


 


VELDDNVWFFAMNMDMPTSDGLGLRQAITKEVLKQEKIIP


 


SEQ ID No. 379:


MLSRYSKTLAFAVVACTLAISTATAHAELWRNDLKRVFDDAGVSGTFVLMDITADR


 


TYVVDPARAARSIHPASTFKIPNSLIAFDTGAVRDDQEVLPYGGKPQPYEQWEHDM


 


ALPEAIRLSAVPIYQEVARRVGFERMQAYVDAFDYGNRQLGSAIDQFWLRGPLEISA


 


FEEARFTSRMALKQLPVKPRTWDMVQRMLLIEQQGDAALYAKTGVATEYQPEIGW


 


WAGWVERAGHVYAFALNIDMPREGDMAKRIPLGKQLMRALEVWPAP


 


SEQ ID No. 380:


MRPLLFSALLLLSGHTQASEWNDSQAVDKLFGAAGVKGTFVLYDVQRQRYVGHDR


 


ERAETRFVPASTYKVANSLIGLSTGAVRSADEVLPYGGKPQRFKAWEHDMSLRDAI


 


KASNVPVYQELARRIGLERMRANVSRLGYGNAEIGQVVDNFWLVGPLKISAMEQTR


 


FLLRLAQGELPFPAPVQSTVRAMTLLESGPGWELHGKTGWCFDCTPELGWWVGW


 


VKRNERLYGFALNIDMPGGEADIGKRVELGKASLKALGILP


 


SEQ ID No. 381:


MNKGLHRKRLSKRLLLPMLLCLLAQQTQAVAAEQTKVSDVCSEVTAEGWQEVRRW


 


DKLFESAGVKGSLLLWDQKRSLGLSNNLSRAAEGFIPASTFKLPSSLIALETGAVRD


 


ETSRFSWDGKVREIAVWNRDQSFRTAMKYSVVPVYQQLAREIGPKVMAAMVRQLE


 


YGNQDIGGQADSFWLDGQLRITAFQQVDFLRQLHDNKLPVSERSQRIVKQMMLTE


 


ASTDYIIRAKTGYGVRRTPAIGWWVGWLELDDNTVYFAVNLDLASASQLPLRQQLV


 


KQVLKQEQLLP


 


SEQ ID No. 382:


MNTIISRRWRAGLWRRLVGAVVLPATLAATPAAYAADVPKAALGRITERADWGKLF


 


AAEGVKGTIVVLDARTQTYQAYDAARAEKRMSPASTYKIFNSLLALDSGALDNERAII


 


PWDGKPRRIKNWNAAMDLRTAFRVSCLPCYQVVSHKIGRRYAQAKLNEVGYGNRT


 


IGGAPDAYWVDDSLQISAREQVDFVQRLARGTLPFSARSQDIVRQMSIVEATPDYVL


 


HGKTGWFVDKKPDIGWWVGWIERDGNITSVAINIDMLSEADAPKRARIVKAVLKDLK


 


LI


 


SEQ ID No. 383:


MKTFAAYVITACLSSTALASSITENTFWNKEFSAEAVNGVFVLCKSSSKSCATNNLA


 


RASKEYLPASTFKIPNAIIGLETGVIKNEHQIFKWDGKPRAMKQWERDLSLRGAIQVS


 


AVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLE


 


SLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVE


 


KGAEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG


 


SEQ ID No. 384:


MRVLALSAVLVVASIVGMPAMANEWQEKPSWNTHFSEHKAQGVIVLWNENKQQGF


 


TNNLKRANQAFLPASTFKIPNSLIALDLGVVKDEHQVFKWDGQTRDIAAWNRDHDLI


 


TAMKYSVVPVYQEFARQIGQARMSKMLHAFDYGNEDISGNLDSFWLDGGIRISATE


 


QVAFLRKLYHNKLHVSERSQRIVKQAMLTEANSDYIIRAKTGYSTRIEPQIGWWVGW


 


VELDDNVWFFAMNMDMPTADGLGLRQAITKEVLKQEKIIP


 


SEQ ID No. 385:


MKKITLFLLFLNLVFGQDKILNNWFKEYNTSGTFVFYDGKTWASNDFSRAMETFSPA


 


STFKIFNALIALDSGVIKTKKEIFYHYRGEKVFLSSWAQDMNLSSAIKYSNVLAFKEVA


 


RRIGIKTMQEYLNKLHYGNAKISKIDTFWLDNSLKISAKEQAILLFRLSQNSLPFSQEA


 


MNSVKEMIYLKNMENLELFGKTGFNDGQKIAWIVGFVYLKDENKYKAFALNLDIDKF


 


EDLYKREKILEKYLDELVKKVKNDG


 


SEQ ID No. 386:


MSKKNFILIFIFVILISCKNTEKISNETTLIDNIFTNSNAEGTLVIYNLNDDKYIIHNKERAE


 


QRFYPASTFKIYNSLIGLNEKAVKDVDEVFYKLMAKSFLESWAKDSNLRYAIKNSQV


 


PAYKELARRIGIKKMKENIEKLDFGNKSIGDSVDTFWLEGPLEISAMEQVKLLTKLAQ


 


NELQYPIEIQKAISDITITRANLHITLHGKTGLADSKNMTTEPIGWFVGWLEENDNIYV


 


FALNIDNINSDDLAKRINIVKESLKALNLLK


 


SEQ ID No. 387:


MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPL


 


KVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQV


 


GWLTGWVEQPDGKIVAFALKMEMRSEMPASIRNELLMKSLKQLNII


 


SEQ ID No. 388:


MNIQALLLITSAIFISACSPYIVTANPNYSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRIGYGNADIGTQVDNFWLVGPLKI


 


TPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGISSSVRKEITYRGLEQLGIL


 


SEQ ID No. 389:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKGEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 390:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 391:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 392:


MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQEVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 393:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIHQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGEKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 394:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDKKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWNGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQHEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 395:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKTTTTEVFKWDGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 396:


MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTAVFKWDGQKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGTPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 397:


MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLPRRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 398:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEKLGIL


 


SEQ ID No. 399:


MNIKTLLLITSTIFISACSPYIVTANPNHSTSKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASIEYVPASTFKMLNALIGLEHHKATTTEIFKWDGQKRLFPEWEKD


 


MTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKIT


 


PQQEAQFAYKLANKTLPFSLKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVG


 


WLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 400:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAISVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLAGPL


 


KITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 401:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASALPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPL


 


KITPGQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQ


 


VGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 402:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIHQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGEKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGSVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 403:


MNIKTLLLITSTIFISACSPYIVTANPNHSTSKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASIEYVPASTFKMLNALIGLEHHKATTTEIFKWDGQKRLFPEWEKD


 


MTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKIT


 


PQQEAQFAYKLANKTLPFSLKAQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVG


 


WLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 404:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDKKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 405:


MNIKTLLLITSAIFISACSHYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFTYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 406:


MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 407:


MNIKALLLITSTIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALISLEHHKATTTEVFKWDGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 408:


MNIQALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPHGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 409:


MNIKALFLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 410:


MKLLKILSLVCLSISIGACAEHSMSRAKTSTIPQVNNSIIDQNVQALFNEISADAVFVTY


 


DGQNIKKYGTHLDRAKTAYIPASTFKIANALIGLENHKATSTEIFKWDGKPRFFKAWD


 


KDFTLGEAMQASTVPVYQELARRIGPSLMQSELQRIGYGNMQMGTEVDQFWLKGP


 


LTITPIQEVKFVYDLAQGQLPFKPEVQQQVKEMLYVERRGENRLYAKSGWGMAVD


 


PQVGWYVGFVEKADGQVVAFALNMQMKAGDDIALRKQLSLDVLDKLGVFHYL


 


SEQ ID No. 411:


MNIKALLLITSTIFISACSPYIVTANPNHSTSKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEIFKWDGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSLKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 412:


MNIKTLLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEVHTTGVLVIRQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEMNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 413:


MKLLKILSLVCLSISIGACAEHSMSRAKTSTIPQVNNSIIDQNVQALFNEISGDAVFVTY


 


DGQNIKKYGTHLDRAKTAYIPASTFKIANALIGLENHKATSTEIFKWDGKPRFFKAWD


 


KDFTLGEAMQASTVPVYQELARRIGPSLMQSELQRIGYGNMQIGTEVDQFWLKGPL


 


TITPIQEVKFVYDLAQGQLPFKPEVQQQVKEMLYVERRGENRLYAKSGWGMAVDP


 


QVGWYVGFVEKADGQVVAFALNMQMKAGDDIALRKQLSLDVLDKLGVFHYL


 


SEQ ID No. 414:


MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKSYFDEAQTQGVIIIKEGK


 


NLSTYGNALARANKEYVPASTFKMLNALIGLENHKATTNEIFKWDGKKRTYPMWEK


 


DMTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIGTQVDNFWLVGPL


 


KITPVQEVNFADDLAHNRLPFKLETQEEVKKMLLIKEVNGSKIYAKSGWGMDVTPQV


 


GWLTGWVEQANGKKIPFSLNLEMKEGMSGSIRNEITYKSLENLGII


 


SEQ ID No. 415:


MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLV


 


FDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLR


 


SAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNADPSTSNGDYWIESSLAISAQE


 


QIAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVE


 


WPTGSVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR


 


SEQ ID No. 416:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 417:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAILVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 418:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDKKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWNGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 419:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIHQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGEKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 420:


MNIKALLLITSAIFISACSPYIVTTNPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNTDIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 421:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIQVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 422:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIHQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGEKRLFPEWEK


 


NMTLGDAMKASALPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPL


 


KITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQ


 


VGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 423:


MNIKTLLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEMNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 424:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIHQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGEKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFPLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 425:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGGDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 426:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAILVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKI


 


TPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 427:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 428:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKTTTTEVFKWDGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWWGPLK


 


ITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 429:


MSKKNFILIFIFVILISCKNTEKISNETTLIDNIFTNSNAEGTLVIYNLNDDKYIIHNKERAE


 


QRFYPASTFKIYNSLIGLNEKAVKDVDEVFYKYNGEKVFLESWAKDSNLRYAIKNSQ


 


VPAYKELARRIGLKKMKENIEKLDFGNKSIGDSVDTFWLEGPLEISAMEQVKLLTKLA


 


QNELPYPIEIQKAVSDITILEQTYNYTLHGKTGLADSKNMTTEPIGWFVGWLEENDNI


 


YVFALNIDNINSDDLAKRINIVKESLKALNLLK


 


SEQ ID No. 430:


MSKKNFILIFIFVILTSCKNTEKISNETTLIDNIFTNSNAEGTLVIYNLNDDKYIIHNKERA


 


EQRFYPASTFKIYNSLIGLNEKAVKDVDEVFYKYNGEKVFLESWAKDSNLRYAIKNS


 


QVPAYKELARRIGLKKMKENIEKLDFGNKSIGDSVDTFWLEGPLEISAMEQIKLLTKL


 


AQNELPYPIEIQKAVSDITILEQTYNYTLHGKTGLADSKNMTTEPIGWFVGWLEENDN


 


IYVFALNIDNINSDDLAKRINIVKESLKALNLLK


 


SEQ ID No. 431:


LLITSAIFISACSPYIVSANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIQQGQTQQSY


 


GNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLG


 


DAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQ


 


EAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLT


 


GWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSL


 


SEQ ID No. 432:


LLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSY


 


GNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLG


 


DAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQ


 


EAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLT


 


EWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSL


 


SEQ ID No. 433:


MTVRRLSCALGAALSLSALGGGPVQAAVLCTVVADAADGRILFQQGTQQACAERYT


 


PASTFKLAIALMGADAGILQGPHEPVWNYQPAYPDWGGDAWRQPTDPARWIKYSV


 


VWYSQLTAKALGQDRFQRYTSAFGYGNADVSGEPGKHNGTDGAWIISSLRISPLEQ


 


LAFLRKLVNRQLPVKAAAYELAENLFEAGQADGWRLYGKTGTGSPGSNGVYTAAN


 


AYGWFVGWARKDGRQLVYARLLQDERATRPNAGLRARDELVRDWPAMAGAWRP


 


SEQ ID No. 434:


MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNVLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQEVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 435:


MKTFAAYVIIACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLAR


 


ASKEYLPASTFKIPSAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVS


 


AVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEDQLRISAVNQVEFLES


 


LYLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEK


 


ETEVYFFAFNMDIDNESKLPLRKSIPTKIMESEGIIGG


 


SEQ ID No. 436:


MNIKTLLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 437:


MNIKALLLITSAIFISACSPYIVTTNPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNTDIGTQVDNFWLVGPLKI


 


TPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 438:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAVPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPL


 


KITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNQ


 


QVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 439:


MNIKTLLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEVHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEMTYKSLEQLGIL


 


SEQ ID No. 440:


MNKYFTCYVVASLFFSGCTVQHNLINETQSQIVQGHNQVIHQYFDEKNTSGVLVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTTWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVERIDFGNAEIGQQVDNFWLIGPLK


 


VTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEENNGYKIFGKTGWAMDIKPQV


 


GWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII


 


SEQ ID No. 441:


MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPL


 


KVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAAMDIKPQ


 


VGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII


 


SEQ ID No. 442:


MKTFAAYVITACLSSTALASSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNNLA


 


RASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLSLRGAIQV


 


SAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFLLEGQLRISAVNQVEFLE


 


SLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVE


 


KGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG


 


SEQ ID No. 443:


MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLV


 


FDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLR


 


SAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGDADPSTSNGDYWIEGSLAISAQE


 


QIAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVE


 


WPTGSVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR


 


SEQ ID No. 444:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDKKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKASTTEVFKWNGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVKSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 445:


MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSNEVKHVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 446:


MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSNEVKHVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 447:


MKKFILPILSISTLLSVSACSSIQTKFEDTFHTSNQQHEKAIKSYFDEAQTQGVIIIKKG


 


KNISTYGNNLTRAHTEYVPASTFKMLNALIGLENHKATTTEIFKWDGKKRSYPMWEK


 


DMTLGDAMALSAVPVYQELARRTGLDLMQKEVKRVGFGNMNIGTQVDNFWLVGPL


 


KITPIQEVNFADDFANNRLPFKLETQEEVKKMLLIKEFNGSKIYAKSGWGMDVTPQV


 


GWLTGWVEKSNGEKVAFSLNIEMKQGMPGSIRNEITYKSLENLGII


 


SEQ ID No. 448:


MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQEVQDEVQSILFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 449:


MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKSYFDEAQTQGVIIIKEGK


 


NLSTYGNALARANKEYVPASTFKMLNALIGLENHKATTNEIFKWDGKKRTYPMWEK


 


DMTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIGTQVDNFWLVGPL


 


KITPVQEVNFADDLAHNRLPFKLETQEEVKKMLLIKEVNGSKIYAKSGWGMGVTSQV


 


GWLTGWVEQANGKKIPFSLNLEMKEGMSGSIRNEITYKSLENLGII


 


SEQ ID No. 450:


MRVLALSAVFLVASIIGMPAVAKEWQENKSWNAHFTEHKSQGVVVLWNENKQQGF


 


TNNLKRANQAFLPASTFKIPNSLIALDLGVVKDEHQVFKWDGQTRDIATWNRDHNLI


 


TAMKYSVVPVYQEFARQIGEARMSKMLHAFDYGNEDISGNVDSFWLDGGIRISATE


 


QISFLRKLYHNKLHVSERSQRIVKQAMLTEANGDYIIRAKTGYSARIEPKIGWWVGW


 


VELDDNVWFFAMNMDMPTSDGLGLRQAITKEVLKQEKIIP


 


SEQ ID No. 451:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAVPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPL


 


KITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGLDVNPQ


 


VGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 452:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAVPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPL


 


KITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGLDVNLQ


 


VGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 453:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEKLGIL


 


SEQ ID No. 454:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIRNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 455:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDSKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 456:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDGVQSMLFIEEKNGNKIYAKSGWGWDVNPQ


 


VGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 457:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDSKKRLFPEWEK


 


DMTLGDAMKASAILVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKI


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 458:


MKLLKILSLVCLSISIGACAEHSMSRAKTSTIPQVNNSIIDQNVQALFNEISADAVFVTY


 


DGQNIKKYGTHLDRAKTAYIPASTFKIANALIGLENHKATSTEIFKWDGKPRFLKAWD


 


KDFTLGEAMQASTVPVYQELARRIGPSLMQSELQRIGYGNMQIGTEVDQFWLKGPL


 


TITPIQEVKFVYDLAQGQLPFKPEVQQQVKEMLYVERRGENRLYAKSGWGMAVDP


 


QVGWYVGFVEKADGQVVAFALNMQMKAGDDIALRKQLSLDVLDKLGVFHYL


 


SEQ ID No. 459:


MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPL


 


KVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDVKPQ


 


VGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII


 


SEQ ID No. 460:


MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGALVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPL


 


KVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQV


 


GWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII


 


SEQ ID No. 461:


MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPL


 


KVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQV


 


GWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELMMKSLKQLNII


 


SEQ ID No. 462:


MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPL


 


KVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQV


 


GWLAGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII


 


SEQ ID No. 463:


MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDERNTSGVLVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPL


 


KVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQV


 


GWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII


 


SEQ ID No. 464:


MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPL


 


KVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEKSNGYKIFGKTGWAMDIKPQV


 


GWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII


 


SEQ ID No. 465:


MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPL


 


KVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQV


 


GWLTGWVEQPDGKIVAFALNMEMRSEMPASTRNELLMKSLKQLNII


 


SEQ ID No. 466:


MKKFILPIFSISILLSLSACSSIQTKFEDTFHISNQKHEKAIKSYFDEAQTQGVIIIKEGKN


 


ISSYGNNLVRAHTEYVPASTFKMLNALIGLENHKATTNEIFKWDGKKRSYPMWEKD


 


MTLGEAMALSAVPVYQDLARRIGLNLMQKEVKRVGFGNMNIGTQVDNFWLIGPLKI


 


TPIQEVNFADDLANNRLPFKLETQEEVKKMLLIKEVNGSKIYAKSGWGMDVSPQVG


 


WLTGWVEKSNGEKVSFSLNIEMKQGMSGSIRNEITYKSLENLGII


 


SEQ ID No. 467:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


DMTLGDAMKASAIAVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 468:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


DMTLGDAIKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKI


 


TPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 469:


MKILIFLPLLSCLGLTACSLPVSSLPSQSISTQAIASLFDQAQSSGVLVIQRDQQVQVY


 


GNDLNRANTEYVPASTFKMLNALIGLQHGKATTNEIFKWDGKKRSFTAWEKDMTLG


 


QAMQASAVPVYQELARRIGLELMQQEVQRIQFGNQQIGQQVDNFWLVGPLKVTPK


 


QEVQFVSALAREQLAFDPQVQQQVKAMLFLQERKAYRLYVKSGWGMDVEPQVGW


 


LTGWVETPQAEIVAFSLNMQMQNGIDPAIRLEILQQALAELGLYPKAEG


 


SEQ ID No. 470:


MHKHMSKLFIAFLAFLLSVPAAAEDQTLAELFAQQGIDGTIVISSLHNGKTFIHNDPRA


 


KQRFSTASTFKILNTLISLEEKAISGKDDVLKWDGHIYDFPDWNRDQTLESAFKVSCV


 


WCYQALARQVGAEKYRNYLRKSVYGELREPFEETTFWLDGSLQISAIEQVNFLKKV


 


HLRTLPFSASSYETLRQIMLIEQTPAFTLRAKTGWATRVKPQVGWYVGHVETPTDV


 


WFFATNIEVRDEKDLPLRQKLTRKALQAKGIIE


 


SEQ ID No. 471:


MKTFAAYVITACLSSTALASSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNNLA


 


RASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLSLRGAIQV


 


SAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGTDKFWLEDQLRISAVNQVEFL


 


ESLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWV


 


EKGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG


 


SEQ ID No. 472:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAILVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKI


 


TPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGLDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 473:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIQVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 474:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAMPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPL


 


KITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQ


 


VGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 475:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEVHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 476:


MRVLALSAVFLVASIIGMPAVAKEWQENKSWNAHFTEHKSQGVVVLWNENKQQGF


 


TNNLKRANQAFLPASTFKIPNSLIALDLGVVKDEHQVFKWDGQTRDIATWNRDHNLI


 


TAMKYSVVPVYQEFARQIGEARMSKMLHAFDYGNEDISGNVDSFWLDGGIRISATE


 


QISFLRKLYHNKLHVSERSQRIVKQAMLTEANGDYIIRAKTGYDTKIGWWVGWVELD


 


DNVWFFAMNMDMPTSDGLGLRQAITKEVLKQEKIIP


 


SEQ ID No. 477:


MSKKNFILIFIFVILISCKNTEKTSNETTLIDNIFTNSNAEGTLVIYNLNDDKYIIHNKERA


 


EQRFYPASTFKIYNSLIGLNEKAVKDVDEVFYKYNGEKVFLESWAKDSNLRYAIKNS


 


QVPAYKELARRIGLEKMKENIEKLDFGNKNIGDSVDTFWLEGPLEISAMEQVKLLTKL


 


AQNELPYPIEIQKAVSDITILEQTDNYTLHGKTGLADSENMTTEPIGWLVGWLEENNN


 


IYVFALNIDNINSDDLAKRINIVKESLKALNLLK


 


SEQ ID No. 478:


MNIKALFLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 479:


MNIKALFLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPSSQKVQDEVQSMLFIEEKNGNKMYAKSGWGWDVNPQ


 


VGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 480:


MNIKALFLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEIAYKSLEQLGIL


 


SEQ ID No. 481:


MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLV


 


FDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLR


 


SAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNADPSTSNGDCWIEGSLAISAQE


 


QIAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVE


 


WPTGSVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR


 


SEQ ID No. 482:


MNIKTLLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEVHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLK


 


ITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 483:


MNIKTLLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEVHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEYHKATTTEVFKWDGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 484:


MAIRFLTILLSTFFLTSFVHAQEHVVVRSDWKKFFSDLQAEGAIVIADERQAEHALLV


 


FGQERAAKRYSPASTFKLPHTLFALDAGAVRDEFQVFRWDGVKRSFAGHNQDQDL


 


RSAMRNSAVWVYELFAKEIGEDNARRYLKQIDYGNADPSTIKGNYWIDGNLEISAHE


 


QISFLRKLYRNQLPFQVEHQRLVKYLMITEAGRNWILRAKTGWEGRFGWWIGWVE


 


WPTGPVFFALNIDTPNRTDDLFKREAIARAILRSIDALPPN


 


SEQ ID No. 485:


MRVLALSAVFLVASIIGMPAVAKEWQENKSWNAHFTEHKSQGVVVLWNENKQQGF


 


TNNLKRANQAFLPASTFKIPNSLIALDLGVVKDEHQVFKWDGQTRDIAAWNRDHDLI


 


TAMKYSVVPVYQEFARQIGEARMSKMLHAFDYGNEDISGNVDSFWLDGGIRISATQ


 


QIAFLRKLYHNKLHVSERSQRIVKQAMLTEANGDYIIRAKTGYSTRIEPKIGWWVGW


 


VELDDNVWFFAMNMDMPTSDGLGLRQAITKEVLKQEKIIP


 


SEQ ID No. 486:


MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPL


 


KVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKSQV


 


GWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII


 


SEQ ID No. 487:


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAISVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 488:


MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLV


 


FDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLR


 


SAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNADPSTSNGDYWIEGSLAISAQE


 


QIAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVE


 


WPTGSVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR


 


SEQ ID No. 489:


MKTIAAYLVLVFYASTALSESISENLAWNKEFSSESVHGVFVLCKSSSNSCTTNNAA


 


RASTAYIPASTFKIPNALIGLETGAIKDERQVFKWDGKPRAMKQWEKDLKLRGAIQV


 


SAVPVFQQIAREVGEIRMQKYLNLFSYGNANIGGGIDKFWLEGQLRISAFNQVKFLE


 


SLYLNNLPASKANQLIVKEAIVTEATPEYIVHSKTGYSGVGTESSPGVAWWVGWVE


 


KGTEVYFFAFNMDIDNESKLPSRKSISTKIMASEGIIIGG


 


SEQ ID No. 490:


MKTFAAYVITACLSSTALASSITENTFWNKEFSAEAVNGVFVLCKSSSKLACATNNLA


 


RASKEYLPASTFKIPNAIIGLETGVIKNEHQIFKWDGKPRAMKQWERDLSLRGAIQVS


 


AVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLE


 


SLFLNKLSASKENQLIVKEALVTEAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEK


 


GAEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG


 


SEQ ID No. 491:


MAIRIFAILFSTFVFGTFAHAQEGMRERSDWRKFFSEFQAKGTIVVADERQTDRVILV


 


FDQVRSEKRYSPASTFKIPHTLFALDAGAARDEFQVFRWDGIKRSFAAHNQDQDLR


 


SAMRNSTVWIYELFAKEIGEDKARRYLKQIDYGNADPSTSNGDYWIDGNLAIAAQEQ


 


IAFLRKLYHNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVE


 


WPTGPVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR


 


SEQ ID No. 492:


MKTFAAYVIIACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLAR


 


ASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVS


 


AVPVFQQIAREVGEVRMQKYLKKFSYGSQNISGGIDKFWLEDQLRISAVNQVEFLES


 


LYLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEK


 


ETEVYFFAFNMDIDNESKLPLRKSIPTKIMESEGIIGG


 


SEQ ID No. 493


MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQT


 


DKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWE


 


KDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPL


 


KVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQV


 


GWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII


 


SEQ ID No. 494


MKKLSVLLWLTLFYCGTIWAQSTCFLVQENQTVLKHEGKDCNKRFAPESTFKIALSL


 


MGFDSGILKDTLNPEWPYKKEYELYLNVWKYPHNPRTWIRDSCVWYSQVLTQQLG


 


MTRFKNYVDAFHYGNQDISGDKGQNNGLTHSWLSSSLAISPSEQIQFLQKIVNKKLS


 


VNPKAFTMTKDILYIQELAGGWKLYGKTGNGRQLTKDKSQKLSLQHGWFIGWIEKD


 


GRVITFTKHIADSKKHVTFASFRAKNETLNQLFYLINELEK


 


SEQ ID No. 495


MNIKTLLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEVHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 496


MKFRHALSSAFVLLGCIAASAHAKTICTAIADAGTGKLLVQDGDCGRRASPASTFKIA


 


ISLMGYDAGFLRNEHDPVLPYRDSYIAWGGEAWKQPTDPTRWLKYSVVWYSQQV


 


AHHLGAQRFAQYAKAFGYGNADVSGDPGQNNGLDRAWIGSSLQISPLEQLEFLGK


 


MLNRKLPVSPTAVDMTERIVESTTLADGTWHGKTGVSYPLLADGTRDWARGSGW


 


FVGWIVRGNQTLVFARLTQDERKQPVSAGIRTREAFLRDLPRLLAAR


 


SEQ ID No. 497


MKFRHALSSAFVLLGCIAASAHAKTICTAIADAGTGKLLVQDGDCGRRASPASTFKIA


 


ISLMGYDAGFLRNEHDPVLPYRDSYIAWGGEAWKQPTDPTRWLKYPVVWYSQQV


 


AHHLGAQRFAQYAKAFGYGNADVSGDPGQNNGLDRAWIGSSLQISPLEQLEFLGK


 


MLNRKLPVSPTAVDMTERIVESTTLADGTVVHGKTGVSYPLLADGTRDWARGSGW


 


FVGWIVRGKQTLVFARLTQDERKQPVSAGIRTREAFLRDLPRLLAAR


 


SEQ ID No. 498


MRGKHTVILGAALSALFAGAAGAQMLECTLVADAASGQELYRKGACDKAFAPMSTF


 


KVPLAVMGYDAGILVDAHNPRWDYKPEFNGYKFQQKTTDPTIWEKDSIVWYSQQLT


 


RKMGQKRFAAYVAGFGYGNGDISGEPGKSNGLTHSWLGSSLKISPEGQVRFVRDL


 


LSAKLPASKDAQQMTVSILPHFAAGDWAVQGKTGTGSFIDARGAKAPLGWFIGWAT


 


HEERRVVFARMTAGGKKGEQPAGPAARDAFLKALPDLAKRF


 


SEQ ID No. 499


MKFRHALSSAFVLLGCIAASAHAKTICTAIADAGTGKLLVQDGDCGRRASPASTFKIA


 


ISLMGYDAGFLRNEHDPVLPYRDSYIAWGGEAWKQPTDPTRWLKYSVVWYSQQV


 


AHHLGAQRFAQYAKAFGYGNADVSGDPGQNNGLDRAWIGSSLQISPLEQLEFLGK


 


MLDRKLPVSPTAVDMTERIVESTTLADGTVVHGKTGVSYPLLADGTRDWARGSGW


 


FVGWIVRGKQTLVFARLTQDERKQPVSAGIRTREAFLRDLPRLLAAR


 


SEQ ID No. 500


MKFRHALSSAFVLLGCIAASAHAKTICTAIADAGTGKLLVQDGDCGRRASPASTFKIA


 


ISLMGYDAGFLRNEHDPVLPYRDSYIAWGGEAWKQPTDPTRWLKYSVVWYSQQV


 


AHHLGAQRFAQYAKAFGYGNADVSGDPGQNNGLDRAWIGSSLQISPLEQLEFLGK


 


MLNRKLPVSPTAVDMTERIVESTTILADGTVVHGKTGVSYPLLADGTRDWARGSGW


 


FVGWIVRGKQTLVFARLTQDERKQPVSAGIRTREAFLRDLPRLLAAR


 


SEQ ID No. 501


MKTFAAYVIIACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLAR


 


ASKEYLPVSTFKIPSAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVS


 


AVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLE


 


SLYLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVE


 


KETEVYFFAFNMDIDNESKLPLRKSIPTKIMESEGIIGG


 


SEQ ID No. 502


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 503


MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


NMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 504


MKTFAAYVITACLSSTALASSITENTFWNKEFSAEAVNGVFVLCKSSSKSCATNNLA


 


RASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLSLRGAIQV


 


SAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFL


 


ESLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWV


 


EKGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG


 


SEQ ID No. 505


MKTIAAYLVLVFFAGTALSESISENLAWNKEFSSESVHGVFVLCKSSSNSCTTNNAT


 


RASTAYIPASTFKIPNALIGLETGAIKDARQVFKWDGKPRAMKQWEKDLTLRGAIQV


 


SAVPVFQQIARDIGKKRMQKYLNLFSYGNANIGGGIDKFWLEGQLRISAVNQVKFLE


 


SLYLNNLPASKANQLIVKEAIVTEATPEYIVHSKTGYSGVGTESNPGVAWWVGWVE


 


KGTEVYFFAFNMDIDNESKLPSRKSIPTKIMASEGIIIGG


 


SEQ ID No. 506


MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKSYFDEAQTQGVIIIKEGK


 


NLSTYGNALARANKEYVPASTFKMLIALIGLENHKATTNEIFKWDGKKRTYPMWEKD


 


MTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIGTQVDNFWLVGPLKI


 


TPVQEVNFADDLAHNRLPFKLETQEEVKKMLLIKEVNGSKIYAKSGWGMGVTPQVG


 


WLTGWVEQANGKKIPFSLNLEMKEGMSGSIRNEITYKSLENLGII


 


SEQ ID No. 507


MNIKALLLITSAIFISACSPYIVTANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIHQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWNGQKRLFPEWEK


 


DMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLK


 


ITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL


 


SEQ ID No. 508


MNIKALLLITSAISISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ


 


TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEK


 


DMTLGDAIKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKI


 


TPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQV


 


GWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL






said peptides being chosen, preferably, from the peptides of sequence SEQ ID No. 509 to SEQ ID No. 523, SEQ ID No. 525 to SEQ ID No. 572, SEQ ID No. 574 to SEQ ID No. 604, SEQ ID No. 606 to SEQ ID No. 618, SEQ ID No. 620 to SEQ ID No. 696, SEQ ID No. 698 to SEQ ID No. 1077 and SEQ ID No. 1098 to SEQ ID No. 1109, as defined hereafter:













Peptide

Position of the peptide in the OXA
Clinical


SEQ ID No.
Amino acid sequence
protein(s)
interest







SEQ ID
AAAYELAENLFEAGQADGWR
183-202 for the protein of SEQ No. 433
2d


No. 509


 


SEQ ID
AAEGFIPASTFK
86-97 for the protein of SEQ No. 381
2df


No. 510


 


SEQ ID
AALGR
41-45 for the protein of SEQ No. 382
2df


No. 511


 


SEQ ID
ADGQVVAFALNMQMK
241-255 for the proteins of SEQ No. 410,
2df


No. 512

413, 458


 


SEQ ID
ADINEIFK
95-102 for the protein of SEQ No. 366
2df


No. 513


 


SEQ ID
ADWGK
50-54 for the protein of SEQ No. 382
2df


No. 514


 


SEQ ID
AEGAIVISDER
40-50 for the proteins of SEQ No. 369, 372
OXA


No. 515


 


SEQ ID
AFALNLDIDK
222-231 for the protein of SEQ No. 385
2d


No. 516


 


SEQ ID
AFAPMSTFK
49-57 for the protein of SEQ No. 498; 60-68
OXA


No. 517

for the protein of sequence SEQ ID No. 351


 


SEQ ID
AFGYGNADVSGDPGQNNGLDR
127-147 for the proteins of SEQ No. 496,
2d


No. 518

497, 499, 500


 


SEQ ID
AFTMTK
174-179 for the protein of SEQ No. 494
2d


No. 519


 


SEQ ID
AGDDIALR
256-263 for the proteins of SEQ No. 410,
2df


No. 520

413, 458


 


SEQ ID
AGHVYAFALNIDMPR
233-247 for the protein of SEQ No. 379
2df


No. 521


 


SEQ ID
AGLWR
11-15 for the protein of SEQ No. 382
2df


No. 522


 


SEQ ID
AHTEYVPASTFK
73-84 for the proteins of SEQ No. 447, 466
2df


No. 523


 


SEQ ID
AIIPWDGK
112-119 for the protein of SEQ No. 382
2df


No. 524


 


SEQ ID
AIIPWDGKPR
112-121 for the protein of SEQ No. 382
2df


No. 525


 


SEQ ID
AISDITITR
190-198 for the protein of SEQ No. 386
2d


No. 526


 


SEQ ID
AISGK
82-86 for the protein of SEQ No. 470
2df


No. 527


 


SEQ ID
ALGQDR
121-126 for the protein of SEQ No. 433
2d


No. 528


 


SEQ ID
ALPDLAK
256-262 for the protein of SEQ No. 498
2d


No. 529


 


SEQ ID
ALQAK
254-258 for the protein of SEQ No. 470
2df


No. 530


 


SEQ ID
AMETFSPASTFK
50-61 for the protein of SEQ No. 385
2d


No. 531


 


SEQ ID
AMLFLQER
196-203 for the protein of SEQ No. 469
2df


No. 532


 


SEQ ID
AMLVFDPVR
55-63 for the proteins of SEQ No. 350, 367,
OXA


No. 533

370, 415, 443, 481, 488; 44-52 for the protein




of sequence SEQ ID No. 362


 


SEQ ID
AMTLLESGPGWELHGK
189-204 for the protein of SEQ No. 380
2d


No. 534


 


SEQ ID
ANLHITLHGK
199-208 for the protein of SEQ No. 386
2d


No. 535


 


SEQ ID
ANQLIVK
183-189 for the proteins of SEQ No. 489, 505
OXA


No. 536


 


SEQ ID
ANTEYVPASTFK
71-82 for the proteins of SEQ No. 366, 374,
2df


No. 537

387, 440, 441, 459, 460, 461, 462, 463, 464,




465, 486, 493; 66-77 for the protein of




sequence SEQ ID No. 469


 


SEQ ID
ANVSR
133-137 for the protein of SEQ No. 380
2d


No. 538


 


SEQ ID
APIGWFIGWATR
224-235 for the protein of SEQ No. 351
2de


No. 539


 


SEQ ID
APLGWFIGWATHEER
213-227 for the protein of SEQ No. 498
2d


No. 540


 


SEQ ID
AQDEVQSMLFIEEK
196-209 for the protein of SEQ No. 403
2df


No. 541


 


SEQ ID
AQGVIVLWNENK
40-51 for the protein of SEQ No. 384
2df


No. 542


 


SEQ ID
ASAIAVYQDLAR
126-137 for the protein of SEQ No. 467
2df


No. 543


 


SEQ ID
ASAILVYQDLAR
126-137 for the proteins of SEQ No. 417,
2df


No. 544

426, 457, 472


 


SEQ ID
ASAIPVYQDLAR
126-137 for the proteins of SEQ No. 388,
2df


No. 545

389, 390, 391, 392, 393, 394, 395, 396, 398,




399, 402, 403, 404, 405, 406, 407, 408, 409,




411, 412, 416, 418, 419, 420, 423, 424, 425,




427, 428, 434, 436, 437, 439, 444, 445, 446,




448, 453, 454, 455, 456, 468, 475, 478, 479,




480, 482, 483, 495, 502, 503, 507, 508; 120-131




for the proteins of sequence SEQ ID No.




431, 432


 


SEQ ID
ASAIPVYQDLPR
126-137 for the protein of SEQ No. 397
2df


No. 546


 


SEQ ID
ASAIQVYQDLAR
126-137 for the proteins of SEQ No. 421, 473
2df


No. 547


 


SEQ ID
ASAISVYQDLAR
126-137 for the proteins of SEQ No. 400, 487
2df


No. 548


 


SEQ ID
ASALPVYQDLAR
126-137 for the proteins of SEQ No. 401, 422
2df


No. 549


 


SEQ ID
ASAMPVYQDLAR
126-137 for the protein of SEQ No. 474
2df


No. 550


 


SEQ ID
ASAVPVYQDLAR
126-137 for the proteins of SEQ No. 438,
2df


No. 551

451, 452


 


SEQ ID
ASIEYVPASTFK
72-83 for the proteins of SEQ No. 399, 403
2df


No. 552


 


SEQ ID
ASNVPVYQELAR
113-124 for the protein of SEQ No. 380
2d


No. 553


 


SEQ ID
ASPASTFK
49-56 for the proteins of SEQ No. 496, 497,
2d


No. 554

499, 500


 


SEQ ID
ASTAYIPASTFK
59-70 for the proteins of SEQ No. 489, 505
OXA


No. 555


 


SEQ ID
ASTEYVPASTFK
72-83 for the proteins of SEQ No. 388, 389,
2df


No. 556

390, 391, 392, 393, 394, 395, 396, 397, 398,




400, 401, 402, 404, 405, 406, 407, 408, 409,




411, 412, 416, 417, 418, 419, 420, 421, 422,




423, 424, 425, 426, 427, 428, 434, 436, 437,




438, 439, 444, 445, 446, 448, 451, 452, 453,




454, 455, 456, 457, 467, 468, 472, 473, 474,




475, 478, 479, 480, 482, 483, 487, 495, 502,




503, 507, 508; 66-77 for the proteins of




sequence SEQ ID No. 431, 432


 


SEQ ID
ASTTEVFK
96-103 for the protein of SEQ No. 444
2df


No. 557


 


SEQ ID
ATSTEIFK
99-106 for the proteins of SEQ No. 410, 413,
2df


No. 558

458


 


SEQ ID
ATTNEIFK
97-104 for the proteins of SEQ No. 364, 365,
2df


No. 559

371, 414, 449, 466, 506; 90-97 for the protein




of sequence SEQ ID No. 469


 


SEQ ID
ATTTAVFK
96-103 for the protein of SEQ No. 396
2df


No. 560


 


SEQ ID
ATTTEIFK
97-104 for the protein of SEQ No. 447; 96-103


No. 561

for the proteins of sequence SEQ ID No.
2df




399, 403, 411


 


SEQ ID
ATTTEVFK
96-103 for the proteins of SEQ No. 388, 389,
2df


No. 562

390, 391, 392, 393, 394, 397, 398, 400, 401,




402, 404, 405, 406, 407, 408, 409, 412, 416,




417, 418, 419, 420, 421, 422, 423, 424, 425,




426, 427, 434, 436, 437, 438, 439, 445, 446,




448, 451, 452, 453, 454, 455, 456, 457, 467,




468, 472, 473, 474, 475, 478, 479, 480, 482,




483, 487, 495, 502, 503, 507, 508; 90-97 for




the proteins of sequence SEQ ID No. 431,




432


 


SEQ ID
AVSDITILEQTDNYTLHGK
191-209 for the protein of SEQ No. 477
OXA


No. 563


 


SEQ ID
AVSDITILEQTYNYTLHGK
191-209 for the proteins of SEQ No. 429, 430
2d


No. 564


 


SEQ ID
AVVPHFEAGDWDVQGK
195-210 for the protein of SEQ No. 351
2de


No. 565


 


SEQ ID
AWEHDMSLR
100-108 for the protein of SEQ No. 380
2d


No. 566


 


SEQ ID
AWIGSSLQISPLEQLEFLGK
148-167 for the proteins of SEQ No. 496,
2d


No. 567

497, 499, 500


 


SEQ ID
CAAQMAPDSTFK
63-74 for the protein of SEQ No. 376
2d


No. 568


 


SEQ ID
CATQMAPDSTFK
48-59 for the protein of SEQ No. 361; 63-74
2d


No. 569

for the protein of sequence SEQ ID No. 360


 


SEQ ID
CTIIADAITGNTLYETGECAR
32-52 for the protein of SEQ No. 349
2d


No. 570


 


SEQ ID
DAFLK
251-255 for the protein of SEQ No. 498
2d


No. 571


 


SEQ ID
DDFILHGK
189-196 for the protein of SEQ No. 377
2d


No. 572


 


SEQ ID
DDQEVLPYGGK
92-102 for the protein of SEQ No. 379
2df


No. 573


 


SEQ ID
DDVLK
87-91 for the protein of SEQ No. 470
2df


No. 574


 


SEQ ID
DEFHVFR
90-96 for the proteins of SEQ No. 355, 363
2d


No. 575


 


SEQ ID
DEFQIFR
90-96 for the proteins of SEQ No. 350, 367,
OXA


No. 576

370, 375, 415, 443, 481, 488; 79-85 for the




protein of sequence SEQ ID No. 362


 


SEQ ID
DEFQVFR
90-96 for the proteins of SEQ No. 356, 369,
2d


No. 577

372, 373, 484, 491


 


SEQ ID
DELVR
260-264 for the protein of SEQ No. 433
2d


No. 578


 


SEQ ID
DETSR
112-116 for the protein of SEQ No. 381
2df


No. 579


 


SEQ ID
DFDYGNQDFSGDK
141-153 for the proteins of SEQ No. 360,
2d


No. 580

376; 126-138 for the protein of sequence




SEQ ID No. 361


 


SEQ ID
DFTLGEAMQASTVPVYQELAR
120-140 for the proteins of SEQ No. 410,
2df


No. 581

413, 458


 


SEQ ID
DGNITSVAINIDMLSEADAPK
250-270 for the protein of SEQ No. 382
2df


No. 582


 


SEQ ID
DHDLITAMK
108-116 for the proteins of SEQ No. 384, 485
2df


No. 583


 


SEQ ID
DIAAWNR
101-107 for the proteins of SEQ No. 384, 485
2df


No. 584


 


SEQ ID
DIGEDK
131-136 for the protein of SEQ No. 373
2d


No. 585


 


SEQ ID
DILYIQELAGGWK
180-192 for the protein of SEQ No. 494
2de


No. 586


 


SEQ ID
DITILEK
181-187 for the protein of SEQ No. 377
2d


No. 587


 


SEQ ID
DLLSAK
166-171 for the protein of SEQ No. 498
2d


No. 588


 


SEQ ID
DLMITEAGR
195-203 for the proteins of SEQ No. 369,
2d


No. 589

372, 373


 


SEQ ID
DLMIVEAGR
195-203 for the proteins of SEQ No. 350,
OXA


No. 590

356, 367, 370, 375, 415, 443, 481, 488, 491;




184-192 for the protein of sequence SEQ ID




No. 362


 


SEQ ID
DLMIVEAK
195-202 for the proteins of SEQ No. 355, 363
2d


No. 591


 


SEQ ID
DLPLR
243-247 for the protein of SEQ No. 470
2df


No. 592


 


SEQ ID
DLSGNPGK
131-138 for the protein of SEQ No. 347
2d


No. 593


 


SEQ ID
DLSLR
105-109 for the proteins of SEQ No. 357,
OXA


No. 594

358, 359, 368, 383, 442, 471, 504; 106-110




for the protein of sequence SEQ ID No. 490


 


SEQ ID
DLTLR
105-109 for the proteins of SEQ No. 352,
OXA


No. 595

435, 492, 501, 505; 96-100 for the proteins of




sequence SEQ ID No. 348, 353, 354


 


SEQ ID
DMTLGDAIK
117-125 for the proteins of SEQ No. 468, 508
2df


No. 596


 


SEQ ID
DMTLGDAMALSAVPVYQELAR
118-138 for the protein of SEQ No. 447
2df


No. 597


 


SEQ ID
DMTLGDAMK
117-125 for the proteins of SEQ No. 389,
2df


No. 598

390, 391, 394, 395, 398, 399, 400, 401, 403,




404, 407, 408, 409, 411, 412, 417, 418, 420,




421, 423, 425, 426, 427, 428, 436, 437, 438,




439, 444, 451, 452, 453, 454, 455, 456, 457,




467, 472, 473, 474, 478, 479, 480, 482, 483,




487, 495, 502, 507


 


SEQ ID
DMTLGEAMALSAVPVYQDLAR
118-138 for the protein of SEQ No. 466
2df


No. 599


 


SEQ ID
DMTLGEAMALSAVPVYQELAR
118-138 for the proteins of SEQ No. 364,
2df


No. 600

365, 371, 414, 449, 506


 


SEQ ID
DMTLGEAMK
116-124 for the proteins of SEQ No. 366,
2df


No. 601

374, 387, 440, 441, 459, 460, 461, 462, 463,




464, 465, 486, 493


 


SEQ ID
DMTLGQAMQASAVPVYQELAR
111-131 for the protein of SEQ No. 469
2df


No. 602


 


SEQ ID
DNNGK
214-218 for the protein of SEQ No. 349
2d


No. 603


 


SEQ ID
DQDLR
110-114 for the proteins of SEQ No. 350,
2d


No. 604

356, 367, 369, 370, 372, 373, 375, 415, 443,




481, 484, 488, 491; 99-103 for the protein of




sequence SEQ ID No. 362


 


SEQ ID
DQQIGWFVGWASK
213-225 for the protein of SEQ No. 347
2d


No. 605


 


SEQ ID
DQQIGWFVGWASKPGK
213-228 for the protein of SEQ No. 347
2d


No. 606


 


SEQ ID
DQQVQVYGNDLNR
53-65 for the protein of SEQ No. 469
2df


No. 607


 


SEQ ID
DQSFR
132-136 for the protein of SEQ No. 381
2df


No. 608


 


SEQ ID
DQTLESAFK
105-113 for the protein of SEQ No. 470
2df


No. 609


 


SEQ ID
DSCVWYSQVLTQQLGMTR
98-115 for the protein of SEQ No. 494
2de


No. 610


 


SEQ ID
DSIVWYSQELTR
113-124 for the protein of SEQ No. 351
2de


No. 611


 


SEQ ID
DSIVWYSQQLTR
102-113 for the protein of SEQ No. 498
2d


No. 612


 


SEQ ID
DSNLR
109-113 for the proteins of SEQ No. 429,
2d


No. 613

430, 477; 96-100 for the proteins of sequence




SEQ ID No. 377, 386


 


SEQ ID
DSYIAWGGEAWK
81-92 for the proteins of SEQ No. 496, 497,
2d


No. 614

499, 500


 


SEQ ID
DTLNPEWPYK
67-76 for the protein of SEQ No. 494
2de


No. 615


 


SEQ ID
DVDEVFYK
88-95 for the proteins of SEQ No. 386, 429,
2d


No. 616

430, 477


 


SEQ ID
DVSGDPGK
144-151 for the protein of SEQ No. 351
2de


No. 617


 


SEQ ID
DWILR
204-208 for the proteins of SEQ No. 355, 363
2d


No. 618


 


SEQ ID
DWPAMAGAWR
265-274 for the protein of SEQ No. 433
2d


No. 619


 


SEQ ID
EAFLR
256-260 for the proteins of SEQ No. 496,
2d


No. 620

497, 499, 500


 


SEQ ID
EAIAR
250-254 for the proteins of SEQ No. 355,
2d


No. 621

363, 369, 372, 373, 375, 484


 


SEQ ID
EAIVR
250-254 for the proteins of SEQ No. 350,
OXA


No. 622

356, 367, 370, 415, 443, 481, 488, 491; 239-243




for the protein of sequence SEQ ID No.




362


 


SEQ ID
EAIVTEATPEYIVHSK
190-205 for the proteins of SEQ No. 489, 505
OXA


No. 623


 


SEQ ID
EALVTEAAPEYLVHSK
190-205 for the proteins of SEQ No. 352,
OXA


No. 624

357, 358, 359, 368, 383, 435, 442, 471, 492,




501, 504; 181-196 for the proteins of




sequence SEQ ID No. 348, 353, 354


 


SEQ ID
EALVTEAPEYLVHSK
191-205 for the protein of SEQ No. 490
2d


No. 625


 


SEQ ID
EEIVR
240-244 for the protein of SEQ No. 377
2d


No. 626


 


SEQ ID
EEVLAALPAQLK
251-262 for the protein of SEQ No. 347
2d


No. 627


 


SEQ ID
EFNGSK
209-214 for the protein of SEQ No. 447
2df


No. 628


 


SEQ ID
EFSAEAVNGVFVLCK
31-45 for the proteins of SEQ No. 352, 357,
OXA


No. 629

358, 359, 368, 383, 435, 442, 471, 490, 492,




501, 504; 22-36 for the proteins of sequence




SEQ ID No. 348, 353, 354


 


SEQ ID
EFSSESVHGVFVLCK
31-45 for the proteins of SEQ No. 489, 505
OXA


No. 630


 


SEQ ID
EGDMAK
248-253 for the protein of SEQ No. 379
2df


No. 631


 


SEQ ID
EGMSGSIR
254-261 for the proteins of SEQ No. 364,
2df


No. 632

371, 414, 449, 506


 


SEQ ID
EGMTGSIR
254-261 for the protein of SEQ No. 365
2df


No. 633


 


SEQ ID
EGSCDK
54-59 for the protein of SEQ No. 351
2de


No. 634


 


SEQ ID
EIAVWNR
125-131 for the protein of SEQ No. 381
2df


No. 635


 


SEQ ID
EIAYK
262-266 for the protein of SEQ No. 480
2df


No. 636


 


SEQ ID
EIFER
20-24 for the protein of SEQ No. 377
2d


No. 637


 


SEQ ID
EIFYHYR
79-85 for the protein of SEQ No. 385
2d


No. 638


 


SEQ ID
EIGDDK
131-136 for the proteins of SEQ No. 350,
OXA


No. 639

367, 370, 415, 443, 481, 488; 120-125 for the




protein of sequence SEQ ID No. 362


 


SEQ ID
EIGDGK
131-136 for the protein of SEQ No. 375
2d


No. 640


 


SEQ ID
EIGEDK
131-136 for the proteins of SEQ No. 356,
2d


No. 641

372, 491


 


SEQ ID
EIGEDNAR
131-138 for the protein of SEQ No. 484
OXA


No. 642


 


SEQ ID
EIGENK
131-136 for the proteins of SEQ No. 355, 363
2d


No. 643


 


SEQ ID
EIGPK
153-157 for the protein of SEQ No. 381
2df


No. 644


 


SEQ ID
EIGSEIDK
136-143 for the protein of SEQ No. 377
2d


No. 645


 


SEQ ID
EITYK
262-266 for the proteins of SEQ No. 389,
2df


No. 646

390, 391, 392, 393, 394, 395, 396, 397, 398,




399, 400, 401, 402, 403, 404, 405, 406, 407,




408, 409, 411, 412, 416, 417, 418, 419, 420,




421, 422, 423, 424, 425, 426, 427, 428, 434,




436, 437, 438, 444, 445, 446, 448, 451, 452,




453, 454, 455, 456, 457, 467, 468, 472, 473,




474, 475, 478, 479, 482, 483, 487, 495, 502,




503, 507, 508; 263-267 for the proteins of




sequence SEQ ID No. 364, 365, 371, 414,




447, 449, 466, 506; 256-260 for the proteins




of sequence SEQ ID No. 431, 432


 


SEQ ID
EITYR
262-266 for the protein of SEQ No. 388
2df


No. 647


 


SEQ ID
EMIYLK
181-186 for the protein of SEQ No. 385
2d


No. 648


 


SEQ ID
EMLYVER
205-211 for the proteins of SEQ No. 410,
2df


No. 649

413, 458


 


SEQ ID
EMTYK
262-266 for the protein of SEQ No. 439
2df


No. 650


 


SEQ ID
ENIEK
138-142 for the proteins of SEQ No. 429,
2d


No. 651

430, 477; 137-141 for the protein of sequence




SEQ ID No. 386


 


SEQ ID
ENQLIVK
183-189 for the proteins of SEQ No. 352,
OXA


No. 652

357, 358, 359, 368, 383, 435, 442, 471, 492,




501, 504; 174-180 for the proteins of




sequence SEQ ID No. 348, 353, 354; 184-190




for the protein of sequence SEQ ID No.




490


 


SEQ ID
EQAILLFR
156-163 for the protein of SEQ No. 385
2d


No. 653


 


SEQ ID
EQIQFLLR
165-172 for the protein of SEQ No. 349
2d


No. 654


 


SEQ ID
EQLAFDPQVQQQVK
182-195 for the protein of SEQ No. 469
2df


No. 655


 


SEQ ID
EQVDFVQR
189-196 for the protein of SEQ No. 382
2df


No. 656


 


SEQ ID
ETEVYFFAFNMDIDNESK
229-246 for the proteins of SEQ No. 352,
OXA


No. 657

435, 492, 501; 220-237 for the proteins of




sequence SEQ ID No. 348, 353, 354


 


SEQ ID
ETTTPR
90-95 for the protein of SEQ No. 347
2d


No. 658


 


SEQ ID
EVGEIR
126-131 for the protein of SEQ No. 489
2d


No. 659


 


SEQ ID
EVGEVR
126-131 for the proteins of SEQ No. 352,
OXA


No. 660

357, 358, 359, 368, 383, 435, 442, 471, 492,




501, 504; 117-122 for the proteins of




sequence SEQ ID No. 348, 353, 354; 127-132




for the protein of sequence SEQ ID No.




490


 


SEQ ID
EVNGSK
209-214 for the proteins of SEQ No. 364,
2df


No. 661

365, 371, 414, 449, 466, 506


 


SEQ ID
EWQENK
24-29 for the proteins of SEQ No. 378, 450,
2df


No. 662

476, 485


 


SEQ ID
EYELYLNVWK
78-87 for the protein of SEQ No. 494
2de


No. 663


 


SEQ ID
EYLPASTFK
62-70 for the proteins of SEQ No. 352, 357,
OXA


No. 664

358, 359, 368, 383, 435, 442, 471, 492, 504;




53-61 for the proteins of sequence SEQ ID




No. 348, 353, 354; 63-71 for the protein of




sequence SEQ ID No. 490


 


SEQ ID
EYLPVSTFK
62-70 for the protein of SEQ No. 501
2de


No. 665


 


SEQ ID
EYNTSGTFVFYDGK
27-40 for the protein of SEQ No. 385
2d


No. 666


 


SEQ ID
EYVPASTFX
75-83 for the proteins of SEQ No. 388, 389,
2df


No. 667

390, 391, 392, 393, 394, 395, 396, 397, 398,




399, 400, 401, 402, 403, 404, 405, 406, 407,




408, 409, 411, 412, 416, 417, 418, 419, 420,




421, 422, 423, 424, 425, 426, 427, 428, 434,




436, 437, 438, 439, 444, 445, 446, 448, 451,




452, 453, 454, 455, 456, 457, 467, 468, 472,




473, 474, 475, 478, 479, 480, 482, 483, 487,




495, 502, 503, 507, 508; 69-77 for the




proteins of sequence SEQ ID No. 431, 432,




469; 74-82 for the proteins of sequence SEQ




ID No. 366, 374, 387, 440, 441, 459, 460,




461, 462, 463, 464, 465, 486, 493; 76-84 for




the proteins of sequence SEQ ID No. 364,




365, 371, 414, 447, 449, 466, 506


 


SEQ ID
FAAYVAGFGYGNGDISGEPGK
120-140 for the protein of SEQ No. 498
2d


No. 668


 


SEQ ID
FAPESTFK
45-52 for the protein of SEQ No. 494
2de


No. 669


 


SEQ ID
FAQYAK
121-126 for the proteins of SEQ No. 496,
2d


No. 670

497, 499, 500


 


SEQ ID
FDYGNK
138-143 for the protein of SEQ No. 351
2de


No. 671


 


SEQ ID
FDYGNR
146-151 for the protein of SEQ No. 379; 125-130


No. 672

for the protein of sequence SEQ ID No.
2d




347


 


SEQ ID
FEDLYK
232-237 for the protein of SEQ No. 385
2d


No. 673


 


SEQ ID
FEDTFHISNQK
27-37 for the protein of SEQ No. 466
2df


No. 674


 


SEQ ID
FEDTFHTSNQQHEK
27-40 for the protein of SEQ No. 447
2df


No. 675


 


SEQ ID
FEYGNQDVSGDSGK
133-146 for the protein of SEQ No. 349
2d


No. 676


 


SEQ ID
FFSDFQAK
34-41 for the protein of SEQ No. 375
2d


No. 677


 


SEQ ID
FFSDLQAEGAIVIADER
34-50 for the proteins of SEQ No. 373, 484
2d


No. 678


 


SEQ ID
FFSDLR
34-39 for the proteins of SEQ No. 369, 372
OXA


No. 679


 


SEQ ID
FFSEFQAK
34-41 for the proteins of SEQ No. 350, 356,
OXA


No. 680

367, 370, 415, 443, 481, 488, 491; 23-30 for




the protein of sequence SEQ ID No. 362


 


SEQ ID
FGLEGQLR
153-160 for the protein of SEQ No. 359
2de


No. 681


 


SEQ ID
FILPIFSISILVSLSACSSIK
4-24 for the proteins of SEQ No. 364, 365,
2df


No. 682

371, 414, 449, 506


 


SEQ ID
FLALLFSAVVVSLGHAQDK
5-24 for the protein of SEQ No. 363
2d


No. 683


 


SEQ ID
FLALLFSAVVLVSLGHAQEK
5-24 for the protein of SEQ No. 355
2d


No. 684


 


SEQ ID
FLESLYLNNLPASK
169-182 for the proteins of SEQ No. 489, 505
OXA


No. 685


 


SEQ ID
FLLEGQLR
153-160 for the protein of SEQ No. 442
2de


No. 686


 


SEQ ID
FQQYVDR
118-124 for the protein of SEQ No. 347
2d


No. 687


 


SEQ ID
FSDYVQR
131-137 for the protein of SEQ No. 351
2de


No. 688


 


SEQ ID
FSTASTFK
63-70 for the protein of SEQ No. 470
2df


No. 689


 


SEQ ID
FSWDGK
117-122 for the protein of SEQ No. 381
2df


No. 690


 


SEQ ID
FSYGNQNISGGIDK
139-152 for the proteins of SEQ No. 352,
OXA


No. 691

357, 358, 359, 368, 383, 435, 442, 501, 504;




130-143 for the proteins of sequence SEQ ID




No. 348, 353, 354; 140-153 for the protein of




sequence SEQ ID No. 490


 


SEQ ID
FSYGNQNISGGTDK
139-152 for the protein of SEQ No. 471
2de


No. 692


 


SEQ ID
FSYGSQNISGGIDK
139-152 for the protein of SEQ No. 492
2de


No. 693


 


SEQ ID
FTEYVK
126-131 for the protein of SEQ No. 349
2d


No. 694


 


SEQ ID
FVAHK
173-177 for the protein of SEQ No. 349
2d


No. 695


 


SEQ ID
FVPASTYK
62-69 for the protein of SEQ No. 380
2d


No. 696


 


SEQ ID
FVYDLAQGQLPFK
184-196 for the proteins of SEQ No. 410,
2df


No. 697

413, 458


 


SEQ ID
FVYDLAQGQLPFKPEVQQQVK
184-204 for the proteins of SEQ No. 410,
2df


No. 698

413, 458


 


SEQ ID
FWLEDQLR
153-160 for the proteins of SEQ No. 358,
2de


No. 699

435, 471, 492; 144-151 for the proteins of




sequence SEQ ID No. 348, 353


 


SEQ ID
FWLEGPLK
144-151 for the protein of SEQ No. 377
2d


No. 700


 


SEQ ID
FWLEGQLR
153-160 for the proteins of SEQ No. 352,
OXA


No. 701

357, 368, 383, 489, 501, 504, 505; 144-151




for the protein of sequence SEQ ID No. 354;




154-161 for the protein of sequence SEQ ID




No. 490


 


SEQ ID
FYPASSFK
53-60 for the protein of SEQ No. 377
2d


No. 702


 


SEQ ID
FYPASTFK
66-73 for the proteins of SEQ No. 386, 429,
2d


No. 703

430, 477


 


SEQ ID
GACDK
44-48 for the protein of SEQ No. 498
2d


No. 704


 


SEQ ID
GAEVYFFAFNMDIDNENK
229-246 for the proteins of SEQ No. 383, 490
2d


No. 705


 


SEQ ID
GAIQVSAVPVFQQIAR
110-125 for the proteins of SEQ No. 352,
OXA


No. 706

357, 358, 359, 368, 383, 435, 442, 471, 489,




492, 501, 504, 505; 101-116 for the proteins




of sequence SEQ ID No. 348, 354; 111-126




for the protein of sequence SEQ ID No. 490


 


SEQ ID
GAIQVSAVPVFQQITR
101-116 for the protein of SEQ No. 353
2de


No. 707


 


SEQ ID
GDYWIDGNLEISAREQISFER
156-176 for the proteins of SEQ No. 369, 372
OXA


No. 708


 


SEQ ID
GDYWIDGNLK
156-165 for the protein of SEQ No. 373
2d


No. 709


 


SEQ ID
GELPVSEDALEMTK
181-194 for the protein of SEQ No. 351
2de


No. 710


 


SEQ ID
GEQPAGPAAR
241-250 for the protein of SEQ No. 498; 252-261
OXA


No. 711

for the protein of sequence SEQ ID No.




351


 


SEQ ID
GFAGHNQDQDLR
103-114 for the proteins of SEQ No. 350,
OXA


No. 712

367, 370, 415, 443, 481, 488; 92-103 for the




protein of sequence SEQ ID No. 362


 


SEQ ID
GIPSSVR
254-260 for the proteins of SEQ No. 389,
2df


No. 713

390, 391, 392, 393, 394, 395, 397, 398, 399,




400, 401, 402, 403, 404, 405, 406, 407, 408,




409, 411, 412, 416, 417, 418, 419, 420, 421,




422, 423, 424, 425, 426, 427, 428, 434, 436,




437, 438, 439, 444, 445, 446, 448, 451, 452,




453, 454, 455, 456, 457, 467, 468, 472, 473,




474, 475, 478, 479, 480, 482, 483, 487, 495,




502, 503, 507, 508; 248-254 for the proteins




of sequence SEQ ID No. 431, 432


 


SEQ ID
GISSSVR
254-260 for the protein of SEQ No. 388
2df


No. 714


 


SEQ ID
GLNGTFVVYDLK
26-37 for the protein of SEQ No. 377
2d


No. 715


 


SEQ ID
GMEIWNSNHTPK
101-112 for the proteins of SEQ No. 360,
2d


No. 716

376; 86-97 for the protein of sequence SEQ




ID No. 361


 


SEQ ID
GNQTLVFAR
230-238 for the protein of SEQ No. 496
2d


No. 717


 


SEQ ID
GNYWIDGNLEISAHEQISFLR
156-176 for the protein of SEQ No. 484
OXA


No. 718


 


SEQ ID
GPLEISAFEEAR
164-175 for the protein of SEQ No. 379
2df


No. 719


 


SEQ ID
GPLTITPIQEVK
172-183 for the proteins of SEQ No. 410,
2df


No. 720

413, 458


 


SEQ ID
GSGWFVGWIVR
219-229 for the proteins of SEQ No. 496,
2d


No. 721

497, 499, 500


 


SEQ ID
GSLLEWDQK
66-74 for the protein of SEQ No. 381
2df


No. 722


 


SEQ ID
GTEVYFFAFNMDIDNENK
229-246 for the proteins of SEQ No. 357,
OXA


No. 723

358, 359, 368, 442, 471, 504


 


SEQ ID
GTEVYFFAFNMDIDNESK
229-246 for the proteins of SEQ No. 489, 505
OXA


No. 724


 


SEQ ID
GTFVEYDVQR
38-47 for the protein of SEQ No. 380
2d


No. 725


 


SEQ ID
GTIVVADER
42-50 for the proteins of SEQ No. 350, 356,
OXA


No. 726

367, 370, 375, 415, 443, 481, 488, 491; 31-39




for the protein of sequence SEQ ID No. 362


 


SEQ ID
GTIVVLDAR
63-71 for the protein of SEQ No. 382
2df


No. 727


 


SEQ ID
GTIVVVDER
42-50 for the proteins of SEQ No. 355, 363
2d


No. 728


 


SEQ ID
GTLPFSAR
200-207 for the protein of SEQ No. 382
2df


No. 729


 


SEQ ID
GTPSSVR
254-260 for the protein of SEQ No. 396
2df


No. 730


 


SEQ ID
HALSSAFVLLGCIAASAHAK
5-24 for the proteins of SEQ No. 496, 497,
2d


No. 731

499, 500


 


SEQ ID
HIADSK
234-239 for the protein of SEQ No. 494
2de


No. 732


 


SEQ ID
HNGLTHAWLASSLK
152-165 for the protein of SEQ No. 351
2de


No. 733


 


SEQ ID
HNGLTQSWLMSSLTISPK
147-164 for the protein of SEQ No. 349
2d


No. 734


 


SEQ ID
HNGTDGAWIISSLR
148-161 for the protein of SEQ No. 433
2d


No. 735


 


SEQ ID
HTLSVFDQER
54-63 for the protein of SEQ No. 373
2d


No. 736


 


SEQ ID
HVTFASFR
241-248 for the protein of SEQ No. 494
2de


No. 737


 


SEQ ID
IAISLMGYDAGFLR
57-70 for the proteins of SEQ No. 496, 497,
2d


No. 738

499, 500


 


SEQ ID
IALSLMAFDAEIIDQK
75-90 for the proteins of SEQ No. 360, 376;
2d


No. 739

60-75 for the protein of sequence SEQ ID




No. 361


 


SEQ ID
IALSLMGFDSGILK
53-66 for the protein of SEQ No. 494
2de


No. 740


 


SEQ ID
IANALIGLENHK
87-98 for the proteins of SEQ No. 410, 413,
2df


No. 741

458


 


SEQ ID
IAWIVGEVYLK
205-215 for the protein of SEQ No. 385
2d


No. 742


 


SEQ ID
IDTFWLDNSLK
141-151 for the protein of SEQ No. 385
2d


No. 743


 


SEQ ID
IDYYNLDR
41-48 for the protein of SEQ No. 377
2d


No. 744


 


SEQ ID
IFNALIALDSGVIK
62-75 for the protein of SEQ No. 385
2d


No. 745


 


SEQ ID
IFNSLLALDSGALDNER
95-111 for the protein of SEQ No. 382
2df


No. 746


 


SEQ ID
IFNTLIGLENGIVK
61-74 for the protein of SEQ No. 377
2d


No. 747


 


SEQ ID
IGLDLMQK
138-145 for the proteins of SEQ No. 366,
2df


No. 748

374, 387, 440, 441, 459, 460, 461, 462, 463,




464, 465, 486, 493


 


SEQ ID
IGLEK
131-135 for the protein of SEQ No. 477
OXA


No. 749


 


SEQ ID
IGLELMQQEVQR
133-144 for the protein of SEQ No. 469
2df


No. 750


 


SEQ ID
IGLELMSK
139-146 for the proteins of SEQ No. 389,
2df


No. 751

390, 391, 393, 395, 398, 399, 400, 401, 402,




403, 404, 408, 409, 411, 412, 417, 419, 420,




421, 422, 423, 424, 425, 426, 427, 428, 436,




437, 438, 439, 451, 452, 453, 454, 455, 456,




457, 467, 468, 472, 473, 474, 478, 479, 480,




482, 483, 487, 495, 502, 508


 


SEQ ID
IGLELMSNEVK
139-149 for the proteins of SEQ No. 388,
2df


No. 752

392, 394, 396, 397, 405, 406, 407, 416, 418,




434, 444, 445, 446, 448, 475, 503, 507; 133-143




for the proteins of sequence SEQ ID No.




431, 432


 


SEQ ID
IGLER
126-130 for the protein of SEQ No. 380
2d


No. 753


 


SEQ ID
IGLNK
130-134 for the proteins of SEQ No. 360,
2d


No. 754

376; 115-119 for the protein of sequence




SEQ ID No. 361


 


SEQ ID
IGLNLMQK
140-147 for the protein of SEQ No. 466
2df


No. 755


 


SEQ ID
IGPSLMQSELQR
142-153 for the proteins of SEQ No. 410,
2df


No. 756

413, 458


 


SEQ ID
IGYGNMQIGTEVDQFWLK
154-171 for the proteins of SEQ No. 413, 458
2df


No. 757


 


SEQ ID
IGYGNMQMGTEVDQFWLK
154-171 for the protein of SEQ No. 410
2df


No. 758


 


SEQ ID
IINHNLPVK
167-175 for the protein of SEQ No. 361; 182-190
2d


No. 759

for the protein of sequence SEQ ID No.




360


 


SEQ ID
IINHNLPVR
182-190 for the protein of SEQ No. 376
2d


No. 760


 


SEQ ID
ILFQQGTQQACAER
41-54 for the protein of SEQ No. 433
2d


No. 761


 


SEQ ID
ILNNWFK
20-26 for the protein of SEQ No. 385
2d


No. 762


 


SEQ ID
ILNTLISLEEK
71-81 for the protein of SEQ No. 470
2df


No. 763


 


SEQ ID
ILSLVCLSISIGACAEHSMSR
6-26 for the proteins of SEQ No. 410, 413,
2df


No. 764

458


 


SEQ ID
INESR
219-223 for the protein of SEQ No. 349
2d


No. 765


 


SEQ ID
INIVK
255-259 for the proteins of SEQ No. 429,
2d


No. 766

430, 477; 254-258 for the protein of sequence




SEQ ID No. 386


 


SEQ ID
INLYGNALSR
61-70 for the proteins of SEQ No. 366, 374,
2df


No. 767

387, 440, 441, 459, 460, 461, 462, 463, 464,




465, 486, 493


 


SEQ ID
IPFSLNLEMK
244-253 for the proteins of SEQ No. 364,
2df


No. 768

365, 371, 414, 449, 506


 


SEQ ID
IPHTLFALDADAVR
76-89 for the protein of SEQ No. 373
2d


No. 769


 


SEQ ID
IPHTLFALDAGAAR
76-89 for the proteins of SEQ No. 356, 491
2d


No. 770


 


SEQ ID
IPHTLFALDAGAVR
76-89 for the proteins of SEQ No. 350, 355,
OXA


No. 771

363, 367, 370, 375, 415, 443, 481, 488; 65-78




for the protein of sequence SEQ ID No. 362


 


SEQ ID
IPLGK
255-259 for the protein of SEQ No. 379
2df


No. 772


 


SEQ ID
IPNAIIGLETGVIK
71-84 for the proteins of SEQ No. 352, 358,
OXA


No. 773

359, 368, 383, 442, 471, 492, 504; 62-75 for




the proteins of sequence SEQ ID No. 348,




353; 72-85 for the protein of sequence SEQ




ID No. 490


 


SEQ ID
IPNALIGLETGAIK
71-84 for the proteins of SEQ No. 489, 505
OXA


No. 774


 


SEQ ID
IPNSLIAFDTGAVR
78-91 for the protein of SEQ No. 379
2df


No. 775


 


SEQ ID
IPSAIIGLETGVIK
71-84 for the proteins of SEQ No. 357, 435,


No. 776

501; 62-75 for the protein of sequence SEQ
2de




ID No. 354


 


SEQ ID
ISAFNQVK
161-168 for the protein of SEQ No. 489
2d


No. 777


 


SEQ ID
ISAHEQILFLR
166-176 for the protein of SEQ No. 373
2d


No. 778


 


SEQ ID
ISAMEQTR
160-167 for the protein of SEQ No. 380
2d


No. 779


 


SEQ ID
ISAMEQVK
165-172 for the proteins of SEQ No. 429,
2d


No. 780

477; 152-159 for the protein of sequence




SEQ ID No. 377; 164-171 for the protein of




sequence SEQ ID No. 386


 


SEQ ID
ISATEQVAFLR
164-174 for the protein of SEQ No. 384
2df


No. 781


 


SEQ ID
ISATQQIAFLR
164-174 for the protein of SEQ No. 485
2df


No. 782


 


SEQ ID
ISAVNQVEFLESLFLNK
161-177 for the proteins of SEQ No. 357,
OXA


No. 783

358, 359, 368, 383, 442, 471, 504; 162-178




for the protein of sequence SEQ ID No. 490


 


SEQ ID
ISAVNQVEFLESLYLNK
161-177 for the proteins of SEQ No. 352,
OXA


No. 784

435, 492, 501; 152-168 for the proteins of




sequence SEQ ID No. 348, 353, 354


 


SEQ ID
ISAVNQVK
161-168 for the protein of SEQ No. 505
2de


No. 785


 


SEQ ID
ISPEEQIQFLR
170-180 for the proteins of SEQ No. 360,
2d


No. 786

376; 155-165 for the protein of sequence




SEQ ID No. 361


 


SEQ ID
ISPEEQVR
166-173 for the protein of SEQ No. 351
2de


No. 787


 


SEQ ID
ISPEGQVR
155-162 for the protein of SEQ No. 498
2d


No. 788


 


SEQ ID
ISPLEQLAFLR
162-172 for the protein of SEQ No. 433
2d


No. 789


 


SEQ ID
ITAFQQVDFLR
188-198 for the protein of SEQ No. 381
2df


No. 790


 


SEQ ID
ITLFLLFLNLVFGQDK
4-19 for the protein of SEQ No. 385
2d


No. 791


 


SEQ ID
ITPIQEVNFADDFANNR
174-190 for the protein of SEQ No. 447
2df


No. 792


 


SEQ ID
ITPIQEVNFADDLANNR
174-190 for the protein of SEQ No. 466
2df


No. 793


 


SEQ ID
ITPQQEAQFAYK
173-184 for the proteins of SEQ No. 388,
2df


No. 794

389, 390, 391, 392, 393, 394, 395, 396, 397,




398, 399, 400, 401, 402, 403, 404, 406, 407,




408, 409, 411, 412, 416, 417, 418, 419, 420,




421, 422, 423, 424, 425, 426, 427, 428, 434,




436, 437, 438, 439, 444, 445, 446, 448, 451,




452, 453, 454, 455, 456, 457, 467, 468, 472,




473, 474, 475, 478, 479, 480, 482, 483, 487,




495, 502, 503, 507, 508; 167-178 for the




proteins of sequence SEQ ID No. 431, 432


 


SEQ ID
ITPQQEAQFTYK
173-184 for the protein of SEQ No. 405
2df


No. 795


 


SEQ ID
ITPVQEVNFADDLAHNR
174-190 for the proteins of SEQ No. 364,
2df


No. 796

365, 371, 414, 449, 506


 


SEQ ID
IVAFALK
241-247 for the proteins of SEQ No. 366, 387
2df


No. 797


 


SEQ ID
IVAFALNMEMR
241-251 for the proteins of SEQ No. 440,
2df


No. 798

459, 460, 461, 462, 463, 464, 465, 486, 493;




242-252 for the proteins of sequence SEQ ID




No. 374, 441


 


SEQ ID
IVESTTLADGTVVHGK
186-201 for the proteins of SEQ No. 496,
2d


No. 799

497, 499, 500


 


SEQ ID
IYNSLIGLNEK
74-84 for the proteins of SEQ No. 386, 429,
2d


No. 800

430, 477


 


SEQ ID
KPDIGWWVGWIER
237-249 for the protein of SEQ No. 382
2df


No. 801


 


SEQ ID
LACATNNLAR
50-59 for the protein of SEQ No. 490
2d


No. 802


 


SEQ ID
LAQGELPFPAPVQSTVR
172-188 for the protein of SEQ No. 380
2d


No. 803


 


SEQ ID
LAQNELPYPIEIQK
177-190 for the proteins of SEQ No. 429,
2d


No. 804

430, 477


 


SEQ ID
LAQNELQYPIEIQK
176-189 for the protein of SEQ No. 386
2d


No. 805


 


SEQ ID
LDFGNK
143-148 for the proteins of SEQ No. 429,
2d


No. 806

430, 477; 142-147 for the protein of sequence




SEQ ID No. 386


 


SEQ ID
LDGSLNR
206-212 for the protein of SEQ No. 347
2d


No. 807


 


SEQ ID
LEIGK
244-248 for the protein of SEQ No. 349
2d


No. 808


 


SEQ ID
LEILQQALAELGLYPK
255-270 for the protein of SEQ No. 469
2df


No. 809


 


SEQ ID
LENQEQVK
173-180 for the protein of SEQ No. 377
2d


No. 810


 


SEQ ID
LETQEEVEK
195-203 for the protein of SEQ No. 364
2df


No. 811


 


SEQ ID
LETQEEVK
195-202 for the proteins of SEQ No. 365,
2df


No. 812

371, 414, 447, 449, 466, 506


 


SEQ ID
LFAAEGVK
55-62 for the protein of SEQ No. 382
2df


No. 813


 


SEQ ID
LFESAGVK
58-65 for the protein of SEQ No. 381
2df


No. 814


 


SEQ ID
LFGAAGVK
30-37 for the protein of SEQ No. 380
2d


No. 815


 


SEQ ID
LFPEWEK
110-116 for the proteins of SEQ No. 388,
2df


No. 816

389, 390, 391, 392, 393, 394, 395, 396, 397,




398, 399, 400, 401, 402, 403, 404, 405, 406,




407, 408, 409, 411, 412, 416, 417, 418, 419,




420, 421, 422, 423, 424, 425, 426, 427, 428,




434, 436, 437, 438, 439, 444, 445, 446, 448,




451, 452, 453, 454, 455, 456, 457, 467, 468,




472, 473, 474, 475, 478, 479, 480, 482, 483,




487, 495, 502, 503, 507, 508; 104-110 for the




proteins of sequence SEQ ID No. 431, 432


 


SEQ ID
LGESR
126-130 for the protein of SEQ No. 351
2de


No. 817


 


SEQ ID
LGVDR
121-125 for the protein of SEQ No. 349
2d


No. 818


 


SEQ ID
LHVSER
181-186 for the proteins of SEQ No. 378,
2df


No. 819

384, 450, 476, 485


 


SEQ ID
LHYGNAK
131-137 for the protein of SEQ No. 385
2d


No. 820


 


SEQ ID
LLNLLSQSK
160-168 for the protein of SEQ No. 377
2d


No. 821


 


SEQ ID
LLQDER
243-248 for the protein of SEQ No. 433
2d


No. 822


 


SEQ ID
LLVQDGDCGR
38-47 for the proteins of SEQ No. 496, 497,
2d


No. 823

499, 500


 


SEQ ID
LNEVGYGNR
160-168 for the protein of SEQ No. 382
2df


No. 824


 


SEQ ID
LNYGNADPSTK
144-154 for the proteins of SEQ No. 355, 363
2d


No. 825


 


SEQ ID
LNYGNK
130-135 for the protein of SEQ No. 377
2d


No. 826


 


SEQ ID
LPASK
178-182 for the proteins of SEQ No. 489,
2d


No. 827

505; 172-176 for the protein of sequence




SEQ ID No. 498


 


SEQ ID
LPHTLFALDADAVR
76-89 for the proteins of SEQ No. 369, 372
OXA


No. 828


 


SEQ ID
LPHTLFALDAGAVR
76-89 for the protein of SEQ No. 484
OXA


No. 829


 


SEQ ID
LPLAIMGFDSGILQSPK
62-78 for the protein of SEQ No. 349
2d


No. 830


 


SEQ ID
LPLAIMGYDADILLDATTPR
69-88 for the protein of SEQ No. 351
2de


No. 831


 


SEQ ID
LPSSLIALETGAVR
98-111 for the protein of SEQ No. 381
2df


No. 832


 


SEQ ID
LPVSAQTLQYTANILK
170-185 for the protein of SEQ No. 347
2d


No. 833


 


SEQ ID
LPVSER
205-210 for the protein of SEQ No. 381
2df


No. 834


 


SEQ ID
LPVSPTAVDMTER
173-185 for the proteins of SEQ No. 496,
2d


No. 835

497, 499, 500


 


SEQ ID
LSASK
178-182 for the proteins of SEQ No. 352,
OXA


No. 836

357, 358, 359, 368, 383, 435, 442, 471, 492,




501, 504; 169-173 for the proteins of




sequence SEQ ID No. 348, 353, 354; 179-183




for the protein of sequence SEQ ID No.




490


 


SEQ ID
LSAVPIYQEVAR
121-132 for the protein of SEQ No. 379
2df


No. 837


 


SEQ ID
LSAVPVYQELAR
127-138 for the proteins of SEQ No. 364,
2df


No. 838

365, 371, 414, 447, 449, 506; 125-136 for the




proteins of sequence SEQ ID No. 366, 374,




387, 440, 441, 459, 460, 461, 462, 463, 464,




465, 486, 493


 


SEQ ID
LSCTLVIDEASGDLLHR
37-53 for the protein of SEQ No. 351
2de


No. 839


 


SEQ ID
LSLQHGWFIGWIEK
211-224 for the protein of SEQ No. 494
2de


No. 840


 


SEQ ID
LSQNSLPFSQEAMNSVK
164-180 for the protein of SEQ No. 385
2d


No. 841


 


SEQ ID
LSVNPK
168-173 for the protein of SEQ No. 494
2de


No. 842


 


SEQ ID
LTQDER
239-244 for the proteins of SEQ No. 496,


No. 843

497, 499, 500
2d


 


SEQ ID
LTVGAR
245-250 for the protein of SEQ No. 351
2de


No. 844


 


SEQ ID
LYGFALNIDMPGGEADIGK
228-246 for the protein of SEQ No. 380
2d


No. 845


 


SEQ ID
LYHNELPFR
178-186 for the proteins of SEQ No. 356, 491
2d


No. 846


 


SEQ ID
LYHNK
176-180 for the proteins of SEQ No. 378,
2df


No. 847

384, 450, 476, 485


 


SEQ ID
LYQNDLPFR
178-186 for the protein of SEQ No. 375
2d


No. 848


 


SEQ ID
MDDLFK
243-248 for the proteins of SEQ No. 350,
OXA


No. 849

356, 367, 370, 375, 415, 443, 481, 488, 491;




232-237 for the protein of sequence SEQ ID




No. 362


 


SEQ ID
MEDLHK
243-248 for the proteins of SEQ No. 355, 363
2d


No. 850


 


SEQ ID
MLIALIGLENHK
85-96 for the protein of SEQ No. 506
2df


No. 851


 


SEQ ID
MLLIEQQGDAALYAK
198-212 for the protein of SEQ No. 379
2df


No. 852


 


SEQ ID
MLLIK
204-208 for the proteins of SEQ No. 364,
2df


No. 853

365, 371, 414, 447, 449, 466, 506


 


SEQ ID
MLNTALIGLEHHK
84-95 for the proteins of SEQ No. 388, 389,
2df


No. 854

390, 391, 392, 393, 394, 395, 396, 397, 398,




399, 400, 401, 402, 403, 404, 405, 406, 408,




409, 411, 412, 416, 417, 418, 419, 420, 421,




422, 423, 424, 425, 426, 427, 428, 434, 436,




437, 438, 439, 444, 445, 446, 448, 451, 452,




453, 454, 455, 456, 457, 467, 468, 472, 473,




474, 475, 478, 479, 480, 482, 487, 495, 502,




503, 507, 508; 78-89 for the proteins of




sequence SEQ ID No. 431, 432


 


SEQ ID
MLNALIGLENHK
85-96 for the proteins of SEQ No. 364, 365,
2df


No. 855

371, 414, 447, 449, 466


 


SEQ ID
MLNALIGLENQK
83-94 for the proteins of SEQ No. 366, 374,
2df


No. 856

387, 440, 441, 459, 460, 461, 462, 463, 464,




465, 486, 493


 


SEQ ID
MLNALIGLEYHK
84-95 for the protein of SEQ No. 483
2df


No. 857


 


SEQ ID
MLNALIGLQHGK
78-89 for the protein of SEQ No. 469
2df


No. 858


 


SEQ ID
MLNALISLEHHK
84-95 for the protein of SEQ No. 407
2df


No. 859


 


SEQ ID
MQAYVDAFDYGNR
139-151 for the protein of SEQ No. 379
2df


No. 860


 


SEQ ID
MQEGLNK
123-129 for the protein of SEQ No. 377
2d


No. 861


 


SEQ ID
MSPASTYK
87-94 for the protein of SEQ No. 382
2df


No. 862


 


SEQ ID
MTAGGK
234-239 for the protein of SEQ No. 498
2d


No. 863


 


SEQ ID
MVSGK
165-169 for the protein of SEQ No. 347
2d


No. 864


 


SEQ ID
NEHDPVLPYR
71-80 for the proteins of SEQ No. 496, 497,
2d


No. 865

499, 500


 


SEQ ID
NEHQIFK
86-92 for the protein of SEQ No. 490; 85-91
2d


No. 866

for the protein of sequence SEQ ID No. 383


 


SEQ ID
NEHQVFK
85-91 for the proteins of SEQ No. 352, 357,
OXA


No. 867

358, 359, 368, 435, 442, 471, 492, 501, 504;




76-82 for the proteins of sequence SEQ ID




No. 348, 353, 354


 


SEQ ID
NEITYK
262-267 for the proteins of SEQ No. 364,
2df


No. 868

365, 371, 414, 447, 449, 466, 506


 


SEQ ID
NELLMK
260-265 for the proteins of SEQ No. 366,
2df


No. 869

387, 440, 459, 460, 462, 463, 464, 465, 486,




493; 261-266 for the proteins of sequence




SEQ ID No. 374, 441


 


SEQ ID
NELMMK
260-265 for the protein of SEQ No. 461
2df


No. 870


 


SEQ ID
NELPFR
181-186 for the proteins of SEQ No. 350,
OXA


No. 871

355, 356, 363, 367, 370, 415, 443, 481, 488,




491; 170-175 for the protein of sequence




SEQ ID No. 362


 


SEQ ID
NFILIFIFVILISCK
5-19 for the proteins of SEQ No. 386, 429,
2d


No. 872

477


 


SEQ ID
NFILIFIFVILTSCK
5-19 for the protein of SEQ No. 430
2d


No. 873


 


SEQ ID
NISSYGNNLVR
62-72 for the protein of SEQ No. 466
2df


No. 874


 


SEQ ID
NISTYGNNLTR
62-72 for the protein of SEQ No. 447
2df


No. 875


 


SEQ ID
NLFNEVHTTGVLVIR
43-57 for the protein of SEQ No. 412
2df


No. 876


 


SEQ ID
NLSTYGNALAR
62-72 for the proteins of SEQ No. 364, 365,
2df


No. 877

371, 414, 449, 506


 


SEQ ID
NMENLELFGK
187-196 for the protein of SEQ No. 385
2d


No. 878


 


SEQ ID
NMLLLEENNGYK
201-212 for the protein of SEQ No. 440
2df


No. 879


 


SEQ ID
NMLLLEESNGYK
201-212 for the proteins of SEQ No. 366,
2df


No. 880

374, 387, 441, 459, 460, 461, 462, 463, 465,




486, 493


 


SEQ ID
NMLLLEK
201-207 for the protein of SEQ No. 464
2df


No. 881


 


SEQ ID
NMTLGDAMK
117-125 for the proteins of SEQ No. 388,
2df


No. 882

392, 393, 396, 397, 402, 405, 406, 416, 419,




422, 424, 434, 445, 446, 448, 475, 503; 111-119




for the proteins of sequence SEQ ID No.




431, 432


 


SEQ ID
NNGLTEAWLESSLK
156-169 for the proteins of SEQ No. 360,
2d


No. 883

376; 141-154 for the protein of sequence




SEQ ID No. 361


 


SEQ ID
NQLPFK
181-186 for the protein of SEQ No. 373
2d


No. 884


 


SEQ ID
NQLPFQVEHQR
181-191 for the proteins of SEQ No. 369,
OXA


No. 885

372, 484


 


SEQ ID
NSAIENTIDNMYLQDLENSTK
191-211 for the protein of SEQ No. 376
2d


No. 886


 


SEQ ID
NSAIENTIENMYLQDLDNSTK
191-211 for the protein of SEQ No. 360
2d


No. 887


 


SEQ ID
NSAIENTIENMYLQDLENSTK
176-196 for the protein of SEQ No. 361
2d


No. 888


 


SEQ ID
NSAVWVYELFAK
119-130 for the proteins of SEQ No. 369,
OXA


No. 889

372, 484


 


SEQ ID
NSQVPAYK
118-125 for the proteins of SEQ No. 429,
2d


No. 890

430, 477; 117-124 for the protein of sequence




SEQ ID No. 386


 


SEQ ID
NSTVWIYELFAK
119-130 for the proteins of SEQ No. 356, 491
2d


No. 891


 


SEQ ID
NSTVWVYELFAK
119-130 for the proteins of SEQ No. 350,
OXA


No. 892

367, 370, 373, 375, 415, 443, 481, 488; 108-119




for the protein of sequence SEQ ID No.




362


 


SEQ ID
NSTVWVYQLFAK
119-130 for the proteins of SEQ No. 355, 363
2d


No. 893


 


SEQ ID
NTSGALVIQTDK
48-59 for the protein of SEQ No. 460
2df


No. 894


 


SEQ ID
NTSGVLVIQTDK
48-59 for the proteins of SEQ No. 366, 374,
2df


No. 895

387, 440, 441, 459, 461, 462, 463, 464, 465,




486, 493


 


SEQ ID
NVDEMFYYYDGSK
75-87 for the protein of SEQ No. 377
2d


No. 896


 


SEQ ID
NWILR
204-208 for the proteins of SEQ No. 350,
OXA


No. 897

356, 367, 369, 370, 372, 375, 415, 443, 481,




484, 488, 491; 193-197 for the protein of




sequence SEQ ID No. 362


 


SEQ ID
NWNAAMDLR
125-133 for the protein of SEQ No. 382
2df


No. 898


 


SEQ ID
NYVDAFHYGNQDISGDK
118-134 for the protein of SEQ No. 494
2de


No. 899


 


SEQ ID
QADHAILVFDQAR
51-63 for the protein of SEQ No. 375
2d


No. 900


 


SEQ ID
QAEHALLVFGQER
51-63 for the proteins of SEQ No. 369, 372,
OXA


No. 901

484


 


SEQ ID
QAITK
251-255 for the proteins of SEQ No. 378,
2df


No. 902

384, 450, 485; 247-251 for the protein of




sequence SEQ ID No. 476


 


SEQ ID
QAMLTEANSDYIIR
193-206 for the protein of SEQ No. 384
2df


No. 903


 


SEQ ID
QEVQFVSALAR
171-181 for the protein of SEQ No. 469
2df


No. 904


 


SEQ ID
QFASIK
243-248 for the protein of SEQ No. 347
2d


No. 905


 


SEQ ID
QGMPGSIR
254-261 for the protein of SEQ No. 447
2df


No. 906


 


SEQ ID
QGMSGSIR
254-261 for the protein of SEQ No. 466
2df


No. 907


 


SEQ ID
QGQTQQSYGNDLAR
58-71 for the proteins of SEQ No. 388, 389,
2df


No. 908

390, 391, 392, 393, 394, 395, 396, 397, 398,




399, 400, 401, 402, 403, 404, 405, 406, 407,




408, 409, 411, 412, 416, 417, 418, 419, 420,




421, 422, 423, 424, 425, 426, 427, 428, 436,




437, 438, 439, 444, 445, 446, 448, 451, 452,




453, 454, 455, 456, 457, 467, 468, 472, 473,




474, 475, 478, 479, 480, 482, 483, 487, 495,




502, 503, 507, 508; 52-65 for the proteins of




sequence SEQ ID No. 431, 432


 


SEQ ID
QIDYGNADPSTIK
143-155 for the proteins of SEQ No. 369,
OXA


No. 909

372, 484


 


SEQ ID
QIDYGNVDPSTIK
143-155 for the protein of SEQ No. 373
2d


No. 910


 


SEQ ID
QIGEAR
129-134 for the proteins of SEQ No. 378,
2df


No. 911

450, 476, 485


 


SEQ ID
QIGQAR
129-134 for the protein of SEQ No. 384
2df


No. 912


 


SEQ ID
QIMLIEQTPAFTLR
190-203 for the protein of SEQ No. 470
2df


No. 913


 


SEQ ID
QLGSAIDQFWLR
152-163 for the protein of SEQ No. 379
2df


No. 914


 


SEQ ID
QLHDNK
199-204 for the protein of SEQ No. 381
2df


No. 915


 


SEQ ID
QLIFVHTVVQK
229-239 for the protein of SEQ No. 347
2d


No. 916


 


SEQ ID
QLIFVHTVVQKPGK
229-242 for the protein of SEQ No. 347
2d


No. 917


 


SEQ ID
QLPVK
178-182 for the protein of SEQ No. 433; 184-188
OXA


No. 918

for the protein of sequence SEQ ID No.




379


 


SEQ ID
QLPVKPR
184-190 for the protein of SEQ No. 379
2df


No. 919


 


SEQ ID
QLSLDVLDK
265-273 for the proteins of SEQ No. 410,
2df


No. 920

413, 458


 


SEQ ID
QLVYAR
237-242 for the protein of SEQ No. 433
2d


No. 921


 


SEQ ID
QMMLTEASTDYIIR
217-230 for the protein of SEQ No. 381
2df


No. 922


 


SEQ ID
QMSIVEATPDYVLHGK
214-229 for the protein of SEQ No. 382
2df


No. 923


 


SEQ ID
QPTDPAR
99-105 for the protein of SEQ No. 433
2d


No. 924


 


SEQ ID
QPTDPTR
93-99 for the proteins of SEQ No. 496, 497,
2d


No. 925

499, 500


 


SEQ ID
QPVSAGIR
246-253 for the proteins of SEQ No. 496,
2d


No. 926

497, 499, 500


 


SEQ ID
QQLVK
275-279 for the protein of SEQ No. 381
2df


No. 927


 


SEQ ID
QTLVFAR
232-238 for the proteins of SEQ No. 496,
2d


No. 928

497, 499, 500


 


SEQ ID
QVGAEK
126-131 for the protein of SEQ No. 470
2df


No. 929


 


SEQ ID
QVVFAR
238-243 for the protein of SEQ No. 349
2d


No. 930


 


SEQ ID
SADEVLPYGGK
84-94 for the protein of SEQ No. 380
2d


No. 931


 


SEQ ID
SADEVLPYGGKPQR
84-97 for the protein of SEQ No. 380
2d


No. 932


 


SEQ ID
SCATNDLAR
50-58 for the proteins of SEQ No. 352, 435,
OXA


No. 933

492, 501; 41-49 for the proteins of sequence




SEQ ID No. 348, 353, 354


 


SEQ ID
SCATNNLAR
50-58 for the proteins of SEQ No. 357, 358,
OXA


No. 934

359, 368, 383, 442, 471, 504


 


SEQ ID
SDIPGGSK
251-258 for the protein of SEQ No. 349
2d


No. 935


 


SEQ ID
SDWGK
29-33 for the protein of SEQ No. 375
2d


No. 936


 


SEQ ID
SEDNFHISSQQHEK
27-40 for the proteins of SEQ No. 364, 365,
2df


No. 937

371, 414, 449, 506


 


SEQ ID
SEMPASIR
252-259 for the proteins of SEQ No. 366,
2df


No. 938

387, 440, 459, 460, 461, 462, 463, 464, 486,




493; 253-260 for the proteins of sequence




SEQ ID No. 374, 441


 


SEQ ID
SEMPASTR
252-259 for the protein of SEQ No. 465
2df


No. 939


 


SEQ ID
SFAAHNQDQDLR
103-114 for the proteins of SEQ No. 356, 491
2d


No. 940


 


SEQ ID
SFAGHNK
103-109 for the protein of SEQ No. 375
2d


No. 941


 


SEQ ID
SFAGHNQDQDLR
103-114 for the proteins of SEQ No. 369,
2d


No. 942

372, 373, 484


 


SEQ ID
SFAGHNQDQNLR
103-114 for the proteins of SEQ No. 355, 363
2d


No. 943


 


SEQ ID
SFLESWAK
100-107 for the protein of SEQ No. 386
2d


No. 944


 


SEQ ID
SFTAWEK
109-115 for the proteins of SEQ No. 366,
2df


No. 945

374, 387, 441, 459, 460, 461, 462, 463, 464,




465, 486, 493; 104-110 for the protein of




sequence SEQ ID No. 469


 


SEQ ID
SFTTWEK
109-115 for the protein of SEQ No. 440
2df


No. 946


 


SEQ ID
SGSGWLR
207-213 for the protein of SEQ No. 349
2d


No. 947


 


SEQ ID
SGWGMAVDPQVGWYVGFVEK
221-240 for the proteins of SEQ No. 410,
2df


No. 948

413, 458


 


SEQ ID
SGWGMDVSPQVGWLTGWVEK
219-238 for the protein of SEQ No. 466
2df


No. 949


 


SEQ ID
SGWGMDVTPQVGWLTGWVEK
219-238 for the protein of SEQ No. 447
2df


No. 950


 


SEQ ID
SIHPASTFK
69-77 for the protein of SEQ No. 379
2df


No. 951


 


SEQ ID
SIPTK
252-256 for the proteins of SEQ No. 352,
OXA


No. 952

357, 358, 359, 368, 383, 435, 442, 471, 490,




492, 501, 504, 505; 243-247 for the proteins




of sequence SEQ ID No. 348, 353, 354


 


SEQ ID
SISTK
252-256 for the protein of SEQ No. 489
2d


No. 953


 


SEQ ID
SLGLSNNLSR
76-85 for the protein of SEQ No. 381
2df


No. 959


 


SEQ ID
SLSMSGK
4-10 for the protein of SEQ No. 351
2de


No. 955


 


SEQ ID
SMLFIEEK
202-209 for the proteins of SEQ No. 388,
2df


No. 956

389, 390, 391, 392, 393, 394, 395, 396, 397,




398, 399, 400, 401, 402, 403, 404, 405, 406,




407, 408, 409, 411, 416, 417, 418, 419, 420,




421, 422, 424, 425, 426, 427, 428, 434, 436,




437, 438, 439, 444, 445, 446, 451, 452, 453,




454, 455, 456, 457, 467, 468, 472, 473, 474,




475, 478, 479, 480, 482, 483, 487, 495, 502,




503, 507, 508; 196-203 for the proteins of




sequence SEQ ID No. 431, 432


 


SEQ ID
SNGEK
239-243 for the proteins of SEQ No. 447, 466
2df


No. 957


 


SEQ ID
SNGLTHSWLGSSLK
141-154 for the protein of SEQ No. 498
2d


No. 958


 


SEQ ID
SNGYK
208-212 for the proteins of SEQ No. 366,
2df


No. 959

374, 387, 441, 459, 460, 461, 462, 463, 464,




465, 486, 493


 


SEQ ID
SPTWELK
79-85 for the protein of SEQ No. 349
2d


No. 960


 


SEQ ID
SPTWELKPEYNPSPR
79-93 for the protein of SEQ No. 349
2d


No. 961


 


SEQ ID
SQDIVR
208-213 for the protein of SEQ No. 382
2df


No. 962


 


SEQ ID
SQQKPTDPTIWLK
100-112 for the protein of SEQ No. 351
2de


No. 963


 


SEQ ID
SQVGWLTGWVEQPDGK
225-240 for the protein of SEQ No. 486
2df


No. 969


 


SEQ ID
SSSNSCTTNNAAR
46-58 for the protein of SEQ No. 489
2d


No. 965


 


SEQ ID
SSSNSCTTNNATR
46-58 for the protein of SEQ No. 505
2de


No. 966


 


SEQ ID
SVYGELR
139-145 for the protein of SEQ No. 470
2df


No. 967


 


SEQ ID
SWILR
204-208 for the protein of SEQ No. 373
2d


No. 968


 


SEQ ID
SYFDEAQTQGVIIIK
44-58 for the proteins of SEQ No. 364, 365,
2df


No. 969

371, 414, 447, 449, 466, 506


 


SEQ ID
SYLEK
139-143 for the proteins of SEQ No. 355, 363
2d


No. 970


 


SEQ ID
SYPMWEK
111-117 for the proteins of SEQ No. 447, 466
2df


No. 971


 


SEQ ID
TAYIPASTFK
61-70 for the proteins of SEQ No. 489, 505;
2df


No. 972

77-86 for the proteins of sequence SEQ ID




No. 410, 413, 458


 


SEQ ID
TDDLFK
243-248 for the proteins of SEQ No. 369,
2d


No. 973

372, 373, 484


 


SEQ ID
TDINEIFK
95-102 for the proteins of SEQ No. 374, 387,
2df


No. 974

440, 441, 459, 460, 461, 462, 463, 464, 465,




486, 493


 


SEQ ID
TFIHNDPR
51-58 for the protein of SEQ No. 470
2df


No. 975


 


SEQ ID
TGAGFTANR
216-224 for the proteins of SEQ No. 360,
2d


No. 976

376; 201-209 for the protein of sequence




SEQ ID No. 361


 


SEQ ID
TGFNDGQK
197-204 for the protein of SEQ No. 385
2d


No. 977


 


SEQ ID
TGLADSK
210-216 for the proteins of SEQ No. 429,
2d


No. 978

430; 209-215 for the protein of sequence




SEQ ID No. 386


 


SEQ ID
TGLDLMQK
140-147 for the protein of SEQ No. 447
2df


No. 979


 


SEQ ID
TGLELMQK
140-147 for the proteins of SEQ No. 364,
2df


No. 980

365, 371, 414, 449, 506


 


SEQ ID
TGMGYPK
198-204 for the protein of SEQ No. 347
2d


No. 981


 


SEQ ID
TGNGR
197-201 for the protein of SEQ No. 494
2de


No. 982


 


SEQ ID
TGTGSFIDAR
200-209 for the protein of SEQ No. 498
2d


No. 983


 


SEQ ID
TGTGSLSDAK
211-220 for the protein of SEQ No. 351
2de


No. 984


 


SEQ ID
TGVATEYQPEIGWWAGWVER
213-232 for the protein of SEQ No. 379
2df


No. 985


 


SEQ ID
TGVSYPLLADGTR
202-214 for the proteins of SEQ No. 496,
2d


No. 986

497, 499, 500


 


SEQ ID
TGWAAMDIK
217-225 for the proteins of SEQ No. 374, 441
2df


No. 987


 


SEQ ID
TGWAMDIK
217-224 for the proteins of SEQ No. 366,
2df


No. 988

387, 440, 460, 461, 462, 463, 464, 465, 486,




493


 


SEQ ID
TGWAMDVK
217-224 for the protein of SEQ No. 459
2df


No. 989


 


SEQ ID
TGWATR
206-211 for the protein of SEQ No. 470
2df


No. 990


 


SEQ ID
TGWCFDCTPELGWWVGWVK
205-223 for the protein of SEQ No. 380
2d


No. 991


 


SEQ ID
TGWEGR
211-216 for the proteins of SEQ No. 350,
OXA


No. 992

356, 367, 369, 370, 372, 373, 415, 443, 481,




484, 488, 491; 200-205 for the protein of




sequence SEQ ID No. 362


 


SEQ ID
TGWFVDK
230-236 for the protein of SEQ No. 382
2df


No. 993


 


SEQ ID
TGYDTK
209-214 for the protein of SEQ No. 476
2df


No. 994


 


SEQ ID
TGYGVR
233-238 for the protein of SEQ No. 381
2df


No. 995


 


SEQ ID
TGYSAR
209-214 for the protein of SEQ No. 450
2df


No. 996


 


SEQ ID
TGYSTR
209-214 for the proteins of SEQ No. 378,
2df


No. 997

384, 485


 


SEQ ID
THESSNWGK
25-33 for the proteins of SEQ No. 355, 363
2d


No. 998


 


SEQ ID
TICTAIADAGTGK
25-37 for the proteins of SEQ No. 496, 497,
2d


No. 999

499, 500


 


SEQ ID
TIGGAPDAYWVDDSLQISAR
169-188 for the protein of SEQ No. 382
2df


No. 1000


 


SEQ ID
TLPFSASSYETLR
177-189 for the protein of SEQ No. 470
2df


No. 1001


 


SEQ ID
TLPFSLK
189-195 for the proteins of SEQ No. 399,
2df


No. 1002

403, 411


 


SEQ ID
TLPFSPK
189-195 for the proteins of SEQ No. 389,
2df


No. 1003

395, 412, 423, 428, 439, 445, 467, 482, 483,




495


 


SEQ ID
TLPFSQEVQDEVQSILFIEEK
189-209 for the protein of SEQ No. 448
2df


No. 1004


 


SEQ ID
TLPFSQEVQDEVQSMLFIEEK
189-209 for the proteins of SEQ No. 392, 434
2df


No. 1005


 


SEQ ID
TLPFSQK
189-195 for the proteins of SEQ No. 388,
2df


No. 1006

390, 391, 393, 394, 396, 397, 398, 400, 401,




402, 404, 405, 406, 407, 408, 409, 416, 417,




418, 419, 420, 421, 422, 424, 425, 426, 427,




436, 437, 438, 444, 446, 451, 452, 453, 454,




455, 456, 457, 468, 472, 473, 474, 475, 478,




480, 487, 502, 503, 507, 508; 183-189 for the




proteins of sequence SEQ ID No. 431, 432


 


SEQ ID
TLPSSQK
189-195 for the protein of SEQ No. 479
2df


No. 1007


 


SEQ ID
TLQNGWFEGFIISK
225-238 for the proteins of SEQ No. 360,
2d


No. 1008

376; 210-223 for the protein of sequence




SEQ ID No. 361


 


SEQ ID
TMQEYLNK
123-130 for the protein of SEQ No. 385
2d


No. 1009


 


SEQ ID
TNGNSTSVYNESR
51-63 for the proteins of SEQ No. 355, 363
2d


No. 1010


 


SEQ ID
TQTYQAYDAAR
72-82 for the protein of SEQ No. 382
2df


No. 1011


 


SEQ ID
TTDPTIWEK
93-101 for the protein of SEQ No. 498
2d


No. 1012


 


SEQ ID
TTTTEVFK
96-103 for the proteins of SEQ No. 395, 428
2df


No. 1013


 


SEQ ID
TWASNDFSR
41-49 for the protein of SEQ No. 385
2d


No. 1014


 


SEQ ID
TWDMVQR
191-197 for the protein of SEQ No. 379
2df


No. 1015


 


SEQ ID
TWMQFSVVWVSQEITQK
113-129 for the proteins of SEQ No. 360,
2d


No. 1016

376; 98-114 for the protein of sequence SEQ




ID No. 361


 


SEQ ID
TYPMWEK
111-117 for the proteins of SEQ No. 364,
2df


No. 1017

365, 371, 414, 449, 506


 


SEQ ID
TYVVDPAR
58-65 for the protein of SEQ No. 379
2df


No. 1018


 


SEQ ID
VAFSLNIEMK
244-253 for the protein of SEQ No. 447
2df


No. 1019


 


SEQ ID
VANSLIGLSTGAVR
70-83 for the protein of SEQ No. 380
2d


No. 1020


 


SEQ ID
VEHQR
187-191 for the proteins of SEQ No. 350,
OXA


No. 1021

355, 356, 363, 367, 369, 370, 372, 373, 375,




415, 443, 481, 484, 488, 491; 176-180 for the




protein of sequence SEQ ID No. 362


 


SEQ ID
VELGK
248-252 for the protein of SEQ No. 380
2d


No. 1022


 


SEQ ID
VEDDAGVSGTFVLMDITADR
38-57 for the protein of SEQ No. 379
2df


No. 1023


 


SEQ ID
VFLDSWAK
88-95 for the protein of SEQ No. 377
2d


No. 1024


 


SEQ ID
VFLESWAK
101-108 for the proteins of SEQ No. 429,
2d


No. 1025

430, 477


 


SEQ ID
VFLSSWAQDMNLSSAIK
89-105 for the protein of SEQ No. 385
2d


No. 1026


 


SEQ ID
VGFER
134-138 for the protein of SEQ No. 379
2df


No. 1027


 


SEQ ID
VILVFDQVR
55-63 for the proteins of SEQ No. 356, 491
2d


No. 1028


 


SEQ ID
VITFTK
228-233 for the protein of SEQ No. 494
2de


No. 1029


 


SEQ ID
VMAAMVR
158-164 for the protein of SEQ No. 381
2df


No. 1030


 


SEQ ID
VPLAVMGYDAGILVDAHNPR
58-77 for the protein of SEQ No. 498
2d


No. 1031


 


SEQ ID
VQANVK
195-200 for the proteins of SEQ No. 366,
2df


No. 1032

374, 387, 440, 441, 459, 460, 461, 462, 463,




464, 465, 486, 493


 


SEQ ID
VQDEVK
196-201 for the protein of SEQ No. 444
2df


No. 1033


 


SEQ ID
VQDEVQSMLFIEEK
196-209 for the proteins of SEQ No. 388,
2df


No. 1034

389, 390, 391, 392, 393, 395, 396, 397, 398,




399, 400, 401, 402, 404, 405, 406, 407, 408,




409, 411, 416, 417, 418, 419, 420, 421, 422,




424, 425, 426, 427, 428, 434, 436, 437, 438,




439, 445, 446, 451, 452, 453, 454, 455, 457,




467, 468, 472, 473, 474, 475, 478, 479, 480,




482, 483, 487, 495, 502, 503, 507, 508; 190-203




for the proteins of sequence SEQ ID No.




431, 432


 


SEQ ID
VQDEVQSMLFIEEMNGNK
196-213 for the proteins of SEQ No. 412, 423
2df


No. 1035


 


SEQ ID
VQDGVQSMLFIEEK
196-209 for the protein of SEQ No. 456
2df


No. 1036


 


SEQ ID
VQHEVQSMLFIEEK
196-209 for the protein of SEQ No. 394
2df


No. 1037


 


SEQ ID
VSCLPCYQVVSHK
138-150 for the protein of SEQ No. 382
2df


No. 1038


 


SEQ ID
VSCVWCYQALAR
114-125 for the protein of SEQ No. 470
2df


No. 1039


 


SEQ ID
VSDVCSEVTAEGWQEVR
37-53 for the protein of SEQ No. 381
2df


No. 1040


 


SEQ ID
VSEVEGWQIHGK
186-197 for the protein of SEQ No. 347
2d


No. 1041


 


SEQ ID
VSFSLNIEMK
244-253 for the protein of SEQ No. 466
2df


No. 1042


 


SEQ ID
VSPCSSFK
54-61 for the protein of SEQ No. 349
2d


No. 1043


 


SEQ ID
VSQVPAYK
105-112 for the protein of SEQ No. 377
2d


No. 1044


 


SEQ ID
VVFAR
229-233 for the protein of SEQ No. 498; 239-243
OXA


No. 1045

for the proteins of sequence SEQ ID No.




349.351


 


SEQ ID
WDGAK
97-101 for the proteins of SEQ No. 355, 363
2d


No. 1046


 


SEQ ID
WDGEK
104-108 for the proteins of SEQ No. 393,
2df


No. 1047

402, 419, 422, 424


 


SEQ ID
WDGHIYDFPDWNR
92-104 for the protein of SEQ No. 470
2df


No. 1048


 


SEQ ID
WDGIK
97-101 for the proteins of SEQ No. 356, 491
2d


No. 1049


 


SEQ ID
WDGKPR
92-97 for the proteins of SEQ No. 352, 357,
OXA


No. 1050

358, 359, 368, 383, 435, 442, 471, 489, 492,




501, 504, 505; 83-88 for the proteins of




sequence SEQ ID No. 348, 353, 354; 107-112




for the proteins of sequence SEQ ID No.




410, 413, 458; 93-98 for the protein of




sequence SEQ ID No. 490; 116-121 for the




protein of sequence SEQ ID No. 382;


 


SEQ ID
WDGQK
104-108 for the proteins of SEQ No. 388,
2df


No. 1051

389, 392, 395, 396, 397, 399, 403, 405, 406,




407, 411, 412, 423, 428, 434, 439, 445, 446,




448, 467, 468, 482, 483, 495, 503, 508; 98-102




for the proteins of sequence SEQ ID No.




431, 432


 


SEQ ID
WDGQTR
95-100 for the proteins of SEQ No. 378, 384,
2df


No. 1052

450, 476, 485


 


SEQ ID
WDGVK
97-101 for the proteins of SEQ No. 369, 372,
2d


No. 1053

375, 484


 


SEQ ID
WDGVNR
97-102 for the proteins of SEQ No. 350, 367,
OXA


No. 1054

370, 373, 415, 443, 481, 488; 86-91 for the




protein of sequence SEQ ID No. 362


 


SEQ ID
WDYKPEFNGYK
78-88 for the protein of SEQ No. 498; 89-99
OXA


No. 1055

for the protein of sequence SEQ ID No. 351


 


SEQ ID
WETYSVVWFSQQITEWLGMER
97-117 for the protein of SEQ No. 347
2d


No. 1056


 


SEQ ID
WNGQK
104-108 for the proteins of SEQ No. 394,
2df


No. 1057

418, 444, 507


 


SEQ ID
YAQAK
155-159 for the protein of SEQ No. 382
2df


No. 1058


 


SEQ ID
YFSDFNAK
34-41 for the proteins of SEQ No. 355, 363
2d


No. 1059


 


SEQ ID
YGTHLDR
68-74 for the proteins of SEQ No. 410, 413,
2df


No. 1060

458


 


SEQ ID
YIIHNK
54-59 for the proteins of SEQ No. 386, 429,
2d


No. 1061

430, 477


 


SEQ ID
YLDELVK
245-251 for the protein of SEQ No. 385
2d


No. 1062


 


SEQ ID
YLMITEAGR
195-203 for the protein of SEQ No. 484
OXA


No. 1063


 


SEQ ID
YLNLFSYGNANIGGGIDK
135-152 for the proteins of SEQ No. 489, 505
OXA


No. 1064


 


SEQ ID
YNGEK
96-100 for the proteins of SEQ No. 429, 430,
2d


No. 1065

477


 


SEQ ID
YPHNPR
88-93 for the protein of SEQ No. 494
2de


No. 1066


 


SEQ ID
YPVVWYSQQVAHHLGAQR
103-120 for the protein of SEQ No. 497
2d


No. 1067


 


SEQ ID
YSNVLAFK
106-113 for the protein of SEQ No. 385
2d


No. 1068


 


SEQ ID
YSPASTFK
68-75 for the proteins of SEQ No. 350, 355,
OXA


No. 1069

356, 363, 367, 369, 370, 372, 373, 375, 415,




443, 481, 484, 488, 491; 57-64 for the protein




of sequence SEQ ID No. 362


 


SEQ ID
YSVVPVYQQLAR
141-152 for the protein of SEQ No. 381
2df


No. 1070


 


SEQ ID
YSVVWYSQLTAK
109-120 for the protein of SEQ No. 433
2d


No. 1071


 


SEQ ID
YSVVWYSQQVAHHLGAQR
103-120 for the proteins of SEQ No. 496,
2d


No. 1072

499, 500


 


SEQ ID
YTPASTFK
55-62 for the protein of SEQ No. 433
2d


No. 1073


 


SEQ ID
YTSAFGYGNADVSGEPGK
130-147 for the protein of SEQ No. 433
2d


No. 1074


 


SEQ ID
YVFVSALTGNLGSNLTSSIK
228-247 for the protein of SEQ No. 361; 243-262
2d


No. 1075

for the protein of sequence SEQ ID No.




360


 


SEQ ID
YVFVSALTGSLGSNLTSSIK
243-262 for the protein of SEQ No. 376
2d


No. 1076


 


SEQ ID
YVGHDR
50-55 for the protein of SEQ No. 380
2d


No. 1077


 


SEQ ID
ANQAFLPASTFK
62-73 for the proteins of SEQ No. 378, 384,
2df


No. 1098

450, 476, 485


 


SEQ ID
DEHQVFK
88-94 for the proteins of SEQ No. 378, 384,
2df


No. 1099

450, 476, 485


 


SEQ ID
DHNLITAMK
108-116 for the proteins of SEQ No. 378,
2df


No. 1100

450, 476


 


SEQ ID
DIATWNR
101-107 for the proteins of SEQ No. 378,
2df


No. 1101

450, 476


 


SEQ ID
IPNSLIALDLGVVK
74-87 for the proteins of SEQ No. 378, 384,
2df


No. 1102

450, 476, 485


 


SEQ ID
ISATEQISFLR
164-174 for the proteins of SEQ No. 378,
2df


No. 1103

450, 476


 


SEQ ID
QAMLTEANGDYIIR
193-206 for the proteins of SEQ No. 378,
2df


No. 1104

450, 476, 485


 


SEQ ID
QQGFTNNLK
52-60 for the proteins of SEQ No. 378, 384,
2df


No. 1105

450, 476, 485


 


SEQ ID
SQGVVVLWNENK
40-51 for the proteins of SEQ No. 378, 450,
2df


No. 1106

476, 485


 


SEQ ID
SWNAHFTEHK
30-39 for the proteins of SEQ No. 378, 450,
2df


No. 1107

476, 485


 


SEQ ID
VLALSAVFLVASIIGMPAVAK
3-23 for the proteins of SEQ No. 378, 450,
2df


No. 1108

476, 485


 


SEQ ID
YSVVPVYQEFAR
117-128 for the proteins of SEQ No. 378,
2df


No. 1109

384, 450, 476, 485









In the clinical interest column, the entries 2d, 2de, 2df correspond to the functional subgroups of OXA beta-lactamases which the corresponding peptide makes it possible to detect. Therefore, the detection of a 2df peptide will indicate the presence of a carbapenemase beta-lactamase capable of hydrolysing carbapenems.
The entry 2de will indicate the presence of a beta-lactamase with an extended spectrum (ESBL) capable of hydrolysing penicillins, first-generation cephalosporins such as cephaloridine and cefalotin, and at least one antibiotic from the oxyimino-beta-lactam class such as cefotaxime, ceftazidime or monobactams such as aztreonam.
The entry OXA indicates a common peptide between at least two of the subgroups 2d, 2de and 2df. The corresponding peptide indicates the presence of an OXA beta-lactamase and the presence of a mechanism of resistance at least to penicillins and to first-generation cephalosporins.
The detection of a mechanism of resistance to carbapenems induced by an OXA protein is characterised by the detection of at least one resistance-marking carba peptide chosen from the sequences SEQ ID No. 510, 511, 512, 513, 514, 520, 521, 522, 523, 525, 527, 530, 532, 537, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 556, 557, 558, 559, 560, 561, 562, 574, 579, 581, 582, 583, 584, 592, 596, 597, 598, 599, 600, 601, 602, 607, 608, 609, 628, 631, 632, 633, 635, 636, 644, 646, 647, 649, 650, 655, 656, 661, 662, 667, 674, 675, 682, 689, 690, 698, 713, 714, 719, 720, 722, 727, 729, 730, 741, 746, 748, 750, 751, 752, 755, 756, 757, 758, 763, 764, 767, 768, 772, 775, 781, 782, 790, 792, 793, 794, 795, 796, 797, 798, 801, 809, 811, 812, 813, 814, 816, 819, 824, 832, 834, 837, 838, 847, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 862, 868, 869, 870, 874, 875, 876, 877, 879, 880, 881, 882, 894, 895, 898, 902, 903, 904, 906, 907, 908, 911, 912, 913, 914, 915, 919, 920, 922, 923, 927, 929, 937, 938, 939, 945, 946, 948, 949, 950, 951, 954, 956, 957, 959, 962, 964, 967, 969, 971, 972, 974, 975, 979, 980, 985, 988, 990, 993, 994, 995, 996, 997, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1011, 1013, 1015, 1017, 1018, 1019, 1023, 1027, 1030, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1042, 1047, 1048, 1051, 1052, 1057, 1058, 1060, 1070, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109
Certain peptide sequences can be common to several resistance mechanisms. Therefore, the following sequences are identical:
SEQ ID No. 24 and SEQ ID No. 287
In all cases, the sequences above indicate the expression of a mechanism of resistance to penicillins, to cephalosporins, including those of the third generation such as cefotaxime/ceftazidime, to monobactams and to carbapenems.
The method of the invention and its advantages will become apparent from the rest of the present description which presents several non-limiting examples of implementation of said method.


EXAMPLE 1: IDENTIFICATION OF MICROORGANISMS FROM A SAMPLE BY BIOCHEMICAL PROFILE
1. Culturing of the Sample on a Culture Medium
The optimum culture media and the optimum culture conditions are different according to the species of microorganism. By default, the sample is seeded on different media:

    
    
        sheep blood Columbia agar (bioMérieux ref. 43041) for 18 to 24 h at 35° C., in an aerobic or anaerobic atmosphere;
        TSA agar (bioMérieux ref. 43011) for 18 to 24 h at 37° C.
    
    


2. Identification of the Microorganisms
The identification is performed as follows:

    
    
        1. Selection of isolated colonies
        2. While maintaining the aseptic conditions, transfer of 3.0 mL of aqueous sterile saline solution (0.45-0.50% NaCl, pH 4.5 to 7.0) into a transparent plastic (polystyrene) test tube
        3. With the aid of a stirrer or a sterile swab, transfer of a sufficient number of identical colonies into the saline solution tube prepared in step 2, and adjustment of the bacterial suspension between 0.50 and 0.63 McFarland with a calibrated DENSICHEK from VITEK®
        4. Positioning of the bacterial suspension tube and of a VITEK® identification card on a VITEK® cartridge
        5. Loading of the cartridge into the VITEK® instrument
        6. The filling, sealing, incubation and reading operations are automatic
        7. Acquisition of a biochemical profile
        8. Identification with the VITEK® system performed by comparing to the biochemical profiles of known strains
    
    


EXAMPLE 2: PREPARATION OF A PRIMARY URINE SAMPLE BY MICROORGANISM ENRICHMENT
The following protocol is performed in 16 steps (steps 5 to 12 are optional and could be omitted if the enriched sample is subsequently treated according to examples 4 and onwards):

    
    
        1. Centrifuging of 5 mL of contaminated urine, at 2000 g for 30 seconds
        2. Recovery of the supernatant
        3. Centrifuging at 15000 g for 5 minutes
        4. Elimination of the supernatant
        5. Washing of the pellet with 3 mL of distilled water by resuspension
        6. Centrifuging at 15000 g for 5 minutes
        7. Elimination of the supernatant
        8. Place the pellet in the presence of solvent (8 acetone volumes for 1 methanol volume) for 1/10 dilution
        9. Leave for 1 hour at −20° C.
        10. Centrifuging at 15000 g for 5 minutes
        11. Elimination of the supernatant
        12. Place the pellet in the presence of solvent (8 acetone volumes for 1 methanol volume) for 1/10 dilution
        13. Leave for 1 hour at −20° C.
        14. Centrifuging at 15000 g for 5 minutes
        15. Elimination of the supernatant
        16. The pellet constitutes the microorganism-enriched sample
    
    


EXAMPLE 3: IDENTIFICATION OF MICROORGANISMS FROM A SAMPLE BY MALDI-TOF
The identification is performed as follows:

    
    
        1. Transfer, with the aid of a 1 μl oese, of a portion of microorganism colony obtained according to Example 1, or of an enriched sample according to Example 2, and uniform deposition on a plate for MALDI-TOF mass spectrometry
        2. Covering the deposit with 1 μl of matrix. The matrix used is a saturated solution of HCCA (alpha-cyano-4-hydroxycinnamic acid) in organic solvent (50% acetonitrile and 2.5% trifluoroacetic acid)
        3. Drying at ambient temperature
        4. Introducing the plate into the mass spectrometer
        5. Acquiring a mass spectrum
        6. Comparing the obtained spectrum with the spectra contained in a knowledge base
        7. Identification of the microorganism by comparing the obtained peaks with those in the knowledge base
    
    


EXAMPLE 4: IDENTIFICATION OF MICROORGANISMS FROM A SAMPLE BY ESI-TOF
The identification is performed as follows:

    
    
        1. Sampling of a microorganism colony, obtained according to Example 1, or of an enriched sample according to Example 2, and suspension in 100 μl of demineralised water.
        2. Centrifuging at 3000 g for 5 minutes.
        3. Elimination of the supernatant.
        4. Resuspension in 100 μl of demineralised water.
        5. Centrifuging at 3000 g for 5 minutes.
        6. Elimination of the supernatant.
        7. Resuspension in 100 μl of an acetonitrile, demineralised water and formic acid mixture (50/50/0.1%).
        8. Filtration with a filter with a porosity of 0.45 μm.
        9. Injection into a mass spectrometer in single MS mode.
        10. Acquisition of a mass spectrum.
        11. Comparing the obtained spectrum with the spectra contained in a knowledge base.
        12. Identification of the microorganism by referring to reference spectra.
    
    


EXAMPLE 5: OBTAINING DIGESTED PROTEINS FROM MICROORGANISMS
The following protocol is conventionally performed in 17 steps:

    
    
        1. Sampling of a microorganism colony, obtained according to Example 1, or of an enriched sample according to Example 2, and suspension in 10 to 100 μl of a 6M guanidine hydrochloride solution, 50 mM Tris-HCl, pH=8.0.
        2. Addition of dithiothreitol (DTT) to achieve an end concentration of 5 mM.
        3. Reduction for 20 minutes at 95° C. in a water bath.
        4. Cooling the tubes to ambient temperature.
        5. Addition of iodoacetamide to obtain an end concentration of 12.5 mM.
        6. Alkylation for 40 minutes at ambient temperature and in the dark.
        7. Dilution by a factor of 6 with a 50 mM NH4HCO3 solution, pH=8.0 to obtain an end guanidine hydrochloride concentration of 1M.
        8. Addition of 1 μg of trypsin.
        9. Digestion at 37° C. for between 6 hours and one night.
        10. Addition of formic acid down to a pH below 4 to stop the reaction.
        11. The sample volume is made up to 1 mL with water/0.5% (v/v) formic acid
        12. Balancing of the Waters Oasis HLB columns with 1 ml of methanol and then 1 ml of H2O/0.1% (v/v) formic acid
        13. Deposition of the sample which runs off by gravity
        14. Washing with 1 ml of H2O/0.1% (v/v) formic acid
        15. Elution with 1 ml of a mixture of 80% methanol and 20% water/0.1% (v/v) formic acid
        16. The eluate is evaporated with a SpeedVac® SPD2010 evaporator (Thermo Electron Corporation, Waltham, Mass., United States of America) over 2 hours, in order to obtain a volume of around 100 μl.
        17. The eluate is then taken up in a water/0.5% (v/v) formic acid solution in a quantity sufficient for (QSF) 250 μl
    
    


EXAMPLE 6: IDENTIFICATION OF A RESISTANCE TO NDM-1 BETA-LACTAMS
Samples Sam1 to Sam9 are identified according to one of the methods described in examples 1, 3 or 4. The identification of the species is set out in TABLE 1.









TABLE 1






Names
Species








Sam1
K. pneumoniae



Sam2
C. freundii



Sam3
A. baumannii



Sam4
A. caviae



Sam5
C. braakii



Sam6
E. cloacae



Sam7
P. rettgeri



Sam8
E. coli



Sam9
K. pneumoniae









Samples Sam1 to Sam9 correspond to a species able to comprise an NDM-1 resistance mechanism (Enterobacteriaceae, Pseudomonas species, Acinetobacter species . . . ). The following method is then performed to search for such a mechanism.
Each sample is treated according to Example 5, then a volume of 50 μl of digested proteins is injected and analysed according to the following conditions:

    
    
        Dionex Ultimate 3000 chromatographic channel from the Dionex Corporation (Sunnyvale, United States of America).
        Waters BEH130 C18 Column, 2.1 mm inner diameter, 100 mm length, 3.5 μm particle size (Waters, Saint-Quentin En Yvelines, France).
        Solvent A: H2O+0.1% formic acid.
        Solvent B: ACN+0.1% formic acid.
    
    


HPLC gradient defined in Table 2 hereafter:











TABLE 2






Time (min)
Flow (μl)
Solvent A (%)
Solvent B (%)




















0
300
98
2



3
300
98
2



34
300
54.6
45.4



35
300
0
100



55
300
0
100



55.1
300
98
2



74
300
98
2









    
    
        The eluate coming from the chromatographic column is directly injected into the ionising source of the QTRAP® 5500 mass spectrometer from Applied Biosystems (Foster City, United States of America).
        The peptides coming from the digestion of the microorganism proteins are analysed by the mass spectrometer in MRM mode. Only the peptides indicated in TABLE 3 are detected. To this end, the fragment(s) indicated in TABLE 3 is/are detected.
    
    
















TABLE 3







Charge









state

Retention
(m/z)
(m/z)
Collision


Transition

of the

time
filtered
filtered in
energy


number
Peptide
precursor
Fragment ion
(minutes)
in Q1
Q3
(eV)






















1
AAITHTAR
2
y4
5.61
420.74
484.26
24





monocharged


 


2
AAITHTAR
2
y5
5.61
420.74
585.31
24





monocharged


 


3
AAITHTAR
2
y6
5.61
420.74
698.39
24





monocharged


 


4
AFGAAFPK
2
y6
16.03
404.72
590.33
23





monocharged


 


5
AFGAAFPK
2
y7
16.03
404.72
737.4
23





monocharged


 


6
AFGAAFPK
2
y7 dicharged
16.03
404.72
369.2
23


 


7
ASMIVMSHSAPDSR
2
y7
13.65
744.85
769.36
38





monocharged


 


8
ASMIVMSHSAPDSR
2
y8
13.65
744.85
856.39
38





monocharged


 


9
ASMIVMSHSAPDSR
2
y9
13.65
744.85
987.43
38





monocharged


 


10
FGDLVFR
2
y4
19.14
427.23
534.34
24





monocharged


 


11
FGDLVFR
2
y5
19.14
427.23
649.37
24





monocharged


 


12
FGDLVFR
2
y6
19.14
427.23
706.39
24





monocharged


 


13
MELPNIMHPVAK
2
y10 dicharged
19.09
690.36
560.32
35


 


14
MELPNIMHPVAK
2
y9
19.09
690.36
1006.55
35





monocharged


 


15
MELPNIMHPVAK
2
y9 dicharged
19.09
690.36
503.78
35


 


16
QEINLPVALAVVTHAHQDK
3
y14 dicharged
21.34
695.05
743.41
39


 


17
QEINLPVALAVVTHAHQDK
3
y7
21.34
695.05
836.4
39





monocharged


 


18
QEINLPVALAWTHAHQDK
3
y8
21.34
695.05
935.47
39





monocharged


 


19
SLGNLGDADTEHYAASAR
2
y14 dicharged
14.64
924.43
738.84
46


 


20
SLGNLGDADTEHYAASAR
2
y16 dicharged
14.64
924.43
824.37
46


 


21
SLGNLGDADTEHYAASAR
2
y7
14.64
924.43
775.38
46





monocharged


 


22
VLVVDTAWTDDQTAQILNWIK
3
y5
27.16
810.43
673.4
45





monocharged


 


23
VLVVDTAWTDDQTAQILNWIK
3
y6
27.16
810.43
786.49
45





monocharged


 


24
VLVVDTAWTDDQTAQILNWIK
3
y7
27.16
810.43
914.55
45





monocharged









The precursor peptide charge state, its retention time, the fragment ion type and the transitions, i.e. the (m/z)1 ratio in Q1 and (m/z)2 ratio in Q3 are indicated in TABLE 3. The collision energy used to fragment the precursor ion is also indicated in TABLE 3.

    
    
        The other machine parameters used are as follows:
        Scan type: MRM
        MRM planned: yes
        Polarity: Positive
        Ionising source: Turbo VTM (Applied BioSystems)
        Q1 setting: Filtering with unit resolution
        Q3 setting: Filtering with unit resolution
        Inter-scan pause: 5.00 msec
        Scanning speed: 10 Da/s
        Curtain gas: 50.00 psi
        Cone voltage: 5500.00 V
        Source temperature: 500.00° C.
        Nebulising gas: 50.00 psi
        Heating gas: 40.00 psi
        Collision gas which induces dissociation: 9.00 psi
        Dynamic filling: activated
        Declustering potential (DP): 80.00 V
        Entry potential before Q0 (EP): 10.00 V
        Collision cell exit potential (CXP): 35 V
        Total cycle time: 1.2 sec
        Detection window: 90 sec
    
    


The areas obtained for each of the transitions and for each of the microorganisms studied were measured. All the transitions having an area greater than or equal to 2500 (arbitrary unit) are considered to be positive and have been labelled “1” in TABLE 4. All the transitions having an area less than 2500 are considered to be negative and have been labelled 0 in TABLE 4. When no signal peak was observed, the transition has been labelled as negative.
















TABLE 4





Tran-











sition











number
Sam1
Sam2
Sam3
Sam4
Sam5
Sam6
Sam7
Sam8
Sam9
























1
1
1
1
1
1
1
0
1
1


2
1
1
1
1
1
1
1
1
1


3
1
1
0
1
1
1
0
1
1


4
1
1
1
1
1
1
1
1
1


5
1
1
1
1
1
1
1
1
1


6
1
1
0
1
1
1
1
1
1


7
0
0
0
0
0
0
0
0
0


8
0
0
0
0
0
0
0
0
0


9
0
0
0
0
0
0
0
0
0


10
1
1
1
1
1
1
1
1
1


11
1
1
1
1
1
1
1
1
1


12
1
1
1
1
1
1
1
1
1


13
0
0
0
0
0
0
0
0
0


14
0
0
0
0
0
0
0
0
0


15
0
0
0
0
0
0
0
0
0


16
1
1
0
1
1
0
0
0
1


17
1
1
0
1
1
1
1
0
1


18
1
1
0
1
1
0
1
0
1


19
0
0
0
0
0
0
0
0
0


20
0
0
0
0
0
0
0
0
0


21
0
0
0
0
0
0
0
0
0


22
0
0
0
0
0
0
0
0
0


23
0
0
0
0
0
0
0
0
0


24
0
0
0
0
0
0
0
0
0









The number of positive transitions is then added up and set out in TABLE 5:










TABLE 5








Number of positive



Names
Species
transitions



















Sam1
K. pneumoniae
12



Sam2
C. freundii
12



Sam3
A. baumannii
7



Sam4
A. caviae
12



Sam5
C. braakii
12



Sam6
E. cloacae
10



Sam7
P. rettgeri
9



Sam8
E. coli
9



Sam9
K. pneumoniae
12









Samples Sam1 to Sam9 comprise more than 6 positive transitions, they therefore contain bacteria which express the NDM-1 protein. The bacteria of Sam1 to Sam9 are therefore resistant to penicillins, to cephalosporins and to carbapenems.
EXAMPLE 7: IDENTIFICATION OF A RESISTANCE TO KPC BETA-LACTAMS
Samples Sam62 to Sam73 are identified according to one of the methods described in examples 1, 3 or 4. The identification of the species is set out in TABLE 6.










TABLE 6







Names
Species









Sam62
K. pneumoniae



Sam63
K. pneumoniae



Sam64
K. pneumoniae



Sam65
K. pneumoniae



Sam66
K. pneumoniae



Sam67
K. pneumoniae



Sam68
K. pneumoniae



Sam69
K. pneumoniae



Sam70
K. pneumoniae



Sam71
K. pneumoniae



Sam72
K. pneumoniae



Sam73
K. pneumoniae










Samples Sam62 to Sam73 correspond to a species able to comprise a KPC resistance mechanism. The following method is then performed to detect such a mechanism.
Each sample is treated according to Example 5, then analysed according to Example 6 by detecting the peptides from TABLE 7 instead of the peptides from TABLE 3.












TABLE 7








Charge




Transition

Methionine
state of the

Clinical


number
Peptide
oxidation
precursor
Fragment ion
interest




















1
AAVPADWAVGDK
no
2
y9 dicharged
2f


 


2
AAVPADWAVGDK
no
2
y10 dicharged
2f


 


3
AAVPADWAVGDK
no
2
y9 monocharged
2f


 


4
APIVLAVYTR
no
2
y7 monocharged
2f


 


5
APIVLAVYTR
no
2
y5 monocharged
2f


 


6
APIVLAVYTR
no
2
y6 monocharged
2f


 


7
AVTESLQK
no
2
y5 monocharged
2f


 


8
AVTESLQK
no
2
y6 monocharged
2f


 


9
AVTESLQK
no
2
y4 monocharged
2f


 


10
ELGGPAGLTAFMR
yes
2
y7 monocharged
2f


 


11
ELGGPAGLTAFMR
yes
2
y5 monocharged
2f


 


12
ELGGPAGLTAFMR
yes
2
y9 dicharged
2f


 


13
ELGGPAGLTAFMR
no
2
y7 monocharged
2f


 


14
ELGGPAGLTAFMR
no
2
y5 monocharged
2f


 


15
ELGGPAGLTAFMR
no
2
y9 dicharged
2f


 


16
FPLCSSFK
no
2
y6 monocharged
2f


 


17
FPLCSSFK
no
2
y7 monocharged
2f


 


18
FPLCSSFK
no
2
y5 monocharged
2f


 


19
GFLAAAVLAR
no
2
y6 monocharged
2f


 


20
GFLAAAVLAR
no
2
y7 monocharged
2f


 


21
GFLAAAVLAR
no
2
y5 monocharged
2f


 


22
GNTTGNHR
no
2
y5 monocharged
2f


 


23
GNTTGNHR
no
2
y6 monocharged
2f


 


24
GNTTGNHR
no
2
y4 monocharged
2f


 


25
LALEGLGVNGQ
no
3
y8 monocharged
2f


 


26
LALEGLGVNGQ
no
3
y7 monocharged
2f


 


27
LALEGLGVNGQ
no
3
y6 monocharged
2f


 


28
LTLGSALAAPQR
no
3
y9 monocharged
2f


 


29
LTLGSALAAPQR
no
3
y5 monocharged
2f


 


30
LTLGSALAAPQR
no
3
y6 monocharged
2f


 


31
NALVPWSPISEK
no
2
y8 monocharged
2f


 


32
NALVPWSPISEK
no
2
y8 dicharged
2f


 


33
NALVPWSPISEK
no
2
y5 monocharged
2f


 


34
QQFVDWLK
no
2
y5 monocharged
2f


 


35
QQFVDWLK
no
2
y6 monocharged
2f


 


36
QQFVDWLK
no
2
y4 monocharged
2f


 


37
SIGDTTFR
no
2
y5 monocharged
2f


 


38
SIGDTTFR
no
2
y6 monocharged
2f


 


39
SIGDTTFR
no
2
y4 monocharged
2f


 


40
SQQQAGLLDTPIR
no
2
y8 monocharged
2f


 


41
SQQQAGLLDTPIR
no
2
y9 monocharged
2f


 


42
SQQQAGLLDTPIR
no
2
y10 monocharged
2f


 


43
WELELNSAIPGDAR
no
2
y5 monocharged
2f


 


44
WELELNSAIPGDAR
no
2
y8 monocharged
2f


 


45
WELELNSAIPGDAR
no
2
y9 monocharged
2f









The transitions mentioned in TABLE 7 are detected by using the parameters set out in TABLE 8.
















Retention
(m/z)
(m/z)
Collision



Transition
time
filtered
filtered in
energy
Positivity


number
(minutes)
in Q1
Q3
(eV)
threshold




















1
16.29
600.31
479.73
31
2000


2
16.29
600.31
529.27
31
2000


3
16.29
600.31
958.46
31
2000


4
19.07
551.83
821.49
29
13000


5
19.07
551.83
609.33
29
13000


6
19.07
551.83
722.42
29
13000


7
10.38
438.25
604.33
24
2000


8
10.38
438.25
705.38
24
2000


9
10.38
438.25
475.29
24
2000


10
18.55
668.34
811.41
34
2000


11
18.55
668.34
641.31
34
2000


12
18.55
668.34
490.26
34
2000


13
21.72
660.34
795.42
34
2000


14
21.72
660.34
625.31
34
2000


15
21.72
660.34
482.26
34
2000


16
17.56
493.24
741.36
27
2000


17
17.56
493.24
838.41
27
2000


18
17.56
493.24
628.28
27
2000


19
20.67
494.8
600.38
27
14000


20
20.67
494.8
671.42
27
14000


21
20.67
494.8
529.35
27
14000


22
1.19
428.7
584.29
24
2000


23
1.19
428.7
685.34
24
2000


24
1.19
428.7
483.24
24
2000


25
18.89
535.8
773.38
42
2000


26
18.89
535.8
644.34
42
2000


27
18.89
535.8
587.31
42
2000


28
17.37
599.35
870.48
42
2000


29
17.37
599.35
542.3
42
2000


30
17.37
599.35
655.39
42
2000


31
20
670.86
943.49
35
2000


32
20
670.86
472.25
35
2000


33
20
670.86
573.32
35
2000


34
20.48
532.28
660.37
28
2000


35
20.48
532.28
807.44
28
2000


36
20.48
532.28
561.3
28
2000


37
13.42
448.73
639.31
25
2000


38
13.42
448.73
696.33
25
2000


39
13.42
448.73
524.28
25
2000


40
17.6
713.89
884.52
36
2000


41
17.6
713.89
955.56
36
2000


42
17.6
713.89
1083.62
36
2000


43
21.1
785.9
515.26
40
2000


44
21.1
785.9
786.41
40
2000


45
21.1
785.9
900.45
40
2000









The areas obtained for each of the transitions and for each of the microorganisms studied were measured. When the areas of the 3 transitions of the same peptide are greater than or equal to the positivity threshold described in TABLE 8, the detection of the peptide is considered to be positive and is labelled “1” in TABLE 9. When at least one transition comprises an area less than the positivity threshold described in TABLE 8, the corresponding peptide is considered non-detected and is labelled “0” in TABLE 9.



















TABLE 9





Transition














number
Sam62
Sam63
Sam64
Sam65
Sam66
Sam67
Sam68
Sam69
Sam70
Sam71
Sam72
Sam73



























1
0
0
0
0
0
0
1
1
1
1
1
1


2
0
0
0
0
0
0
1
1
1
1
1
1


3
0
0
0
0
0
0
1
1
1
1
1
1


4
0
0
0
0
0
0
1
1
1
1
1
1


5
0
0
0
0
0
0
1
1
1
1
1
1


6
0
0
0
0
0
0
1
1
1
1
1
1


7
0
0
0
0
0
0
0
0
0
0
0
0


8
0
0
0
0
0
0
0
0
0
0
0
0


9
0
0
0
0
0
0
0
0
0
0
0
0


10
0
0
0
0
0
0
0
0
0
0
0
0


11
0
0
0
0
0
0
0
0
0
0
0
0


12
0
0
0
0
0
0
0
0
0
0
0
0


13
0
0
0
0
0
0
1
1
1
1
1
1


14
0
0
0
0
0
0
1
1
1
1
1
1


15
0
0
0
0
0
0
1
1
1
1
1
1


16
0
0
0
0
0
0
0
0
0
0
0
0


17
0
0
0
0
0
0
0
0
0
0
0
0


18
0
0
0
0
0
0
0
0
0
0
0
0


19
0
0
0
0
0
0
1
1
1
1
1
1


20
0
0
0
0
0
0
1
1
1
1
1
1


21
0
0
0
0
0
0
1
1
1
1
1
1


22
0
0
0
0
0
0
0
0
0
0
0
0


23
0
0
0
0
0
0
0
0
0
0
0
0


24
0
0
0
0
0
0
0
0
0
0
0
0


25
0
0
0
0
0
0
0
0
0
0
0
0


26
0
0
0
0
0
0
0
0
0
0
0
0


27
0
0
0
0
0
0
0
0
0
0
0
0


28
0
0
0
0
0
0
1
1
1
1
1
1


29
0
0
0
0
0
0
1
1
1
1
1
1


30
0
0
0
0
0
0
1
1
1
1
1
1


31
0
0
0
0
0
0
1
1
1
1
1
1


32
0
0
0
0
0
0
1
1
1
1
1
1


33
0
0
0
0
0
0
1
1
1
1
1
1


34
0
0
0
0
0
0
0
0
0
0
0
0


35
0
0
0
0
0
0
0
0
0
0
0
0


36
0
0
0
0
0
0
0
0
0
0
0
0


37
0
0
0
0
0
0
1
1
1
1
1
1


38
0
0
0
0
0
0
1
1
1
1
1
1


39
0
0
0
0
0
0
0
0
0
0
0
0


40
0
0
0
0
0
0
1
1
1
1
1
1


41
0
0
0
0
0
0
1
1
1
1
1
1


42
0
0
0
0
0
0
1
1
1
1
1
1


43
0
0
0
0
0
0
0
0
0
0
0
0


44
0
0
0
0
0
0
0
0
0
0
0
0


45
0
0
0
0
0
0
0
0
0
0
0
0


Sum of the
0
0
0
0
0
0
23
23
23
23
23
23


transitions









Samples Sam68 to Sam73 comprise at least one transition which is characteristic of KPCs. The bacteria present in samples Sam68 to Sam73 therefore express a beta-lactamase which confers on them a resistance to penicillins, to cephalosporins, including third-generation cephalosporins such as cefotaxime/ceftazidime, to monobactams and to carbapenems.
Samples Sam62 to Sam67 comprise no transition which is characteristic of KPCs. The bacteria present in samples Sam62 to Sam67 therefore do not express KPC beta-lactamase and may be sensitive to carbapenem antibiotics.
EXAMPLE 8: IDENTIFICATION OF A RESISTANCE TO NDM-1 OR KPC BETA-LACTAMS
The samples corresponding to a species able to comprise an NDM-1 or KPC resistance mechanism can be detected by employing the following method.
Each sample is treated according to Example 5, then analysed according to Example 6 by detecting the peptides from TABLE 10 instead of the peptides from TABLE 3.












TABLE 10






Transition

First-generation
Charge state of
Clinical


Proteins
number
Peptide
fragment ion
the precursor
interest




















NDM-1
1
AAITHTAR
y4 monocharged
2
3a


 


NDM-1
2
AAITHTAR
y5 monocharged
2
3a


 


NDM-1
3
AAITHTAR
y6 monocharged
2
3a


 


NDM-1
4
AFGAAFPK
y6 monocharged
2
3a


 


NDM-1
5
AFGAAFPK
y7 monocharged
2
3a


 


NDM-1
6
AFGAAFPK
y7 dicharged
2
3a


 


NDM-1
7
FGDLVFR
y4 monocharged
2
3a


 


NDM-1
8
FGDLVFR
y5 monocharged
2
3a


 


NDM-1
9
FGDLVFR
y6 monocharged
2
3a


 


NDM-1
10
QEINLPVALAVVTHAHQDK
y14 dicharged
3
3a


 


NDM-1
11
QEINLPVALAVVTHAHQDK
y7 monocharged
3
3a


 


NDM-1
12
QEINLPVALAVVTHAHQDK
y8 monocharged
3
3a


 


KPC
13
AAVPADWAVGDK
y9 dicharged
2
2f


 


KPC
14
AAVPADWAVGDK
y10 dicharged
2
2f


 


KPC
15
AAVPADWAVGDK
y9 monocharged
2
2f


 


KPC
16
APIVLAVYTR
y7 monocharged
2
2f


 


KPC
17
APIVLAVYTR
y5 monocharged
2
2f


 


KPC
18
APIVLAVYTR
y6 monocharged
2
2f


 


KPC
19
ELGGPAGLTAFMR
y7 monocharged
2
2f


 


KPC
20
ELGGPAGLTAFMR
y5 monocharged
2
2f


 


KPC
21
ELGGPAGLTAFMR
y9 dicharged
2
2f


 


KPC
22
GFLAAAVLAR
y6 monocharged
2
2f


 


KPC
23
GFLAAAVLAR
y7 monocharged
2
2f


 


KPC
24
GFLAAAVLAR
y5 monocharged
2
2f


 


KPC
25
LTLGSALAAPQR
y9 monocharged
3
2f


 


KPC
26
LTLGSALAAPQR
y5 monocharged
3
2f


 


KPC
27
LTLGSALAAPQR
y6 monocharged
3
2f


 


KPC
28
NALVPWSPISEK
y8 monocharged
2
2f


 


KPC
29
NALVPWSPISEK
y8 dicharged
2
2f


 


KPC
30
NALVPWSPISEK
y5 monocharged
2
2f


 


KPC
31
SQQQAGLLDTPIR
y8 monocharged
2
2f


 


KPC
32
SQQQAGLLDTPIR
y9 monocharged
2
2f


 


KPC
33
SQQQAGLLDTPIR
y10 monocharged
2
2f









The entry 2f indicates the presence of a carbapenemase beta-lactamase from subgroup 2f according to the Bush and Jacoby classification [Antimicrob Agents Chemother. 2010 March; 54(3):969-76. Epub 2009 Dec. 7. Updated functional classification of beta-lactamases], capable of hydrolysing carbapenems.
The entry 3a indicates the presence of a metallo-beta-lactamase from subgroup 3a according to the Bush and Jacoby classification [9], supra, capable of hydrolysing penicillins, cephalosporins and carbapenems.
The transitions mentioned in TABLE 10 are detected by using the parameters set out in TABLE 11.












TABLE 11






Retention
(m/z)
(m/z)
Collision



Transition
time
filtered in
filtered in
energy
Positivity


number
(minutes)
Q1
Q3
(eV)
threshold




















1
5.61
420.74
484.26
24
2500


2
5.61
420.74
585.31
24
2500


3
5.61
420.74
698.39
24
2500


4
16.03
404.72
590.33
23
2500


5
16.03
404.72
737.4
23
2500


6
16.03
404.72
369.2
23
2500


7
19.14
427.23
534.34
24
2500


8
19.14
427.23
649.37
24
2500


9
19.14
427.23
706.39
24
2500


10
21.34
695.05
743.41
39
2500


11
21.34
695.05
836.4
39
2500


12
21.34
695.05
935.47
39
2500


13
16.29
600.31
479.73
31
2000


14
16.29
600.31
529.27
31
2000


15
16.29
600.31
958.46
31
2000


16
19.07
551.83
821.49
29
13000


17
19.07
551.83
609.33
29
13000


18
19.07
551.83
722.42
29
13000


19
21.72
660.34
795.42
34
2000


20
21.72
660.34
625.31
34
2000


21
21.72
660.34
482.26
34
2000


22
20.67
494.8
600.38
27
14000


23
20.67
494.8
671.42
27
14000


24
20.67
494.8
529.35
27
14000


25
17.37
599.35
870.48
42
2000


26
17.37
599.35
542.3
42
2000


27
17.37
599.35
655.39
42
2000


28
20
670.86
943.49
35
2000


29
20
670.86
472.25
35
2000


30
20
670.86
573.32
35
2000


31
17.6
713.89
884.52
36
2000


32
17.6
713.89
955.56
36
2000


33
17.6
713.89
1083.62
36
2000









When the areas of at least two transitions of the same peptide are greater than or equal to the positivity threshold described in TABLE 11, the detection of the peptide is considered to be positive. When more than two transitions of the same peptide comprise an area less than the positivity threshold described in TABLE 11, the corresponding peptide is considered non-detected.
A sample contains bacteria which express the NDM-1 protein, when at least one peptide corresponding to the NDM-1 resistance mechanism is detected. These bacteria are resistant to penicillins, to cephalosporins and to carbapenems.
A sample contains bacteria which express the KPC protein, when at least one peptide corresponding to the KPC resistance mechanism is detected. These bacteria are resistant to penicillins, to cephalosporins, including third-generation cephalosporins such as cefotaxime/ceftazidime, to monobactams and to carbapenems.
EXAMPLE 9: IDENTIFICATION OF A RESISTANCE TO IND BETA-LACTAMS
Samples Sam84 to Sam88 are identified according to one of the methods described in examples 1, 3 or 4. The identification of the species is set out in TABLE 12.










TABLE 12







Names
Species









Sam84
C. indologenes



Sam85
C. indologenes



Sam86
C. indologenes



Sam87
C. indologenes



Sam88
C. indologenes










Samples Sam84 to Sam88 correspond to a species able to comprise an IND resistance mechanism. The following method is then performed to detect such a mechanism.
Each sample is treated according to Example 5, then analysed according to Example 6 unless otherwise stated in the rest of the example, by detecting the peptides from TABLE 13 instead of the peptides from TABLE 3.















TABLE 13












Collision





Retention
(m/z)
(m/z)
Declustering
Collision
cell exit


Transition

time
filtered
filtered
potential
energy
potential
Positivity


number
Peptide
(minutes)
in Q1
in Q3
(eV)
(eV)
(eV)
threshold























1
AATDLGYIK
14.66
476.26
593.37
65.8
26
15
2000


 


2
AATDLGYIK
14.66
476.26
708.39
65.8
26
15
2000


 


3
AATDLGYIK
14.66
476.26
809.44
65.8
26
15
2000


 


4
AGDLSFFNNK
18.08
556.77
522.27
71.7
29.5
15
2000


 


5
AGDLSFFNNK
18.08
556.77
669.34
71.7
29.5
15
2000


 


6
AGDLSFFNNK
18.08
556.77
756.37
71.7
29.5
15
2000


 


7
AGDLSFYNK
14.82
507.75
424.22
68.1
27.3
15
2000


 


8
AGDLSFYNK
14.84
507.75
571.29
68.1
27.3
15
2000


 


9
AGDLSFYNK
14.84
507.75
658.32
68.1
27.3
15
2000


 


10
AGDLSFYNQK
14.91
571.78
552.28
72.8
30.2
15
2000


 


11
AGDLSFYNQK
14.93
571.78
699.35
72.8
30.2
15
2000


 


12
AGDLSFYNQK
14.93
571.78
786.38
72.8
30.2
15
2000


 


13
AQYQSLMDTIK
18.01
649.33
1098.55
78.5
33.6
15
2000


 


14
AQYQSLMDTIK
18.01
649.33
607.31
78.5
33.6
15
2000


 


15
AQYQSLMDTIK
18.01
649.33
807.43
78.5
33.6
15
2000


 


16
ASLVIPGHDEWK
16.84
676.35
434.70
80.4
34.8
15
2000


 


17
ASLVIPGHDEWK
16.8
676.35
868.40
80.4
34.8
15
2000


 


18
ASLVIPGHDEWK
16.82
676.35
981.48
80.4
34.8
15
2000


 


19
ATLIIPGHDDWK
17.47
683.36
427.69
80.9
35.1
15
2000


 


20
ATLIIPGHDDWK
17.47
683.36
854.38
80.9
35.1
15
2000


 


21
ATLIIPGHDDWK
17.47
683.36
967.46
80.9
35.1
15
2000


 


22
ATLIIPGHDEWK
17.54
690.37
1094.56
81.4
35.4
10
2000


 


23
ATLIIPGHDEWK
17.54
690.37
868.40
81.4
35.4
10
2000


 


24
ATLIIPGHDEWK
17.54
690.37
981.48
81.4
35.4
10
2000


 


25
ATSTELIKPGK
11.63
572.83
301.19
72.9
30.2
15
2000


 


26
ATSTELIKPGK
11.67
572.83
486.79
72.9
30.2
15
2000


 


27
ATSTELIKPGK
11.67
572.83
655.45
72.9
30.2
15
2000


 


28
DFVIEPPIK
19.93
529.30
454.30
69.7
28.3
15
2000


 


29
DFVIEPPIK
19.93
529.30
696.43
69.7
28.3
15
2000


 


30
DFVIEPPIK
19.93
529.30
795.50
69.7
28.3
15
2000


 


31
DFVIEPPVKPNLYLYK
22.03
645.69
730.91
78.2
36.3
15
2000


 


32
DFVIEPPVKPNLYLYK
22.03
645.69
787.45
78.2
36.3
15
2000


 


33
DFVIEPPVKPNLYLYK
22.08
645.69
836.99
78.2
36.3
15
2000


 


34
DFVIEQPFGK
19.77
590.31
448.26
74.2
31
15
2000


 


35
DFVIEQPFGK
19.75
590.31
705.36
74.2
31
15
2000


 


36
DFVIEQPFGK
19.75
590.31
818.44
74.2
31
15
2000


 


37
EANLEQWPK
15.53
557.78
430.25
71.8
29.5
15
2000


 


38
EANLEQWPK
15.55
557.78
558.30
71.8
29.5
15
2000


 


39
EANLEQWPK
15.55
557.78
687.35
71.8
29.5
15
2000


 


40
EANVEQWPITIDK
19.5
514.93
343.71
68.7
29.7
10
2000


 


41
EANVEQWPITIDK
19.5
514.93
686.41
68.7
29.7
10
2000


 


42
EANVEQWPITIDK
19.48
514.93
872.49
68.7
29.7
10
2000


 


43
EANVEQWPK
13.84
550.77
430.25
71.3
29.2
15
2000


 


44
EANVEQWPK
13.86
550.77
558.30
71.3
29.2
15
2000


 


45
EANVEQWPK
13.86
550.77
687.35
71.3
29.2
15
2000


 


46
EQYQTLMDTIQK
17.9
749.37
735.37
85.7
38
10
2000


 


47
EQYQTLMDTIQK
17.9
749.37
848.46
85.7
38
10
2000


 


48
EQYQTLMDTIQK
17.9
749.37
949.50
85.7
38
10
2000


 


49
EYSANAVYLTTK
15.26
680.34
1067.57
80.7
34.9
10
2000


 


50
EYSANAVYLTTK
15.28
680.34
625.36
80.7
34.9
10
2000


 


51
EYSANAVYLTTK
15.26
680.34
795.46
80.7
34.9
10
2000


 


52
EYSANSMYLVTK
16.5
703.34
1113.56
82.4
35.9
10
2000


 


53
EYSANSMYLVTK
16.5
703.34
841.45
82.4
35.9
10
2000


 


54
EYSANSMYLVTK
16.5
703.34
955.49
82.4
35.9
10
2000


 


55
EYSANSVYLVTK
16.19
687.35
1081.59
81.2
35.2
10
2000


 


56
EYSANSVYLVTK
16.14
687.35
623.38
81.2
35.2
10
2000


 


57
EYSANSVYLVTK
16.12
687.35
923.52
81.2
35.2
10
2000


 


58
EYSANSVYLVTQK
16.19
501.26
376.22
67.7
29.1
10
2000


 


59
EYSANSVYLVTQK
16.19
501.26
475.29
67.7
29.1
10
2000


 


60
EYSANSVYLVTQK
16.21
501.26
751.44
67.7
29.1
10
2000


 


61
EYSTNALYLVTK
18.83
701.37
1109.62
82.2
35.9
10
2000


 


62
EYSTNALYLVTK
18.83
701.37
460.31
82.2
35.9
10
2000


 


63
EYSTNALYLVTK
18.81
701.37
623.38
82.2
35.9
10
2000


 


64
GGGHVEHTLELLDK
15.6
502.26
730.44
67.7
29.1
10
2000


 


65
GGGHVEHTLELLDK
15.6
502.26
831.48
67.7
29.1
10
2000


 


66
GGGHVEHTLELLDK
15.6
502.26
968.54
67.7
29.1
10
2000


 


67
GGGHVEHTLELLNK
15
501.94
616.37
67.7
29.1
10
2000


 


68
GGGHVEHTLELLNK
15
501.94
729.45
67.7
29.1
10
2000


 


69
GGGHVEHTLELLNK
15
501.94
830.50
67.7
29.1
10
2000


 


70
GGGHVQHTLDLLDK
15.35
745.39
1082.58
85.5
37.8
10
2000


 


71
GGGHVQHTLDLLDK
15.35
745.39
1181.65
85.5
37.8
10
2000


 


72
GGGHVQHTLDLLDK
15.35
745.39
488.31
85.5
37.8
10
2000


 


73
GIPTYATAK
12.63
461.26
376.20
64.7
25.3
15
2000


 


74
GIPTYATAK
12.63
461.26
654.35
64.7
25.3
15
2000


 


75
GIPTYATAK
12.63
461.26
751.40
64.7
25.3
15
2000


 


76
GNDHVK
1.3
335.17
383.24
55.6
19.7
15
2000


 


77
GNDHVK
1.3
335.17
498.27
55.6
19.7
15
2000


 


78
GNDHVK
1.3
335.17
612.31
55.6
19.7
15
2000


 


79
GVVLFDVPWEK
23.79
644.86
559.29
78.1
33.4
15
2000


 


80
GVVLFDVPWEK
23.82
644.86
658.36
78.1
33.4
15
2000


 


81
GVVLFDVPWEK
23.82
644.86
920.45
78.1
33.4
15
2000


 


82
GVVLFDVPWQK
23.32
644.36
558.30
78.1
33.4
15
2000


 


83
GVVLFDVPWQK
23.32
644.36
772.40
78.1
33.4
15
2000


 


84
GVVLFDVPWQK
23.32
644.36
919.47
78.1
33.4
15
2000


 


85
HNLPVIAVFATHSHSDR
17.94
634.33
768.90
77.4
35.7
15
2000


 


86
HNLPVIAVFATHSHSDR
17.95
634.33
825.44
77.4
35.7
15
2000


 


87
HNLPVIAVFATHSHSDR
17.93
634.33
882.46
77.4
35.7
15
2000


 


88
HNLPVVAVFATHSHDDR
17.17
638.99
775.89
77.7
35.9
15
2000


 


89
HNLPVVAVFATHSHDDR
17.17
638.99
832.43
77.7
35.9
15
2000


 


90
HNLPVVAVFATHSHDDR
17.17
638.99
889.45
77.7
35.9
15
2000


 


91
HTLELLDQQK
15.02
612.83
403.23
75.8
32
15
2000


 


92
HTLELLDQQK
15.02
612.83
518.26
75.8
32
15
2000


 


93
HTLELLDQQK
15.02
612.83
986.55
75.8
32
15
2000


 


94
HTLELLNK
14.44
484.28
616.37
66.4
26.3
15
2000


 


95
HTLELLNK
14.44
484.28
729.45
66.4
26.3
15
2000


 


96
HTLELLNK
14.44
484.28
830.50
66.4
26.3
15
2000


 


97
IQYQSLMDTIK
19.41
670.34
1098.55
80
34.5
15
2000


 


98
IQYQSLMDTIK
19.38
670.34
607.31
80
34.5
15
2000


 


99
IQYQSLMDTIK
19.41
670.34
807.43
80
34.5
15
2000


 


100
NLHIYK
11.54
394.23
337.21
59.9
22.3
15
2000


 


101
NLHIYK
11.54
394.23
423.26
59.9
22.3
15
2000


 


102
NLHIYK
11.54
394.23
560.32
59.9
22.3
15
2000


 


103
NLYIYK
14.93
407.23
423.26
60.8
22.9
15
2000


 


104
NLYIYK
14.91
407.23
586.32
60.8
22.9
15
2000


 


105
NLYIYK
14.93
407.23
699.41
60.8
22.9
15
2000


 


106
NNLHIYK
11.29
451.25
423.26
64
24.9
15
2000


 


107
NNLHIYK
11.29
451.25
560.32
64
24.9
15
2000


 


108
NNLHIYK
11.27
451.25
673.40
64
24.9
15
2000


 


109
QLYLYK
15.22
414.24
423.26
61.3
23.2
15
2000


 


110
QLYLYK
15.2
414.24
586.32
61.3
23.2
15
2000


 


111
QLYLYK
15.22
414.24
699.41
61.3
23.2
15
2000


 


112
QWPETMR
14.84
474.22
317.16
65.7
25.9
15
2000


 


113
QWPETMR
14.75
474.22
407.21
65.7
25.9
15
2000


 


114
QWPETMR
14.73
474.22
633.30
65.7
25.9
15
2000


 


115
SFGVFGGK
16.69
399.71
356.20
60.3
22.6
15
2000


 


116
SFGVFGGK
16.69
399.71
408.22
60.3
22.6
15
2000


 


117
SFGVFGGK
16.69
399.71
564.31
60.3
22.6
15
2000


 


118
SIQLLMMSMFLSPLINAQVK
32.4
755.41
441.77
86.2
41.8
15
2000


 


119
SIQLLMMSMFLSPLINAQVK
32.4
755.41
882.54
86.2
41.8
15
2000


 


120
SIQLLMMSMFLSPLINAQVK
32.4
755.41
969.57
86.2
41.8
15
2000


 


121
SNSATDLGYIK
14.71
584.80
593.37
73.7
30.7
15
2000


 


122
SNSATDLGYIK
14.71
584.80
809.44
73.7
30.7
15
2000


 


123
SNSATDLGYIK
14.71
584.80
967.51
73.7
30.7
15
2000


 


124
TATDLGYTGEANVK
13.61
720.35
718.37
83.6
36.7
10
2000


 


125
TATDLGYTGEANVK
13.61
720.35
881.44
83.6
36.7
10
2000


 


126
TATDLGYTGEANVK
13.61
720.35
938.46
83.6
36.7
10
2000


 


127
TFGVFDGK
16.56
435.72
466.23
62.9
24.2
15
2000


 


128
TFGVFDGK
16.58
435.72
622.32
62.9
24.2
15
2000


 


129
TFGVFDGK
16.58
435.72
769.39
62.9
24.2
15
2000


 


130
TFGVFGGK
16.78
406.72
408.22
60.8
22.9
15
2000


 


131
TFGVFGGK
16.76
406.72
564.31
60.8
22.9
15
2000


 


132
TFGVFGGK
16.78
406.72
711.38
60.8
22.9
15
2000


 


133
TGKPYK
1.41
347.20
407.23
56.4
20.3
15
2000


 


134
TGKPYK
1.41
347.20
535.32
56.4
20.3
15
2000


 


135
TGKPYK
1.41
347.20
592.35
56.4
20.3
15
2000


 


136
TGKPYR
1.41
361.20
435.24
57.4
20.9
15
2000


 


137
TGKPYR
1.41
361.20
563.33
57.4
20.9
15
2000


 


138
TGKPYR
1.41
361.20
620.35
57.4
20.9
15
2000


 


139
TGVVLFDVPWEK
24.03
695.37
1033.54
81.8
35.6
10
2000


 


140
TGVVLFDVPWEK
23.97
695.37
559.29
81.8
35.6
10
2000


 


141
TGVVLFDVPWEK
23.97
695.37
920.45
81.8
35.6
10
2000


 


142
TNEFLK
12.85
376.20
407.27
58.5
21.6
15
2000


 


143
TNEFLK
12.88
376.20
536.31
58.5
21.6
15
2000


 


144
TNEFLK
12.85
376.20
650.35
58.5
21.6
15
2000


 


145
TNELLK
11.69
359.21
373.28
57.3
20.8
15
2000


 


146
TNELLK
11.72
359.21
502.32
57.3
20.8
15
2000


 


147
TNELLK
11.69
359.21
616.37
57.3
20.8
15
2000


 


148
TNQFLK
12.3
375.71
407.27
58.5
21.5
15
2000


 


149
TNQFLK
12.27
375.71
535.32
58.5
21.5
15
2000


 


150
TNQFLK
12.27
375.71
649.37
58.5
21.5
15
2000


 


151
TQYQSLMDTIK
18.12
664.33
1098.55
79.5
34.2
15
2000


 


152
TQYQSLMDTIK
18.1
664.33
607.31
79.5
34.2
15
2000


 


153
TQYQSLMDTIK
18.12
664.33
807.43
79.5
34.2
15
2000


 


154
TYATAK
1.9
327.68
319.20
55
19.4
15
2000


 


155
TYATAK
1.85
327.68
390.24
55
19.4
15
2000


 


156
TYATAK
1.9
327.68
553.30
55
19.4
15
2000


 


157
TYATPK
7.79
340.68
345.21
56
20
15
2000


 


158
TYATPK
7.77
340.68
416.25
56
20
15
2000


 


159
TYATPK
7.79
340.68
579.31
56
20
15
2000


 


160
TYATSK
1.45
335.67
335.19
55.6
19.8
15
2000


 


161
TYATSK
1.45
335.67
406.23
55.6
19.8
15
2000


 


162
TYATSK
1.47
335.67
569.29
55.6
19.8
15
2000


 


163
VIPGHDEWK
12.43
540.78
434.70
70.5
28.8
15
2000


 


164
VIPGHDEWK
12.45
540.78
771.34
70.5
28.8
15
2000


 


165
VIPGHDEWK
12.43
540.78
868.40
70.5
28.8
15
2000


 


166
VLDGGCLVK
14.44
480.76
633.34
66.2
26.2
15
2000


 


167
VLDGGCLVK
14.44
480.76
748.37
66.2
26.2
15
2000


 


168
VLDGGCLVK
14.46
480.76
861.45
66.2
26.2
15
2000


 


169
VQYQSLMDTIQK
18.24
727.37
1063.55
84.1
37
10
2000


 


170
VQYQSLMDTIQK
18.24
727.37
1226.61
84.1
37
10
2000


 


171
VQYQSLMDTIQK
18.24
727.37
935.49
84.1
37
10
2000


 


172
YAQATLVIPGHDEWK
18.03
576.63
577.26
73.2
32.8
10
2000


 


173
YAQATLVIPGHDEWK
18.03
576.63
747.39
73.2
32.8
10
2000


 


174
YAQATLVIPGHDEWK
18.05
576.63
868.40
73.2
32.8
10
2000


 


175
YAQATLVIPGHEEWK
17.99
581.30
690.37
73.5
33.1
10
2000


 


176
YAQATLVIPGHEEWK
17.95
581.30
754.40
73.5
33.1
10
2000


 


177
YAQATLVIPGHEEWK
17.97
581.30
882.41
73.5
33.1
10
2000


 


178
YNVLDGGCLVK
17.86
619.32
633.34
76.3
32.2
15
2000


 


179
YNVLDGGCLVK
17.86
619.32
748.37
76.3
32.2
15
2000


 


180
YNVLDGGCLVK
17.86
619.32
861.45
76.3
32.2
15
2000


 


181
YPSTAK
4.3
333.68
319.20
55.4
19.7
15
2000


 


182
YPSTAK
4.44
333.68
406.23
55.4
19.7
15
2000


 


183
YPSTAK
4.28
333.68
503.28
55.4
19.7
15
2000


 


184
YSEAVLIIPGHDEWK
19.76
586.30
753.90
73.9
33.3
15
2000


 


185
YSEAVLIIPGHDEWK
19.72
586.30
797.42
73.9
33.3
15
2000


 


186
YSEAVLIIPGHDEWK
19.72
586.30
868.40
73.9
33.3
15
2000









    
    
        The other machine parameters used are as follows:
        Scan type: MRM
        MRM planned: no
        Polarity: Positive
        Ionising source: Turbo VTM (Applied BioSystems)
        Q1 setting: Filtering with unit resolution
        Q3 setting: Filtering with unit resolution
        Inter-scan pause: 5.00 msec
        Scanning speed: 10 Da/s
        Curtain gas: 40.00 psi
        Cone voltage: 5500.00 V
        Source temperature: 500.00° C.
        Nebulising gas: 50.00 psi
        Heating gas: 50.00 psi
        Collision gas which induces dissociation: 9.00 psi
        Dynamic filling: activated
        Entry potential before Q0 (EP): 10.00 V
    
    


The areas obtained for each of the transitions and for each of the microorganisms studied were measured. When the areas of the transitions are greater than or equal to the positivity threshold described in TABLE 13, the detection of the transition is considered to be positive and is labelled “1” in TABLE 14. When a transition has an area less than the positivity threshold described in TABLE 13, the transition is considered non-detected and is labelled “0” in TABLE 14.
For a given peptide, when at least 3 transitions are labelled “1”, the peptide is considered as being detected.












TABLE 14





Transition number
Sam84
Sam85
Sam86
Sam87
Sam88




















1
0
1
1
1
1


2
0
0
1
1
0


3
0
0
0
1
0


4
0
0
0
0
0


5
0
0
0
0
0


6
0
0
0
0
0


7
0
0
0
0
0


8
0
0
0
1
0


9
0
0
0
0
0


10
0
1
1
0
1


11
0
0
0
0
0


12
0
0
1
0
0


13
0
0
0
0
0


14
0
0
0
0
0


15
0
0
0
0
0


16
0
0
0
1
0


17
0
0
0
1
0


18
0
1
0
1
1


19
0
0
0
0
0


20
0
0
0
0
0


21
1
1
1
1
0


22
0
0
0
0
0


23
0
0
0
0
0


24
0
0
0
0
0


25
1
1
1
1
1


26
1
1
0
1
1


27
1
1
0
1
1


28
0
1
0
1
1


29
0
1
0
1
1


30
0
1
0
1
1


31
0
0
0
0
0


32
0
0
0
0
0


33
0
0
0
0
0


34
0
0
0
0
0


35
0
0
0
0
0


36
0
0
0
0
0


37
0
0
0
0
0


38
0
0
0
0
0


39
0
0
0
0
0


40
0
0
0
0
0


41
0
0
0
0
0


42
0
0
0
0
0


43
0
0
0
0
0


44
0
0
0
0
0


45
0
0
0
0
0


46
0
0
0
0
0


47
0
0
0
0
0


48
0
0
0
0
0


49
0
0
0
0
0


50
0
0
0
0
0


51
0
0
0
0
0


52
0
0
0
1
0


53
0
0
0
1
0


54
0
0
0
1
0


55
0
0
0
0
0


56
0
0
0
0
0


57
0
0
0
0
0


58
0
0
0
0
0


59
0
0
0
0
0


60
0
0
0
0
0


61
0
0
0
0
0


62
0
0
0
0
0


63
0
0
0
0
0


64
0
0
0
0
0


65
0
0
0
0
0


66
0
0
0
0
0


67
0
0
0
0
0


68
0
0
0
0
0


69
0
0
0
0
0


70
0
0
0
0
0


71
0
0
0
0
0


72
0
0
0
0
0


73
0
0
0
0
0


74
1
0
0
0
0


75
0
0
0
0
0


76
0
0
0
0
0


77
0
0
0
0
0


78
1
0
0
0
0


79
0
0
0
0
0


80
0
0
0
0
0


81
0
0
0
0
0


82
1
0
0
1
0


83
0
0
0
0
0


84
0
0
0
0
0


85
0
0
0
0
0


86
0
0
0
0
0


87
0
0
0
0
0


88
0
0
0
0
0


89
0
0
0
0
0


90
0
0
0
0
0


91
0
0
0
0
0


92
0
0
0
0
0


93
0
0
0
0
0


94
0
0
0
0
0


95
0
0
0
0
0


96
0
0
0
0
0


97
0
0
0
0
0


98
0
0
0
0
0


99
0
0
0
0
0


100
0
0
0
0
0


101
0
0
0
0
0


102
0
0
0
0
0


103
0
0
0
0
0


104
0
0
0
0
0


105
0
0
0
0
0


106
0
0
0
0
0


107
0
0
0
0
0


108
0
0
0
0
0


109
0
0
0
0
0


110
0
0
0
0
0


111
0
0
0
0
0


112
0
0
0
0
0


113
0
0
0
0
0


114
0
0
0
0
0


115
0
0
0
0
0


116
0
0
0
0
0


117
0
0
0
0
0


118
0
0
0
0
0


119
0
0
0
0
0


120
0
0
0
0
0


121
0
0
0
0
0


122
0
0
0
0
0


123
0
0
0
0
0


124
0
0
0
0
0


125
0
0
0
0
0


126
0
0
0
0
0


127
0
0
0
0
0


128
0
0
0
0
0


129
0
0
0
0
0


130
0
0
0
0
0


131
0
0
0
0
0


132
0
0
0
0
0


133
0
1
0
0
1


134
0
1
0
0
1


135
0
1
0
0
1


136
1
0
0
0
0


137
1
0
0
1
0


138
1
0
0
0
1


139
0
0
0
0
0


140
0
0
0
0
0


141
0
0
0
0
0


142
0
0
0
0
0


143
0
0
0
0
0


144
0
0
0
0
0


145
1
0
0
0
0


146
1
0
0
1
0


147
1
0
0
0
0


148
0
0
0
0
0


149
0
0
0
0
0


150
0
0
0
0
0


151
0
0
0
0
0


152
0
0
0
0
0


153
0
0
0
0
0


154
0
0
0
0
0


155
0
0
0
0
0


156
0
0
0
0
0


157
0
0
0
0
0


158
0
0
0
0
0


159
0
0
0
0
0


160
0
0
0
0
0


161
0
0
0
0
0


162
0
0
0
0
0


163
0
0
0
0
0


164
0
0
0
0
0


165
0
0
0
0
0


166
0
0
0
0
0


167
0
0
0
0
0


168
0
0
0
0
0


169
0
0
0
0
0


170
0
0
0
0
0


171
0
0
0
0
0


172
0
0
0
0
0


173
0
0
0
0
0


174
0
0
0
0
0


175
0
1
0
1
1


176
0
1
0
1
1


177
1
1
0
1
1


178
0
0
0
0
0


179
0
0
0
0
0


180
0
0
0
0
0


181
0
0
0
0
0


182
0
0
0
0
0


183
0
0
0
0
0


184
0
0
0
0
0


185
0
0
0
0
0


186
0
0
0
0
0


187
0
0
0
1
0


188
0
0
0
1
0


189
0
1
0
1
0


190
0
0
0
0
0


191
0
0
0
0
0


192
0
0
0
0
0


193
0
0
0
0
0


194
0
0
0
0
0


195
0
0
0
0
0









Samples Sam84 to Sam88 comprise at least one peptide which is characteristic of INDs. The bacteria present in samples Sam84 to Sam88 therefore express a beta-lactamase which confers on them a resistance to penicillins, to cephalosporins and to carbapenems.
EXAMPLE 10: IDENTIFICATION OF A RESISTANCE TO GES BETA-LACTAMS
Samples Sam89 and Sam90 are identified according to one of the methods described in examples 1, 3 or 4. The identification of the species is set out in TABLE 15.










TABLE 15







Names
Species









Sam89
E. coli



Sam90
P. aeruginosa










Samples Sam89 and Sam90 correspond to a species able to comprise a GES resistance mechanism. The following method is then performed to detect such a mechanism.
Each sample is treated according to Example 5, then analysed according to Example 6 unless otherwise stated in the rest of the example, by detecting the peptides from TABLE 16 instead of the peptides from TABLE 3.













TABLE 16










Decluste





Retention
(m/z)
(m/z)
ring
Collision


Transition

time
filtered
filtered
potential
energy


number
Peptide
(minutes)
in Q1
in Q3
(eV)
(eV)





















1
AAEIGVAIVDPQGEIVAGHR
19.11
668.03
695.88
79.8
37.4


 


2
AAEIGVAIVDPQGEIVAGHR
19.13
668.03
731.39
79.8
37.4


 


3
AAEIGVAIVDPQGEIVAGHR
19.11
668.03
809.44
79.8
37.4


 


4
AAQIGVAIVDPQGEIVAGHR
18.76
667.70
695.88
79.8
37.4


 


5
AAQIGVAIVDPQGEIVAGHR
18.76
667.70
731.39
79.8
37.4


 


6
AAQIGVAIVDPQGEIVAGHR
18.76
667.70
809.44
79.8
37.4


 


7
DTTTPIAMAR
14.23
538.77
658.37
70.4
28.7


 


8
DTTTPIAMAR
14.23
538.77
759.42
70.4
28.7


 


9
DTTTPIAMAR
14.23
538.77
860.47
70.4
28.7


 


10
DWVVGEK
14.41
416.71
432.25
61.5
23.3


 


11
DWVVGEK
14.43
416.71
531.31
61.5
23.3


 


12
DWVVGEK
14.45
416.71
717.39
61.5
23.3


 


13
DYAVAVYTTAPK
15.83
649.84
680.36
78.5
33.6


 


14
DYAVAVYTTAPK
15.83
649.84
779.43
78.5
33.6


 


15
DYAVAVYTTAPK
15.85
649.84
850.47
78.5
33.6


 


16
EIGGPAAMTQYFR
20.03
720.85
1198.57
83.7
36.7


 


17
EIGGPAAMTQYFR
20.03
720.85
845.40
83.7
36.7


 


18
EIGGPAAMTQYFR
20.03
720.85
916.44
83.7
36.7


 


19
EPEMGDNTPGDLR
13.53
715.81
557.30
83.3
36.5


 


20
EPEMGDNTPGDLR
13.53
715.81
772.40
83.3
36.5


 


21
EPEMGDNTPGDLR
13.53
715.81
944.44
83.3
36.5


 


22
ESEMSDNTPGDLR
12.72
725.81
557.30
84
36.9


 


23
ESEMSDNTPGDLR
12.7
725.81
887.42
84
36.9


 


24
ESEMSDNTPGDLR
12.71
725.81
974.45
84
36.9


 


25
FAMCSTFK
16.14
496.22
642.29
67.3
26.8


 


26
FAMCSTFK
16.12
496.22
773.33
67.3
26.8


 


27
FAMCSTFK
16.12
496.22
844.37
67.3
26.8


 


28
FIHALLLAGIAHSAYASEK
20.93
671.37
1204.60
80.1
37.6


 


29
FIHALLLAGIAHSAYASEK
20.92
671.37
807.95
80.1
37.6


 


30
FIHALLLAGIAHSAYASEK
20.93
671.37
876.48
80.1
37.6


 


31
FIHALLLAGTAHSAYASEK
18.21
667.36
766.41
79.8
37.4


 


32
FIHALLLAGTAHSAYASEK
18.21
667.36
801.93
79.8
37.4


 


33
FIHALLLAGTAHSAYASEK
18.21
667.36
870.46
79.8
37.4


 


34
FPLAALVFER
24.46
581.84
734.42
73.5
30.6


 


35
FPLAALVFER
24.46
581.84
805.46
73.5
30.6


 


36
FPLAALVFER
24.44
581.84
918.54
73.5
30.6


 


37
IDSGTER
1.66
389.19
462.23
59.5
22.1


 


38
IDSGTER
1.84
389.19
549.26
59.5
22.1


 


39
IDSGTER
1.75
389.19
664.29
59.5
22.1


 


40
IGDSVSR
8.48
367.20
448.25
57.9
21.2


 


41
IGDSVSR
8.46
367.20
563.28
57.9
21.2


 


42
IGDSVSR
8.44
367.20
620.30
57.9
21.2


 


43
LSAVER
9.1
337.70
403.23
55.7
19.9


 


44
LSAVER
9.08
337.70
474.27
55.7
19.9


 


45
LSAVER
9.1
337.70
561.30
55.7
19.9


 


46
LSYGPDMIVEWSPATER
22.31
650.98
573.30
78.6
36.5


 


47
LSYGPDMIVEWSPATER
22.29
650.98
660.33
78.6
36.5


 


48
LSYGPDMIVEWSPATER
22.26
650.98
846.41
78.6
36.5


 


49
LSYGPDMIVK
17.71
561.80
1009.50
72.1
29.7


 


50
LSYGPDMIVK
17.69
561.80
759.41
72.1
29.7


 


51
LSYGPDMIVK
17.69
561.80
922.47
72.1
29.7


 


52
NDIGFFK
17.71
420.72
498.27
61.8
23.5


 


53
NDIGFFK
17.69
420.72
611.36
61.8
23.5


 


54
NDIGFFK
17.74
420.72
726.38
61.8
23.5


 


55
TDLEK
3.66
303.16
389.24
53.2
18.3


 


56
TDLEK
3.73
303.16
459.21
53.2
18.3


 


57
TDLEK
3.6
303.16
504.27
53.2
18.3


 


58
TGACANGAR
1.48
439.20
648.29
63.1
24.3


 


59
TGACANGAR
1.48
439.20
719.33
63.1
24.3


 


60
TGACANGAR
1.48
439.20
776.35
63.1
24.3


 


61
TGTCANGAR
1.48
454.21
648.29
64.2
25


 


62
TGTCANGAR
1.48
454.21
749.34
64.2
25


 


63
TGTCANGAR
1.48
454.21
806.36
64.2
25


 


64
TGTCANGGR
1.48
447.20
474.24
63.7
24.7


 


65
TGTCANGGR
1.48
447.20
634.27
63.7
24.7


 


66
TGTCANGGR
1.48
447.20
735.32
63.7
24.7


 


67
VLYGGALTSTSTHTIER
15.87
602.65
1245.64
75.1
34.1


 


68
VLYGGALTSTSTHTIER
15.85
602.65
715.87
75.1
34.1


 


69
VLYGGALTSTSTHTIER
15.87
602.65
797.40
75.1
34.1


 


70
WLIGNQTGDATLR
18.93
722.88
1032.51
83.8
36.8


 


71
WLIGNQTGDATLR
19.02
722.88
1145.59
83.8
36.8


 


72
WLIGNQTGDATLR
18.96
722.88
733.38
83.8
36.8


 


73
WSPATER
11.37
423.71
476.25
62
23.6


 


74
WSPATER
11.37
423.71
573.30
62
23.6


 


75
WSPATER
11.34
423.71
660.33
62
23.6









    
    
        The other machine parameters used are as follows:
        Scan type: MRM
        MRM planned: yes
        Polarity: Positive
        Ionising source: Turbo VTM (Applied BioSystems)
        Q1 setting: Filtering with unit resolution
        Q3 setting: Filtering with unit resolution
        Inter-scan pause: 5.00 msec
        Scanning speed: 10 Da/s
        Curtain gas: 40.00 psi
        Cone voltage: 5500.00 V
        Source temperature: 500.00° C.
        Nebulising gas: 50.00 psi
        Heating gas: 50.00 psi
        Collision gas which induces dissociation: 9.00 psi
        Dynamic filling: activated
        Entry potential before Q0 (EP): 10.00 V
        Collision cell exit potential (CXP): 15.00 V
    
    


The areas obtained for each of the transitions and for each of the microorganisms studied were measured. When the areas of the transitions are greater than or equal to the positivity threshold described in TABLE 16, the detection of the transition is considered to be positive and is labelled “1” in TABLE 17. When a transition has an area less than the positivity threshold described in TABLE 16, the transition is considered non-detected and is labelled “0” in TABLE 17.
For a given peptide, when at least 3 transitions are labelled “1”, the peptide is considered as being detected.









TABLE 17





Transition




number
Sam89
Sam90

















1
0
0


2
0
0


3
0
0


4
0
0


5
1
1


6
0
0


7
1
1


8
1
1


9
1
1


10
1
1


11
1
1


12
1
1


13
0
0


14
0
0


15
0
0


16
0
0


17
0
0


18
0
0


19
0
0


20
0
0


21
0
0


22
0
0


23
0
0


24
0
0


25
0
0


26
0
0


27
0
0


28
0
0


29
0
0


30
0
0


31
0
0


32
0
0


33
0
0


34
0
0


35
0
0


36
0
0


37
1
1


38
1
1


39
1
1


40
1
1


41
1
1


42
1
1


43
1
1


44
1
1


45
1
1


46
1
1


47
1
1


48
1
1


49
0
0


50
0
0


51
0
0


52
1
1


53
1
1


54
1
1


55
0
0


56
0
0


57
0
0


58
0
0


59
0
0


60
0
0


61
0
0


62
0
0


63
0
0


64
1
0


65
0
1


66
1
1


67
1
1


68
1
1


69
1
1


70
1
1


71
1
1


72
1
1


73
0
0


74
0
0


75
0
0









Samples Sam89 and Sam90 comprise at least one peptide which is characteristic of the carbapenemase phenotype. The bacteria present in samples Sam89 to Sam90 therefore express a beta-lactamase which confers on them a resistance to penicillins, to cephalosporins and to carbapenems.
EXAMPLE 11: IDENTIFICATION OF A RESISTANCE TO SME BETA-LACTAMS
Samples Sam91 to Sam95 are identified according to one of the methods described in examples 1, 3 or 4. The identification of the species is set out in TABLE 18.










TABLE 18







Names
Species









Sam91
S. marcescens



Sam92
S. marcescens



Sam93
S. marcescens



Sam94
S. marcescens



Sam95
S. marcescens










Samples Sam91 to Sam95 correspond to a species able to comprise an SME resistance mechanism. The following method is then performed to detect such a mechanism.
Each sample is treated according to Example 5, then analysed according to Example 6 unless otherwise stated in the rest of the example, by detecting the peptides from TABLE 19 instead of the peptides from TABLE 3.













TABLE 19







Retention
(m/z)
(m/z)
Collision



Transition

time
filtered in
filtered in
energy
positivity


number
Peptide
(minutes)
Q1
Q3
(eV)
threshold





















1
AIYQNWLK
18.69
518.29
426.22
25.3
2500


 


2
AIYQNWLK
18.69
518.29
688.38
25.3
2500


 


3
AIYQNWLK
18.69
518.29
851.44
25.3
2500


 


4
APLIVSIYTTR
20.21
617.36
740.39
30.9
2500


 


5
APLIVSIYTTR
20.21
617.36
839.46
30.9
2500


 


6
APLIVSIYTTR
20.21
617.36
952.55
30.9
2500


 


7
ASVPADWVVGDK
17.56
622.32
493.75
31.2
2500


 


8
ASVPADWVVGDK
17.56
622.32
543.29
31.2
2500


 


9
ASVPADWVVGDK
17.56
622.32
986.49
31.2
2500


 


10
AVANSLNK
8.75
408.73
461.27
19
2500


 


11
AVANSLNK
8.75
408.73
575.32
19
2500


 


12
AVANSLNK
8.75
408.73
646.35
19
2500


 


13
DLEYHSPITTK
14.48
435.22
473.75
20.6
2500


 


14
DLEYHSPITTK
14.48
435.22
538.28
20.6
2500


 


15
DLEYHSPITTK
14.48
435.22
646.38
20.6
2500


 


16
DLEYYSPITTK
17.4
665.33
559.35
33.7
2500


 


17
DLEYYSPITTK
17.4
665.33
646.38
33.7
2500


 


18
DLEYYSPITTK
17.4
665.33
809.44
33.7
2500


 


19
DTSTPK
1.45
324.66
345.21
14.2
2500


 


20
DTSTPK
1.45
324.66
432.25
14.2
2500


 


21
DTSTPK
1.45
324.66
533.29
14.2
2500


 


22
FLGGPEGMTK
14.94
518.76
662.32
25.3
2500


 


23
FLGGPEGMTK
14.94
518.76
719.34
25.3
2500


 


24
FLGGPEGMTK
14.94
518.76
776.36
25.3
2500


 


25
GFLAAAVLER
20.49
523.80
587.35
25.6
2500


 


26
GFLAAAVLER
20.49
523.80
658.39
25.6
2500


 


27
GFLAAAVLER
20.49
523.80
729.43
25.6
2500


 


28
GNTTGDAR
6.45
396.19
418.20
18.3
2500


 


29
GNTTGDAR
6.45
396.19
519.25
18.3
2500


 


30
GNTTGDAR
6.45
396.19
620.30
18.3
2500


 


31
IGVFAIDTGSGNTFGYR
21.45
592.30
542.27
25.4
2500


 


32
IGVFAIDTGSGNTFGYR
21.45
887.94
1174.51
46.3
2500


 


33
IGVFAIDTGSGNTFGYR
21.45
887.94
958.44
46.3
2500


 


34
LALGNVLNAK
18.56
506.81
414.75
24.6
2500


 


35
LALGNVLNAK
18.56
506.81
715.41
24.6
2500


 


36
LALGNVLNAK
18.56
506.81
828.49
24.6
2500


 


37
LDINQK
10.3
365.71
389.21
16.6
2500


 


38
LDINQK
10.3
365.71
502.30
16.6
2500


 


39
LDINQK
10.3
365.71
617.33
16.6
2500


 


40
LEEDFDGR
12.51
490.72
609.26
23.7
2500


 


41
LEEDFDGR
12.51
490.72
738.31
23.7
2500


 


42
LEEDFDGR
12.51
490.72
867.35
23.7
2500


 


43
SDAAAK
7.06
281.65
289.19
11.8
2500


 


44
SDAAAK
7.06
281.65
360.22
11.8
2500


 


45
SDAAAK
7.06
281.65
475.25
11.8
2500


 


46
SIGDNEFR
12.81
469.22
565.27
22.5
2500


 


47
SIGDNEFR
12.81
469.22
680.30
22.5
2500


 


48
SIGDNEFR
12.81
469.22
737.32
22.5
2500


 


49
TGSCGAIGTANDYAVIWPK
20.29
660.99
430.25
27.6
2500


 


50
TGSCGAIGTANDYAVIWPK
20.29
660.99
713.43
27.6
2500


 


51
TGSCGAIGTANDYAVIWPK
20.29
990.98
430.25
52.2
2500


 


52
TGSCGAYGTANDYAVIWPK
19.78
1015.97
430.25
53.6
2500


 


53
TGSCGAYGTANDYAVIWPK
19.78
677.65
642.40
28.1
2500


 


54
TGSCGAYGTANDYAVIWPK
19.78
677.65
713.43
28.1
2500


 


55
TIAEASR
6.98
374.20
333.19
17.1
2500


 


56
TIAEASR
6.98
374.20
462.23
17.1
2500


 


57
TIAEASR
6.98
374.20
646.35
17.1
2500


 


58
WELELNTAIPGDK
21.06
495.92
416.21
22.5
2500


 


59
WELELNTAIPGDK
21.06
743.38
1170.64
38.1
2500


 


60
WELELNTAIPGDK
21.06
743.38
416.21
38.1
2500









    
    
        The other machine parameters used are as follows:
        Scan type: MRM
        MRM planned: yes
        Polarity: Positive
        Ionising source: Turbo VTM (Applied BioSystems)
        Q1 setting: Filtering with unit resolution
        Q3 setting: Filtering with unit resolution
        Inter-scan pause: 5.00 msec
        Scanning speed: 10 Da/s
        Curtain gas: 40.00 psi
        Cone voltage: 5500.00 V
        Source temperature: 500.00° C.
        Nebulising gas: 50.00 psi
        Heating gas: 50.00 psi
        Collision gas which induces dissociation: 9.00 psi
        Dynamic filling: activated
        Declustering potential (DP): 100.00 V
        Entry potential before Q0 (EP): 10.00 V
        Collision cell exit potential (CXP): 15.00 V
    
    


The areas obtained for each of the transitions and for each of the microorganisms studied were measured. When the areas of the transitions are greater than or equal to the positivity threshold described in TABLE 19, the detection of the transition is considered to be positive and is labelled “1” in TABLE 20. When a transition has an area less than the positivity threshold described in TABLE 19, the transition is considered non-detected and is labelled “0” in TABLE 20.
For a given peptide, when at least 3 transitions are labelled “1”, the peptide is considered as being detected.












TABLE 20





Transition







number
Sam91
Sam92
Sam93
Sam94
Sam95




















1
0
1
0
0
0


2
1
1
0
0
1


3
0
1
0
0
0


4
0
0
0
0
0


5
0
0
0
0
0


6
0
0
0
0
0


7
1
1
1
1
1


8
1
1
1
1
1


9
1
1
1
1
1


10
1
1
1
1
1


11
1
1
1
1
1


12
1
1
1
1
1


13
1
1
1
1
1


14
1
1
1
1
1


15
1
1
1
1
1


16
0
0
0
0
0


17
0
0
0
0
0


18
0
0
0
0
0


19
0
0
0
0
0


20
0
0
0
0
0


21
0
0
0
0
0


22
1
1
1
0
1


23
1
1
1
0
1


24
1
1
1
0
1


25
1
1
1
1
1


26
1
1
1
1
1


27
1
1
1
1
1


28
0
0
0
0
0


29
0
0
0
0
0


30
0
0
0
0
0


31
0
0
0
0
0


32
0
0
0
0
0


33
0
0
0
0
0


34
1
1
1
1
1


35
1
1
1
1
1


36
1
1
1
1
1


37
0
0
0
0
0


38
0
0
0
0
0


39
0
0
0
0
0


40
1
1
1
0
1


41
1
1
1
0
1


42
1
1
1
0
1


43
0
0
0
0
0


44
0
0
0
0
0


45
0
0
0
0
0


46
0
0
1
0
0


47
0
0
1
0
0


48
0
0
1
0
0


49
0
0
0
0
0


50
0
0
0
0
0


51
0
0
0
0
0


52
0
0
0
0
0


53
0
0
0
0
0


54
0
0
0
0
0


55
0
0
0
0
0


56
0
0
0
0
0


57
0
0
0
0
0


58
0
0
0
0
0


59
0
0
0
0
0


60
0
0
0
0
0









Samples Sam91 to Sam95 comprise at least one peptide which is characteristic of SMEs. The bacteria present in samples Sam91 to Sam95 therefore express a beta-lactamase which confers on them a resistance to penicillins, to cephalosporins and to carbapenems.
EXAMPLE 12: IDENTIFICATION OF A RESISTANCE TO IMP BETA-LACTAMS
The samples corresponding to a species able to comprise an IMP resistance mechanism can be detected by employing the following method.
Each sample is treated according to Example 5, then analysed according to Example 6 by detecting the peptides from TABLE 21 instead of the peptides from TABLE 3.












TABLE 21








(m/z)
(m/z)



Transition

Retention time
filtered in
filtered in
Collision


number
Peptide
(minutes)
Q1
Q3
energy (eV)




















1
EVNGWGVVPK
16.02
542.79
742.35
29


 


2
EVNGWGVVPK
16.02
542.79
856.47
29


 


3
EVNGWGVVPK
16.02
542.79
955.54
29


 


4
GSISSHFHSDSTGGIGWLNSR
16.97
551.26
675.36
31


 


5
GSISSHFHSDSTGGIGWLNSR
16.97
551.26
732.38
31


 


6
GSISSHFHSDSTGGIGWLNSR
16.97
734.68
959.51
41


 


7
HGLVILVNTDAYLIDTPFTAK
24.53
767.75
892.48
42


 


8
HGLVILVNTDAYLIDTPFTAK
24.53
767.75
1005.56
42


 


9
HGLVILVNTDAYLIDTPFTAK
24.53
767.75
1133.63
42


 


10
HGLVVLVNNDAYLIDTPFTNK
22.75
781.75
822.4
43


 


11
HGLWLVNNDAYLIDTPFTNK
22.75
781.75
935.48
43


 


12
HGLVVLVNNDAYLIDTPFTNK
22.75
781.75
1132.61
43


 


13
HGLVVLVNTDAYLIDTPFTAK
23.91
763.08
779.39
42


 


14
HGLVVLVNTDAYLIDTPFTAK
23.91
763.08
892.48
42


 


15
HGLVVLVNTDAYLIDTPFTAK
23.91
763.08
1119.62
42


 


16
HGLVVLVNTEAYLIDTPFTAK
24.53
767.75
779.39
42


 


17
HGLVVLVNTEAYLIDTPFTAK
24.53
767.75
892.48
42


 


18
HGLVVLVNTEAYLIDTPFTAK
24.53
767.75
1133.63
42


 


19
IEVFYPGPGHTQDNVVVWLPK
22.25
599.57
642.4
33


 


20
IEVFYPGPGHTQDNVVVWLPK
22.25
599.57
741.47
33


 


21
IEVFYPGPGHTQDNVVVWLPK
22.25
799.09
872.46
44


 


22
ILMEK
11.28
317.19
407.2
19


 


23
ILMEK
11.28
317.19
487.26
19


 


24
ILMEK
11.28
317.19
520.28
19


 


25
ILMSK
10.48
296.18
365.19
18


 


26
ILMSK
10.48
296.18
445.25
18


 


27
ILMSK
10.48
296.18
478.27
18


 


28
LDEGVYVHTSFK
15.03
465.57
482.26
27


 


29
LDEGVYVHTSFK
15.03
465.57
619.32
27


 


30
LDEGVYVHTSFK
15.03
465.57
881.45
27


 


31
LEEGVYVHTSYEEVK
14.55
594.62
855.41
34


 


32
LEEGVYVHTSYEEVK
14.55
594.62
992.47
34


 


33
LEEGVYVHTSYEEVK
14.55
891.43
992.47
44


 


34
LLISK
12.19
287.2
347.23
18


 


35
LLISK
12.19
287.2
427.29
18


 


36
LLISK
12.19
287.2
460.31
18


 


37
LLMSK
11.18
296.18
365.19
18


 


38
LLMSK
11.18
296.18
445.25
18


 


39
LLMSK
11.18
296.18
478.27
18


 


40
LLVSK
10.48
280.19
333.21
17


 


41
LLVSK
10.48
280.19
413.28
17


 


42
LLVSK
10.48
280.19
446.3
17


 


43
LPDLK
12.56
293.18
375.22
18


 


44
LPDLK
12.56
293.18
439.26
18


 


45
LPDLK
12.56
293.18
472.28
18


 


46
LVVSGHSETGDATHLK
11.41
413.47
569.34
24


 


47
LVVSGHSETGDATHLK
11.41
550.95
719.85
32


 


48
LVVSGHSETGDATHLK
11.41
550.95
1058.51
32


 


49
NSFDGVSYVVLAK
20.75
693.84
767.41
36


 


50
NSFDGVSYWLAK
20.75
693.84
1038.53
36


 


51
NSFDGVSYWLAK
20.75
693.84
1185.59
36









The areas obtained for each of the transitions and for each of the microorganisms studied were measured. When the areas of the three transitions of the same peptide are greater than or equal to 2500, the detection of the peptide is considered to be positive and is labelled “1”. When at least one transition comprises an area less than 2500, the corresponding peptide is considered non-detected and is labelled “0”.
EXAMPLE 13: IDENTIFICATION OF A RESISTANCE TO KPC BETA-LACTAMS
The samples corresponding to a species able to comprise a KPC resistance mechanism can be detected by employing the following method.
Each sample is treated according to Example 5, then analysed according to Example 6 by detecting the peptides from TABLE 22 instead of the peptides from TABLE 3.












TABLE 22







Retention
(m/z)
(m/z)
Collision


Transition

time
filtered in
filtered in
energy


number
Peptide
(minutes)
Q1
Q3
(eV)




















1
NALVR
8.14
286.68
387.27
18


 


2
NALVR
8.14
286.68
398.24
18


 


3
NALVR
8.14
286.68
458.31
18


 


4
TGTC[CAM]GAYGTANDYAVVWPTGR
18.76
739.67
1169.45
41


 


5
TGTC[CAM]GAYGTANDYAVVWPTGR
18.76
1109.01
1163.58
54


 


6
TGTC[CAM]GAYGTANDYAVVWPTGR
18.76
1109.01
1169.45
54


 


7
WELELNSAIPSDAR
20.43
534.27
545.27
31


 


8
WELELNSAIPSDAR
20.43
800.9
930.46
40


 


9
WELELNSAIPSDAR
20.43
800.9
1043.55
40


 


10
WELEMNSAIPGDAR
19.35
794.87
900.45
40


 


11
WELEMNSAIPGDAR
19.35
794.87
1031.49
40


 


12
WELEMNSAIPGDAR
19.35
794.87
1074.49
40









The areas obtained for each of the transitions and for each of the microorganisms studied were measured. When the areas of the three transitions of the same peptide are greater than or equal to 2500, the detection of the peptide is considered to be positive and is labelled “1”. When at least one transition comprises an area less than 2500, the corresponding peptide is considered non-detected and is labelled “0”.
EXAMPLE 14: IDENTIFICATION OF A RESISTANCE TO NDM BETA-LACTAMS
The samples corresponding to a species able to comprise an NDM resistance mechanism can be detected by employing the following method.
Each sample is treated according to Example 5, then analysed according to Example 6 by detecting the peptides from TABLE 23 instead of the peptides from TABLE 3.












TABLE 23








(m/z)
(m/z)



Transition

Retention time
filtered in
filtered in
Collision


number
Peptide
(minutes)
Q1
Q3
energy (eV)




















1
VLLVDTAWTDDQTAQILNWIK
27.87
815.1
914.55
45


 


2
VLLVDTAWTDDQTAQILNWIK
27.86
815.1
985.58
45


 


3
VLLVDTAWTDDQTAQILNWIK
27.85
815.1
1086.63
45









The areas obtained for each of the transitions and for each of the microorganisms studied were measured. When the areas of the three transitions of the same peptide are greater than or equal to 2500, the detection of the peptide is considered to be positive and is labelled “1”. When at least one transition comprises an area less than 2500, the corresponding peptide is considered non-detected and is labelled “0”.
EXAMPLE 15: IDENTIFICATION OF A RESISTANCE TO VIM BETA-LACTAMS
The samples corresponding to a species able to comprise a VIM resistance mechanism can be detected by employing the following method.
Each sample is treated according to Example 5, then analysed according to Example 6 by detecting the peptides from TABLE 24 instead of the peptides from TABLE 3.












TABLE 24








(m/z)
(m/z)



Transition

Retention time
filtered in
filtered in
Collision


number
Peptide
(minutes)
Q1
Q3
energy (eV)




















1
LANEIPTHSLEGLSSSGDAVR
16.72
718.37
778.37
40


 


2
LANEIPTHSLEGLSSSGDAVR
16.72
718.37
948.47
40


 


3
LANEIPTHSLEGLSSSGDAVR
16.72
718.37
1077.52
40









The areas obtained for each of the transitions and for each of the microorganisms studied were measured. When the areas of the three transitions of the same peptide are greater than or equal to 2500, the detection of the peptide is considered to be positive and is labelled “1”. When at least one transition comprises an area less than 2500, the corresponding peptide is considered non-detected and is labelled “0”.
EXAMPLE 16: IDENTIFICATION OF A RESISTANCE TO OXA BETA-LACTAMS
The samples corresponding to a species able to comprise an OXA resistance mechanism can be detected by employing the following method.
Each sample is treated according to Example 5, then analysed according to Example 6 by detecting the peptides from TABLE 25 instead of the peptides from TABLE 3.












TABLE 25







Retention
(m/z)
(m/z)
Collision


Transition

time
filtered in
filtered in
energy


number
Peptide
(minutes)
Q1
Q3
(eV)




















1
AAAYELAENLFEAGQADGWR
24.48
728.01
1249.6
40


 


2
AAAYELAENLFEAGQADGWR
24.48
1091.51
1193.58
53


 


3
AAAYELAENLFEAGQADGWR
24.48
1091.51
1249.6
53


 


4
AAEGFIPASTFK
17.74
619.82
763.43
32


 


5
AAEGFIPASTFK
17.74
619.82
910.5
32


 


6
AAEGFIPASTFK
17.74
619.82
967.52
32


 


7
ADGQVVAFALNMQMK
21.27
811.91
982.48
41


 


8
ADGQVVAFALNMQMK
21.29
811.91
1053.52
41


 


9
ADGQVVAFALNMQMK
21.27
811.91
1152.59
41


 


10
ADINEIFK
17.3
475.25
650.35
26


 


11
ADINEIFK
17.3
475.25
763.43
26


 


12
ADINEIFK
17.3
475.25
878.46
26


 


13
ADWGK
6.9
288.64
390.21
18


 


14
ADWGK
6.91
288.64
430.17
18


 


15
ADWGK
6.89
288.64
505.24
18


 


16
AEGAIVISDER
13.52
387.2
419.19
23


 


17
AEGAIVISDER
13.53
387.2
506.22
23


 


18
AEGAIVISDER
13.52
387.2
619.3
23


 


19
AFALNLDIDK
20.16
560.31
717.38
30


 


20
AFALNLDIDK
20.16
560.31
830.46
30


 


21
AFALNLDIDK
20.16
560.31
901.5
30


 


22
AFAPMSTFK
16.96
500.25
710.35
27


 


23
AFAPMSTFK
16.96
500.25
781.39
27


 


24
AFAPMSTFK
16.96
500.25
928.46
27


 


25
AFGYGNADVSGDPGQNNGLDR
15.12
708.65
873.42
39


 


26
AFGYGNADVSGDPGQNNGLDR
15.12
708.65
970.47
39


 


27
AFGYGNADVSGDPGQNNGLDR
15.12
708.65
1154.47
39


 


28
AFTMTK
11.32
349.68
480.25
20


 


29
AFTMTK
11.33
349.68
552.25
20


 


30
AFTMTK
11.33
349.68
627.32
20


 


31
AGDDIALR
12.23
415.72
587.35
23


 


32
AGDDIALR
12.23
415.72
702.38
23


 


33
AGDDIALR
12.23
415.72
759.4
23


 


34
AGHVYAFALNIDMPR
20.63
558.95
631.32
32


 


35
AGHVYAFALNIDMPR
20.63
558.95
745.37
32


 


36
AGHVYAFALNIDMPR
20.63
558.95
817.4
32


 


37
AGLWR
13.44
301.67
361.2
18


 


38
AGLWR
13.44
301.67
474.28
18


 


39
AGLWR
13.44
301.67
531.3
18


 


40
AHTEYVPASTFK
13.18
450.89
553.3
27


 


41
AHTEYVPASTFK
13.18
450.89
602.26
27


 


42
AHTEYVPASTFK
13.18
450.89
650.35
27


 


43
AIIPWDGKPR
15.84
384.89
428.23
23


 


44
AIIPWDGKPR
15.84
384.89
457.29
23


 


45
AIIPWDGKPR
15.84
384.89
572.32
23


 


46
AISDITITR
14.8
495.28
603.38
27


 


47
AISDITITR
14.8
495.28
718.41
27


 


48
AISDITITR
14.8
495.28
805.44
27


 


49
ALGQDR
11.25
330.18
475.23
20


 


50
ALGQDR
11.25
330.18
485.24
20


 


51
ALGQDR
11.25
330.18
588.31
20


 


52
ALQAK
1.86
265.67
346.21
17


 


53
ALQAK
1.87
265.67
384.22
17


 


54
ALQAK
1.87
265.67
459.29
17


 


55
AMETFSPASTFK
17.06
658.81
737.38
34


 


56
AMETFSPASTFK
17.05
658.81
985.5
34


 


57
AMETFSPASTFK
17.06
658.81
1114.54
34


 


58
AMLFLQER
18.48
504.27
545.3
27


 


59
AMLFLQER
18.48
504.27
692.37
27


 


60
AMLFLQER
18.48
504.27
805.46
27


 


61
AMLVFDPVR
19.87
524.29
732.4
28


 


62
AMLVFDPVR
19.87
524.29
845.49
28


 


63
AMLVFDPVR
19.87
524.29
976.53
28


 


64
AMTLLESGPGWELHGK
19.32
575.96
923.47
33


 


65
AMTLLESGPGWELHGK
19.32
575.96
980.49
33


 


66
AMTLLESGPGWELHGK
19.32
575.96
1067.53
33


 


67
ANLHITLHGK
12.18
368.55
403.24
22


 


68
ANLHITLHGK
12.18
368.55
555.32
22


 


69
ANLHITLHGK
12.18
368.55
668.41
22


 


70
ANQLIVK
11.87
393.25
600.41
22


 


71
ANQLIVK
11.86
393.25
639.38
22


 


72
ANQLIVK
11.86
393.25
714.45
22


 


73
ANTEYVPASTFK
14.54
664.33
912.48
34


 


74
ANTEYVPASTFK
14.54
664.33
1041.53
34


 


75
ANTEYVPASTFK
14.54
664.33
1142.57
34


 


76
ANVSR
9.57
273.65
361.22
17


 


77
ANVSR
9.57
273.65
372.19
17


 


78
ANVSR
9.57
273.65
475.26
17


 


79
APIGWFIGWATR
25.58
687.87
850.46
35


 


80
APIGWFIGWATR
25.58
687.87
1093.56
35


 


81
APIGWFIGWATR
25.58
687.87
1206.64
35


 


82
APLGWFIGWATHEER
24.69
590.63
742.35
34


 


83
APLGWFIGWATHEER
24.69
590.63
985.45
34


 


84
APLGWFIGWATHEER
24.69
590.63
1098.53
34


 


85
AQDEVQSMLFIEEK
20.15
833.9
996.51
42


 


86
AQDEVQSMLFIEEK
20.14
833.9
1124.57
42


 


87
AQDEVQSMLFIEEK
20.15
833.9
1223.63
42


 


88
AQGVIVLWNENK
18.95
685.87
902.47
35


 


89
AQGVIVLWNENK
18.95
685.87
1015.56
35


 


90
AQGVIVLWNENK
18.95
685.87
1171.65
35


 


91
ASAIAVYQDLAR
18.05
639.35
765.39
33


 


92
ASAIAVYQDLAR
18.05
639.35
864.46
33


 


93
ASAIAVYQDLAR
18.05
639.35
935.49
33


 


94
ASAILVYQDLAR
19.08
660.37
765.39
34


 


95
ASAILVYQDLAR
19.08
660.37
864.46
34


 


96
ASAILVYQDLAR
19.08
660.37
977.54
34


 


97
ASAIPVYQDLAR
17.45
652.35
765.39
34


 


98
ASAIPVYQDLAR
17.45
652.35
864.46
34


 


99
ASAIPVYQDLAR
17.45
652.35
961.51
34


 


100
ASAIPVYQDLPR
17.59
665.36
791.4
34


 


101
ASAIPVYQDLPR
17.59
665.36
890.47
34


 


102
ASAIPVYQDLPR
17.6
665.36
987.53
34


 


103
ASAIQVYQDLAR
18.37
667.86
765.39
34


 


104
ASAIQVYQDLAR
18.37
667.86
864.46
34


 


105
ASAIQVYQDLAR
18.37
667.86
992.52
34


 


106
ASAISVYQDLAR
17.93
647.34
765.39
33


 


107
ASAISVYQDLAR
17.93
647.34
864.46
33


 


108
ASAISVYQDLAR
17.93
647.34
951.49
33


 


109
ASALPVYQDLAR
17.77
652.35
864.46
34


 


110
ASALPVYQDLAR
17.77
652.35
961.51
34


 


111
ASALPVYQDLAR
17.77
652.35
1074.59
34


 


112
ASAMPVYQDLAR
16.64
661.33
765.39
34


 


113
ASAMPVYQDLAR
16.64
661.33
864.46
34


 


114
ASAMPVYQDLAR
16.64
661.33
961.51
34


 


115
ASAVPVYQDLAR
16.29
645.35
765.39
33


 


116
ASAVPVYQDLAR
16.29
645.35
864.46
33


 


117
ASAVPVYQDLAR
16.29
645.35
961.51
33


 


118
ASIEYVPASTFK
16.7
656.84
749.42
34


 


119
ASIEYVPASTFK
16.7
656.84
912.48
34


 


120
ASIEYVPASTFK
16.7
656.84
1041.53
34


 


121
ASNVPVYQELAR
18.48
673.86
779.4
35


 


122
ASNVPVYQELAR
18.48
673.86
878.47
35


 


123
ASNVPVYQELAR
18.48
673.86
975.53
35


 


124
ASPASTFK
10.29
404.71
553.3
23


 


125
ASPASTFK
10.29
404.71
650.35
23


 


126
ASPASTFK
10.28
404.71
737.38
23


 


127
ASTAYIPASTFK
15.69
628.83
763.43
33


 


128
ASTAYIPASTFK
15.69
628.83
926.5
33


 


129
ASTAYIPASTFK
15.69
628.83
997.54
33


 


130
ASTEYVPASTFK
14.59
650.82
749.42
34


 


131
ASTEYVPASTFK
14.59
650.82
912.48
34


 


132
ASTEYVPASTFK
14.6
650.82
1041.53
34


 


133
ASTTEVFK
11.78
441.73
623.34
24


 


134
ASTTEVFK
11.78
441.73
724.39
24


 


135
ASTTEVFK
11.78
441.73
811.42
24


 


136
ATSTEIFK
13.15
448.74
637.36
25


 


137
ATSTEIFK
13.15
448.74
724.39
25


 


138
ATSTEIFK
13.15
448.74
825.44
25


 


139
ATTNEIFK
13.21
462.25
650.35
25


 


140
ATTNEIFK
13.21
462.25
751.4
25


 


141
ATTNEIFK
13.21
462.25
852.45
25


 


142
ATTTAVFK
11.9
419.74
464.29
23


 


143
ATTTAVFK
11.9
419.74
565.33
23


 


144
ATTTAVFK
11.9
419.74
666.38
23


 


145
ATTTEIFK
13.64
455.75
637.36
25


 


146
ATTTEIFK
13.65
455.75
738.4
25


 


147
ATTTEIFK
13.65
455.75
839.45
25


 


148
ATTTEVFK
11.98
448.74
623.34
25


 


149
ATTTEVFK
11.98
448.74
724.39
25


 


150
ATTTEVFK
11.98
448.74
825.44
25


 


151
AVSDITILEQTDNYTLHGK
19.19
706.7
974.49
39


 


152
AVSDITILEQTDNYTLHGK
19.19
706.7
1048.51
39


 


153
AVSDITILEQTDNYTLHGK
19.18
706.7
1176.56
39


 


154
AVSDITILEQTYNYTLHGK
22.29
722.71
995.49
40


 


155
AVSDITILEQTYNYTLHGK
22.29
722.71
998.5
40


 


156
AVSDITILEQTYNYTLHGK
22.28
722.71
1224.6
40


 


157
AVVPHFEAGDWDVQGK
17.81
585.62
743.34
33


 


158
AVVPHFEAGDWDVQGK
17.81
585.62
792.88
33


 


159
AVVPHFEAGDWDVQGK
17.81
585.62
904.42
33


 


160
AWEHDMSLR
13.99
572.76
758.36
30


 


161
AWEHDMSLR
13.99
572.76
887.4
30


 


162
AWEHDMSLR
13.99
572.76
1073.48
30


 


163
AWIGSSLQISPLEQLEFLGK
26.98
739.4
963.51
41


 


164
AWIGSSLQISPLEQLEFLGK
26.99
739.4
1173.65
41


 


165
AWIGSSLQISPLEQLEFLGK
26.98
1108.6
1173.65
54


 


166
DAFLK
12.42
297.17
407.27
18


 


167
DAFLK
12.43
297.17
447.22
18


 


168
DAFLK
12.42
297.17
478.3
18


 


169
DDFILHGK
13.99
472.75
714.43
26


 


170
DDFILHGK
13.99
472.75
798.38
26


 


171
DDFILHGK
13.99
472.75
829.46
26


 


172
DDVLK
8.62
295.16
359.27
18


 


173
DDVLK
8.63
295.16
443.21
18


 


174
DDVLK
8.62
295.16
474.29
18


 


175
DEFHVFR
15.39
475.23
705.38
26


 


176
DEFHVFR
15.39
475.23
775.34
26


 


177
DEFHVFR
15.39
475.23
834.43
26


 


178
DEFQIFR
19.02
477.74
520.2
26


 


179
DEFQIFR
19.02
477.74
563.33
26


 


180
DEFQIFR
19.02
477.74
710.4
26


 


181
DEFQVFR
17.29
470.73
549.31
26


 


182
DEFQVFR
17.28
470.73
619.27
26


 


183
DEFQVFR
17.29
470.73
696.38
26


 


184
DELVR
9.33
316.17
387.27
19


 


185
DELVR
9.35
316.17
457.23
19


 


186
DELVR
9.33
316.17
516.31
19


 


187
DFDYGNQDFSGDK
14.72
754.3
967.41
38


 


188
DFDYGNQDFSGDK
14.72
754.3
1130.47
38


 


189
DFDYGNQDFSGDK
14.72
754.3
1245.5
38


 


190
DFTLGEAMQASTVPVYQELAR
24.19
776.05
975.53
43


 


191
DFTLGEAMQASTVPVYQELAR
24.19
776.05
1074.59
43


 


192
DFTLGEAMQASTVPVYQELAR
24.19
1163.57
1175.64
56


 


193
DHDLITAMK
14.23
522.26
563.32
28


 


194
DHDLITAMK
14.23
522.26
695.34
28


 


195
DHDLITAMK
14.23
522.26
791.43
28


 


196
DIAAWNR
13.63
423.22
546.28
24


 


197
DIAAWNR
13.63
423.22
617.32
24


 


198
DIAAWNR
13.62
423.22
730.4
24


 


199
DILYIQELAGGWK
24.49
753.4
888.46
38


 


200
DILYIQELAGGWK
24.48
753.4
1001.54
38


 


201
DILYIQELAGGWK
24.49
753.4
1164.6
38


 


202
DITILEK
15.9
416.24
603.37
23


 


203
DITILEK
15.91
416.24
685.38
23


 


204
DITILEK
15.91
416.24
716.46
23


 


205
DLLSAK
12.45
323.69
429.23
19


 


206
DLLSAK
12.44
323.69
500.27
19


 


207
DLLSAK
12.45
323.69
531.35
19


 


208
DLMITEAGR
15.07
503.26
533.27
27


 


209
DLMITEAGR
15.07
503.26
646.35
27


 


210
DLMITEAGR
15.07
503.26
777.39
27


 


211
DLMIVEAGR
16.68
502.27
531.29
27


 


212
DLMIVEAGR
16.68
502.27
644.37
27


 


213
DLMIVEAGR
16.68
502.27
775.41
27


 


214
DLMIVEAK
16.23
459.75
473.24
25


 


215
DLMIVEAK
16.23
459.75
559.34
25


 


216
DLMIVEAK
16.23
459.75
690.39
25


 


217
DLSGNPGK
6.69
394.2
472.25
22


 


218
DLSGNPGK
6.69
394.2
559.28
22


 


219
DLSGNPGK
6.7
394.2
672.37
22


 


220
DLSLR
12.37
302.18
375.24
18


 


221
DLSLR
12.35
302.18
429.23
18


 


222
DLSLR
12.36
302.18
488.32
18


 


223
DLTLR
12.48
309.18
389.25
19


 


224
DLTLR
12.47
309.18
443.25
19


 


225
DLTLR
12.47
309.18
502.33
19


 


226
DMTLGDAIK
15.97
482.24
503.28
26


 


227
DMTLGDAIK
15.97
482.24
616.37
26


 


228
DMTLGDAIK
15.97
482.24
717.41
26


 


229
DMTLGDAMALSAVPVYQELAR
25.76
751.04
975.53
42


 


230
DMTLGDAMALSAVPVYQELAR
25.76
1126.06
1145.63
55


 


231
DMTLGDAMALSAVPVYQELAR
25.75
1126.06
1232.66
55


 


232
DMTLGDAMK
14.46
491.22
634.32
27


 


233
DMTLGDAMK
14.46
491.22
735.37
27


 


234
DMTLGDAMK
14.46
491.22
866.41
27


 


235
DMTLGEAMALSAVPVYQDLAR
25.92
751.04
961.51
42


 


236
DMTLGEAMALSAVPVYQDLAR
25.92
1126.06
1131.62
55


 


237
DMTLGEAMALSAVPVYQDLAR
25.92
1126.06
1218.65
55


 


238
DMTLGEAMALSAVPVYQELAR
26.48
755.71
779.4
42


 


239
DMTLGEAMALSAVPVYQELAR
26.48
755.71
975.53
42


 


240
DMTLGEAMALSAVPVYQELAR
26.47
1133.07
1232.66
55


 


241
DMTLGEAMK
15.09
498.23
535.25
27


 


242
DMTLGEAMK
15.09
498.23
648.34
27


 


243
DMTLGEAMK
15.09
498.23
749.39
27


 


244
DMTLGQAMQASAVPVYQELAR
23.29
760.38
779.4
42


 


245
DMTLGQAMQASAVPVYQELAR
23.29
760.38
975.53
42


 


246
DMTLGQAMQASAVPVYQELAR
23.29
760.38
976.42
42


 


247
DQDLR
2.54
323.66
403.23
19


 


248
DQDLR
2.55
323.66
472.2
19


 


249
DQDLR
2.55
323.66
531.29
19


 


250
DQQIGWFVGWASKPGK
21.64
601.98
830.45
34


 


251
DQQIGWFVGWASKPGK
21.64
902.46
929.52
45


 


252
DQQIGWFVGWASKPGK
21.64
902.46
1076.59
45


 


253
DQQVQVYGNDLNR
13.59
774.87
851.4
39


 


254
DQQVQVYGNDLNR
13.58
774.87
950.47
39


 


255
DQQVQVYGNDLNR
13.59
774.87
1078.53
39


 


256
DQTLESAFK
15.21
519.76
581.29
28


 


257
DQTLESAFK
15.21
519.76
694.38
28


 


258
DQTLESAFK
15.21
519.76
795.42
28


 


259
DSIVWYSQELTR
19.61
748.87
896.45
38


 


260
DSIVWYSQELTR
19.61
748.87
1082.53
38


 


261
DSIVWYSQELTR
19.61
748.87
1181.59
38


 


262
DSIVWYSQQLTR
19.1
748.38
895.46
38


 


263
DSIVWYSQQLTR
19.11
748.38
1081.54
38


 


264
DSIVWYSQQLTR
19.1
748.38
1180.61
38


 


265
DSNLR
1.77
302.66
402.25
18


 


266
DSNLR
1.77
302.66
430.19
18


 


267
DSNLR
1.77
302.66
489.28
18


 


268
DSYIAWGGEAWK
19.67
691.82
833.39
35


 


269
DSYIAWGGEAWK
19.67
691.82
904.43
35


 


270
DSYIAWGGEAWK
19.66
691.82
1017.52
35


 


271
DTLNPEWPYK
17.3
631.81
819.4
33


 


272
DTLNPEWPYK
17.3
631.81
933.45
33


 


273
DTLNPEWPYK
17.3
631.81
1046.53
33


 


274
DVDEVFYK
15.62
507.74
685.36
27


 


275
DVDEVFYK
15.62
507.74
800.38
27


 


276
DVDEVFYK
15.62
507.74
899.45
27


 


277
DWILR
17.44
351.7
415.2
20


 


278
DWILR
17.44
351.7
528.28
20


 


279
DWILR
17.44
351.7
587.37
20


 


280
EAFLR
12.51
318.18
435.27
19


 


281
EAFLR
12.51
318.18
461.24
19


 


282
EAFLR
12.51
318.18
506.31
19


 


283
EAIVR
7.84
294.18
387.27
18


 


284
EAIVR
7.84
294.18
413.24
18


 


285
EAIVR
7.84
294.18
458.31
18


 


286
EAIVTEATPEYIVHSK
16.43
596.31
746.42
34


 


287
EAIVTEATPEYIVHSK
16.43
596.31
972.51
34


 


288
EAIVTEATPEYIVHSK
16.42
596.31
1073.56
34


 


289
EALVTEAAPEYLVHSK
17.3
586.31
875.46
33


 


290
EALVTEAAPEYLVHSK
17.3
586.31
972.51
33


 


291
EALVTEAAPEYLVHSK
17.3
586.31
1114.59
33


 


292
EALVTEAPEYLVHSK
17.58
562.63
637.32
32


 


293
EALVTEAPEYLVHSK
17.58
562.63
972.51
32


 


294
EALVTEAPEYLVHSK
17.58
562.63
1043.55
32


 


295
EEIVR
8.41
323.18
387.27
19


 


296
EEIVR
8.4
323.18
471.24
19


 


297
EEIVR
8.4
323.18
516.31
19


 


298
EEVLAALPAQLK
19.48
641.37
740.47
33


 


299
EEVLAALPAQLK
19.47
641.37
811.5
33


 


300
EEVLAALPAQLK
19.47
641.37
924.59
33


 


301
EFSAEAVNGVFVLC[CAM]K
21.1
835.42
936.5
42


 


302
EFSAEAVNGVFVLC[CAM]K
21.1
835.42
1106.6
42


 


303
EFSAEAVNGVFVLC[CAM]K
21.1
835.42
1235.65
42


 


304
EFSSESVHGVFVLC[CAM]K
18.26
575.62
666.36
33


 


305
EFSSESVHGVFVLC[CAM]K
18.26
575.62
822.45
33


 


306
EFSSESVHGVFVLC[CAM]K
18.26
575.62
959.51
33


 


307
EGMSGSIR
9.88
418.7
432.26
23


 


308
EGMSGSIR
9.88
418.7
519.29
23


 


309
EGMSGSIR
9.88
418.7
707.35
23


 


310
EGMTGSIR
10.63
425.71
432.26
24


 


311
EGMTGSIR
10.63
425.71
533.3
24


 


312
EGMTGSIR
10.63
425.71
664.34
24


 


313
EIAVWNR
14.78
444.24
475.24
25


 


314
EIAVWNR
14.77
444.24
574.31
25


 


315
EIAVWNR
14.77
444.24
645.35
25


 


316
EIAYK
8.46
312.17
381.21
19


 


317
EIAYK
8.46
312.17
477.23
19


 


318
EIAYK
8.46
312.17
494.3
19


 


319
EIFER
11.7
347.18
451.23
20


 


320
EIFER
11.7
347.18
519.24
20


 


321
EIFER
11.7
347.18
564.31
20


 


322
EIFYHYR
13.31
514.25
785.37
28


 


323
EIFYHYR
13.31
514.25
853.39
28


 


324
EIFYHYR
13.32
514.25
898.46
28


 


325
EIGDDK
1.99
338.66
434.19
20


 


326
EIGDDK
1.99
338.66
530.21
20


 


327
EIGDDK
1.99
338.66
547.27
20


 


328
EIGDGK
1.76
309.66
376.18
19


 


329
EIGDGK
1.75
309.66
472.2
19


 


330
EIGDGK
1.75
309.66
489.27
19


 


331
EIGEDK
2.32
345.67
448.2
20


 


332
EIGEDK
2.33
345.67
544.22
20


 


333
EIGEDK
2.33
345.67
561.29
20


 


334
EIGEDNAR
10.05
452.21
604.27
25


 


335
EIGEDNAR
10.05
452.21
661.29
25


 


336
EIGEDNAR
10.06
452.21
774.37
25


 


337
EIGENK
1.86
345.18
447.22
20


 


338
EIGENK
1.86
345.18
543.24
20


 


339
EIGENK
1.86
345.18
560.3
20


 


340
EIGSEIDK
11.04
445.73
591.3
25


 


341
EIGSEIDK
11.04
445.73
648.32
25


 


342
EIGSEIDK
11.04
445.73
761.4
25


 


343
EMIYLK
15.11
398.72
536.34
23


 


344
EMIYLK
15.11
398.72
650.32
23


 


345
EMIYLK
15.11
398.72
667.38
23


 


346
EMLYVER
14.12
470.23
566.29
26


 


347
EMLYVER
14.12
470.23
679.38
26


 


348
EMLYVER
14.12
470.23
810.42
26


 


349
ENIEK
11.07
316.67
389.24
19


 


350
ENIEK
11.07
316.67
486.22
19


 


351
ENIEK
11.07
316.67
503.28
19


 


352
ENQLIVK
12.15
422.25
472.35
24


 


353
ENQLIVK
12.15
422.25
600.41
24


 


354
ENQLIVK
12.15
422.25
714.45
24


 


355
EQAILLFR
19.88
495.29
548.36
27


 


356
EQAILLFR
19.88
495.29
661.44
27


 


357
EQAILLFR
19.88
495.29
732.48
27


 


358
EQIQFLLR
19.45
523.8
548.36
28


 


359
EQIQFLLR
19.45
523.8
676.41
28


 


360
EQIQFLLR
19.45
523.8
789.5
28


 


361
EQLAFDPQVQQQVK
16.43
829.43
954.54
41


 


362
EQLAFDPQVQQQVK
16.42
829.43
1069.56
41


 


363
EQLAFDPQVQQQVK
16.42
829.43
1216.63
41


 


364
EQVDFVQR
13.09
510.76
549.31
27


 


365
EQVDFVQR
13.09
510.76
664.34
27


 


366
EQVDFVQR
13.09
510.76
763.41
27


 


367
EVGEIR
9.35
351.69
474.27
20


 


368
EVGEIR
9.35
351.69
528.27
20


 


369
EVGEIR
9.35
351.69
573.34
20


 


370
EVGEVR
6.91
344.68
460.25
20


 


371
EVGEVR
6.91
344.68
514.25
20


 


372
EVGEVR
6.91
344.68
559.32
20


 


373
EYLPASTFK
15.41
528.27
553.3
28


 


374
EYLPASTFK
15.41
528.27
650.35
28


 


375
EYLPASTFK
15.41
528.27
763.43
28


 


376
EYLPVSTFK
17.16
542.29
581.33
29


 


377
EYLPVSTFK
17.16
542.29
678.38
29


 


378
EYLPVSTFK
17.16
542.29
791.47
29


 


379
EYNTSGTFVFYDGK
18.2
814.37
1033.5
41


 


380
EYNTSGTFVFYDGK
18.2
814.37
1120.53
41


 


381
EYNTSGTFVFYDGK
18.2
814.37
1221.58
41


 


382
EYVPASTFK
13.89
521.27
553.3
28


 


383
EYVPASTFK
13.89
521.27
650.35
28


 


384
EYVPASTFK
13.89
521.27
749.42
28


 


385
FAPESTFK
13.67
463.73
482.26
25


 


386
FAPESTFK
13.67
463.73
611.3
25


 


387
FAPESTFK
13.67
463.73
708.36
25


 


388
FAQYAK
9.39
364.19
509.27
21


 


389
FAQYAK
9.39
364.19
580.31
21


 


390
FAQYAK
9.39
364.19
581.27
21


 


391
FDYGNR
10.1
386.17
509.25
22


 


392
FDYGNR
10.1
386.17
597.23
22


 


393
FDYGNR
10.09
386.17
624.27
22


 


394
FEDLYK
13.52
407.7
423.26
23


 


395
FEDLYK
13.52
407.7
538.29
23


 


396
FEDLYK
13.52
407.7
667.33
23


 


397
FEDTFHISNQK
14.33
455.89
476.25
27


 


398
FEDTFHISNQK
14.33
455.89
589.33
27


 


399
FEDTFHISNQK
14.33
455.89
726.39
27


 


400
FEDTFHTSNQQHEK
10.66
583.26
870.41
33


 


401
FEDTFHTSNQQHEK
10.66
583.26
971.45
33


 


402
FEDTFHTSNQQHEK
10.66
583.26
1108.51
33


 


403
FEYGNQDVSGDSGK
11.95
751.82
764.34
38


 


404
FEYGNQDVSGDSGK
11.95
751.82
1063.47
38


 


405
FEYGNQDVSGDSGK
11.95
751.82
1226.53
38


 


406
FFSDFQAK
16
495.24
608.3
27


 


407
FFSDFQAK
16
495.24
695.34
27


 


408
FFSDFQAK
16
495.24
842.4
27


 


409
FFSDLQAEGAIVIADER
20.44
627.65
1143.6
35


 


410
FFSDLQAEGAIVIADER
20.43
940.97
1143.6
46


 


411
FFSDLQAEGAIVIADER
20.44
940.97
1179.57
46


 


412
FFSDLR
15.38
392.7
490.26
22


 


413
FFSDLR
15.38
392.7
610.29
22


 


414
FFSDLR
15.38
392.7
637.33
22


 


415
FFSEFQAK
16.13
502.25
622.32
27


 


416
FFSEFQAK
16.13
502.25
709.35
27


 


417
FFSEFQAK
16.13
502.25
856.42
27


 


418
FGLEGQLR
15.8
460.25
473.28
25


 


419
FGLEGQLR
15.8
460.25
602.33
25


 


420
FGLEGQLR
15.8
460.25
772.43
25


 


421
FLESLYLNNLPASK
20.75
804.94
856.49
40


 


422
FLESLYLNNLPASK
20.75
804.94
1019.55
40


 


423
FLESLYLNNLPASK
20.75
804.94
1219.67
40


 


424
FLLEGQLR
18.06
488.28
602.33
26


 


425
FLLEGQLR
18.06
488.28
715.41
26


 


426
FLLEGQLR
18.06
488.28
828.49
26


 


427
FQQYVDR
11.19
478.24
552.28
26


 


428
FQQYVDR
11.19
478.24
680.34
26


 


429
FQQYVDR
11.19
478.24
808.39
26


 


430
FSDYVQR
11.83
457.72
565.31
25


 


431
FSDYVQR
11.83
457.72
680.34
25


 


432
FSDYVQR
11.83
457.72
767.37
25


 


433
FSTASTFK
12.71
444.73
553.3
25


 


434
FSTASTFK
12.7
444.73
654.35
25


 


435
FSTASTFK
12.7
444.73
741.38
25


 


436
FSWDGK
14.32
370.17
505.24
21


 


437
FSWDGK
14.32
370.17
592.27
21


 


438
FSWDGK
14.32
370.17
593.24
21


 


439
FSYGNQNISGGIDK
14.61
750.36
803.43
38


 


440
FSYGNQNISGGIDK
14.61
750.36
1045.53
38


 


441
FSYGNQNISGGIDK
14.61
750.36
1102.55
38


 


442
FSYGNQNISGGTDK
12.74
744.34
791.39
38


 


443
FSYGNQNISGGTDK
12.74
744.34
1033.49
38


 


444
FSYGNQNISGGTDK
12.74
744.34
1090.51
38


 


445
FSYGSQNISGGIDK
14.74
736.85
803.43
37


 


446
FSYGSQNISGGIDK
14.74
736.85
1075.54
37


 


447
FSYGSQNISGGIDK
14.75
736.85
1238.6
37


 


448
FTEYVK
11.81
393.71
538.29
22


 


449
FTEYVK
11.81
393.71
639.33
22


 


450
FTEYVK
11.81
393.71
640.3
22


 


451
FVPASTYK
11.76
456.74
498.26
25


 


452
FVPASTYK
11.76
456.74
569.29
25


 


453
FVPASTYK
11.77
456.74
666.35
25


 


454
FVYDLAQGQLPFKPEVQQQVK
20.48
821.44
955.52
45


 


455
FVYDLAQGQLPFKPEVQQQVK
20.48
821.44
1108.59
45


 


456
FVYDLAQGQLPFKPEVQQQVK
20.49
821.44
1109.07
45


 


457
FWLEDQLR
20.39
553.79
660.33
29


 


458
FWLEDQLR
20.39
553.79
773.42
29


 


459
FWLEDQLR
20.38
553.79
959.49
29


 


460
FWLEGPLK
20.63
495.28
543.31
27


 


461
FWLEGPLK
20.63
495.28
656.4
27


 


462
FWLEGPLK
20.63
495.28
842.48
27


 


463
FWLEGQLR
19.49
524.78
602.33
28


 


464
FWLEGQLR
19.49
524.78
715.41
28


 


465
FWLEGQLR
19.48
524.78
901.49
28


 


466
FYPASSFK
14.74
473.74
636.34
26


 


467
FYPASSFK
14.74
473.74
799.4
26


 


468
FYPASSFK
14.74
473.74
800.36
26


 


469
FYPASTFK
14.98
480.74
553.3
26


 


470
FYPASTFK
14.99
480.74
650.35
26


 


471
FYPASTFK
14.98
480.74
813.41
26


 


472
GAIQVSAVPVFQQIAR
21.6
842.48
958.55
42


 


473
GAIQVSAVPVFQQIAR
21.6
842.48
1057.62
42


 


474
GAIQVSAVPVFQQIAR
21.59
842.48
1128.65
42


 


475
GAIQVSAVPVFQQITR
21.52
857.49
988.56
43


 


476
GAIQVSAVPVFQQITR
21.51
857.49
1087.63
43


 


477
GAIQVSAVPVFQQITR
21.52
857.49
1158.66
43


 


478
GELPVSEDALEMTK
18.1
759.87
936.43
38


 


479
GELPVSEDALEMTK
18.11
759.87
1023.47
38


 


480
GELPVSEDALEMTK
18.11
759.87
1122.53
38


 


481
GISSSVR
8.65
353.2
448.25
21


 


482
GISSSVR
8.65
353.2
535.28
21


 


483
GISSSVR
8.67
353.2
648.37
21


 


484
GNQTLVFAR
14.83
503.28
605.38
27


 


485
GNQTLVFAR
14.83
503.28
706.42
27


 


486
GNQTLVFAR
14.83
503.28
834.48
27


 


487
GPLEISAFEEAR
18.95
659.84
809.38
34


 


488
GPLEISAFEEAR
18.94
659.84
922.46
34


 


489
GPLEISAFEEAR
18.94
659.84
1051.51
34


 


490
GPLTITPIQEVK
18.14
648.38
814.47
34


 


491
GPLTITPIQEVK
18.15
648.38
927.55
34


 


492
GPLTITPIQEVK
18.14
648.38
1028.6
34


 


493
GSLLLWDQK
19.61
530.3
576.28
28


 


494
GSLLLWDQK
19.61
530.3
689.36
28


 


495
GSLLLWDQK
19.61
530.3
802.45
28


 


496
GTFVLYDVQR
17.93
599.32
680.34
31


 


497
GTFVLYDVQR
17.93
599.32
793.42
31


 


498
GTFVLYDVQR
17.93
599.32
892.49
31


 


499
GTIVVADER
11.82
480.26
490.23
26


 


500
GTIVVADER
11.82
480.26
589.29
26


 


501
GTIVVADER
11.82
480.26
688.36
26


 


502
GTIVVLDAR
15.77
472.28
573.34
26


 


503
GTIVVLDAR
15.77
472.28
672.4
26


 


504
GTIVVLDAR
15.77
472.28
785.49
26


 


505
GTIVVVDER
13.6
494.28
518.26
27


 


506
GTIVVVDER
13.6
494.28
617.33
27


 


507
GTIVVVDER
13.6
494.28
716.39
27


 


508
GTLPFSAR
14.96
424.73
577.31
24


 


509
GTLPFSAR
14.96
424.73
690.39
24


 


510
GTLPFSAR
14.97
424.73
791.44
24


 


511
HIADSK
11.91
335.68
420.21
20


 


512
HIADSK
11.9
335.68
524.25
20


 


513
HIADSK
11.91
335.68
533.29
20


 


514
HNGTDGAWIISSLR
19.36
509.6
575.35
29


 


515
HNGTDGAWIISSLR
19.35
509.6
653.26
29


 


516
HNGTDGAWIISSLR
19.36
509.6
688.44
29


 


517
HTLSVFDQER
14.25
411.21
432.22
25


 


518
HTLSVFDQER
14.25
411.21
547.25
25


 


519
HTLSVFDQER
14.25
411.21
694.32
25


 


520
HVTFASFR
14.36
322.17
338.18
20


 


521
HVTFASFR
14.36
322.17
409.22
20


 


522
HVTFASFR
14.36
322.17
485.25
20


 


523
IAISLMGYDAGFLR
23.93
763.91
898.44
39


 


524
IAISLMGYDAGFLR
23.93
763.91
1029.48
39


 


525
IAISLMGYDAGFLR
23.94
763.91
1229.6
39


 


526
IALSLMGFDSGILK
24.91
732.91
836.45
37


 


527
IALSLMGFDSGILK
24.91
732.91
967.49
37


 


528
IALSLMGFDSGILK
24.91
732.91
1167.61
37


 


529
IANALIGLENHK
15.95
431.58
697.36
26


 


530
IANALIGLENHK
15.95
646.87
697.36
33


 


531
IANALIGLENHK
15.95
646.87
810.45
33


 


532
IDTFWLDNSLK
21.79
676.35
689.38
35


 


533
IDTFWLDNSLK
21.79
676.35
875.46
35


 


534
IDTFWLDNSLK
21.79
676.35
1123.58
35


 


535
IDYYNLDR
14.85
536.26
680.34
29


 


536
IDYYNLDR
14.85
536.26
843.4
29


 


537
IDYYNLDR
14.85
536.26
958.43
29


 


538
IFNALIALDSGVIK
24.74
737.44
802.47
37


 


539
IFNALIALDSGVIK
24.74
737.44
915.55
37


 


540
IFNALIALDSGVIK
24.74
737.44
1028.64
37


 


541
IFNSLLALDSGALDNER
22.76
924.48
976.43
46


 


542
IFNSLLALDSGALDNER
22.77
924.48
1089.52
46


 


543
IFNSLLALDSGALDNER
22.76
924.48
1160.55
46


 


544
IFNTLIGLENGIVK
23.29
765.95
829.48
39


 


545
IFNTLIGLENGIVK
23.3
765.95
942.56
39


 


546
IFNTLIGLENGIVK
23.3
765.95
1055.65
39


 


547
IGLDLMQK
17.7
459.26
634.32
25


 


548
IGLDLMQK
17.7
459.26
747.41
25


 


549
IGLDLMQK
17.7
459.26
804.43
25


 


550
IGLEK
8.54
280.18
389.24
17


 


551
IGLEK
8.55
280.18
413.24
17


 


552
IGLEK
8.54
280.18
446.26
17


 


553
IGLELMQQEVQR
18.73
722.38
787.41
37


 


554
IGLELMQQEVQR
18.73
722.38
918.45
37


 


555
IGLELMQQEVQR
18.73
722.38
1031.53
37


 


556
IGLELMSK
17.52
445.75
478.27
25


 


557
IGLELMSK
17.52
445.75
720.4
25


 


558
IGLELMSK
17.52
445.75
777.42
25


 


559
IGLELMSNEVK
18.73
616.83
707.34
32


 


560
IGLELMSNEVK
18.73
616.83
820.42
32


 


561
IGLELMSNEVK
18.73
616.83
949.47
32


 


562
IGLER
10.96
294.18
304.16
18


 


563
IGLER
10.96
294.18
417.25
18


 


564
IGLER
10.96
294.18
474.27
18


 


565
IGLNK
9.59
272.68
374.24
17


 


566
IGLNK
9.59
272.68
398.24
17


 


567
IGLNK
9.59
272.68
431.26
17


 


568
IGLNLMQK
17.1
458.77
633.34
25


 


569
IGLNLMQK
17.09
458.77
746.42
25


 


570
IGLNLMQK
17.11
458.77
803.44
25


 


571
IGPSLMQSELQR
17.02
679.86
760.39
35


 


572
IGPSLMQSELQR
17.02
679.86
891.44
35


 


573
IGPSLMQSELQR
17.02
679.86
1188.6
35


 


574
IGYGNMQIGTEVDQFWLK
24.31
700.35
935.5
39


 


575
IGYGNMQIGTEVDQFWLK
24.32
1050.02
1164.54
51


 


576
IGYGNMQIGTEVDQFWLK
24.3
1050.02
1222.61
51


 


577
IINHNLPVK
11.88
349.88
456.32
21


 


578
IINHNLPVK
11.88
349.88
570.36
21


 


579
IINHNLPVK
11.88
349.88
592.32
21


 


580
IINHNLPVR
12.04
359.22
598.37
22


 


581
IINHNLPVR
12.04
538.32
598.37
29


 


582
IINHNLPVR
12.04
538.32
849.47
29


 


583
ILFQQGTQQAC[CAM]AER
14.51
550.61
606.27
32


 


584
ILFQQGTQQAC[CAM]AER
14.51
825.41
1020.45
41


 


585
ILFQQGTQQAC[CAM]AER
14.51
825.41
1148.51
41


 


586
ILNNWFK
18.98
467.76
594.3
26


 


587
ILNNWFK
18.98
467.76
708.35
26


 


588
ILNNWFK
18.97
467.76
821.43
26


 


589
ILNTLISLEEK
19.98
636.87
718.4
33


 


590
ILNTLISLEEK
19.98
636.87
1046.57
33


 


591
ILNTLISLEEK
19.98
636.87
1159.66
33


 


592
INIVK
11.43
293.7
359.27
18


 


593
INIVK
11.43
293.7
440.29
18


 


594
INIVK
11.43
293.7
473.31
18


 


595
INLYGNALSR
16.05
560.81
617.34
30


 


596
INLYGNALSR
16.05
560.81
780.4
30


 


597
INLYGNALSR
16.05
560.81
893.48
30


 


598
IPFSLNLEMK
21.68
596.33
834.44
31


 


599
IPFSLNLEMK
21.67
596.33
981.51
31


 


600
IPFSLNLEMK
21.67
596.33
1078.56
31


 


601
IPHTLFALDADAVR
20
513.62
531.29
30


 


602
IPHTLFALDADAVR
20
513.62
646.32
30


 


603
IPHTLFALDADAVR
20
769.92
1191.64
39


 


604
IPHTLFALDAGAAR
18.58
726.9
744.4
37


 


605
IPHTLFALDAGAAR
18.58
726.9
891.47
37


 


606
IPHTLFALDAGAAR
18.58
726.9
1004.55
37


 


607
IPHTLFALDAGAVR
19.72
494.28
588.31
29


 


608
IPHTLFALDAGAVR
19.71
494.28
780.44
29


 


609
IPHTLFALDAGAVR
19.72
740.92
1133.63
38


 


610
IPNAIIGLETGVIK
21.75
719.44
816.48
37


 


611
IPNAIIGLETGVIK
21.75
719.44
929.57
37


 


612
IPNAIIGLETGVIK
21.75
719.44
1227.73
37


 


613
IPNALIGLETGAIK
20.96
705.42
788.45
36


 


614
IPNALIGLETGAIK
20.96
705.42
901.54
36


 


615
IPNALIGLETGAIK
20.96
705.42
1014.62
36


 


616
IPNSLIAFDTGAVR
20.24
737.41
765.39
37


 


617
IPNSLIAFDTGAVR
20.24
737.41
836.43
37


 


618
IPNSLIAFDTGAVR
20.24
737.41
949.51
37


 


619
IPSAIIGLETGVIK
21.66
705.93
816.48
36


 


620
IPSAIIGLETGVIK
21.67
705.93
929.57
36


 


621
IPSAIIGLETGVIK
21.66
705.93
1200.72
36


 


622
ISAFNQVK
13.02
453.76
488.28
25


 


623
ISAFNQVK
13.02
453.76
706.39
25


 


624
ISAFNQVK
13.02
453.76
793.42
25


 


625
ISAHEQILFLR
18.28
442.92
548.36
26


 


626
ISAHEQILFLR
18.28
442.92
789.5
26


 


627
ISAHEQILFLR
18.28
663.88
918.54
34


 


628
ISAMEQTR
9.84
468.23
664.31
26


 


629
ISAMEQTR
9.84
468.23
735.35
26


 


630
ISAMEQTR
9.84
468.23
822.38
26


 


631
ISAMEQVK
11.65
453.24
634.32
25


 


632
ISAMEQVK
11.65
453.24
705.36
25


 


633
ISAMEQVK
11.65
453.24
792.39
25


 


634
ISATEQVAFLR
17.7
412.23
435.27
25


 


635
ISATEQVAFLR
17.71
412.23
506.31
25


 


636
ISATEQVAFLR
17.7
412.23
605.38
25


 


637
ISATQQIAFLR
18.58
624.36
747.45
32


 


638
ISATQQIAFLR
18.58
624.36
1047.59
32


 


639
ISATQQIAFLR
18.58
624.36
1134.63
32


 


640
ISAVNQVEFLESLFLNK
28.77
976.03
988.51
48


 


641
ISAVNQVEFLESLFLNK
28.77
976.03
1110.62
48


 


642
ISAVNQVEFLESLFLNK
28.77
976.03
1239.66
48


 


643
ISAVNQVK
10.32
429.76
488.28
24


 


644
ISAVNQVK
10.32
429.76
658.39
24


 


645
ISAVNQVK
10.32
429.76
745.42
24


 


646
ISPEEQIQFLR
18.87
680.37
933.52
35


 


647
ISPEEQIQFLR
18.87
680.37
1062.56
35


 


648
ISPEEQIQFLR
18.87
680.37
1159.61
35


 


649
ISPEEQVR
10.49
479.25
531.29
26


 


650
ISPEEQVR
10.49
479.25
660.33
26


 


651
ISPEEQVR
10.49
479.25
757.38
26


 


652
ISPEGQVR
9.86
443.24
459.27
25


 


653
ISPEGQVR
9.86
443.24
588.31
25


 


654
ISPEGQVR
9.86
443.24
685.36
25


 


655
ISPLEQLAFLR
24.02
643.88
876.49
33


 


656
ISPLEQLAFLR
24.01
643.88
989.58
33


 


657
ISPLEQLAFLR
24.02
643.88
1086.63
33


 


658
ITAFQQVDFLR
21.11
669.36
777.43
34


 


659
ITAFQQVDFLR
21.12
669.36
905.48
34


 


660
ITAFQQVDFLR
21.12
669.36
1123.59
34


 


661
ITPIQEVNFADDFANNR
21.25
655.32
736.34
37


 


662
ITPIQEVNFADDFANNR
21.25
655.32
851.36
37


 


663
ITPIQEVNFADDFANNR
21.25
655.32
922.4
37


 


664
ITPIQEVNFADDLANNR
20.95
643.99
817.38
36


 


665
ITPIQEVNFADDLANNR
20.95
965.49
1149.53
47


 


666
ITPIQEVNFADDLANNR
20.96
965.49
1248.6
47


 


667
ITPQQEAQFAYK
14.52
712.36
856.42
36


 


668
ITPQQEAQFAYK
14.52
712.36
984.48
36


 


669
ITPQQEAQFAYK
14.52
712.36
1209.59
36


 


670
ITPQQEAQFTYK
14.33
485.25
558.29
28


 


671
ITPQQEAQFTYK
14.33
727.37
1014.49
37


 


672
ITPQQEAQFTYK
14.33
727.37
1239.6
37


 


673
ITPVQEVNFADDLAHNR
18.98
646.99
840.4
36


 


674
ITPVQEVNFADDLAHNR
18.98
646.99
862.92
36


 


675
ITPVQEVNFADDLAHNR
18.98
646.99
911.43
36


 


676
IVAFALK
17.21
381.25
478.3
22


 


677
IVAFALK
17.22
381.25
549.34
22


 


678
IVAFALK
17.21
381.25
648.41
22


 


679
IVAFALNMEMR
17.95
647.84
864.41
34


 


680
IVAFALNMEMR
17.95
647.84
1011.48
34


 


681
IVAFALNMEMR
17.97
647.84
1082.51
34


 


682
IVESTTLADGTWHGK
13.69
542.96
697.4
31


 


683
IVESTTLADGTWHGK
13.69
542.96
812.43
31


 


684
IVESTTLADGTWHGK
13.68
542.96
883.46
31


 


685
IYNSLIGLNEK
17.37
632.35
673.39
33


 


686
IYNSLIGLNEK
17.37
632.35
786.47
33


 


687
IYNSLIGLNEK
17.37
632.35
987.55
33


 


688
KPDIGVVWVGWIER
24.47
547.96
660.35
31


 


689
KPDIGVVWVGWIER
24.47
547.96
883.45
31


 


690
KPDIGVVWVGWIER
24.46
821.43
1188.59
41


 


691
LAC[CAM]ATNNLAR
11.22
552.28
688.37
29


 


692
LAC[CAM]ATNNLAR
11.22
552.28
759.41
29


 


693
LAC[CAM]ATNNLAR
11.22
552.28
919.44
29


 


694
LAQGELPFPAPVQSTVR
19.84
905.5
954.54
45


 


695
LAQGELPFPAPVQSTVR
19.84
905.5
1101.61
45


 


696
LAQGELPFPAPVQSTVR
19.84
905.5
1198.66
45


 


697
LAQNELPYPIEIQK
19.09
828.45
929.47
41


 


698
LAQNELPYPIEIQK
19.09
828.45
987.55
41


 


699
LAQNELPYPIEIQK
19.08
828.45
1100.64
41


 


700
LAQNELQYPIEIQK
17.98
843.96
890.5
42


 


701
LAQNELQYPIEIQK
17.98
843.96
1018.56
42


 


702
LAQNELQYPIEIQK
17.98
843.96
1131.64
42


 


703
LDFGNK
11.75
347.18
465.25
20


 


704
LDFGNK
11.74
347.18
547.25
20


 


705
LDFGNK
11.75
347.18
580.27
20


 


706
LDGSLNR
9.48
387.71
402.25
22


 


707
LDGSLNR
9.48
387.71
546.3
22


 


708
LDGSLNR
9.48
387.71
661.33
22


 


709
LEILQQALAELGLYPK
29.81
900.02
1003.58
45


 


710
LEILQQALAELGLYPK
29.81
900.02
1074.62
45


 


711
LEILQQALAELGLYPK
29.81
900.02
1202.68
45


 


712
LENQEQVK
7.6
494.26
631.34
27


 


713
LENQEQVK
7.59
494.26
745.38
27


 


714
LENQEQVK
7.59
494.26
874.43
27


 


715
LETQEEVEK
9.88
552.77
633.31
29


 


716
LETQEEVEK
9.88
552.77
862.42
29


 


717
LETQEEVEK
9.88
552.77
991.46
29


 


718
LETQEEVK
9.5
488.25
504.27
26


 


719
LETQEEVK
9.49
488.25
733.37
26


 


720
LETQEEVK
9.49
488.25
862.42
26


 


721
LFAAEGVK
13.53
417.74
503.28
23


 


722
LFAAEGVK
13.53
417.74
574.32
23


 


723
LFAAEGVK
13.53
417.74
721.39
23


 


724
LFESAGVK
12.99
425.74
461.27
24


 


725
LFESAGVK
12.99
425.74
590.31
24


 


726
LFESAGVK
12.99
425.74
737.38
24


 


727
LFGAAGVK
13.94
381.73
445.28
22


 


728
LFGAAGVK
13.94
381.73
502.3
22


 


729
LFGAAGVK
13.94
381.73
649.37
22


 


730
LGVDR
8.51
280.16
290.15
17


 


731
LGVDR
8.51
280.16
389.21
17


 


732
LGVDR
8.5
280.16
446.24
17


 


733
LLNLLSQSK
17.97
508.31
562.32
27


 


734
LLNLLSQSK
17.97
508.31
789.45
27


 


735
LLNLLSQSK
17.97
508.31
902.53
27


 


736
LLQDER
9.34
387.21
547.25
22


 


737
LLQDER
9.31
387.21
599.3
22


 


738
LLQDER
9.34
387.21
660.33
22


 


739
LLVQDGDC[CAM]GR
11.92
566.77
679.25
30


 


740
LLVQDGDC[CAM]GR
11.92
566.77
807.3
30


 


741
LLVQDGDC[CAM]GR
11.92
566.77
906.37
30


 


742
LNEVGYGNR
10.74
511.26
566.27
27


 


743
LNEVGYGNR
10.74
511.26
665.34
27


 


744
LNEVGYGNR
10.73
511.26
794.38
27


 


745
LNYGNADPSTK
10.76
590.29
732.35
31


 


746
LNYGNADPSTK
10.76
590.29
789.37
31


 


747
LNYGNADPSTK
10.76
590.29
952.44
31


 


748
LNYGNK
7.21
354.69
481.24
21


 


749
LNYGNK
7.24
354.69
562.26
21


 


750
LNYGNK
7.22
354.69
595.28
21


 


751
LPASK
1.93
258.16
305.18
16


 


752
LPASK
1.93
258.16
369.21
16


 


753
LPASK
1.93
258.16
402.23
16


 


754
LPHTLFALDADAVR
19.98
769.92
977.51
39


 


755
LPHTLFALDADAVR
19.98
769.92
1090.59
39


 


756
LPHTLFALDADAVR
19.98
769.92
1191.64
39


 


757
LPHTLFALDAGAVR
19.7
740.92
919.5
38


 


758
LPHTLFALDAGAVR
19.67
740.92
1032.58
38


 


759
LPHTLFALDAGAVR
19.7
740.92
1133.63
38


 


760
LPLAIMGFDSGILQSPK
25.08
893.99
944.5
44


 


761
LPLAIMGFDSGILQSPK
25.08
893.99
1091.57
44


 


762
LPLAIMGFDSGILQSPK
25.08
893.99
1148.59
44


 


763
LPLAIMGYDADILLDATTPR
27.86
720.39
773.42
40


 


764
LPLAIMGYDADILLDATTPR
27.87
720.39
886.5
40


 


765
LPLAIMGYDADILLDATTPR
27.87
720.39
1160.57
40


 


766
LPSSLIALETGAVR
20.6
713.92
816.46
36


 


767
LPSSLIALETGAVR
20.6
713.92
929.54
36


 


768
LPSSLIALETGAVR
20.6
713.92
1216.69
36


 


769
LPVSAQTLQYTANILK
21.84
880.5
950.53
44


 


770
LPVSAQTLQYTANILK
21.84
880.5
1063.61
44


 


771
LPVSAQTLQYTANILK
21.85
880.5
1164.66
44


 


772
LPVSER
9.57
350.7
490.26
20


 


773
LPVSER
9.57
350.7
526.29
20


 


774
LPVSER
9.57
350.7
587.31
20


 


775
LPVSPTAVDMTER
16.21
708.36
1019.48
36


 


776
LPVSPTAVDMTER
16.21
708.36
1106.51
36


 


777
LPVSPTAVDMTER
16.21
708.36
1205.58
36


 


778
LSASK
10.72
253.15
305.18
16


 


779
LSASK
10.71
253.15
359.19
16


 


780
LSASK
10.71
253.15
392.21
16


 


781
LSAVPIYQEVAR
17.96
673.38
765.39
35


 


782
LSAVPIYQEVAR
17.96
673.38
975.53
35


 


783
LSAVPIYQEVAR
17.95
673.38
1074.59
35


 


784
LSAVPVYQELAR
18.45
449.25
616.34
26


 


785
LSAVPVYQELAR
18.44
673.38
779.4
35


 


786
LSAVPVYQELAR
18.44
673.38
975.53
35


 


787
LSC[CAM]TLVIDEASGDLLHR
20.38
633.66
797.43
36


 


788
LSC[CAM]TLVIDEASGDLLHR
20.38
633.66
868.46
36


 


789
LSC[CAM]TLVIDEASGDLLHR
20.38
633.66
1112.53
36


 


790
LSLQHGWFIGWIEK
23.95
571.98
632.34
33


 


791
LSLQHGWFIGWIEK
23.95
571.98
892.49
33


 


792
LSLQHGWFIGWIEK
23.95
571.98
969.49
33


 


793
LSQNSLPFSQEAMNSVK
18.64
627.31
1140.54
35


 


794
LSQNSLPFSQEAMNSVK
18.63
940.46
1140.54
46


 


795
LSQNSLPFSQEAMNSVK
18.64
940.46
1237.59
46


 


796
LSVNPK
9.8
329.2
457.28
19


 


797
LSVNPK
9.79
329.2
511.29
19


 


798
LSVNPK
9.8
329.2
544.31
19


 


799
LTVGAR
9.51
308.69
402.25
19


 


800
LTVGAR
9.51
308.69
442.27
19


 


801
LTVGAR
9.51
308.69
503.29
19


 


802
LYGFALNIDMPGGEADIGK
23.35
661
843.42
37


 


803
LYGFALNIDMPGGEADIGK
23.35
990.99
1089.49
49


 


804
LYGFALNIDMPGGEADIGK
23.35
990.99
1202.57
49


 


805
LYHNELPFR
15.29
396.88
414.21
24


 


806
LYHNELPFR
15.29
396.88
419.24
24


 


807
LYHNELPFR
15.29
396.88
657.3
24


 


808
LYHNK
8.54
337.68
414.21
20


 


809
LYHNK
8.53
337.68
528.26
20


 


810
LYHNK
8.53
337.68
561.28
20


 


811
LYQNDLPFR
17.2
583.3
761.39
31


 


812
LYQNDLPFR
17.2
583.3
889.45
31


 


813
LYQNDLPFR
17.2
583.3
1052.52
31


 


814
MDDLFK
15.5
384.68
522.29
22


 


815
MDDLFK
15.5
384.68
622.25
22


 


816
MDDLFK
15.5
384.68
637.32
22


 


817
MEDLHK
6.66
386.69
512.28
22


 


818
MEDLHK
6.65
386.69
626.26
22


 


819
MEDLHK
6.66
386.69
641.33
22


 


820
MLIALIGLENHK
21.33
451.26
527.26
27


 


821
MLIALIGLENHK
21.33
451.26
697.36
27


 


822
MLIALIGLENHK
21.33
451.26
810.45
27


 


823
MLLIK
15.81
309.21
373.28
19


 


824
MLLIK
15.81
309.21
471.3
19


 


825
MLLIK
15.81
309.21
486.36
19


 


826
MLNALIGLEHHK
16.89
459.26
550.27
27


 


827
MLNALIGLEHHK
16.89
459.26
720.38
27


 


828
MLNALIGLEHHK
16.89
459.26
833.46
27


 


829
MLNALIGLENHK
18.39
451.58
697.36
27


 


830
MLNALIGLENHK
18.38
676.87
697.36
35


 


831
MLNALIGLENHK
18.39
676.87
810.45
35


 


832
MLNALIGLENQK
19.71
672.37
688.36
35


 


833
MLNALIGLENQK
19.71
672.37
801.45
35


 


834
MLNALIGLENQK
19.71
672.37
914.53
35


 


835
MLNALIGLEYHK
19.6
701.38
746.38
36


 


836
MLNALIGLEYHK
19.6
701.38
859.47
36


 


837
MLNALIGLEYHK
19.6
701.38
1157.63
36


 


838
MLNALIGLQHGK
17.5
432.25
582.34
26


 


839
MLNALIGLQHGK
17.5
432.25
639.36
26


 


840
MLNALIGLQHGK
17.5
432.25
752.44
26


 


841
MLNALISLEHHK
17.2
352.2
359.17
21


 


842
MLNALISLEHHK
17.21
469.26
750.39
27


 


843
MLNALISLEHHK
17.2
469.26
863.47
27


 


844
MQAYVDAFDYGNR
17.56
775.34
957.41
39


 


845
MQAYVDAFDYGNR
17.56
775.34
1056.47
39


 


846
MQAYVDAFDYGNR
17.56
775.34
1219.54
39


 


847
MQEGLNK
8.68
410.21
560.3
23


 


848
MQEGLNK
8.66
410.21
673.3
23


 


849
MQEGLNK
8.68
410.21
688.36
23


 


850
MSPASTYK
9.49
442.71
569.29
24


 


851
MSPASTYK
9.49
442.71
666.35
24


 


852
MSPASTYK
9.49
442.71
753.38
24


 


853
NEHDPVLPYR
13.09
413.88
435.24
25


 


854
NEHDPVLPYR
13.09
620.31
744.44
32


 


855
NEHDPVLPYR
13.09
620.31
859.47
32


 


856
NEHQIFK
9.91
458.24
509.21
25


 


857
NEHQIFK
9.91
458.24
622.29
25


 


858
NEHQIFK
9.91
458.24
672.38
25


 


859
NEHQVFK
7.74
451.23
658.37
25


 


860
NEHQVFK
7.74
451.23
755.35
25


 


861
NEHQVFK
7.74
451.23
787.41
25


 


862
NEITYK
9.35
384.2
524.31
22


 


863
NEITYK
9.35
384.2
621.29
22


 


864
NEITYK
9.35
384.2
653.35
22


 


865
NELLMK
13.08
374.21
504.32
21


 


866
NELLMK
13.09
374.21
601.3
21


 


867
NELLMK
13.09
374.21
633.36
21


 


868
NELPFR
14.39
388.21
419.24
22


 


869
NELPFR
14.39
388.21
532.32
22


 


870
NELPFR
14.4
388.21
661.37
22


 


871
NISSYGNNLVR
14.36
618.82
835.44
32


 


872
NISSYGNNLVR
14.36
618.82
922.47
32


 


873
NISSYGNNLVR
14.36
618.82
1009.51
32


 


874
NISTYGNNLTR
13.1
626.82
674.36
33


 


875
NISTYGNNLTR
13.09
626.82
837.42
33


 


876
NISTYGNNLTR
13.1
626.82
1025.5
33


 


877
NLFNEVHTTGVLVIR
20.69
571.32
757.49
33


 


878
NLFNEVHTTGVLVIR
20.7
571.32
858.54
33


 


879
NLFNEVHTTGVLVIR
20.7
571.32
995.6
33


 


880
NLSTYGNALAR
14.34
590.31
764.4
31


 


881
NLSTYGNALAR
14.35
590.31
865.45
31


 


882
NLSTYGNALAR
14.35
590.31
952.48
31


 


883
NMENLELFGK
19.08
597.79
820.46
31


 


884
NMENLELFGK
19.08
597.79
949.5
31


 


885
NMENLELFGK
19.08
597.79
1080.54
31


 


886
NMLLLEENNGYK
16.71
719.36
853.37
37


 


887
NMLLLEENNGYK
16.69
719.36
966.45
37


 


888
NMLLLEENNGYK
16.68
719.36
1079.54
37


 


889
NMLLLEESNGYK
18.12
705.85
939.44
36


 


890
NMLLLEESNGYK
18.13
705.85
1052.53
36


 


891
NMLLLEESNGYK
18.11
705.85
1165.61
36


 


892
NMLLLEK
16.99
430.75
502.32
24


 


893
NMLLLEK
16.98
430.75
615.41
24


 


894
NMLLLEK
16.98
430.75
746.45
24


 


895
NMTLGDAMK
14.42
490.73
521.24
27


 


896
NMTLGDAMK
14.42
490.73
634.32
27


 


897
NMTLGDAMK
14.42
490.73
735.37
27


 


898
NNGLTEAWLESSLK
20.61
781.4
862.47
39


 


899
NNGLTEAWLESSLK
20.6
781.4
933.5
39


 


900
NNGLTEAWLESSLK
20.62
781.4
1163.59
39


 


901
NQLPFK
13.49
373.71
391.23
21


 


902
NQLPFK
13.49
373.71
504.32
21


 


903
NQLPFK
13.49
373.71
632.38
21


 


904
NQLPFQVEHQR
14.33
698.36
796.41
36


 


905
NQLPFQVEHQR
14.33
698.36
1040.53
36


 


906
NQLPFQVEHQR
14.33
698.36
1153.61
36


 


907
NSAIENTIDNMYLQDLENSTK
22.77
805.04
934.45
44


 


908
NSAIENTIDNMYLQDLENSTK
22.77
805.04
1047.53
44


 


909
NSAIENTIDNMYLQDLENSTK
22.77
805.04
1210.6
44


 


910
NSAIENTIENMYLQDLDNSTK
23.13
805.04
920.43
44


 


911
NSAIENTIENMYLQDLDNSTK
23.13
805.04
1033.52
44


 


912
NSAIENTIENMYLQDLDNSTK
23.14
805.04
1196.58
44


 


913
NSAIENTIENMYLQDLENSTK
23.7
809.72
934.45
44


 


914
NSAIENTIENMYLQDLENSTK
23.7
809.72
1047.53
44


 


915
NSAIENTIENMYLQDLENSTK
23.7
809.72
1217.55
44


 


916
NSAVWVYELFAK
24.66
713.87
869.48
36


 


917
NSAVWVYELFAK
24.66
713.87
1055.56
36


 


918
NSAVWVYELFAK
24.65
713.87
1154.62
36


 


919
NSQVPAYK
9.78
453.74
478.27
25


 


920
NSQVPAYK
9.78
453.74
577.33
25


 


921
NSQVPAYK
9.78
453.74
705.39
25


 


922
NSTVWIYELFAK
25.64
735.88
883.49
37


 


923
NSTVWIYELFAK
25.64
735.88
1069.57
37


 


924
NSTVWIYELFAK
25.64
735.88
1168.64
37


 


925
NSTVWVYELFAK
24.42
728.88
770.41
37


 


926
NSTVWVYELFAK
24.43
728.88
869.48
37


 


927
NSTVWVYELFAK
24.42
728.88
1055.56
37


 


928
NSTVWVYQLFAK
23.9
728.39
769.42
37


 


929
NSTVWVYQLFAK
23.91
728.39
1054.57
37


 


930
NSTVWVYQLFAK
23.91
728.39
1153.64
37


 


931
NTSGALVIQTDK
13.34
623.84
816.48
32


 


932
NTSGALVIQTDK
13.34
623.84
944.54
32


 


933
NTSGALVIQTDK
13.34
623.84
1031.57
32


 


934
NTSGVLVIQTDK
14.9
637.85
816.48
33


 


935
NTSGVLVIQTDK
14.9
637.85
972.57
33


 


936
NTSGVLVIQTDK
14.91
637.85
1059.6
33


 


937
NVDEMFYYYDGSK
18.86
815.84
895.38
41


 


938
NVDEMFYYYDGSK
18.86
815.84
1042.45
41


 


939
NVDEMFYYYDGSK
18.85
815.84
1173.49
41


 


940
NWILR
16.3
351.21
414.21
20


 


941
NWILR
16.29
351.21
527.3
20


 


942
NWILR
16.3
351.21
587.37
20


 


943
NWNAAMDLR
16.54
545.76
605.31
29


 


944
NWNAAMDLR
16.55
545.76
676.34
29


 


945
NWNAAMDLR
16.54
545.76
790.39
29


 


946
NYVDAFHYGNQDISGDK
15.76
648.29
933.43
36


 


947
NYVDAFHYGNQDISGDK
15.77
648.29
1096.49
36


 


948
NYVDAFHYGNQDISGDK
15.76
971.93
1233.55
48


 


949
QADHAILVFDQAR
16.58
495.26
523.23
29


 


950
QADHAILVFDQAR
16.61
495.26
636.31
29


 


951
QADHAILVFDQAR
16.58
495.26
735.38
29


 


952
QAEHALLVFGQER
16.86
499.93
636.31
29


 


953
QAEHALLVFGQER
16.85
499.93
735.38
29


 


954
QAEHALLVFGQER
16.87
499.93
763.41
29


 


955
QAITK
11
280.67
361.24
17


 


956
QAITK
11
280.67
414.23
17


 


957
QAITK
11.01
280.67
432.28
17


 


958
QAMLTEANSDYIIR
18.26
812.9
951.49
41


 


959
QAMLTEANSDYIIR
18.25
812.9
1080.53
41


 


960
QAMLTEANSDYIIR
18.26
812.9
1181.58
41


 


961
QEVQFVSALAR
17.69
624.34
763.45
32


 


962
QEVQFVSALAR
17.68
624.34
891.5
32


 


963
QEVQFVSALAR
17.68
624.34
990.57
32


 


964
QFASIK
11.66
347.2
434.2
20


 


965
QFASIK
11.66
347.2
547.29
20


 


966
QFASIK
11.68
347.2
565.33
20


 


967
QGMPGSIR
11.4
423.22
529.31
24


 


968
QGMPGSIR
11.43
423.22
660.35
24


 


969
QGMPGSIR
11.4
423.22
717.37
24


 


970
QGMSGSIR
9.44
418.21
519.29
23


 


971
QGMSGSIR
9.45
418.21
650.33
23


 


972
QGMSGSIR
9.44
418.21
707.35
23


 


973
QGQTQQSYGNDLAR
11.16
783.37
895.43
39


 


974
QGQTQQSYGNDLAR
11.17
783.37
1023.49
39


 


975
QGQTQQSYGNDLAR
11.16
783.37
1151.54
39


 


976
QIDYGNADPSTIK
13.41
711.35
845.44
36


 


977
QIDYGNADPSTIK
13.42
711.35
902.46
36


 


978
QIDYGNADPSTIK
13.42
711.35
1065.52
36


 


979
QIDYGNVDPSTIK
15.08
725.36
873.47
37


 


980
QIDYGNVDPSTIK
15.07
725.36
930.49
37


 


981
QIDYGNVDPSTIK
15.07
725.36
1093.55
37


 


982
QIGQAR
2.3
336.69
431.24
20


 


983
QIGQAR
2.33
336.69
498.27
20


 


984
QIGQAR
2.32
336.69
544.32
20


 


985
QIMLIEQTPAFTLR
24.42
830.96
933.52
42


 


986
QIMLIEQTPAFTLR
24.42
830.96
1062.56
42


 


987
QIMLIEQTPAFTLR
24.42
830.96
1175.64
42


 


988
QLGSAIDQFWLR
22.67
717.38
864.44
37


 


989
QLGSAIDQFWLR
22.68
717.38
977.52
37


 


990
QLGSAIDQFWLR
22.67
717.38
1192.61
37


 


991
QLPVK
9.57
292.69
343.23
18


 


992
QLPVK
9.58
292.69
438.27
18


 


993
QLPVK
9.57
292.69
456.32
18


 


994
QLSLDVLDK
18.63
515.79
589.32
28


 


995
QLSLDVLDK
18.62
515.79
789.44
28


 


996
QLSLDVLDK
18.63
515.79
902.52
28


 


997
QLVYAR
11.04
375.22
508.29
22


 


998
QLVYAR
11.04
375.22
575.32
22


 


999
QLVYAR
11.04
375.22
621.37
22


 


1000
QMMLTEASTDYIIR
19.82
836.41
867.46
42


 


1001
QMMLTEASTDYIIR
19.82
836.41
1067.54
42


 


1002
QMMLTEASTDYIIR
19.82
836.41
1168.58
42


 


1003
QMSIVEATPDYVLHGK
18.77
894.45
1029.54
44


 


1004
QMSIVEATPDYVLHGK
18.77
894.45
1100.57
44


 


1005
QMSIVEATPDYVLHGK
18.77
894.45
1229.62
44


 


1006
QTLVFAR
14.65
417.75
492.29
23


 


1007
QTLVFAR
14.65
417.75
605.38
23


 


1008
QTLVFAR
14.65
417.75
706.42
23


 


1009
QVVFAR
12.06
360.21
492.29
21


 


1010
QVVFAR
12.04
360.21
545.31
21


 


1011
QVVFAR
12.06
360.21
591.36
21


 


1012
SADEVLPYGGKPQR
12.96
506.26
642.37
29


 


1013
SADEVLPYGGKPQR
12.96
506.26
805.43
29


 


1014
SADEVLPYGGKPQR
12.96
506.26
902.48
29


 


1015
SC[CAM]ATNDLAR
9.37
504.23
689.36
27


 


1016
SC[CAM]ATNDLAR
9.37
504.23
760.39
27


 


1017
SC[CAM]ATNDLAR
9.37
504.23
920.43
27


 


1018
SC[CAM]ATNNLAR
8.66
503.74
688.37
27


 


1019
SC[CAM]ATNNLAR
8.66
503.74
759.41
27


 


1020
SC[CAM]ATNNLAR
8.67
503.74
919.44
27


 


1021
SDIPGGSK
7.63
380.7
558.32
22


 


1022
SDIPGGSK
7.63
380.7
614.28
22


 


1023
SDIPGGSK
7.63
380.7
673.35
22


 


1024
SDWGK
5.75
296.64
390.21
18


 


1025
SDWGK
5.75
296.64
446.17
18


 


1026
SDWGK
5.75
296.64
505.24
18


 


1027
SEDNFHISSQQHEK
10.36
422.19
541.27
24


 


1028
SEDNFHISSQQHEK
10.36
422.19
730.28
24


 


1029
SEDNFHISSQQHEK
10.36
422.19
756.36
24


 


1030
SEMPASIR
12.02
445.72
674.37
25


 


1031
SEMPASIR
12.02
445.72
716.33
25


 


1032
SEMPASIR
12.02
445.72
803.41
25


 


1033
SEMPASIR
8.2
439.71
662.33
24


 


1034
SEMPASTR
8.19
439.71
704.29
24


 


1035
SEMPASTR
8.19
439.71
791.37
24


 


1036
SFAAHNQDQDLR
10.35
467.89
531.29
27


 


1037
SFAAHNQDQDLR
10.35
467.89
871.37
27


 


1038
SFAAHNQDQDLR
10.35
467.89
888.42
27


 


1039
SFAGHNK
9.4
380.69
455.24
22


 


1040
SFAGHNK
9.4
380.69
526.27
22


 


1041
SFAGHNK
9.38
380.69
673.34
22


 


1042
SFAGHNQDQDLR
10.18
694.32
888.42
36


 


1043
SFAGHNQDQDLR
10.18
694.32
1025.48
36


 


1044
SFAGHNQDQDLR
10.18
694.32
1082.5
36


 


1045
SFAGHNQDQNLR
9.8
462.89
530.3
27


 


1046
SFAGHNQDQNLR
9.8
462.89
773.39
27


 


1047
SFAGHNQDQNLR
9.8
462.89
887.43
27


 


1048
SFLESWAK
18.27
484.25
491.26
26


 


1049
SFLESWAK
18.27
484.25
620.3
26


 


1050
SFLESWAK
18.27
484.25
733.39
26


 


1051
SFTAWEK
14.44
434.71
462.23
24


 


1052
SFTAWEK
14.44
434.71
533.27
24


 


1053
SFTAWEK
14.44
434.71
634.32
24


 


1054
SFTTWEK
14.1
449.72
462.23
25


 


1055
SFTTWEK
14.1
449.72
563.28
25


 


1056
SFTTWEK
14.1
449.72
664.33
25


 


1057
SGSGWLR
13.25
381.7
531.3
22


 


1058
SGSGWLR
13.25
381.7
618.34
22


 


1059
SGSGWLR
13.25
381.7
675.36
22


 


1060
SGWGMAVDPQVGWYVGFVEK
24.65
738.02
841.45
41


 


1061
SGWGMAVDPQVGWYVGFVEK
24.65
738.02
1029.45
41


 


1062
SGWGMAVDPQVGWYVGFVEK
24.68
1106.53
1128.51
54


 


1063
SGWGMDVSPQVGWLTGWVEK
26.32
1110.03
1144.51
54


 


1064
SGWGMDVSPQVGWLTGWVEK
26.32
1110.03
1174.63
54


 


1065
SGWGMDVSPQVGWLTGWVEK
26.32
1110.03
1201.53
54


 


1066
SGWGMDVTPQVGWLTGWVEK
26.61
745.03
832.46
41


 


1067
SGWGMDVTPQVGWLTGWVEK
26.61
745.03
1018.54
41


 


1068
SGWGMDVTPQVGWLTGWVEK
26.61
745.03
1075.56
41


 


1069
SIHPASTFK
10.74
494.27
650.35
27


 


1070
SIHPASTFK
10.73
494.27
787.41
27


 


1071
SIHPASTFK
10.73
494.27
900.49
27


 


1072
SISTK
10.41
268.16
335.19
17


 


1073
SISTK
10.42
268.16
389.2
17


 


1074
SISTK
10.42
268.16
448.28
17


 


1075
SLGLSNNLSR
14.23
530.79
690.35
28


 


1076
SLGLSNNLSR
14.23
530.79
803.44
28


 


1077
SLGLSNNLSR
14.23
530.79
860.46
28


 


1078
SLSMSGK
9.31
355.18
509.24
21


 


1079
SLSMSGK
9.32
355.18
563.25
21


 


1080
SLSMSGK
9.32
355.18
622.32
21


 


1081
SMLFIEEK
17.82
498.76
518.28
27


 


1082
SMLFIEEK
17.82
498.76
665.35
27


 


1083
SMLFIEEK
17.82
498.76
778.43
27


 


1084
SNGLTHSWLGSSLK
16.78
743.89
877.48
38


 


1085
SNGLTHSWLGSSLK
16.78
743.89
1014.54
38


 


1086
SNGLTHSWLGSSLK
16.78
743.89
1115.58
38


 


1087
SPTWELKPEYNPSPR
16.02
600.97
733.36
34


 


1088
SPTWELKPEYNPSPR
16.02
600.97
808.91
34


 


1089
SPTWELKPEYNPSPR
16.02
600.97
959.46
34


 


1090
SQDIVR
8.4
359.2
502.3
21


 


1091
SQDIVR
8.38
359.2
543.28
21


 


1092
SQDIVR
8.4
359.2
630.36
21


 


1093
SQQKPTDPTIWLK
16.6
514.62
660.41
30


 


1094
SQQKPTDPTIWLK
16.6
514.62
757.46
30


 


1095
SQQKPTDPTIWLK
16.6
514.62
785.38
30


 


1096
SQVGWLTGWVEQPDGK
22.27
893.94
1015.5
44


 


1097
SQVGWLTGWVEQPDGK
22.28
893.94
1116.53
44


 


1098
SQVGWLTGWVEQPDGK
22.28
893.94
1229.62
44


 


1099
SSSNSC[CAM]TTNNAAR
16.84
685.29
907.41
35


 


1100
SSSNSC[CAM]TTNNAAR
16.85
685.29
994.44
35


 


1101
SSSNSC[CAM]TTNNAAR
16.84
685.29
1108.48
35


 


1102
SVYGELR
12.65
412.22
417.25
23


 


1103
SVYGELR
12.65
412.22
474.27
23


 


1104
SVYGELR
12.65
412.22
637.33
23


 


1105
SWILR
16.33
337.7
401.29
20


 


1106
SWILR
16.32
337.7
500.29
20


 


1107
SWILR
16.33
337.7
587.37
20


 


1108
SYLEK
9.09
320.17
389.24
19


 


1109
SYLEK
9.09
320.17
493.23
19


 


1110
SYLEK
9.1
320.17
552.3
19


 


1111
TAYIPASTFK
15.43
549.8
650.35
29


 


1112
TAYIPASTFK
15.43
549.8
763.43
29


 


1113
TAYIPASTFK
15.43
549.8
926.5
29


 


1114
TDDLFK
13.48
369.69
407.27
21


 


1115
TDDLFK
13.48
369.69
522.29
21


 


1116
TDDLFK
13.48
369.69
637.32
21


 


1117
TDINEIFK
17.44
490.26
650.35
27


 


1118
TDINEIFK
17.44
490.26
763.43
27


 


1119
TDINEIFK
17.44
490.26
878.46
27


 


1120
TFIHNDPR
18.92
500.25
751.38
27


 


1121
TFIHNDPR
18.92
500.25
825.39
27


 


1122
TFIHNDPR
18.92
500.25
898.45
27


 


1123
TGAGFTANR
9.64
447.72
461.25
25


 


1124
TGAGFTANR
9.64
447.72
665.34
25


 


1125
TGAGFTANR
9.64
447.72
793.4
25


 


1126
TGFNDGQK
7.5
433.7
561.26
24


 


1127
TGFNDGQK
7.5
433.7
708.33
24


 


1128
TGFNDGQK
7.5
433.7
765.35
24


 


1129
TGLADSK
9.7
346.18
533.29
20


 


1130
TGLADSK
9.67
346.18
545.26
20


 


1131
TGLADSK
9.7
346.18
590.31
20


 


1132
TGLDLMQK
15.32
453.24
634.32
25


 


1133
TGLDLMQK
15.32
453.24
747.41
25


 


1134
TGLDLMQK
15.32
453.24
804.43
25


 


1135
TGLELMQK
15.03
460.25
648.34
25


 


1136
TGLELMQK
15.03
460.25
761.42
25


 


1137
TGLELMQK
15.03
460.25
818.44
25


 


1138
TGMGYPK
10.28
377.18
464.25
22


 


1139
TGMGYPK
10.28
377.18
595.29
22


 


1140
TGMGYPK
10.28
377.18
652.31
22


 


1141
TGNGR
0.8
252.63
330.14
16


 


1142
TGNGR
0.8
252.63
346.18
16


 


1143
TGNGR
0.81
252.63
403.2
16


 


1144
TGTGSFIDAR
13.35
512.76
708.37
28


 


1145
TGTGSFIDAR
13.35
512.76
765.39
28


 


1146
TGTGSFIDAR
13.35
512.76
866.44
28


 


1147
TGTGSLSDAK
8.32
468.74
620.32
26


 


1148
TGTGSLSDAK
8.32
468.74
677.35
26


 


1149
TGTGSLSDAK
8.32
468.74
778.39
26


 


1150
TGVATEYQPEIGWWAGWVER
25.49
779.04
903.45
43


 


1151
TGVATEYQPEIGWWAGWVER
25.5
779.04
1146.55
43


 


1152
TGVATEYQPEIGWWAGWVER
25.52
1168.06
1189.57
56


 


1153
TGVSYPLLADGTR
17.4
675.36
842.47
35


 


1154
TGVSYPLLADGTR
17.41
675.36
1005.54
35


 


1155
TGVSYPLLADGTR
17.4
675.36
1092.57
35


 


1156
TGWAMDIK
16.71
461.23
577.3
25


 


1157
TGWAMDIK
16.71
461.23
763.38
25


 


1158
TGWAMDIK
16.72
461.23
820.4
25


 


1159
TGWATR
9.71
346.18
517.24
20


 


1160
TGWATR
9.69
346.18
533.28
20


 


1161
TGWATR
9.69
346.18
590.3
20


 


1162
TGWC[CAM]FDC[CAM]TPELGWWVGWVK
28.39
795.36
960.51
44


 


1163
TGWC[CAM]FDC[CAM]TPELGWWVGWVK
28.39
795.36
1017.53
44


 


1164
TGWC[CAM]FDC[CAM]TPELGWWVGWVK
28.38
795.36
1028.36
44


 


1165
TGWEGR
9.1
353.17
531.22
21


 


1166
TGWEGR
9.09
353.17
547.26
21


 


1167
TGWEGR
9.09
353.17
604.28
21


 


1168
TGWFVDK
16.08
426.72
694.36
24


 


1169
TGWFVDK
16.1
426.72
706.32
24


 


1170
TGWFVDK
16.08
426.72
751.38
24


 


1171
TGYDTK
2.09
342.66
526.25
20


 


1172
TGYDTK
2.09
342.66
538.21
20


 


1173
TGYDTK
2.08
342.66
583.27
20


 


1174
TGYGVR
8.09
326.67
478.23
19


 


1175
TGYGVR
8.1
326.67
494.27
19


 


1176
TGYGVR
8.1
326.67
551.29
19


 


1177
TGYSAR
2.24
327.66
480.21
19


 


1178
TGYSAR
2.24
327.66
496.25
19


 


1179
TGYSAR
2.24
327.66
553.27
19


 


1180
TGYSTR
2.08
342.67
510.22
20


 


1181
TGYSTR
2.08
342.67
526.26
20


 


1182
TGYSTR
2.08
342.67
583.28
20


 


1183
THESSNWGK
5.36
523.24
678.32
28


 


1184
THESSNWGK
5.37
523.24
807.36
28


 


1185
THESSNWGK
5.37
523.24
944.42
28


 


1186
TIC[CAM]TAIADAGTGK
14.35
639.82
732.39
33


 


1187
TIC[CAM]TAIADAGTGK
14.35
639.82
904.47
33


 


1188
TIC[CAM]TAIADAGTGK
14.35
639.82
1064.5
33


 


1189
TIGGAPDAYWVDDSLQISAR
21.22
712.35
1004.5
40


 


1190
TIGGAPDAYWVDDSLQISAR
21.22
712.35
1103.57
40


 


1191
TIGGAPDAYWVDDSLQISAR
21.21
1068.02
1103.57
52


 


1192
TLPFSASSYETLR
18.73
736.37
855.42
37


 


1193
TLPFSASSYETLR
18.73
736.37
1013.49
37


 


1194
TLPFSASSYETLR
18.73
736.37
1160.56
37


 


1195
TLPFSPK
15
395.23
478.27
22


 


1196
TLPFSPK
15
395.23
575.32
22


 


1197
TLPFSPK
15
395.23
688.4
22


 


1198
TLPFSQEVQDEVQSILFIEEK
28.55
827.09
891.52
45


 


1199
TLPFSQEVQDEVQSILFIEEK
28.56
827.09
978.55
45


 


1200
TLPFSQEVQDEVQSILFIEEK
28.56
827.09
1106.61
45


 


1201
TLPFSQEVQDEVQSMLFIEEK
27.7
833.08
996.51
46


 


1202
TLPFSQEVQDEVQSMLFIEEK
27.69
833.08
1124.57
46


 


1203
TLPFSQEVQDEVQSMLFIEEK
27.7
833.08
1223.63
46


 


1204
TLQNGWFEGFIISK
24.12
820.43
940.51
41


 


1205
TLQNGWFEGFIISK
24.11
820.43
1126.59
41


 


1206
TLQNGWFEGFIISK
24.11
820.43
1183.61
41


 


1207
TMQEYLNK
12.6
513.75
666.35
28


 


1208
TMQEYLNK
12.6
513.75
794.4
28


 


1209
TMQEYLNK
12.6
513.75
925.44
28


 


1210
TQTYQAYDAAR
11.2
644.3
666.32
33


 


1211
TQTYQAYDAAR
11.2
644.3
957.44
33


 


1212
TQTYQAYDAAR
11.2
644.3
1058.49
33


 


1213
TTDPTIWEK
14.39
545.77
676.37
29


 


1214
TTDPTIWEK
14.39
545.77
773.42
29


 


1215
TTDPTIWEK
14.39
545.77
888.45
29


 


1216
TTTTEVFK
12.06
463.75
522.29
25


 


1217
TTTTEVFK
12.06
463.75
623.34
25


 


1218
TTTTEVFK
12.06
463.75
724.39
25


 


1219
TWASNDFSR
13.73
542.25
638.29
29


 


1220
TWASNDFSR
13.73
542.25
725.32
29


 


1221
TWASNDFSR
13.73
542.25
796.36
29


 


1222
TWDMVQR
14.28
468.22
648.31
26


 


1223
TWDMVQR
14.28
468.22
761.33
26


 


1224
TWDMVQR
14.28
468.22
834.39
26


 


1225
TYWDPAR
12.15
460.75
557.3
25


 


1226
TYWDPAR
12.14
460.75
656.37
25


 


1227
TYWDPAR
12.15
460.75
819.44
25


 


1228
VAFSLNIEMK
20.65
576.31
747.41
30


 


1229
VAFSLNIEMK
20.65
576.31
834.44
30


 


1230
VAFSLNIEMK
20.65
576.31
981.51
30


 


1231
VANSLIGLSTGAVR
17.97
679.39
760.43
35


 


1232
VANSLIGLSTGAVR
17.97
679.39
873.52
35


 


1233
VANSLIGLSTGAVR
17.97
679.39
986.6
35


 


1234
VELGK
7.74
273.17
342.2
17


 


1235
VELGK
7.75
273.17
399.22
17


 


1236
VELGK
7.74
273.17
446.26
17


 


1237
VFLDSWAK
18.2
483.26
606.29
26


 


1238
VFLDSWAK
18.2
483.26
719.37
26


 


1239
VFLDSWAK
18.2
483.26
866.44
26


 


1240
VFLESWAK
18.11
490.27
620.3
27


 


1241
VFLESWAK
18.11
490.27
733.39
27


 


1242
VFLESWAK
18.11
490.27
880.46
27


 


1243
VFLSSWAQDMNLSSAIK
23.66
948.98
978.49
47


 


1244
VFLSSWAQDMNLSSAIK
23.66
948.98
1106.55
47


 


1245
VFLSSWAQDMNLSSAIK
23.66
948.98
1177.59
47


 


1246
VGFER
10.32
304.16
433.21
18


 


1247
VGFER
10.32
304.16
451.23
18


 


1248
VGFER
10.32
304.16
508.25
18


 


1249
VILVFDQVR
19.69
544.83
664.34
29


 


1250
VILVFDQVR
19.69
544.83
763.41
29


 


1251
VILVFDQVR
19.69
544.83
876.49
29


 


1252
VMAAMVR
12.3
389.21
476.26
22


 


1253
VMAAMVR
12.3
389.21
547.3
22


 


1254
VMAAMVR
12.3
389.21
678.34
22


 


1255
VPLAVMGYDAGILVDAHNPR
21.61
703.37
709.34
39


 


1256
VPLAVMGYDAGILVDAHNPR
21.61
703.37
808.41
39


 


1257
VPLAVMGYDAGILVDAHNPR
21.61
703.37
921.49
39


 


1258
VQDEVQSMLFIEEK
20.48
847.92
996.51
42


 


1259
VQDEVQSMLFIEEK
20.48
847.92
1124.57
42


 


1260
VQDEVQSMLFIEEK
20.47
847.92
1223.63
42


 


1261
VQDGVQSMLFIEEK
20.26
811.91
996.51
41


 


1262
VQDGVQSMLFIEEK
20.27
811.91
1124.57
41


 


1263
VQDGVQSMLFIEEK
20.25
811.91
1223.63
41


 


1264
VSC[CAM]LPC[CAM]YQVVSHK
14.32
526.26
569.34
30


 


1265
VSC[CAM]LPC[CAM]YQVVSHK
14.32
526.26
860.46
30


 


1266
VSC[CAM]LPC[CAM]YQVVSHK
14.31
526.26
1020.49
30


 


1267
VSC[CAM]VWC[CAM]YQALAR
18.41
756.86
881.43
38


 


1268
VSC[CAM]VWC[CAM]YQALAR
18.41
756.86
1067.51
38


 


1269
VSC[CAM]VWC[CAM]YQALAR
18.41
756.86
1166.58
38


 


1270
VSDVC[CAM]SEVTAEGWQEVR
17.33
650.97
774.39
37


 


1271
VSDVC[CAM]SEVTAEGWQEVR
17.34
975.95
1075.52
48


 


1272
VSDVC[CAM]SEVTAEGWQEVR
17.34
975.95
1174.59
48


 


1273
VSEVEGWQIHGK
13.92
456.9
582.34
27


 


1274
VSEVEGWQIHGK
13.92
456.9
768.42
27


 


1275
VSEVEGWQIHGK
13.92
456.9
825.44
27


 


1276
VSFSLNIEMK
20.65
584.31
834.44
31


 


1277
VSFSLNIEMK
20.64
584.31
981.51
31


 


1278
VSFSLNIEMK
20.65
584.31
1068.54
31


 


1279
VSPC[CAM]SSFK
11.04
456.22
468.25
25


 


1280
VSPC[CAM]SSFK
11.04
456.22
628.28
25


 


1281
VSPC[CAM]SSFK
11.04
456.22
725.33
25


 


1282
VSQVPAYK
10.68
446.25
478.27
25


 


1283
VSQVPAYK
10.68
446.25
577.33
25


 


1284
VSQVPAYK
10.68
446.25
705.39
25


 


1285
WFAR
11.17
296.18
393.22
18


 


1286
WFAR
11.17
296.18
417.25
18


 


1287
WFAR
11.17
296.18
492.29
18


 


1288
WDGAK
4.9
288.64
302.11
18


 


1289
WDGAK
4.9
288.64
390.2
18


 


1290
WDGAK
4.9
288.64
430.17
18


 


1291
WDGHIYDFPDWNR
20.52
574.25
590.27
33


 


1292
WDGHIYDFPDWNR
20.52
574.25
687.32
33


 


1293
WDGHIYDFPDWNR
20.52
574.25
887.37
33


 


1294
WDGIK
12.03
309.67
359.13
19


 


1295
WDGIK
12.03
309.67
432.25
19


 


1296
WDGIK
12.03
309.67
472.22
19


 


1297
WDGKPR
6.36
379.7
457.29
22


 


1298
WDGKPR
6.35
379.7
572.32
22


 


1299
WDGKPR
6.36
379.7
584.28
22


 


1300
WDGQTR
7.41
381.68
461.25
22


 


1301
WDGQTR
7.41
381.68
576.27
22


 


1302
WDGQTR
7.41
381.68
588.24
22


 


1303
WDGVK
10.1
302.66
359.13
18


 


1304
WDGVK
10.1
302.66
418.23
18


 


1305
WDGVK
10.1
302.66
458.2
18


 


1306
WDGVNR
10.39
373.68
445.25
21


 


1307
WDGVNR
10.39
373.68
560.28
21


 


1308
WDGVNR
10.42
373.68
572.25
21


 


1309
YAQAK
12.58
290.66
363.17
18


 


1310
YAQAK
12.58
290.66
417.25
18


 


1311
YAQAK
12.58
290.66
434.2
18


 


1312
YFSDFNAK
14.21
496.23
681.32
27


 


1313
YFSDFNAK
14.21
496.23
828.39
27


 


1314
YFSDFNAK
14.21
496.23
828.39
27


 


1315
YGTHLDR
8.51
431.21
641.34
24


 


1316
YGTHLDR
8.52
431.21
687.31
24


 


1317
YGTHLDR
8.51
431.21
698.36
24


 


1318
YLDELVK
15.52
440.24
488.31
24


 


1319
YLDELVK
15.53
440.24
603.33
24


 


1320
YLDELVK
15.52
440.24
716.42
24


 


1321
YLMITEAGR
15.86
527.27
533.27
28


 


1322
YLMITEAGR
15.86
527.27
646.35
28


 


1323
YLMITEAGR
15.86
527.27
777.39
28


 


1324
YLNLFSYGNANIGGGIDK
22.16
639.32
773.42
36


 


1325
YLNLFSYGNANIGGGIDK
22.16
958.48
1015.52
47


 


1326
YLNLFSYGNANIGGGIDK
22.16
958.48
1178.58
47


 


1327
YPVVWYSQQVAHHLGAQR
18.11
535.53
544.32
30


 


1328
YPVVWYSQQVAHHLGAQR
18.11
535.53
681.38
30


 


1329
YPVVWYSQQVAHHLGAQR
18.11
535.53
889.48
30


 


1330
YSNVLAFK
16.44
471.26
478.3
26


 


1331
YSNVLAFK
16.44
471.26
691.41
26


 


1332
YSNVLAFK
16.44
471.26
778.45
26


 


1333
YSPASTFK
12.22
450.73
553.3
25


 


1334
YSPASTFK
12.22
450.73
650.35
25


 


1335
YSPASTFK
12.22
450.73
737.38
25


 


1336
YSVVPVYQQLAR
18.42
711.89
778.42
36


 


1337
YSVVPVYQQLAR
18.42
711.89
974.54
36


 


1338
YSVVPVYQQLAR
18.43
711.89
1073.61
36


 


1339
YSVVWYSQLTAK
19.75
722.88
810.44
37


 


1340
YSVVWYSQLTAK
19.76
722.88
996.51
37


 


1341
YSVVWYSQLTAK
19.76
722.88
1095.58
37


 


1342
YSVVWYSQQVAHHLGAQR
18.61
533.02
544.32
30


 


1343
YSVVWYSQQVAHHLGAQR
18.61
533.02
681.38
30


 


1344
YSVVWYSQQVAHHLGAQR
18.61
533.02
889.48
30


 


1345
YTPASTFK
11.95
305.49
553.3
19


 


1346
YTPASTFK
11.98
457.73
553.3
25


 


1347
YTPASTFK
11.98
457.73
650.35
25


 


1348
YTSAFGYGNADVSGEPGK
15.03
607.28
673.35
34


 


1349
YTSAFGYGNADVSGEPGK
15.02
607.28
788.38
34


 


1350
YTSAFGYGNADVSGEPGK
15.02
910.41
1030.48
45


 


1351
YVFVSALTGNLGSNLTSSIK
23.66
691.04
906.49
39


 


1352
YVFVSALTGNLGSNLTSSIK
23.66
1036.06
1165.63
51


 


1353
YVFVSALTGNLGSNLTSSIK
23.67
1036.06
1190.64
51


 


1354
YVFVSALTGSLGSNLTSSIK
24.04
682.04
906.49
38


 


1355
YVFVSALTGSLGSNLTSSIK
24.04
1022.55
1106.61
50


 


1356
YVFVSALTGSLGSNLTSSIK
24.04
1022.55
1163.63
50









The areas obtained for each of the transitions and for each of the microorganisms studied were measured. When the areas of the three transitions of the same peptide are greater than or equal to 2500, the detection of the peptide is considered to be positive and is labelled “1”. When at least one transition comprises an area less than 2500, the corresponding peptide is considered non-detected and is labelled “0”.
EXAMPLE 17: IDENTIFICATION OF A RESISTANCE TO IMP BETA-LACTAMS
Samples Sam145 to Sam154 are identified according to one of the methods described in examples 1, 3 or 4. The identification of the species is set out in TABLE 26.










TABLE 26







Names
Species









Sam145
A. baumannii



Sam146
A. baumannii



Sam147
E. coli



Sam148
K. pneumoniae



Sam149
K. pneumoniae



Sam150
P. aeruginosa



Sam151
P. aeruginosa



Sam152
P. aeruginosa



Sam153
P. aeruginosa



Sam154
P. putida










Samples Sam145 to Sam154 correspond to a species able to comprise an IMP resistance mechanism. The following method is then performed to detect such a mechanism.
Each sample is treated according to Example 5, then analysed according to Example 6 unless otherwise stated in the rest of the example, by detecting the peptides from TABLE 27 instead of the peptides from TABLE 3.













TABLE 27







Retention
(m/z)
(m/z)
Collision



Transition

time
filtered in
filtered in
energy
Positivity


number
Peptide
(minutes)
Q1
Q3
(eV)
threshold





















1
DTENLVNWFVER
24.3
761.37
550.3
39.1
2000


 


2
DTENLVNWFVER
24.3
761.37
850.42
39.1
2000


 


3
DTENLVNWFVER
24.3
761.37
949.49
39.1
2000


 


4
GDASLMK
10.6
361.18
391.24
16.3
2000


 


5
GDASLMK
10.6
361.18
478.27
16.3
2000


 


6
GDASLMK
10.6
361.18
549.31
16.3
2000


 


7
GFNESK
2
341.16
312.65
15.2
2000


 


8
GFNESK
2
341.16
363.19
15.2
2000


 


9
GFNESK
2
341.16
477.23
15.2
2000


 


10
GLNESK
1.1
324.17
363.19
14.2
2000


 


11
GLNESK
1.1
324.17
477.23
14.2
2000


 


12
GLNESK
1.1
324.17
590.31
14.2
2000


 


13
GLNESR
2.2
338.18
309.66
15
2000


 


14
GLNESR
2.2
338.18
391.19
15
2000


 


15
GLNESR
2.1
338.18
505.24
15
2000


 


16
GVYVHTSFEEVK
15.1
465.57
488.74
21.5
2000


 


17
GVYVHTSFEEVK
15.1
465.57
538.28
21.5
2000


 


18
GVYVHTSFEEVK
15.1
465.57
619.81
21.5
2000


 


19
GWGVVTK
14.3
373.71
345.2
17
2000


 


20
GWGVVTK
14.3
373.71
347.23
17
2000


 


21
GWGVVTK
14.3
373.71
503.32
17
2000


 


22
GWSVVTK
14.2
388.72
347.23
17.9
2000


 


23
GWSVVTK
14.2
388.72
446.3
17.9
2000


 


24
GWSVVTK
14.2
388.72
533.33
17.9
2000


 


25
HGLVVLVK
15.4
432.79
557.4
20.4
2000


 


26
HGLVVLVK
15.5
432.79
670.49
20.4
2000


 


27
HGLVVLVK
15.4
432.79
727.51
20.4
2000


 


28
HSFNGVSYSLIK
17
451.24
460.31
21.1
2000


 


29
HSFNGVSYSLIK
17
451.24
623.38
21.1
2000


 


30
HSFNGVSYSLIK
17
451.24
710.41
21.1
2000


 


31
LEEGVYVHTSFEEVK
16.9
589.29
697.85
25.4
2000


 


32
LEEGVYVHTSFEEVK
16.9
589.29
762.37
25.4
2000


 


33
LEEGVYVHTSFEEVK
16.9
589.29
826.89
25.4
2000


 


34
LFVLCVCFLCSITAAGAR
19.5
686.68
659.38
28.4
2000


 


35
LFVLCVCFLCSITAAGAR
19.6
686.68
906.45
28.4
2000


 


36
LFVLCVCFLCSITAAGAR
19.5
1029.52
374.22
54.4
2000


 


37
LFVLCVCFLCSITAAGAR
19.5
1029.52
659.38
54.4
2000


 


38
LTLEQAVK
15.2
451.27
574.32
21.5
2000


 


39
LTLEQAVK
15.2
451.27
687.4
21.5
2000


 


40
LTLEQAVK
15.2
451.27
788.45
21.5
2000


 


41
LTWEQAVK
16.3
487.77
574.32
23.5
2000


 


42
LTWEQAVK
16.3
487.77
760.4
23.5
2000


 


43
LTWEQAVK
16.3
487.77
861.45
23.5
2000


 


44
LTWEQTVK
15.4
502.77
395.71
24.4
2000


 


45
LTWEQTVK
15.4
502.77
604.33
24.4
2000


 


46
LTWEQTVK
15.4
502.77
790.41
24.4
2000


 


47
LVAWFVGR
21.3
474.28
478.28
22.8
2000


 


48
LVAWFVGR
21.3
474.28
664.36
22.8
2000


 


49
LVAWFVGR
21.3
474.28
735.39
22.8
2000


 


50
LVNWFIEHGYR
20.1
478.58
611.29
21.9
2000


 


51
LVNWFIEHGYR
20.1
478.58
660.83
21.9
2000


 


52
LVNWFIEHGYR
20.1
478.58
661.31
21.9
2000


 


53
LVNWFVER
20.9
531.79
550.3
26
2000


 


54
LVNWFVER
20.9
531.79
736.38
26
2000


 


55
LVNWFVER
20.9
531.79
850.42
26
2000


 


56
LVTWFVER
20.6
525.29
550.3
25.7
2000


 


57
LVTWFVER
20.6
525.29
736.38
25.7
2000


 


58
LVTWFVER
20.6
525.29
837.43
25.7
2000


 


59
LVVPGHSEVGDASLLK
17.6
540.97
655.34
23.9
2000


 


60
LVVPGHSEVGDASLLK
17.6
540.97
704.88
23.9
2000


 


61
LVVPGHSEVGDASLLK
17.6
810.95
655.34
42
2000


 


62
LVVPSHSDIGDASLLK
18
550.97
670.35
24.2
2000


 


63
LVVPSHSDIGDASLLK
18
550.97
719.88
24.2
2000


 


64
LVVPSHSDIGDASLLK
18
825.96
670.35
42.8
2000


 


65
LVVPSHSDIGDSSLLK
17.7
556.31
678.34
24.3
2000


 


66
LVVPSHSDIGDSSLLK
17.7
556.31
719.39
24.3
2000


 


67
LVVPSHSDIGDSSLLK
17.7
556.31
727.88
24.3
2000


 


68
LVVPSHSDVGDASLLK
17.5
546.3
663.34
24
2000


 


69
LVVPSHSDVGDASLLK
17.5
546.3
712.87
24
2000


 


70
LVVPSHSDVGDASLLK
17.5
818.95
663.34
42.4
2000


 


71
LVVPSHSEAGDASLLK
16.1
541.63
656.33
23.9
2000


 


72
LVVPSHSEAGDASLLK
16.1
541.63
705.87
23.9
2000


 


73
LVVPSHSEAGDASLLK
16.1
541.63
755.4
23.9
2000


 


74
LVVPSHSEVGDASLLK
17.5
550.97
670.35
24.2
2000


 


75
LVVPSHSEVGDASLLK
17.5
550.97
719.88
24.2
2000


 


76
LVVPSHSEVGDASLLK
17.5
825.96
670.35
42.8
2000


 


77
LVVSGHSEIGNASLLK
16.8
541.97
656.85
23.9
2000


 


78
LVVSGHSEIGNASLLK
16.8
541.97
706.38
23.9
2000


 


79
LVVSGHSEIGNASLLK
16.8
541.97
755.92
23.9
2000


 


80
LVVSSHSDIGDVSLLK
18.9
556.98
679.35
24.3
2000


 


81
LVVSSHSDIGDVSLLK
18.9
556.98
728.89
24.3
2000


 


82
LVVSSHSDIGDVSLLK
18.9
556.98
778.42
24.3
2000


 


83
LVVSSHSEIGDASLLK
17.6
552.31
672.34
24.2
2000


 


84
LWSSHSEIGDASLLK
17.6
552.31
721.88
24.2
2000


 


85
LWSSHSEIGDASLLK
17.6
552.31
771.41
24.2
2000


 


86
LVVSSHSEIGNASLLQR
16.8
604
416.26
25.8
2000


 


87
LVVSSHSEIGNASLLQR
16.8
604
616.38
25.8
2000


 


88
LWSSHSEIGNASLLQR
16.8
604
799.42
25.8
2000


 


89
LVVSSHSEK
8.1
329.18
387.19
17.3
2000


 


90
LVVSSHSEK
8.1
329.18
587.28
17.3
2000


 


91
LVVSSHSEK
8.1
493.27
773.38
23.9
2000


 


92
LVVSSHSETGNASLLK
14.7
547.97
665.83
24.1
2000


 


93
LVVSSHSETGNASLLK
14.7
547.97
715.37
24.1
2000


 


94
LVVSSHSETGNASLLK
14.7
547.97
764.9
24.1
2000


 


95
NDAYLIDTPITAK
18.8
717.88
745.41
36.7
2000


 


96
NDAYLIDTPITAK
18.8
717.88
858.49
36.7
2000


 


97
NDAYLIDTPITAK
18.8
717.88
971.58
36.7
2000


 


98
NSFGGVNYWLVK
21.4
692.36
822.45
35.2
2000


 


99
NSFGGVNYWLVK
21.4
692.36
1035.56
35.2
2000


 


100
NSFGGVNYWLVK
21.4
692.36
1182.63
35.2
2000


 


101
NSFSGASYWLVK
20.8
679.84
795.44
34.5
2000


 


102
NSFSGASYWLVK
20.8
679.84
923.5
34.5
2000


 


103
NSFSGASYWLVK
20.8
679.84
1010.53
34.5
2000


 


104
NSFSGGSYWLVNNK
18.8
786.88
375.2
40.6
2000


 


105
NSFSGGSYWLVNNK
18.8
786.88
474.27
40.6
2000


 


106
NSFSGGSYWLVNNK
18.8
786.88
1224.6
40.6
2000


 


107
NSFSGVSYWLLK
23.6
700.86
809.46
35.7
2000


 


108
NSFSGVSYWLLK
23.6
700.86
1052.58
35.7
2000


 


109
NSFSGVSYWLLK
23.6
700.86
1199.65
35.7
2000


 


110
NSFSGVSYWLVK
22.3
693.86
795.44
35.3
2000


 


111
NSFSGVSYWLVK
22.3
693.86
951.53
35.3
2000


 


112
NSFSGVSYWLVK
22.3
693.86
1038.56
35.3
2000


 


113
SIPTYASELTNELLK
23.8
560.3
717.41
24.5
2000


 


114
SIPTYASELTNELLK
23.8
560.3
739.89
24.5
2000


 


115
SIPTYASELTNELLK
23.8
839.95
739.89
43.6
2000


 


116
TLEQAVK
10.5
394.73
445.28
18.2
2000


 


117
TLEQAVK
10.5
394.73
574.32
18.2
2000


 


118
TLEQAVK
10.5
394.73
687.4
18.2
2000


 


119
TWEQALK
15.1
438.24
459.29
20.7
2000


 


120
TWEQALK
15.1
438.24
588.34
20.7
2000


 


121
TWEQALK
15.1
438.24
774.41
20.7
2000


 


122
TWEQAVK
12.8
431.23
445.28
20.3
2000


 


123
TWEQAVK
12.8
431.23
574.32
20.3
2000


 


124
TWEQAVK
12.8
431.23
760.4
20.3
2000


 


125
VQATNSFSGVNYWLVK
22.1
604.98
708.41
25.8
2000


 


126
VQATNSFSGVNYWLVK
22.1
604.98
822.45
25.8
2000


 


127
VQATNSFSGVNYWLVK
22.1
906.97
1212.64
47.4
2000


 


128
VQATNSFSGVSYSLIK
19.9
567.63
710.41
24.7
2000


 


129
VQATNSFSGVSYSLIK
19.9
567.63
953.53
24.7
2000


 


130
VQATNSFSGVSYSLIK
19.9
850.95
710.41
44.2
2000


 


131
VQATNSFSGVSYWLVK
22.5
595.98
708.41
25.6
2000


 


132
VQATNSFSGVSYWLVK
22.5
595.98
795.44
25.6
2000


 


133
VQATNSFSGVSYWLVK
22.5
893.46
1038.56
46.7
2000


 


134
YSFSEVSYWLVK
23.8
754.38
795.44
38.7
2000


 


135
YSFSEVSYWLVK
23.8
754.38
894.51
38.7
2000


 


136
YSFSEVSYWLVK
23.8
754.38
1110.58
38.7
2000


 


137
YSFSGVSYWLVK
23.4
718.37
795.44
36.7
2000


 


138
YSFSGVSYWLVK
23.4
718.37
951.53
36.7
2000


 


139
YSFSGVSYWLVK
23.4
718.37
1185.63
36.7
2000









    
    
        The other machine parameters used are as follows:
        Scan type: MRM
        MRM planned: yes
        Polarity: Positive
        Ionising source: Turbo VTM (Applied BioSystems)
        Q1 setting: Filtering with unit resolution
        Q3 setting: Filtering with unit resolution
        Inter-scan pause: 5.00 msec
        Scanning speed: 10 Da/s
        Curtain gas: 50.00 psi
        Cone voltage: 5500.00 V
        Source temperature: 500.00° C.
        Nebulising gas: 50.00 psi
        Heating gas: 50.00 psi
        Collision gas which induces dissociation: 9.00 psi
        Dynamic filling: activated
        Declustering potential (DP): 100.00 V
        Entry potential before Q0 (EP): 6.00 V
        Collision cell exit potential (CXP): 15 V
        Total cycle time: 1 sec
        Detection window: 120 sec
    
    


The areas obtained for each of the transitions and for each of the microorganisms studied were measured. When the areas of the transitions are greater than or equal to the positivity threshold described in TABLE 27, the detection of the transition is considered to be positive and is labelled “1” in TABLE 28. When a transition has an area less than the positivity threshold described in TABLE 27, the transition is considered non-detected and is labelled “0” in TABLE 28.
For a given peptide, when at least 3 transitions are labelled “1”, the peptide is considered as being detected.

















TABLE 28





Transition












number
Sam145
Sam146
Sam147
Sam148
Sam149
Sam150
Sam151
Sam152
Sam153
Sam154

























1
0
0
1
0
0
0
0
0
0
0


2
0
0
1
0
0
0
0
0
0
0


3
0
0
0
0
0
0
0
0
0
0


4
0
0
0
0
0
0
0
0
1
0


5
0
0
0
0
0
0
0
0
1
0


6
0
0
0
0
0
0
0
0
1
0


7
0
0
0
0
0
0
0
0
0
0


8
0
0
0
0
0
0
0
0
0
0


9
0
0
0
0
0
0
0
0
0
0


10
1
1
0
0
0
0
0
0
0
0


11
1
1
0
0
0
0
0
0
0
0


12
0
0
0
0
0
0
0
0
0
0


13
0
0
0
0
0
0
0
0
0
0


14
0
0
0
0
0
0
0
0
0
0


15
0
0
0
0
0
0
0
0
0
0


16
0
0
0
0
0
0
0
0
0
0


17
0
0
0
0
0
1
1
0
1
0


18
0
0
0
0
0
0
0
0
0
0


19
0
1
0
0
0
0
0
0
0
0


20
0
0
0
0
0
1
0
1
1
0


21
0
0
0
0
0
0
0
1
0
0


22
0
0
0
0
1
0
0
0
0
0


23
0
0
1
1
1
0
0
0
1
0


24
0
0
0
0
0
0
0
0
0
0


25
0
0
0
0
0
0
0
0
0
0


26
0
0
0
0
0
0
0
0
0
0


27
0
0
0
0
0
0
0
0
0
0


28
0
0
0
0
0
0
0
0
0
0


29
0
0
0
0
0
0
0
0
0
0


30
0
0
0
0
0
0
0
0
0
0


31
0
0
0
0
0
0
0
0
0
0


32
0
0
0
0
0
0
0
0
0
0


33
1
0
0
0
0
0
0
0
0
0


34
0
0
0
0
0
0
0
0
0
0


35
0
0
0
0
0
0
0
0
0
0


36
0
0
0
0
0
0
0
0
0
0


37
0
0
0
0
0
0
0
0
0
0


38
0
1
1
1
0
0
0
1
0
0


39
0
1
1
1
0
0
0
1
0
0


40
0
1
1
1
0
0
0
1
0
0


41
0
0
1
0
0
0
0
0
0
1


42
0
0
0
0
0
0
0
0
0
1


43
0
0
0
0
0
0
0
0
0
1


44
0
0
0
0
0
0
0
0
0
0


45
0
0
0
0
0
0
0
0
0
0


46
0
0
0
0
0
0
0
0
0
0


47
0
0
0
0
0
0
0
0
0
0


48
0
0
0
0
0
0
0
0
0
1


49
0
0
0
0
0
0
0
0
0
0


50
0
0
0
0
0
0
0
0
0
0


51
0
0
0
0
0
0
0
0
0
0


52
0
0
0
0
0
1
0
0
0
0


53
1
0
0
0
1
1
0
0
1
0


54
1
0
1
0
0
1
0
0
1
0


55
1
1
1
0
1
1
0
0
1
0


56
0
1
1
1
1
0
1
1
0
0


57
0
1
1
1
1
0
1
1
0
0


58
0
1
1
1
1
0
1
1
0
0


59
0
0
0
0
0
1
1
0
0
0


60
0
0
0
0
0
1
1
0
0
0


61
0
0
0
0
0
1
1
0
0
0


62
0
0
0
1
0
0
1
1
0
0


63
0
0
0
1
0
0
1
1
0
0


64
0
0
0
1
0
0
1
1
0
0


65
0
0
0
0
0
1
1
1
1
0


66
0
0
0
0
0
0
0
0
0
0


67
0
0
0
0
0
0
0
0
0
0


68
0
0
0
0
0
0
0
0
0
0


69
0
0
0
0
0
0
0
0
0
0


70
0
1
0
0
0
0
0
0
0
0


71
1
1
1
0
0
0
0
0
0
0


72
0
1
1
0
0
0
0
0
0
0


73
0
1
1
0
0
0
0
0
0
0


74
0
0
0
1
0
0
1
1
0
0


75
0
0
0
1
0
0
1
1
0
0


76
0
0
0
1
0
0
1
1
0
0


77
0
0
0
0
0
0
0
0
0
1


78
0
0
0
0
0
0
0
0
0
1


79
0
1
1
0
0
0
0
0
0
1


80
0
0
0
0
0
0
0
0
0
0


81
0
0
0
0
0
0
0
0
0
0


82
0
1
0
0
0
0
0
0
0
0


83
1
0
0
0
1
1
0
0
0
1


84
1
0
0
0
1
1
0
0
1
0


85
1
0
1
1
1
1
1
1
1
0


86
0
0
1
0
0
0
0
0
0
0


87
0
0
1
0
0
0
0
0
0
0


88
0
0
0
0
0
0
0
0
0
0


89
0
0
0
0
0
0
0
0
0
0


90
0
0
0
0
0
0
0
0
1
0


91
0
0
0
0
0
0
0
0
1
0


92
1
0
0
0
0
0
0
0
0
0


93
0
0
0
0
0
0
0
0
0
0


94
0
0
0
0
0
0
0
0
0
0


95
0
1
0
0
0
0
0
0
0
0


96
0
0
0
0
0
0
0
0
0
0


97
0
0
0
0
0
0
0
0
0
0


98
0
1
1
0
0
0
0
0
0
0


99
0
1
1
0
0
0
0
0
0
0


100
0
1
1
1
0
0
0
0
0
0


101
0
0
0
0
0
0
0
0
0
0


102
0
0
0
0
0
0
0
0
0
0


103
0
0
0
0
0
0
1
1
0
0


104
0
0
0
1
0
0
0
0
0
0


105
0
0
0
1
1
0
0
0
0
0


106
0
0
0
0
0
0
0
0
0
0


107
0
0
0
0
0
0
0
0
0
0


108
0
0
0
0
0
0
0
0
0
0


109
0
0
0
0
0
0
0
0
0
0


110
1
1
0
0
0
0
0
0
0
0


111
1
1
0
0
0
0
0
0
1
0


112
1
0
0
0
0
0
0
0
0
0


113
0
0
0
1
0
0
0
0
0
0


114
0
0
0
1
0
0
0
1
0
0


115
0
0
0
1
0
0
0
0
0
0


116
0
1
0
1
0
0
1
0
0
0


117
0
1
1
1
0
0
1
0
0
0


118
0
1
0
1
0
0
1
0
0
0


119
0
0
0
0
0
0
0
0
1
0


120
0
0
0
0
0
0
0
0
1
0


121
0
0
0
0
0
0
0
0
1
0


122
1
0
0
0
1
1
0
0
0
0


123
1
0
0
0
1
1
0
0
0
0


124
1
0
0
0
1
1
0
0
0
0


125
0
0
0
0
0
0
0
0
0
0


126
0
0
0
0
0
0
0
1
0
0


127
0
0
0
1
1
0
0
0
0
0


128
0
0
0
0
0
0
0
0
0
1


129
0
0
0
0
0
0
0
0
0
0


130
0
0
0
0
0
0
0
0
0
0


131
0
0
0
0
0
0
0
0
0
0


132
0
0
0
0
0
0
0
0
0
0


133
0
0
0
0
0
0
0
0
0
0


134
0
0
0
0
0
0
0
0
0
0


135
0
0
0
0
0
0
1
0
0
0


136
0
0
0
0
0
0
0
0
0
0


137
1
0
0
0
0
0
0
0
0
0


138
0
0
0
0
0
0
0
0
0
0


139
0
0
0
0
0
0
0
0
0
0









Samples Sam145 to Sam154 comprise at least one peptide which is characteristic of IMPs. The bacteria present in samples Sam145 to Sam154 therefore express a beta-lactamase which confers on them a resistance to penicillins, to cephalosporins and to carbapenems.
EXAMPLE 18: IDENTIFICATION OF A RESISTANCE TO OXA-48 BETA-LACTAMS
Samples Sam155 to Sam164 are identified according to one of the methods described in examples 1, 3 or 4. The identification of the species is set out in TABLE 29.










TABLE 29







Names
Species









Sam155
K. pneumoniae



Sam156
K. pneumoniae



Sam157
K. pneumoniae



Sam158
E. cloacae



Sam159
E. cloacae



Sam160
K. pneumoniae



Sam161
K. pneumoniae



Sam162
K. pneumoniae



Sam163
K. pneumoniae



Sam164
K. pneumoniae










Samples Sam155 to Sam164 correspond to a species able to comprise an OXA-48 resistance mechanism. The following method is then performed to detect such a mechanism.
Each sample is treated according to Example 5, then analysed according to Example 6 unless otherwise stated in the rest of the example, by detecting the peptides from TABLE 30 instead of the peptides from TABLE 3.















TABLE 30







Charge








Tran-

state of

Retention
(m/z)
(m/z)
Collision


sition

the

time
filtered
filtered
energy
Positivity


number
Peptide
precursor
Fragment ion
(minutes)
in Q1
in Q3
(eV)
threshold























1
ANQAFLPASTFK
2
y6 monocharged
18.09
647.84
650.35
32.7
2000


 


2
ANQAFLPASTFK
2
y7 monocharged
18.11
647.84
763.44
32.7
2000


 


3
ANQAFLPASTFK
2
y8 monocharged
18.09
647.84
910.5
32.7
2000


 


4
DEHQVFK
3
y5 dicharged
9.89
301.48
329.69
16.4
2000


 


5
DEHQVFK
2
y4 monocharged
9.89
451.72
521.31
21.5
2000


 


6
DEHQVFK
2
y5 monocharged
9.91
451.72
658.37
21.5
2000


 


7
DHNLITAMK
3
y3 monocharged
14.57
348.18
349.19
17.9
2000


 


8
DHNLITAMK
3
y4 monocharged
14.57
348.18
450.24
17.9
2000


 


9
DHNLITAMK
2
y7 monocharged
14.57
521.77
790.45
25.5
2000


 


10
DIATWNR
2
y3 monocharged
13.79
438.22
475.24
20.7
2000


 


11
DIATWNR
2
y4 monocharged
13.79
438.22
576.29
20.7
2000


 


12
DIATWNR
2
y5 monocharged
13.79
438.22
647.33
20.7
2000


 


13
IPNSLIALDLGVVK
3
y6 monocharged
23.68
484.63
630.38
22.1
2000


 


14
IPNSLIALDLGVVK
2
y13 dicharged
23.68
726.45
669.9
37.1
2000


 


15
IPNSLIALDLGVVK
2
y8 monocharged
23.68
726.45
814.5
37.1
2000


 


16
ISATEQISFLR
2
y4 monocharged
19.17
632.85
522.3
31.8
2000


 


17
ISATEQISFLR
2
y5 monocharged
19.17
632.85
635.39
31.8
2000


 


18
ISATEQISFLR
2
y6 monocharged
19.17
632.85
763.45
31.8
2000


 


19
QAMLTEANGDYIIR
3
y4 monocharged
18.36
532.27
564.35
23.6
2000


 


20
QAMLTEANGDYIIR
3
y6 monocharged
18.36
532.27
736.4
23.6
2000


 


21
QAMLTEANGDYIIR
2
y10 monocharged
18.36
797.9
1151.57
41.2
2000


 


22
QQGFTNNLK
2
y4 monocharged
12.58
525.27
488.28
25.7
2000


 


23
QQGFTNNLK
2
y5 monocharged
12.58
525.27
589.33
25.7
2000


 


24
QQGFTNNLK
2
y7 monocharged
12.58
525.27
793.42
25.7
2000


 


25
SQGVVVLWNENK
2
y5 monocharged
18.54
686.87
690.32
34.9
2000


 


26
SQGVVVLWNENK
2
y6 monocharged
18.54
686.87
803.41
34.9
2000


 


27
SQGVVVLWNENK
2
y7 monocharged
18.52
686.87
902.47
34.9
2000


 


28
SWNAHFTEHK
3
y8 dicharged
12.23
419.53
492.24
20.1
2000


 


29
SWNAHFTEHK
3
y9 dicharged
12.23
419.53
585.28
20.1
2000


 


30
SWNAHFTEHK
3
y5 monocharged
12.23
419.53
661.33
20.1
2000


 


31
VLALSAVFLVASIIGMPAVAK
3
y6 monocharged
34.92
690.75
616.35
28.5
2000


 


32
VLALSAVFLVASIIGMPAVAK
3
y7 monocharged
34.94
690.75
673.37
28.5
2000


 


33
VLALSAVFLVASIIGMPAVAK
3
y8 monocharged
34.94
690.75
786.45
28.5
2000


 


34
YSVVPVYQEFAR
3
y5 monocharged
20.05
486.59
650.33
22.2
2000


 


35
YSVVPVYQEFAR
2
y8 dicharged
20.07
729.38
505.26
37.3
2000


 


36
YSVVPVYQEFAR
2
y8 monocharged
20.07
729.38
1009.51
37.3
2000









    
    
        The other machine parameters used are as follows:
        Scan type: MRM
        MRM planned: no
        Polarity: Positive
        Ionising source: Turbo VTM (Applied BioSystems)
        Q1 setting: Filtering with unit resolution
        Q3 setting: Filtering with unit resolution
        Inter-scan pause: 5.00 msec
        Scanning speed: 10 Da/s
        Curtain gas: 40.00 psi
        Cone voltage: 5500.00 V
        Source temperature: 500.00° C.
        Nebulising gas: 50.00 psi
        Heating gas: 50.00 psi
        Collision gas which induces dissociation: 9.00 psi
        Dynamic filling: activated
        Declustering potential (DP): 100.00 V
        Entry potential before Q0 (EP): 6.00 V
        Collision cell exit potential (CXP): 15 V
        Total cycle time: 1.1 sec
    
    


The areas obtained for each of the transitions and for each of the microorganisms studied were measured. When the areas of the transitions are greater than or equal to the positivity threshold described in TABLE 30, the detection of the transition is considered to be positive and is labelled “1” in TABLE 31. When a transition has an area less than the positivity threshold described in TABLE 30, the transition is considered non-detected and is labelled “0” in TABLE 31.
For a given peptide, when at least 3 transitions are labelled “1”, the peptide is considered as being detected.

















TABLE 31





Transition












number
Sam155
Sam156
Sam157
Sam158
Sam159
Sam160
Sam161
Sam162
Sam163
Sam164

























1
0
1
1
0
1
1
1
1
1
0


2
0
1
1
0
1
1
1
0
1
0


3
0
1
0
0
0
1
1
0
0
0


4
0
0
0
0
0
0
0
0
0
0


5
0
0
0
0
0
0
0
0
0
0


6
0
0
0
0
0
0
0
0
0
0


7
0
1
0
0
0
1
1
0
0
0


8
0
1
1
1
0
1
1
0
1
0


9
1
1
1
1
1
1
1
1
1
0


10
0
0
0
0
0
0
0
0
0
0


11
0
0
0
1
1
0
0
0
0
0


12
0
0
0
0
0
0
0
1
0
0


13
0
1
1
1
1
1
1
1
1
0


14
0
1
1
1
1
1
1
1
1
1


15
0
1
1
1
1
1
1
1
1
0


16
1
1
1
1
1
1
1
1
1
1


17
1
1
1
1
1
1
1
1
1
1


18
1
1
1
1
1
1
1
1
1
1


19
1
1
1
1
1
1
1
1
1
1


20
1
1
1
1
1
1
1
1
1
0


21
1
1
1
1
1
1
1
1
1
1


22
1
1
1
1
1
1
1
1
1
0


23
1
1
1
1
1
1
1
1
1
1


24
1
1
1
1
1
1
1
1
1
0


25
0
0
0
0
0
0
0
0
0
0


26
0
0
0
0
0
0
0
0
0
0


27
0
0
0
0
0
0
0
0
0
0


28
1
1
1
1
1
1
1
1
1
1


29
1
1
1
1
1
1
1
1
1
1


30
1
1
1
1
1
1
1
1
1
0


31
1
0
0
0
1
0
0
0
0
0


32
1
1
1
1
1
1
1
1
1
0


33
1
1
0
1
1
1
1
1
1
0


34
0
1
1
0
1
1
1
0
1
0


35
0
1
1
0
1
1
1
0
1
0


36
0
1
1
0
1
1
1
0
1
0









Samples Sam155 to Sam164 comprise at least one peptide which is characteristic of the OXA-48 group. The bacteria present in samples Sam155 to Sam164 therefore express a beta-lactamase which confers on them a resistance to penicillins, to first-generation and second-generation cephalosporins (but not to broad-spectrum cephalosporins), and to carbapenems.
EXAMPLE 19: IDENTIFICATION OF A RESISTANCE TO VIM BETA-LACTAMS
Samples Sam165 to Sam170 are identified according to one of the methods described in examples 1, 3 or 4. The identification of the species is set out in TABLE 32.










TABLE 32







Names
Species









Sam165
P. aeruginosa



Sam166
E. coli



Sam167
A. baumannii complex



Sam168
A. junii



Sam169
E. coli



Sam170
K. pneumoniae ssp pneumoniae










Samples Sam165 to Sam170 correspond to a species able to comprise a VIM resistance mechanism. The following method is then performed to detect such a mechanism.
Each sample is treated according to Example 5, then analysed according to Example 6 unless otherwise stated in the rest of the example, by detecting the peptides from TABLE 33 instead of the peptides from TABLE 3.













TABLE 33







Retention
(m/z)
(m/z)
Collision



Transition

time
filtered in
filtered in
energy
Positivity


number
Peptide
(minutes)
Q1
Q3
(eV)
threshold





















1
AAGVATYASPSAR
12.3
611.32
588.31
30.6
2500


 


2
AAGVATYASPSAR
12.3
611.32
852.42
30.6
2500


 


3
AAGVATYASPSAR
12.3
611.32
923.46
30.6
2500


 


4
AAGVATYASPSIR
14.5
632.34
630.36
31.8
2500


 


5
AAGVATYASPSIR
14.5
632.34
894.47
31.8
2500


 


6
AAGVATYASPSIR
14.5
632.34
965.51
31.8
2500


 


7
AAGVATYASPSTR
12
626.32
618.32
31.4
2500


 


8
AAGVATYASPSTR
12
626.32
882.43
31.4
2500


 


9
AAGVATYASPSTR
12
626.32
953.47
31.4
2500


 


10
AAGVATYTSPLTR
15.7
654.35
674.38
33
2500


 


11
AAGVATYTSPLTR
15.7
654.35
938.49
33
2500


 


12
AAGVATYTSPLTR
15.7
654.35
1009.53
33
2500


 


13
AGVATYASPSTR
11.8
590.8
547.28
29.4
2500


 


14
AGVATYASPSTR
11.8
590.8
618.32
29.4
2500


 


15
AGVATYASPSTR
11.8
590.8
781.38
29.4
2500


 


16
ALSSSGDVVR
11.3
495.76
632.34
24
2500


 


17
ALSSSGDVVR
11.3
495.76
719.37
24
2500


 


18
ALSSSGDVVR
11.3
495.76
806.4
24
2500


 


19
AVSTHFHDDR
9.2
395.52
413.68
19.3
2500


 


20
AVSTHFHDDR
9.2
395.52
507.72
19.3
2500


 


21
AVSTHFHDDR
9.2
395.52
689.3
19.3
2500


 


22
DADELLLIDTAWGAK
24.3
544.28
748.36
24
2500


 


23
DADELLLIDTAWGAK
24.3
815.92
544.31
42.2
2500


 


24
DADELLLIDTAWGAK
24.3
815.92
748.36
42.2
2500


 


25
DADELLLIDTAWGAK
24.3
815.92
861.45
42.2
2500


 


26
DGDELLLIDTAWGAK
24
539.61
748.36
23.8
2500


 


27
DGDELLLIDTAWGAK
24
808.91
748.36
41.8
2500


 


28
DGDELLLIDTAWGAK
24
808.91
861.45
41.8
2500


 


29
DGDELLLIDTAWGTK
24.1
549.61
778.37
24.1
2500


 


30
DGDELLLIDTAWGTK
24.1
823.92
778.37
42.7
2500


 


31
DGDELLLIDTAWGTK
24.1
823.92
891.46
42.7
2500


 


32
ESAGNVADANLAEWPATIK
20.2
652.99
529.33
27.3
2500


 


33
ESAGNVADANLAEWPATIK
20.2
652.99
715.41
27.3
2500


 


34
ESAGNVADANLAEWPATIK
20.2
978.99
529.33
51.5
2500


 


35
GEYPTVSEIPVGEVR
18.4
544.61
656.37
24
2500


 


36
GEYPTVSEIPVGEVR
18.4
816.42
641.85
42.3
2500


 


37
GEYPTVSEIPVGEVR
18.4
816.42
656.37
42.3
2500


 


38
HTTNVVK
1.3
399.73
345.25
18.5
2500


 


39
HTTNVVK
1.3
399.73
560.34
18.5
2500


 


40
HTTNVVK
1.3
399.73
661.39
18.5
2500


 


41
IGDGVWSHIATQK
17
471.25
563.8
21.7
2500


 


42
IGDGVWSHIATQK
17
471.25
621.32
21.7
2500


 


43
IGDGVWSHIATQK
17
471.25
649.83
21.7
2500


 


44
LGDTVYSSNGLIVR
17.9
747.4
387.27
38.3
2500


 


45
LGDTVYSSNGLIVR
17.9
747.4
845.48
38.3
2500


 


46
LGDTVYSSNGLIVR
17.9
747.4
1008.55
38.3
2500


 


47
LYQIADGVWSHIATK
20.8
567.97
592.81
24.7
2500


 


48
LYQIADGVWSHIATK
20.8
567.97
649.35
24.7
2500


 


49
LYQIADGVWSHIATK
20.8
567.97
713.38
24.7
2500


 


50
LYQIADGVWSHIATR
21
577.31
606.81
25
2500


 


51
LYQIADGVWSHIATR
21
577.31
663.35
25
2500


 


52
LYQIADGVWSHIATR
21
577.31
727.38
25
2500


 


53
NTAALLAEIEK
19.8
586.83
589.32
29.2
2500


 


54
NTAALLAEIEK
19.8
586.83
702.4
29.2
2500


 


55
NTAALLAEIEK
19.8
586.83
886.52
29.2
2500


 


56
NTVALLAEIEK
21.2
600.85
589.32
30
2500


 


57
NTVALLAEIEK
21.2
600.85
702.4
30
2500


 


58
NTVALLAEIEK
21.2
600.85
886.52
30
2500


 


59
QIGLPVTR
15.6
442.27
472.29
20.9
2500


 


60
QIGLPVTR
15.6
442.27
642.39
20.9
2500


 


61
QIGLPVTR
15.6
442.27
755.48
20.9
2500


 


62
QLAEAAGNEVPAHSLK
13.8
545.62
597.32
24
2500


 


63
QLAEAAGNEVPAHSLK
13.8
545.62
652.38
24
2500


 


64
QLAEAAGNEVPAHSLK
13.8
545.62
697.36
24
2500


 


65
SFDGAVYPSNGLIVR
19.2
797.92
559.32
41.2
2500


 


66
SFDGAVYPSNGLIVR
19.2
797.92
855.51
41.2
2500


 


67
SFDGAVYPSNGLIVR
19.2
797.92
1018.57
41.2
2500


 


68
SISTHFHDDR
10.6
405.52
413.68
19.7
2500


 


69
SISTHFHDDR
10.6
405.52
507.72
19.7
2500


 


70
SISTHFHDDR
10.6
405.52
689.3
19.7
2500


 


71
SVSTHFHDDR
9.2
400.85
413.68
19.5
2500


 


72
SVSTHFHDDR
9.2
400.85
507.72
19.5
2500


 


73
SVSTHFHDDR
9.2
400.85
689.3
19.5
2500


 


74
TSAGNVADADLAEWPGSVER
19.2
682.32
322.67
28.2
2500


 


75
TSAGNVADADLAEWPGSVER
19.2
682.32
644.34
28.2
2500


 


76
TSAGNVADADLAEWPGSVER
19.2
682.32
830.42
28.2
2500


 


77
TSAGNVADADLAEWPGSVER
19.2
1022.98
644.34
54
2500


 


78
TSAGNVADADLAEWPTSIER
20.7
701.67
351.69
28.8
2500


 


79
TSAGNVADADLAEWPTSIER
20.7
701.67
702.38
28.8
2500


 


80
TSAGNVADADLAEWPTSIER
20.7
701.67
888.46
28.8
2500


 


81
TSAGNVADADLAEWPTSIER
20.7
1052
702.38
55.7
2500


 


82
TSAGNVADADLAEWPTSVER
19.6
697
344.69
28.7
2500


 


83
TSAGNVADADLAEWPTSVER
19.6
697
688.36
28.7
2500


 


84
TSAGNVADADLAEWPTSVER
19.6
697
874.44
28.7
2500


 


85
TSAGNVADADLAEWPTSVER
19.6
1045
688.36
55.3
2500


 


86
VGGVDALR
12.8
393.73
474.27
18.2
2500


 


87
VGGVDALR
12.8
393.73
630.36
18.2
2500


 


88
VGGVDALR
12.8
393.73
687.38
18.2
2500


 


89
VGGVDVLR
14.8
407.74
502.3
19
2500


 


90
VGGVDVLR
14.8
407.74
658.39
19
2500


 


91
VGGVDVLR
14.8
407.74
715.41
19
2500


 


92
VLFGGCAVHEASR
15.1
468.24
522.24
21.6
5100


 


93
VLFGGCAVHEASR
15.1
468.24
595.77
21.6
5100


 


94
VLFGGCAVHEASR
15.1
468.24
599.29
21.6
5100


 


95
VLYGGCAVHELSR
15.3
487.58
543.26
22.2
2500


 


96
VLYGGCAVHELSR
15.3
487.58
624.79
22.2
2500


 


97
VLYGGCAVHELSR
15.3
487.58
641.34
22.2
2500









    
    
        The other machine parameters used are as follows:
        Scan type: MRM
        MRM planned: yes
        Polarity: Positive
        Ionising source: Turbo VTM (Applied BioSystems)
        Q1 setting: Filtering with unit resolution
        Q3 setting: Filtering with unit resolution
        Inter-scan pause: 5.00 msec
        Scanning speed: 10 Da/s
        Curtain gas: 50.00 psi
        Cone voltage: 5500.00 V
        Source temperature: 500.00° C.
        Nebulising gas: 50.00 psi
        Heating gas: 50.00 psi
        Collision gas which induces dissociation: 9.00 psi
        Dynamic filling: activated
        Declustering potential (DP): 100.00 V
        Entry potential before Q0 (EP): 6.00 V
        Collision cell exit potential (CXP): 15 V
        Total cycle time: 0.04 sec
        Detection window: 120 sec
    
    


The areas obtained for each of the transitions and for each of the microorganisms studied were measured. When the areas of the transitions are greater than or equal to the positivity threshold described in TABLE 33, the detection of the transition is considered to be positive and is labelled “1” in TABLE 34. When a transition has an area less than the positivity threshold described in TABLE 33, the transition is considered non-detected and is labelled “0” in TABLE 34.
For a given peptide, when at least 3 transitions are labelled “1”, the peptide is considered as being detected.













TABLE 34





Transition








number
Sam165
Sam166
Sam167
Sam168
Sam169
Sam170





















1
0
0
0
0
0
0


2
0
0
0
0
0
0


3
0
0
0
0
0
0


4
0
0
0
0
0
0


5
0
0
0
0
0
0


6
0
0
0
0
0
0


7
0
0
0
0
0
1


8
0
0
0
0
0
1


9
0
0
0
0
0
1


10
0
0
0
0
0
0


11
0
0
0
0
0
0


12
0
0
0
0
0
0


13
0
0
0
0
0
1


14
0
0
0
0
0
1


15
0
0
0
0
0
1


16
0
0
0
0
0
0


17
0
0
0
0
0
0


18
0
0
0
0
0
0


19
1
1
1
1
1
1


20
1
1
1
1
1
1


21
1
1
1
1
1
1


22
0
0
0
0
0
0


23
0
0
0
0
0
0


24
0
0
0
0
0
0


25
0
0
0
0
0
0


26
0
0
0
0
0
0


27
0
0
0
0
0
0


28
0
0
0
0
0
0


29
0
0
0
0
0
0


30
0
0
0
0
0
0


31
0
0
0
0
0
0


32
0
0
0
0
0
0


33
0
0
0
0
0
0


34
0
0
0
0
0
0


35
0
0
0
0
0
0


36
0
0
0
0
0
0


37
0
0
0
0
0
0


38
0
0
0
0
0
0


39
0
0
0
0
0
0


40
0
0
0
0
0
0


41
0
0
0
0
0
0


42
0
0
0
0
0
0


43
0
0
0
0
0
0


44
0
0
0
0
0
0


45
0
0
0
0
0
0


46
0
0
0
0
0
0


47
0
0
0
0
0
0


48
0
0
0
0
0
0


49
0
0
0
0
0
0


50
0
0
0
0
0
0


51
0
0
0
0
0
0


52
0
0
0
0
0
0


53
0
0
0
0
0
0


54
0
0
0
0
0
0


55
0
0
0
0
0
0


56
0
0
0
0
0
0


57
0
0
0
0
0
0


58
0
0
0
0
0
0


59
0
0
0
0
0
0


60
0
0
0
0
0
0


61
0
0
0
0
0
0


62
0
0
0
0
0
0


63
0
0
0
0
0
0


64
0
0
0
0
0
0


65
0
0
0
0
0
0


66
0
0
0
0
0
0


67
0
0
0
0
0
0


68
0
0
0
0
0
0


69
0
0
0
0
0
0


70
0
0
0
0
0
0


71
0
0
0
0
0
0


72
0
0
0
0
0
0


73
0
0
0
0
0
0


74
0
0
0
0
0
0


75
0
0
0
0
0
0


76
0
0
0
0
0
0


77
0
0
0
0
0
0


78
1
0
1
0
0
0


79
1
0
1
0
0
0


80
1
0
1
0
0
0


81
1
0
1
0
0
0


82
0
0
0
1
1
0


83
0
0
0
1
1
0


84
0
0
0
1
1
0


85
0
0
0
1
1
0


86
0
0
0
0
0
0


87
0
0
0
0
0
0


88
0
0
0
0
0
0


89
1
1
1
1
1
1


90
1
1
1
1
1
1


91
1
1
1
1
1
1


92
0
0
0
0
0
0


93
0
0
0
0
0
0


94
0
0
0
0
0
0


95
0
0
0
0
1
1


96
0
0
0
0
1
1


97
0
0
0
0
1
1









Samples Sam165 to Sam170 comprise at least one peptide which is characteristic of VIMs. The bacteria present in samples Sam165 to Sam170 therefore express a beta-lactamase which confers on them a resistance to penicillins, to cephalosporins and to carbapenems.
The detection methods described in examples 6 to 11 are particularly advantageous because they make it possible to assay a large number of peptides and at the same time to detect the presence of one or more resistance mechanisms induced by one or more carbapenemases.
Furthermore, the detection is performed in a short time, less than one hour. In fact, only the part of the gradient between 3 and 34 minutes is useful to the analysis. Furthermore, the retention times of the assayed peptides are all below 34 minutes.
In addition, the detection methods described in examples 6 to 11 are more advantageous than the molecular biology methods because they detect the product of the expression of the genes, and not the genes themselves. The detection of a resistance may not have any clinical meaning if this gene is not expressed, or it if is expressed too weakly to lead to an effective resistance. The detection of a peptide characterising a protein characteristic of a resistance mechanism does not have this disadvantage.
Surprisingly, the above examples show that it is possible to attain by mass spectrometry the sensitivity necessary for the specific detection of the existence of a mechanism of resistance to at least one antimicrobial of a microorganism contained in a sample, without employing an amplification method as is usually the case when molecular biology methods are used.
BIBLIOGRAPHIC REFERENCES


    [1] J. Anhalt & C. Fenselau, 1975, Anal. Chem., 47(2):219-225.
    [2] A. Fox et al., ed., 1990, Analytical microbiology methods: chromatography and mass spectrometry, Plenum Press, New York, N.Y.
    [3] M. Claydon et al., 1996, Nature Biotech. 14:1584-1586.
    [4] T. Krishnamurthy & P. Ross, 1996, Rapid Com. Mass Spec., 10:1992-1996.
    [5] P. Seng et al. 2009, Clin. Infect. Dis., 49:543-551.
    [6] C. Fenselau et al., 2008, Appl. Environ. Microbial., 904-906.
    [7] S. Hofstadler et al., 2005, Int. J. Mass Spectrom., 242:23-41.
    [8] D. Ecker, 2008, Nat. Rev. Microbial., 6(7):553-558.
    [9] Bush and Jacoby, 2010, Antimicrobial Agents and Chemotherapy; 54 (3): 969-976
    [10] W.-J. Chen et al., 2008, Anal. Chem., 80: 9612-9621
    [11] D. Lopez-Ferrer et al., 2008, Anal. Chem., 80:8930-8936
    [12] D. Lopez-Ferrer et al., 2005, J. Proteome res., 4(5): 1569-1574
    [13] T. Fortin et al., 2009, Mol. Cell Proteomics, 8(5): 1006-1015.
    [14] H. Keshishian et al., 2007, Mol. Cell Proteomics, 2212-2229.
    [15] J. Stal-Zeng et al., 2007, Mol. Cell Proteomics, 1809-1817.
    [16] Gaskell, Electrospray: principles and practise, 1997, J. Mass Spectrom., 32, 677-688).
    [17] V. Fusaro et al., 2009, Nature Biotech. 27, 190-198.
    [18] J. Mead et al., 15 Nov. 2008, Mol. Cell Proteomics, E-pub.
    [19] F. Desiere et al., 2006, Nucleic Acids Res., 34 (database issue): D655-8).
    [20] L. Anderson & C. Hunter, 2006, Mol. Cell Proteomics, 573-588).
    [21] B. Han & R. Higgs, 2008, Brief Funct Genomic Proteomic., 7(5):340-54).
    [22] K.-Y. Wang et al., 2008, Anal. Chem, 80(16) 6159-6167).
    [23] J. Bundy & C. Fenselau, 1999, Anal. Chem. 71: 1460-1463.
    [24] K-C Ho et al., 2004, Anal. Chem. 76: 7162-7268.
    [25] Y. S. Lin et al., 2005, Anal. Chem., 77: 1753-1760.
    [26] S. Vaidyanathan et al., 2001, Anal. Chem., 73:4134-4144.
    [27] R. Everley et al., 2009, J. Microbial. Methods, 77:152-158.
    [28] P. Seng et al., 2009, Clin. Infect. Dis., 49:543-551.
    [29] Manes N. et al., 2007, Mol. & Cell. Proteomics, 6(4): 717-727.
    [30] R. Nandakumar et al., 2009, Oral Microbiology Immunology, 24:347-352).
    [31] L. Hernychova et al., 2008, Anal. Chem., 80:7097-7104.
    [32] J.-M. Pratt et al., 2006, Nat. Protoc., 1:1029-1043.
    [33] V. Brun et al., 2007, Mol. Cell Proteomics, 2139-2149.

## Claims

1. A method of detecting a VIM protein in a sample, comprising:
subjecting the sample to MS/MS spectrometry in MRM mode and detecting whether one or more VIM fragments selected from the group consisting of SEQ ID NOs: 314-318 and 320-346 is present, wherein detection of any of the VIM fragments by the MRM mass spectrometry indicates the presence of VIM protein in the sample.

2. The method according to claim 1, further comprising, before performing MS/MS spectrometry in MRM mode, digesting proteins to produce peptides in the sample.

3. The method according to claim 2, wherein the digestion is performed by an enzyme.

4. The method according to claim 3, wherein the enzyme is trypsin.

5. The method according to claim 1, wherein the one or more VIM fragments is selected from the group consisting of SEQ ID NOs: 316, 318, 321, 341, 342, 344, and 346.

6. The method according to claim 1, further comprising performing MS/MS spectometry in MRM mode on the sample to determine whether the sample includes NDM, GES, IMP, IND, SME, and OXA.

7. A method of detecting an OXA protein in a sample, comprising:
subjecting the sample to MS/MS spectrometry in MRM mode and detecting whether one or more OXA fragments selected from the group consisting of SEQ ID NOs: 509-523, 525-572, 574-604, 606-618, 620-696, 698-1077, and 1098-1109 is present, wherein detection of any of the OXA fragments by the MRM mass spectrometry indicates the presence of OXA protein in the sample.

8. The method according to claim 7, further comprising, before performing MS/MS spectrometry in MRM mode, digesting proteins to produce peptides in the sample.

9. The method according to claim 8, wherein the digestion is performed by an enzyme.

10. The method according to claim 9, wherein the enzyme is trypsin.

11. The method according to claim 7, wherein the one or more OXA fragments is selected from the group consisting of SEQ ID NOs: 509, 510, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 525, 526, 528, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 571, 572, 574, 575, 576, 577, 578, 580, 581, 583, 584, 586, 587, 588, 589, 590, 591, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 604, 606, 607, 609, 611, 612, 613, 614, 615, 616, 618, 620, 622, 623, 624, 625, 626, 627, 632, 633, 635, 636, 637, 638, 639, 640, 641, 642, 643, 645, 648, 649, 651, 652, 653, 654, 655, 656, 659, 660, 664, 665, 666, 667, 669, 670, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 696, 698, 699, 700, 701, 702, 703, 706, 707, 710, 714, 717, 719, 720, 722, 725, 726, 727, 728, 729, 732, 735, 736, 737, 738, 740, 741, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 759, 760, 762, 763, 766, 767, 768, 769, 770, 771, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 785, 786, 787, 788, 789, 790, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 803, 804, 805, 806, 807, 809, 810, 811, 812, 813, 814, 815, 818, 821, 822, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 840, 841, 842, 844, 845, 846, 847, 848, 849, 850, 851, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 865, 866, 867, 868, 869, 871, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 912, 913, 914, 918, 920, 921, 922, 923, 928, 930, 932, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 953, 954, 955, 956, 958, 961, 962, 963, 964, 967, 968, 970, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 988, 990, 992, 993, 994, 995, 996, 997, 998, 1000, 1001, 1003, 1004, 1005, 1008, 1009, 1011, 1012, 1013, 1014, 1015, 1018, 1019, 1020, 1022, 1024, 1025, 1026, 1027, 1028, 1030, 1031, 1034, 1036, 1041, 1042, 1044, 1045, 1046, 1048, 1049, 1050, 1052, 1053, 1054, 1058, 1059, 1060, 1062, 1063, 1064, 1067, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, and 1109.

12. The method according to claim 7, wherein the one or more OXA fragments is selected from the group consisting of SEQ ID NOs: 510, 512, 513, 514, 520, 521, 522, 523, 525, 530, 532, 537, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 556, 557, 558, 559, 560, 561, 562, 574, 581, 582, 583, 584, 596, 597, 598, 599, 600, 601, 602, 607, 609, 632, 633, 635, 636, 649, 655, 656, 667, 674, 675, 689, 690, 698, 714, 719, 720, 722, 727, 729, 741, 746, 748, 750, 751, 752, 755, 756, 757, 763, 767, 768, 772, 775, 781, 782, 790, 792, 793, 794, 795, 796, 797, 798, 801, 809, 811, 812, 813, 814, 824, 832, 834, 837, 838, 847, 851, 853, 854, 855, 856, 857, 858, 859, 860, 862, 868, 869, 870, 874, 875, 876, 877, 879, 880, 881, 882, 894, 895, 898, 902, 903, 904, 906, 907, 908, 912, 913, 914, 920, 922, 923, 937, 938, 939, 945, 946, 948, 949, 950, 951, 954, 956, 962, 964, 967, 969, 971, 972, 974, 975, 979, 980, 985, 988, 990, 993, 994, 995, 996, 997, 1000, 1001, 1003, 1004, 1005, 1011, 1013, 1015, 1018, 1019, 1027, 1030, 1034, 1035, 1036, 1042, 1048, 1052, 1058, 1060, 1070, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, and 1109.

13. The method according to claim 7, wherein the one or more OXA fragments is selected from the group consisting of SEQ ID NOs: 1098, 1100, 1102, 1103, 1104, 1105, 1107, 1108, and 1109.

14. The method according to claim 7, further comprising performing MS/MS spectometry in MRM mode on the sample to determine whether the sample includes NDM, GES, IMP, IND, SME, and VIM.